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Cancer occurs because some cells within the body deviate from their usual, controlled 
behaviour. In breast cancer, for instance, a group of cells within the breast multiplies 
abnormally, more rapidly than the normal breast cells, creating tumours. The body has 
mechanisms for combating these uncontrolled cells, such as the immune system. In many 
circumstances, the immune system kills the abnormal cells, suppressing cancer. However, in 
other situations, the immune system actually collaborates with cancer growth. The 
macrophages are part of the immune system, and have been implicated in promoting cancer, 
instead of suppressing it. The tumour evades and even hijacks the immune response by 
changing how macrophages react. Instead of killing cancer cells, macrophages start 
contributing to provide blood supply to the tumour, to reduce the anti-cancer responses of the 
rest of the immune system and to assist in cancer invasion of unaffected organs (metastasis). 
This research had the aim of creating drugs (called monoclonal antibodies) to eliminate 
macrophages and, in this manner, reduce cancer burden. The drugs developed here targeted 
CSF-1R, which is important for macrophage survival and proliferation. Several drug 
candidates were created and tested in a variety of assays. Some candidates could kill 
macrophages and cancer cells that also depended on CSF-1R. However, these initial drugs 
did not possess the necessary potency. They also were not very selective for the CSF-1R 
target, indicating that they could show side-effects in patients. Therefore, to increase potency 
and selectivity, one of the initial drug candidates was modified. This modification generated 
several new possible drug candidates, which were once more tested against CSF-1R and 
macrophages. Some of the latest drugs showed better properties and could kill macrophages 
more effectively and with higher selectivity. Some further steps are now necessary to assess 







The colony-stimulating factor-1 receptor (CSF-1R) is expressed by the mononuclear 
phagocytic lineage, and is important for the development of these cells from their 
progenitors and also for promoting their survival and activation after maturation. The 
receptor has two ligands, CSF-1 and IL-34, which induce the formation of a stable dimer 
between two receptor monomers. This leads to intracellular autophosphorylation of tyrosine 
residues and subsequent signalling cascades, leading to rapid protein expression, 
cytoskeleton remodelling and cellular motility. Although CSF-1R signalling is crucial for 
normal embryogenic development and other physiological functions mediated by the 
phagocytic lineage, it has also been found to promote the pathogenic progression of cancer. 
Tumour-associated macrophages (TAMs) can comprise a large proportion of the cellular 
population in several solid tumours. These cells promote several hallmarks of cancer 
malignancy, such as increased neovascularization, tissue invasion, induction of metastases 
and immunosuppression. In this work, it was confirmed that CSF-1 had a prominent role in 
inducing cancer-promoting cellular phenotypes. Both canine cancer cells and macrophages 
respond to this cytokine, respectively increasing cancer cell proliferation and reducing 
inflammatory activation. Given the importance of CSF-1R signalling in the tumour 
microenvironment, antibodies were generated with the objective of blocking receptor 
function. Mice were immunized with either the extracellular region or the dimerization 
domain of the CSF-1R. Hybridomas were produced using the primed splenocytes, and 
monoclonal antibody (mAb) candidates were selected based on their performance in 
immunostaining and on their capacity to inhibit CSF-1R
+
 cells. The best antibodies were 
subjected to speciation. Chimeric antibodies maintained the ability of the parental mAbs to 
inhibit macrophage proliferation following CSF-1R stimulation. However, the mAbs 
possessed moderate affinity and specificity for their target, failing to stain monocytes and 
presenting a degree of cross-reactivity. The binding properties of one of such mAbs were 
altered by PCR-induced mutations, generating semi-synthetic antibody libraries. These were 
screened by phage display, yielding novel clones that show reduced cross-reactivity with 
unrelated proteins and retain the property of inhibiting macrophage survival. These results 
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 Constituents of the mononuclear phagocytic system include the monocytes, macrophages, 
dendritic cells and their myeloid progenitors. 
 CSF-1R is expressed by most of the mononuclear phagocytes, being crucial for their 
development and function in physiological conditions and in disease. 
 Tumour-associated macrophages and CSF-1R are correlated to cancer progression 
through several mechanisms. Possible therapeutic approaches include targeting the CSF-
1R with a monoclonal antibody. 
 
1.1 The mononuclear phagocytic system 
 
The mononuclear phagocytic system is comprised of a variety of cells that, starting 
with the discovery of macrophages, were found to engulf particles by phagocytosis and were 
derived from the same monoblast progenitor. Mononuclear phagocytes represent circa 10 – 
15 % of the total of cells in many organs. This family of cells also includes the monocytes, 
the microglia in the brain, dendritic antigen presenting cells and the osteoclasts, responsible 
for osseous resorption (Geissmann et al., 2010; Hume, 2006; Sunderkötter et al., 2004). In 
contrast to the adaptive immune system – comprised of lymphocytes – macrophages or 
simpler phagocytes are present in all animal species, demonstrating the importance of these 
cells (Seljelid and Eskeland, 1993).  
The term “mononuclear phagocytic system” stands to highlight the distinction 
between its components and the polymorphonuclear phagocytes (neutrophils), the lymphoid 
cells and the endothelial cells, although some of the divisions between these cells have been 
blurred by recent findings (Gordon, 2007; Hume, 2008; Hume, 2006; Seljelid and Eskeland, 
1993).  
The mononuclear phagocytes are present in a wide variety of activation states. The 
morphology, gene expression and functions of cells within the mononuclear phagocytic 
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system are very heterogeneous, and depend on the site in which they are found. These cells 
differ from each other in relation to maturation levels but they can also vary within a 
spectrum of effector functions and markers (Hume, 2008; Serbina et al., 2008). These are 
presented below. 
 
1.1.1 Bone marrow progenitors 
 
The bone marrow precursors of the mononuclear phagocytes arise from a common 
myeloid progenitor which also gives rise to the neutrophils. These multipotent myeloid 
progenitors generate macrophage/dendritic cell-restricted progenitors that express the 
fractalkine receptor (CX3CR1) and c-Kit (cluster of differentiation 117, CD117). Bone 




) are then formed from the committed 
progenitors, later maturing into monocytes and entering the circulation (Fogg et al., 2006; 
Serbina et al., 2008; Strauss-Ayali et al., 2007). The most commonly accepted pathway of 
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Figure 1.1 – Overview of the mononuclear phagocytic system and markers associated with each cell. 
The arrows indicate the course of cellular maturation. The larger semi-circular arrows indicate self-
renewal of that cellular population. The cell markers that characterize blood and tissue mononuclear 
phagocytes and the pathways that originate macrophages are highly variable and are shown here as 
some of the possible combinations, although many others are described in the literature. Cellular 
maturation and marker expression depend on the tissue considered, presence of inflammation, 
experimental conditions, definition of the terms used, among other factors. References: (Bain et al., 
2013; Davies et al., 2013; Fogg et al., 2006; Geissmann et al., 2010; Jay et al., 2015; Strauss-Ayali et 
al., 2007; Thomas et al., 2015; Wong et al., 2011). 
 
 
Interestingly, it has been found that lineage differentiation generated by various 
progenitors in the bone marrow is less marked than commonly believed. Although generated 
by a different committed myeloid progenitor, the polymorphonuclear cells are very similar to 
the mononuclear phagocytes at the transcriptional level; neutrophils can be reprogrammed 
into macrophages by the addition of granulocyte macrophage-colony-stimulating factor 
(GM-CSF), tumour necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-4 (IL-4), 
followed by colony-stimulating factor-1 (CSF-1) (Araki et al., 2004; Hume, 2006; Sasmono 
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et al., 2007). Even B-lymphocytes, which do not share the myeloid progenitor with 
mononuclear phagocytes, can be transformed into macrophages by altering the transcription 
factor network (Xie et al., 2004). Indeed, the fetal liver can produce mixed colonies of 
macrophages and B-lymphocytes (Hume, 2008). Mononuclear phagocytes can also display 
properties that are similar to those of cells of the vasculature, and monocytes and 
macrophages can be found lining blood vessels, for instance; this characteristic is 
represented in the term “reticuloendothelial system”, which was used until recently to 




Monocytes are the least differentiated cells of the mononuclear phagocytes outside 
the bone marrow. Nonetheless, these cells are capable of effector functions, such as 
phagocytosis and cytokine production (Geissmann et al., 2010). In humans, the monocytes 
are commonly divided into subsets based on the expression of CD14 and CD16. CD14
+
 are 
called classical monocytes due to their larger presence in the human blood (90 % of 
monocytes), and CD16
+
 are termed nonclassical, responding to the remaining 10 % of cells. 
These cells also vary in the expression of other surface receptors. CD14
+
 cells express high 
levels of chemokine (C-C) motif receptor 1 (CCR1), CCR2 and CXC chemokine receptor 2 
(CXCR2). CD16
+ 
monocytes express high levels of CX3CR1, MHC II and CD32, produce 
higher levels of the inflammatory cytokines tumour necrosis factor-α (TNF-α) and IL-1β, 
have lower phagocytic ability and increased antigen-presenting abilities (Chitu and Stanley, 
2006; Serbina et al., 2008; Wong et al., 2011).  







 (classical) monocytes migrate rapidly to sites of injury and infection 
and differentiate into inflammatory macrophages. The nonclassical CD16
+
 monocytes are 
responsible for luminal patrolling and clearing within blood vessels. These cells are rapidly 






 cells, which 
are a minor intermediate subpopulation in the steady-state, may be able to induce 
phagocytosis in response to antibody complexes and present antigen through highly 
expressed MHC II. Nevertheless, the intermediate and nonclassical subsets are similar at the 
transcriptional level (Thomas et al., 2015; Wong et al., 2011).  
Murine monocytes are usually subdivided by the differential expression of Ly6C, 
CX3CR1 and CCR2. Ly6C
High+
 monocytes are also CCR2
+
. These cells are large, granular 
and respond to inflammatory stimuli, and are the murine equivalent of the classical 






 monocytes migrate to tissues to form the resident subset of 
macrophages and have the scavenging functions of the human nonclassical cells. Each of the 
Ly6C subsets is present in equal proportions in the murine blood. It has been suggested that 
the gradient in LyC6 expression may represent stages of cellular maturation, and that LyC6
+
 




 monocytes in response to GM-CSF (Hume, 2006; Serbina 
et al., 2008).  
It must be noted however that the human and murine classical and nonclassical 
monocyte subsets are not entirely parallel and the differences can often make difficult the 
comparison of results between these species. The proportion between the classical and 
nonclassical monocyte subsets is different in each species, for instance (Hume, 2006; Louis 
et al., 2015; Serbina et al., 2008). The human and murine subsets also express different 
levels of CSF-1R, a receptor which will be further discussed below (Louis et al., 2015; 
Wong et al., 2011). 
Variations in the definitions of monocyte subpopulations are significant between 
humans and mice, but the monocytes of other animals have not been so thoroughly examined 
in relation to the function and the relative expression of each marker. Canine monocytes are 
known to express CD14, CD16, CCR2, CX3CR1 and other receptors also used for 
characterizing human cells, but these have only been studied within restricted experimental 




Under inflammatory conditions, the circulating monocytes (LyC6
High
, in the mouse 
or CD14
+
, in humans) are recruited into the peripheral tissues, where they mature into 
macrophages and dendritic cells. The circulating monocytes are also the precursors for many 
resident tissue macrophage populations, such as those of the gut. Resident macrophages in 
the spleen, peritoneal cavity and other tissues can be derived and replenished directly from 




). Among the 
resident macrophages are the Langerhans cells of the skin, the microglia in the brain, 
alveolar macrophages, peritoneal macrophages and the Kupffer cells in the liver. Microglia 
and Langerhans cells can self-renew in situ, without the need for bone marrow precursors. 
These cells are occasionally also classified as dendritic cells (Davies et al., 2013; Geissmann 
et al., 2010). Other tissue macrophages may also be independent from circulating precursors, 
such as those cells under the influence of IL-4 (Jenkins et al., 2013, 2011).  
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1.1.4 Dendritic cells 
 
Dendritic cells are capable of high levels of phagocytosis and antigen presentation. 
They are defined by the expression of CD11c and the ability to activate T-lymphocytes. The 
origin of these cells is varied, depending on the subset being considered, but they can derive 
from a bone marrow precursor or from monocytes (Geissmann et al., 2010; Savina and 
Amigorena, 2007). Myeloid dendritic cells, also named classical dendritic cells, are short-
lived, circulatory (in humans) and are replaced by precursors present in the blood. They can 
express CD4, CD8, CD103 and several other markers. Marker expression varies within 
different tissues and following activation of a specific immune response. Plamacytoid 
dendritic cells are long-lived and express immunoglobulin rearrangements. Both dendritic 
cell types are derived from a common dendritic precursor in the bone marrow. The 
plasmacytoid dendritic cells directly originate from the common dendritic precursor, while 
the classical dendritic cells originate from a second intermediary cell (Geissmann et al., 
2010). However, it has been suggested that plasmacytoid and classical myeloid dendritic 
cells are interchangeable, depending on the presence of certain stimuli (MacDonald et al., 
2005).  
 
1.1.5 Multinucleated phagocytes 
 
Some functionally distinct cells are derived from the fusion of several macrophages. 
Osteoclasts are multinucleated cells derived from CD16
-
 monocytes or macrophages under 
the influence of receptor activator of nuclear factor κ-B ligand (RANKL) and CSF-1. These 
cells are responsible for bone resorption (Komano et al., 2006; Udagawa et al., 1990). 
Langhans cells are multinucleated giant cells generated by the fusion of granuloma 
macrophages in response to infection with Mycobacterium spp. Virulent M. tuberculosis are 
able to induce Langhans cells that lose their phagocytic capacity, while still presenting 
antigens (Lay et al., 2007). 
 
Many more different cellular subsets and marker-defined activation states have been 
described within the mononuclear phagocytic system, especially within the dendritic cell 
classification (Guilliams et al., 2014). Those were not explored here for clarity and brevity. 
Furthermore, it has been argued that the extenuating classification of subtypes of 
mononuclear phagocytes is artificial and does not reflect the natural process of cellular 
development and activation, which is gradual and interchangeable. For example, it has been 
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proposed that myeloid dendritic cells and macrophages are simply differently activated 
phenotypes of a same cell (Hume, 2006), and that resident and pro-inflammatory 
macrophages in the intestine are context variants of cells derived from the same monocyte 
precursor (Bain et al., 2013). 
The several receptors and cytokines produced and recognized by the mononuclear 
phagocytic system are constantly self-regulating, fluidly altering the phenotype of the cells. 
The expression of cell markers changes according to the microenvironment in which the 
cells are inserted and the presence of other stimulants. Some of the possible relationships 
between factors and receptors are shown in Table 1.1 to illustrate the complex interactions 
that guide the mononuclear phagocytic system. Some of these interactions will be further 
discussed in the text.  
 
Table 1.1 – Co-regulation of several factors in the mononuclear phagocytic system. The arrows 
indicate how the factors on the vertical line influence the expression of factors on the horizontal line. 
Changes in expression can refer to protein or mRNA levels. A square with arrows in opposing 
directions indicates divergent results in different conditions or in various references. No references 
were found for the empty squares. References: (Bailey et al., 2008; Barve et al., 2013; Caux et al., 
1992; Ciccia et al., 2013; Eda et al., 2011; Foucher et al., 2013; Lauener et al., 1990; Liu et al., 2001; 
MacDonald et al., 2005; Mantovani and Allavena, 2015; Matsumura et al., 2000; Muzio et al., 2000; 
Park et al., 2004; Rey-Giraud et al., 2012; Ross et al., 2008; Shibata et al., 2001a; Sierra-Filardi et al., 
2014; Sozzani et al., 1997; Sweet et al., 2002; Temeles et al., 1993; Vellenga et al., 1988; Voloshin et 
al., 2013; Wei et al., 2010; Wong et al., 1991; Xu et al., 2015; Yeung and Stanley, 2003). 
 




















      (+CSF-1) (+CSF-1) 
CCL2         
IL-6 
        
TNF-α 
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1.2 A common marker: the CSF-1R 
 
The extensive functional differences between the cells of the mononuclear 
phagocytic system are reflected by the fact that only rare markers, if any, are common to all 
members of this cellular group. Many surface markers such as CD14, CD16, CD11, CD163, 
F4/80 and LyC6 (in mice) and chemokine receptors such as CCR1, CCR2 and CX3CR1 are 
expressed in separate presumptive functional subgroups (Gordon and Taylor, 2005; Sasmono 
et al., 2003). Probably the most widespread marker expressed by the mononuclear 
phagocytes is CSF-1R, the receptor for the macrophage colony-stimulating factor, or colony 
stimulating factor-1 (CSF-1). Signalling through the CSF-1R controls proliferation, 
differentiation, adaptation and survival of a large proportion of the cells of the mononuclear 
phagocytic system (Hume, 2006; Louis et al., 2015; MacDonald et al., 2005).  
CSF-1R is expressed by the majority cells of the mononuclear phagocytic lineage, 
from the macrophage/dendritic cell progenitors (monoblasts), promonocytes and monocytes 
to the macrophages, dendritic cells and osteoclasts. This illustrates the importance of CSF-
1R during the maturation and function of the mononuclear phagocytic lineage (Pixley and 
Stanley, 2004; Stanley and Chitu, 2014; Wiktor-Jedrzejczak et al., 1982).  
The components of the CSF-1R signalling axis are discussed below. 
 
1.2.1 The CSF-1R 
 
The CSF-1 receptor tyrosine kinase (CSF-1R, CD115 or Fms) is encoded by the c-
fms (Csf1r/CSF1R) proto-oncogene (Chihara et al., 2010; Pixley and Stanley, 2004; Sherr et 
al., 1985). It is located in the human chromosome 5, in the mouse chromosome 18 and in the 
canine chromosome 4 (Ensembl). There are two different promoters driving CSF-1R 
expression: the T/OC promoter controls expression in trophoblasts and osteoclasts; the M 
promoter, which is more proximal, controls CSF-1R production in macrophages. In the 
mouse, trophoblast transcripts are started 500 – 300 bp upstream of the start codon in exon 2; 
macrophage transcripts are initiated within 300 bp of the initiation codon. Strong expression 
requires a conserved enhancer element in intron 2, called Fms-intronic regulatory element 
(FIRE) (Stanley and Chitu, 2014).   
CSF-1R is a type III receptor tyrosine kinase, member of the platelet derived growth 
factor receptor (PDGFR) family (Yeung and Stanley, 2003). It possesses structural 
similarities to the PDGFR and c-Kit (Qiu et al., 1988). The c-fms was firstly identified as the 
human homologue of a feline sarcoma viral gene (v-fms) which is capable of cellular 
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transformation and oncogenesis through constitutive activation of the receptor kinase in the 
absence of the ligand (Heisterkamp et al., 1983; Mcdonough et al., 1971; Sherr et al., 1985). 
The feline c-fms and the v-fms differ in a carboxy-terminal truncation and two mutations in 
the dimerization region of the receptor (the feline amino acids L301S and A374S) (Stanley 
and Chitu, 2014). 
The structure of CSF-1R is as follows (Yeung and Stanley, 2003) (Figure 1.2): 
- Extracellular region – five immunoglobulin-like domains, highly glycosylated. 
Binding to the ligands occurs on the second and third extracellular domains, with 
prominence to the second domain. Receptor signalling following ligand contact is 
dependent on homo-dimerization of domain 4 (Stanley and Chitu, 2014); 
- Transmembrane region – amino acids 512-534 (murine), composing a hydrophobic 
region; 
- Intracellular region – a tyrosine kinase domain interrupted by an interkinase domain. 
ATP binding occurs within the N-terminal lobe and the hinge region. Substrate 




                                                   
 
 
Figure 1.2 – Structure of the CSF-1R. “Ig” indicates the immunoglobulin regions. “TM” indicates the 
transmembrane region. The N- and C- termini are indicated. Adapted from Yeung and Stanley, 2003.  
 
 
The receptor is expressed as an immature 130 kD glycoprotein which is transformed 
on its way to the cellular membrane by the addition of N-linked oligosaccharide chains; this 
increases the molecular weight of the receptor to 150 kD (Rettenmier et al., 1987). The CSF-
1R expression pattern within the mononuclear phagocytic system is shown in Figure 1.3. 
Other cell types outside the mononuclear phagocytic system are also CSF-1R
+
: oocytes, 
preimplantation embryos, decidual and trophoblastic cells, neural progenitor cells, renal 
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Figure 1.3 – CSF-1R expression by the cells of the mononuclear phagocytic system. The arrows 
indicate the course of cellular maturation. The larger semi-circular arrows indicate self-renewal of that 
cellular population. The number of crosses under each cell indicates the relative CSF-1R expression, 
from low (-/+) to high (+++). References: (MacDonald et al., 2005, 2010; Sasmono et al., 2003; 
Stanley and Chitu, 2014; Wong et al., 2011). 
 
 
Prior to contact with the ligands, CSF-1R is constantly undergoing rapid changes 
between monomer/dimer forms (Yeung and Stanley, 2003). The result of CSF-1R binding to 
its ligands is the stabilization of the dimer form (through non-covalent bonds) and 
subsequent rapid phosphorylation of CSF-1R and coupled intracellular proteins, which leads 
to the actual signalling process. Subsequently, the receptor undergoes endocytosis and 
lysosomal degradation (Figure 1.4). Consequently, lower surface expression of the CSF-1R 
is seen in cells that have been activated by the presence of the ligands (Sester et al., 1999; 
Yeung and Stanley, 2003). The coupled endocytosis and elimination of CSF-1R along with 
its ligand is a self-regulatory mechanism: a reduction in the concentration of either ligands or 
receptor increases the concentration of the other (Bartocci et al., 1987). It is not known if a 
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similar internalization of the receptors occur after binding of CSF-1R with the membrane 
isoform of CSF-1 (mCSF-1), which will be discussed below (Dai et al., 2004). 
 
 
Figure 1.4 – Schematic representation of the activation and degradation process for CSF-1R. The grey 
line represents the cellular membrane. The immunoglobulin domains of the CSF-1R extracellular 
region are represented by the rectangles. Ligand binding occurs in EC domains 2-3 and promotes 
receptor dimerization. This leads to Tyr559 phosphorylation in the intracellular region, receptor 
signalling and subsequent degradation of the complex. Adapted from Douglass et al., 2008.  
 
 
1.2.2 Intracellular signalling of CSF-1R 
 
Three stages are present during CSF-1 signalling: the first is the active signalling 
stage that occurs through auto-phosphorylation of the receptor and activation of coupled-
protein pathways after ligand binding; the second stage prepares the CSF-1/CSF-1R complex 
for endocytosis; the internalization of the receptor/ligand complex occurs in the third stage 
(Sester et al., 1999; Yeung and Stanley, 2003).  
In the inactive state, before ligand binding, the ATP-binding cleft of the tyrosine 
kinase domain is blocked due to the folding conformation of an activation loop, which, in its 
turn, is caused by the positioning of the juxtamembrane region. The amino acid Asp-796, 
necessary for magnesium coordination of ATP, is also in an “out” conformation. After ligand 
binding, the first residue to be phosphorylated is Tyr-561 in humans or Tyr-559 in mouse 
(Figures 1.4, above and Figure 1.5). From this point, the CSF-1R undergoes two waves of 
phosphorylation. In the first wave, the receptor forms complexes with Grb2/Sos and with 
SFK, Cbl, the regulatory subunit of PI-3 kinase (PI3K) (p85), Grb2, among others. Grb2/Sos 
dissociates and the second wave follows, which also leads to Cbl-dependent CSF-1R 
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ubiquitination. The receptor is internalized and is transported via endosomes to the 
lysosomal system, where CSF-1R and the ligand are degraded. Within the endosomes, the 
CSF-1R can still mediate signalling. The initial response following CSF-1R activation is 
cytoskeletal remodelling, followed by increased motility, chemotaxis and protein synthesis 
(Stanley and Chitu, 2014). 
The signalling pathways following CSF-1R activation and their biological 
consequences are represented in Figure 1.5. Downstream signalling pathways from CSF-1R 
are presented in Table 1.2. 
 
Table 1.2 – Downstream signalling pathways from CSF-1R involved with different cellular functions. 
References: (Caescu et al., 2015; Lee and States, 2006; Stanley and Chitu, 2014). 
Macrophage survival Cell proliferation Cell differentiation Chemotaxis 
PI3K/Akt pathway, activated by 
phosphorylation of Tyr 721 or 
indirectly by ceramide-1-
phosphate (C1P) or the 
Gab2/PI3K pathway. Effect in 
cell glycolysis. PI3K, ERK1/2 and 
NF-κB p65 induce microRNA-21 
(miRNA-21) and suppress 
miRNA-155. miRNA-21 provides 
a negative feedback on the 
activation of ERK1/2 and PI3K 
MEK, PI3K, SFK 
and C1P-induced 
production of 





Grb2/Sos assembly or 
PI3K activity. Adaptor 
proteins Mona and Gab3 
increase ERK1/2 
phosphorylation, but are 
not essential 
First wave of actin 
polymerization through 
GTPases, Cdc42, Rac, and 
Rho and their downstream 
effectors, Wiskott-Aldrich 
syndrome protein (WASP) 
and WASP-family verprolin 
homologous 2 (WAVE 2) 
actin nucleators. SFK 
activation of WASP is 
necessary for chemotaxis to 
CSF-1 
Phospholipase C (PLC) and 
Fms-interacting protein (FIMP) 
 
DAP12-mediated 
activation of Syk, 





PKC-δ leading to 
increased expression of 
PKA-related protein 
kinase (Pkare) 
Rac1/IRS p53 activation of 
the WAVE2/Abi complex in a 
second wave of actin 
polymerization 
  p46/52 Shc  































Figure 1.5 – Sites of tyrosine phosphorylation in the CSF-1R. (A) The biological consequences of 
phosphorylation of each tyrosine residue. (B) Pathway mediators at each tyrosine residue after 
phosphorylation. The intracellular region of CSF-1R is depicted under the horizontal grey line. The 
numbers inside the grey spheres indicate the sites of tyrosine phosphorylation in the mouse. Arrows 
indicate activation; T-shaped lines indicate inhibition. “ATP” indicates the ATP-binding site. 
“Kinase” indicates the major kinase domain. Reference: Stanley and Chitu, 2014.  
 
 
1.2.3 The CSF-1R ligands: CSF-1 and IL-34  
 
CSF-1R has two ligands, CSF-1 and IL-34, which are conserved across vertebrates 
(Chihara et al., 2010; Garceau et al., 2010). CSF-1 can be expressed as three different 
isoforms: either as a secreted 80 – 100 kD glycoprotein or a 130 – 160 kD proteoglycan, 
both found in the circulation, or as a 68 – 86 kD cell surface glycoprotein (csCSF-1 or 
mCSF-1). The secreted isoforms are disulphide-linked homodimers. Differential proteolysis 
from the full-length precursors in secretory vesicles yields the secreted isoforms: the 
glycoprotein by N-terminal cleavage and the proteoglycan by C-terminal cleavage. The latter 
form possesses a longer polypeptide chain and chondroitin sulphate glycosaminoglycan 
(GAG) attached (Droin and Solary, 2010; Stanley, 2000). All three isoforms are glycosylated 
with N- and O- linked carbohydrates. The biologically active portion is comprised of the first 
150 amino acids of the N-terminus of the protein (Dai et al., 2004; Stanley, 2000).  
Different isoforms of CSF-1 have differences in action, even though these are 
overlapping, and are regulated differentially within tissues. Expression of the membrane-
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bound isoform alone is not enough to perform all roles of CSF-1, and developmental defects 
arise if it is the sole form present. Not all of the roles of mCSF-1 are known, neither are its 
dynamics after activation of cells (Dai et al., 2004; Nandi et al., 2006). The secreted isoforms 
of CSF-1 rescue the effects of CSF-1 knockout more efficiently than mCSF-1 does, and of 
the two secreted forms, the proteoglycan is more effective at restoring normal functions. 
Therefore, it seems that the chondroitin sulphate chain which is present on the proteoglycan 
isoform is important for CSF-1 localization and/or signalling (Nandi et al., 2006). 
Interleukin-34 (IL-34) is a homodimeric secreted glycoprotein. IL-34 has no obvious 
sequence homologies to CSF-1, although there are structural similarities. Both ligands have 
four cytokine folds and form self-dimers (Droin and Solary, 2010). Unlike CSF-1, IL-34 is 
capable of binding to another receptor, receptor-type protein tyrosine phosphatase-ζ (PTP-ζ). 
This receptor is expressed by neural progenitors and glial cells. IL-34 binding to this receptor 
induces tyrosine phosphorylation of downstream effectors, leading to inhibition of cellular 
proliferation and motility (Nandi et al., 2013). 
CSF-1 and IL-34 have different spatiotemporal expression patterns. CSF-1 mRNA is 
produced by the uterus during pregnancy between the murine embryonic days 8.5 and 11.5. 
IL-34 is not increased during this stage. Mouse embryos have high mRNA levels of CSF-1 
during development days 11.5 and 13.5, while IL-34 levels are increased between 8.5 and 
17.5 days. Within the embryo, IL-34 mRNA is most apparent in the telencephalon of E11.5 
embryos. CSF-1 appears at day 13.5 in several other areas of the embryo. In adult brain and 
ear, IL-34 mRNA is more present than CSF-1. Keratinocytes and neurons are the main 
sources of IL-34, but the cytokine is also highly produced by proximal renal tubule cells and 
seminiferous tubule germ cells (Y. Wang et al., 2012; Wei et al., 2010). Another group stated 
that IL-34 mRNA is mainly present in the spleen (Lin et al., 2008). Osteoblasts and the adult 
heart preferentially produce CSF-1 over IL-34; other mesenchymal cells that also produce 
CSF-1 include fibroblasts, bone marrow stromal cells, keratinocytes, astrocytes, liver 
parenchymal cells, among others. Secreted isoforms of CSF-1 are thought to be produced by 
endothelial cells (Nandi et al., 2006; Pixley and Stanley, 2004; Stanley, 2000; Wei et al., 
2010).  
In mice, a natural mutation of the Csf1 gene, designated osteopetrotic mutation 




) can both cause a substantial 
reduction in the number of mononuclear phagocytes in most tissues (Dai, 2002; Wiktor-
Jedrzejczak et al., 1982). Removal of CSF-1 in the op/op mouse can be partially 




 animal has a 
stronger phenotype than the op/op knockout (Droin and Solary, 2010). However, IL-34 
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mRNA is not increased to compensate the absence of CSF-1 in the op/op mouse (Wei et al., 
2010). 
 
1.2.4 Consequences of CSF-1R signalling in the mononuclear 
phagocytes 
 
CSF-1 and IL-34 have multiple functions. These cytokines have a major role in the 
stimulation of the survival, proliferation and differentiation from the myeloid precursor of 
the mononuclear phagocytes (Hume, 2008; Pixley and Stanley, 2004).  
IL-34 and CSF-1 share the same receptor, but the signalling activated and their 
biological activities are not identical. Even though they are both capable of supporting cell 
growth in culture systems, they do not elicit the same responses. IL-34 induces a stronger but 
transient tyrosine phosphorylation of CSF-1R, and rapidly down regulates the presence of 
the receptor on the cell surface (Ma et al., 2012). Both ligands stimulate the transcription of a 
similar set of genes, but IL-34 drives an attenuated transcription pattern of some genes. Both 
ligands repress CCR2 transcription, for instance, but IL-34 does so more mildly (Barve et al., 
2013).  
Although both ligands bind to the extracellular domains 2 and 3 of the CSF-1R, 
conformation adaptations occur on the receptor when binding either ligand, explaining the 
capacity of the receptor of interacting with both. The receptor contact points also differ 
between the two ligands. Nevertheless, after binding to the receptor, both ligands drive 
receptor dimerization (Ma et al., 2012). Confirming this difference in binding sites, a 
monoclonal antibody (mAb) was identified that is able to block the binding of both CSF-1 
and IL-34 to CSF-1R, but a second mAb was able to block only the CSF-1/CSF-1R 
interaction, but not that of IL-34 with the receptor (Chihara et al., 2010).  
The roles of CSF-1R signalling throughout the mononuclear phagocytic system are 
detailed below, separated by each of its cellular components. 
Myeloid precursors: These cells respond to CSF-1 signalling (MacDonald et al., 
2005). CSF-1 does not seem to be exclusively required for monopoiesis, since blocking the 
growth factor or its receptor does not reduce total monocyte counts. CSF-1 is important for 
the maintenance of steady-state mature (Ly6C
-
) monocytes, but can be substituted by GM-
CSF for earlier cell precursors (that is, from the myeloid precursors to the Ly6C
+
 cells) 
(Louis et al., 2015).  
Monocytes: Signalling through CSF-1 is required for the proliferation and 
differentiation of monocytes only after the Ly6C
- 
stage of development is reached. This is 
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confirmed by the CSF-1 and CSF-1R-deficient mice, which have only partial reduction in 
monocyte counts (Louis et al., 2015). After maturation, even prolonged CSF-1R blockade 
has only moderate effects over the monocytes, depleting exclusively the Ly6C
-
 monocytes 
(Sauter et al., 2014). CD16
+
 cells, which are the human nonclassical monocyte counterparts 
of the murine Ly6C
-
, express more CSF-1R than CD16
-
. Together with CSF-1R, CD16
+
 
monocytes transcribe a macrophage/dendritic cell set of genes (Ancuta et al., 2009).  
Although monocytopoiesis and classical monocyte survival is not dependent on 
CSF-1R, administration of CSF-1 increases blood monocytes (Stanley, 2000). CSF-1 is also 
important in determining the fate of monocytes. Monocytes that are cultured with CSF-1 and 
interleukin-4 (IL-4) differentiate into macrophages (CD14
+
), while cells kept with GM-CSF 
and IL-4 turn into dendritic cells (CD1a
+
) (Witmer-Pack et al., 1993). 
Macrophages: The dependence of macrophages on CSF-1R for maturation is 
variable across diverse tissues. Resident macrophages in the steady-state can be divided with 
regard to their CSF-1 dependence during development and after maturity (Table 1.3) 
(Stanley, 2000). Therefore, blocking CSF-1R does not reduce macrophage numbers within 
some tissues. In the blood and bone marrow, for instance, only the more mature LyC6
-
 
macrophages are affected by blocking the CSF-1R, as already discussed, whereas liver 
macrophages are readily depleted (Louis et al., 2015; MacDonald et al., 2010).  
Kupffer cells, the liver resident mononuclear phagocytes, are among the most CSF-
1-dependent cells (Wiktor-Jedrzejczak et al., 1994). Osteopetrotic mice respond with 
increasing numbers of Kupffer cells after a single injection of CSF-1, and normal levels are 
almost restored when CSF-1 is given on a daily basis (Yamamoto et al., 2008). Kupffer cells 
are also completely removed by prolonged CSF-1R blockade even after maturity (Sauter et 
al., 2014).  
Langerhans cells and microglia are absent from CSF-1R- but not from CSF-1-
deficient mice; IL-34 produced by keratinocytes and neurons directs the differentiation of the 
resident dendritic cells of the skin and central nervous system (Wang et al., 2012). In the 
microglia, CSF-1 is considered a key regulator of inflammatory responses, increasing brain 
injury due to neurotoxicity, but also improving clearance of abnormal protein aggregates 
since phagocytic activity is enhanced. Apparently in the glia CSF-1 signalling has an 
autocrine pathway (Chitu and Stanley, 2006). 
Administration of CSF-1 increases tissue macrophage numbers, but some tissue 
populations do not require circulating CSF-1, such as peritoneal and alveolar macrophages 
(Stanley, 2000). Nevertheless, these populations are depleted if the CSF-1R is blocked 
(Louis et al., 2015), indicating that they may rely on IL-34 production (Wang et al., 2012). 
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IL-34 is less active than CSF-1 in inducing macrophage proliferation. Either ligand is 
sufficient, however, to sustain tissue macrophage numbers (Wei et al., 2010).  
Other cytokines such as IL-4 and GM-CSF can replace or complement the CSF-1 
signal for stimulating resident tissue macrophages. IL-4 is capable of inducing tissue resident 
macrophage proliferation independently from CSF-1, but this cytokine is not able to recruit 
peripheral macrophages, a function which requires CSF-1R signalling (Jenkins et al., 2013). 
Alveolar macrophages are present at reduced levels in young op/op mice, but were found to 
be normal in the adult mice. This correction after maturity is thought to occur due to 
increased production of IL-3 (Shibata et al., 2001b). 
 
Table 1.3 – CSF-1R dependence of macrophage populations in the steady-state during development 
and after maturity. Adapted from Stanley, 2000. Other references: (Louis et al., 2015; MacDonald et 
al., 2010; Sauter et al., 2014; Y. Wang et al., 2012). 
a
Depending on which tissue population is 
considered. 
b
Depending on the methodology used to assess. 
 




Kidney Complete Complete 
Lymph node subcap. sinus CD11b
+
 Complete  




Peritoneal cavity Complete Complete 
Pleural cavity Complete Complete 
Retina Complete Complete 
Spleen metallophils Complete Complete 
Synovium Complete None 
Tendon Complete None 
Testis Complete Complete 








Liver Partial Complete 
Lung alveolar macrophage Partial  
Osteoclast Partial Complete 
Salivary gland Partial Partial 




Uterus Partial None 
Bone marrow `monocyte' Independent None 
Langerhans/microglia Independent None 
Lymph node Independent None 
Thymus Independent None 
 
 
GM-CSF and CSF-1 are usually seen as opposing cytokines in the development of 
the mononuclear phagocytic system. CSF-1-conditioned macrophages in the steady-state 
show less inflammatory characteristics, decreasing lymphocyte activation, performing 
angiogenesis and tissue repair. GM-CSF macrophages, in contrast, are pro-inflammatory, 
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with increased CD80, CD86 and MHC II when compared to CSF-1 macrophages. GM-CSF-
derived macrophages are also more stellate and have more organelles than the CSF-1-
cultured counterparts. GM-CSF can also overrule the CSF-1R signal to drive the formation 
of inflammatory macrophages. The maintenance of cells with GM-CSF induces a reduction 
in the expression of CSF-1R mRNA (Droin and Solary, 2010; Gliniak and Rohrschneider, 
1990; Rey-Giraud et al., 2012; Sester et al., 1999; Willman et al., 1989; Yeung and Stanley, 
2003).  
Hence, in many circumstances, CSF-1R signalling leads to reduced inflammatory 
responses in vivo; CSF-1R signalling leads to persistence of HIV infection in the brain by 
driving an anti-inflammatory phenotype (Gerngross and Fischer, 2014; Gerngross et al., 
2015), and CSF-1 has also been shown to reduce LPS responses in macrophages through 
modulation of Activin A (Sierra-Filardi et al., 2014, 2011). While CSF-1 can increase 
macrophage activation and the innate response, it is immunosuppressive for antigen-specific 
responses, and CSF-1 expression is inducible in T cells upon activation, which may serve as 
a negative feedback (Sweet and Hume, 2003).  
CSF-1R can also be a promoter of inflammation. Some cell-surface molecules, such 
as CD16 and CD14, are expressed preferentially after LPS stimulation in CSF-1-conditioned 
macrophages when compared to GM-CSF (Droin and Solary, 2010). Cells that are 
maintained in CSF-1 medium express higher levels of IL-1α, an inflammatory cytokine 
(Witsell, 1991). CSF-1 enhances cytotoxicity, superoxide production, phagocytosis, 
chemotaxis and cytokine production in monocytes and macrophages. This factor has 
pronounced effects on macrophage motility. It enhances phagocytic and microbial action 
against several pathogens in vivo (Sweet and Hume, 2003). CSF-1 is important for the 
accumulation of inflammatory macrophages, but is not needed for their local proliferation. 
Blocking CSF-1R with an antibody reduces the number of recruited macrophages in 
peritonitis and lung inflammation models (Louis et al., 2015). However, this effect may be 
antibody-dependent, since another blocking mAb which also reduced resident macrophage 
populations had no effect in inflammatory macrophage recruitment, including in peritoneum, 
lung, in wound healing and in graft-versus-host disease (MacDonald et al., 2010). 
The molecular interactions in inflammation are complex. Signalling through CSF-1R 
induces loss of macrophage surface expression of Toll-like receptor 1 (TLR1), TLR2, TLR6 
and TLR9, has no effect on TLR4 but increases expression of CD14, one of the subunits of 
TLR4. TLR signalling also has the same effect on CSF-1 receptor, that is, it down-regulates 
membrane expression of CSF-1R (Chitu and Stanley, 2006; Sweet et al., 2002). Therefore, 
CSF-1R reduces the response to CpG DNA, which is dependent on TLR9 (Chitu and 
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Stanley, 2006; Sweet et al., 2002). Although it does not affect the expression of TLR4, CSF-
1R enhances LPS responses possibly by inducing autocrine stimulation of macrophages 
through GM-CSF (Conway et al., 2005). Some of the interactions in inflammation between 




Figure 1.6 – The interactions between CSF-1R and GM-CSFR signals in relation to inflammation 
(represented by the TLR receptor). Arrows indicate stimulation and T-shaped lines indicate repression 
of a pathway (not necessarily of the receptor). The mechanisms of interaction are cited with each line. 
References: (Droin and Solary, 2010; Saccani et al., 2006; Sierra-Filardi et al., 2014; Sweet and 
Hume, 2003; Yasukawa et al., 2003). 
 
 
Osteoclasts: Either CSF-1 or IL-34 is required to induce osteoclast formation, in 
association with RANKL (Wei et al., 2010). These cells are dependent on CSF-1R signalling 
even after maturity, since receptor blockade depletes these cells (Sauter et al., 2014). The 
osteopetrotic (op/op) mutation leads to a depletion of functional osteoclasts, which are the 
primary cells involved in bone reabsorption, giving the mutation its name; since the number 
of bone resorbing cells is diminished in this mutation, bones present reduced marrow 
cavities. Tooth eruption is also impaired in op/op animals once this event requires resorption 
of alveolar bone during embryogenesis and soon after birth (Marks and Lane, 1976; Yoshino 
et al., 2003).  
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Dendritic cells: The effect of CSF-1R signalling on dendritic cell development and 
function is still debated. Apparently not all dendritic cells express CSF-1R, such as CD4
+
 
dendritic cells (that could either be immature/precursor cells or dendritic cells of lymphoid 
origin) and other precursor populations that occur in the peripheral blood (Hume et al., 2002; 
MacDonald et al., 2005). Nevertheless, CSF-1-deficient mice have reductions of 50 – 70 % 
of all dendritic cells (MacDonald et al., 2005).  
Until the late cellular maturation state, it is possible that some macrophages and 
dendritic cell subtypes are interconvertible depending on the cytokine microenvironment 
(Palucka et al., 1998). Therefore, dendritic cell numbers are also dependent on macrophages. 
Monocyte stimulation with GM-CSF alone is believed to induce dendritic cell phenotypes, 
while co-stimulation with GM-CSF and CSF-1 leads to a macrophage-like population (Droin 
and Solary, 2010). It has also been highlighted that monocyte stimulation with GM-CSF 
alone produces inflammatory macrophages and that IL-4 is necessary to produce monocyte-
derived dendritic cells (Holla et al., 2014). In the absence of GM-CSF, CSF-1 and IL-4 can 
drive the differentiation of mature tolerogenic dendritic cells, and CSF-1 can suppress 
antigen presentation by dendritic cells through increased MHC II turnover (Chitu and 
Stanley, 2006). After dendritic cell activation, loss of CSF-1R expression is seen as a marker 
of commitment of the dendritic cells to the antigen-presenting phenotype (Sester et al., 
1999). Only CSF-1R
+
 dendritic cells are capable of taking up antigens, indicating a less 
mature phenotype (Chitu and Stanley, 2006).  
After full maturation, it seems that GM-CSF is the essential factor for dendritic cell 
viability and function (Witmer-Pack et al., 1993), and this cytokine is usually held as the 
classical dendritic cell stimulus (van de Laar et al., 2012). Among the dendritic cell 
phenotypes, monocyte-derived dendritic cells appear to be the most sensitive to GM-CSF 
stimulation (Louis et al., 2015).  
 
1.2.5 Pleiotropic effects of CSF-1R signalling  
 




mice are viable, the importance of 
the CSF-1-dependent macrophages is indicated by the incapacity of the mutants to develop. 
Apart from having a crucial role in the immune system, macrophages are important for 
normal embryonic development and homeostasis (Hume, 2008; Hume et al., 2002). 
Deficiencies in CSF-1R signalling are evident in the development of the central nervous 
system (aberrant development of the sex-steroid-hormone feedback response), pancreas 
(delayed and aberrant morphogenesis), mammary glands (impaired branching 
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morphogenesis), in weight gain and in the reproductive functions of both sexes. Severe 
lymphopenia is also seen, as well as an expected monocytopenia, reduced counts of 
microglia, with a ten-fold decrease in the number of marrow cells (Hume et al., 2002; Kondo 
et al., 2007; Marks and Lane, 1976; Pollard, 2004; Wiktor-Jedrzejczak et al., 1982). It is 
noteworthy that CSF-1 also exerts profound effects on pluripotent cell recruitment and 
differentiation in many tissues (Levine et al., 1998). 
In the reproductive system, CSF-1 is an important paracrine factor for normal 
development. Its receptor may be important for steroid-regulated epithelial maturation (Ide et 
al., 2002). CSF-1 regulates cells of the trophoblast and other cells in the female reproductive 
tract via interaction with macrophages. Macrophages in the ovary are needed for correct 
ovulation rates due to effects in gonadotropin responsiveness and steroidogenesis (Stanley, 
2000).   
CSF-1R is essential for embryonic implantation in the endometrial epithelium 
(Stanley, 2000). CSF-1R mRNA is generally increased in the uterus, embryo and placenta 
between the murine embryonic days 8.5 and 17.5, while CSF-1 mRNA is highly present in 
the uterus on days 11.5 to 17.5, as explained above (Wei et al., 2010). In the pregnant uterus, 
CSF-1 is even further upregulated, up to 1000-fold. It is suspected that CSF-1 may 
contribute to maternal tolerance to the fetus through its capacity of controlling T-cell 
activation (Sweet and Hume, 2003). 
Levels of CSF-1 are also highly upregulated in lactating epithelial cells, and its 
receptor, which is not expressed in the nonlactating human breast, begins to be expressed by 
the last trimester of pregnancy. CSF-1 and its receptor can have their expression increased by 
several times through stimulation with steroid hormones. CSF-1R may contribute to ductal 
and alveolar development, milk production and remodelling of breast tissue during 
pregnancy and lactation (Sapi, 2004; Yeung and Stanley, 2003).  
Adipocytes also express CSF-1 and are in close contact with macrophages in the 
adipose tissue. CSF-1 is upregulated in rapidly growing adipose tissues when it is associated 
with inflammation or even if it is a consequence of overfeeding. The presence of CSF-1 in 
adipose tissues is down-regulated by the tumour necrosis factor-α (TNF-α). These 
relationships may be responsible for the weight gain deficiency seen in CSF-1R/CSF-1 
knockouts (Levine et al., 1998; Nandi et al., 2006). It has been reported that macrophages 
can produce insulin-like growth factor (IGF)-1 in response to CSF-1 stimulation, being the 
major extra-hepatic source of this growth factor and also probably regulating its production 
by the liver. IGF-1 is regulated by the growth hormone (GH), and negatively feedbacks the 
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production of GH. It is believed that CSF-1 might interact with the IGF-1/GH axis, and so 
contribute to the control of postnatal growth and organ maturation (Gow et al., 2010). 
Macrophage deficit within the pancreas during maturation is correlated to reduced 
insulin production throughout development and maturation, coupled with abnormal β-cell 
islet morphogenesis. This is probably due to the reduced clearance of apoptotic cells in the 
absence of macrophages and also with the contribution from macrophages in tissue 
remodelling and adaptation (Banaei-Bouchareb et al., 2004).  
In the small intestine, local production of the membrane form of CSF-1 is important 
for the regulation of Paneth cells. These cells are components of the innate immune system 
and are CSF-1R
+
. Although CSF-1R is not expressed by cells of the intestinal crypts, the 
Paneth cells are physically close to the crypt, and CSF-1-defective animals have reduced 
crypt proliferation and villi sizes in consequence. The Paneth cells are important for the 
intestinal stem cell niche, and in their absence the cellular renovation in the intestine is 
affected (Akcora et al., 2013; Huynh et al., 2009). 
Most of the phenotypic defects seen in the Csf1 op/op mice, including the 
reproductive deficiencies and the disturbances in the development of organs, are seen with 




mouse (Conway et al., 2008; Dai, 2002; Wiktor-
Jedrzejczak et al., 1982). Because of the severe pleiotropic effects of the mutations over the 
Csf1 and Csf1r genes on the normal development, the mutant animals cannot clarify about 
the physiologic role of signalling through the CSF-1R in the adult animal (Dai, 2002), and 
this has to be studied by blocking the receptor with antibodies (Sauter et al., 2014).  
Inhibition of the CSF-1R with mAbs demonstrates that the effects of the receptor in 
many tissues, including in the reproductive tract, are more important over the developmental 
period than after maturity. CSF-1 and CSF-1R-knockouts have severe defects in the 
reproductive system due to extensive removal of tissue macrophages. These resident 
macrophages are in intimate association with Leydig cells in the testes, for instance, and may 
have a role in steroidogenesis. Accordingly, the knockouts have reduced testosterone levels 
and low sperm counts. Equally, in the ovary macrophages assist in the regulation of the 
reproductive cycle (Stanley, 2000). However, prolonged treatment with an anti-CSF-1R in 
adult animals does not remove macrophages from the uterus, for instance, and although it 
depletes interstitial macrophages of the testes, it does not affect testosterone and LH 
production. In the intestine, although mAb treatment removes Paneth cells, it is not 
correlated with reduced growth of the villi, as occurs with CSF-1/CSF-1R knockouts. 
Overall, no toxicity arises from blocking CSF-1R in adult animals in the steady-state (Sauter 
et al., 2014). 
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Normal microglia require a functional CSF-1R to provide full cerebral development 
during embryogenesis, at birth and beyond weaning. The loss of CSF-1R causes cerebral 
architectural perturbations, leading to a defect in the olfactory sense, for instance, and slow 
response to external stimuli (Erblich et al., 2011). Dominant inactivating mutations in the 
CSF-1R leads to adult-onset leukoencephalopathy with axonal spheroids and pigmented glia 
(Stanley and Chitu, 2014). CSF-1R and its ligands are expressed as early as day 11.5 in the 
brain of murine embryos, as cited before (Wei et al., 2010).  
However, CSF-1R is also expressed in a small variety of cells outside the 
mononuclear phagocytic system, and can modulate these cells directly, even after maturity. 
Some neurons in the hippocampus and cortex express CSF-1R in the steady-state condition, 
but the receptor is also upregulated in the neurons after injury. The receptor is believed to be 
relevant in the protection of neurons against injury and neurodegeneration (Luo et al., 2013). 
The prostate is another such example of the direct effects of CSF-1R without intermediation 
by the mononuclear phagocytes. In the prostate epithelium, CSF-1R is expressed during the 
prepubertal androgen-driven expansion of the gland, declining in older animals (Ide et al., 
2002). However, the expression of CSF-1R by neurons or other cells outside the 
mononuclear phagocytic system and the trophoblast is contested (Sauter et al., 2014).  
The relative importance of CSF-1R signalling in tissue development and in maturity 
is summarized in Table 1.4. 
 
Table 1.4 – The importance of CSF-1R signalling during development and after maturity for the 
function or phenotype of tissues outside the mononuclear phagocytic system. The relative importance 
of the signalling axis is shown by the “+”, “+/-” or “-” signs. N/A, not applicable. References: 
(MacDonald et al., 2010; Sauter et al., 2014; Stanley, 2000). 
 
Tissue Development Maturity 
Prostate + - 
Testes + - 
Gut + +/- 
Liver + +/- 
Kidney + - 
Ovary + - 
Muscle  - 
Uterus  - 
Placenta - N/A 
Mammary glands +  
Brain + - (+ inflammation) 
Pancreas + - 
Auditory/visual +  
Tooth eruption + N/A 
Weight gain + - 
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1.3 CSF-1R in inflammatory diseases and cancer 
 
Excessive CSF-1R signalling can lead to several diseases, in many of which the 
disease occurs as a consequence of prolonged activation of mononuclear phagocytes. This 
can be illustrated by the fact that local autocrine production of CSF-1 in CSF-1R-bearing 
cells, driven by a transgene, leads to an aggressive inflammatory phenotype with 
osteoporosis followed by an increase in tissue macrophages (Wei et al., 2006). Several 
diseases are correlated with such a pathogenic mechanism following CSF-1R activation. 
Paget’s disease is associated with variants of CSF1 which increase the expression of 
that cytokine, lead to bone remodelling, pain and osteoarthritis through excessive osteoclast 
function (Albagha et al., 2010). CSF-1 and CSF-1R are also correlated to inflammation-
dependent diseases, such as atherosclerosis, for instance, in which macrophages play an 
important role (Murayama et al., 1999), autoimmune diseases (e.g. lupus) and rheumatoid 
arthritis (Chitu and Stanley, 2006). Presence of macrophages has also been connected to 
adipose tissue hyperplasia and obesity; adipocytes are CSF-1 producers (Levine et al., 1998; 
Weisberg et al., 2003). 
The retroviral oncogene v-fms, present in the McDonough strain of feline sarcoma 
virus, induces fibrosarcoma growth in domestic cats (Mcdonough et al., 1971). This gene 
was found to share extensive similarities with c-fms, which codes the CSF-1R. The viral and 
cellular genes differ by 11 amino acids in the C-terminus, and these mutations in the v-fms 
drive constitutive activation, without the need for the receptor ligand (Coussens et al., 1986; 
Sherr et al., 1985; Wheeler et al., 1986). The finding that the v-fms product could drive 
oncogenesis motivated research on the potential of CSF-1R to also promote cancer formation 
(Roussel et al., 1987). Even though several differences exist between the cellular and the 
oncogenic forms of fms, overexpression of normal c-fms is sufficient to induce a transformed 
phenotype. Transfection of mammary carcinoma cells with wild-type CSF1R confers 
invasive and tumorigenic potential and CSF1 enhances ovarian cancer tumourigenesis and 
metastasis (Kluger et al., 2004; Sapi, 2004; Toy et al., 2009).  
Some tumours show increased CSF-1 or CSF-1R expression due to mutations of the 
respective genes or their regulatory elements. A few haematological conditions are derived 
from these mechanisms. Chromosomal translocation combining the N-terminus of RNA-
binding motif-6 and the C-terminus of CSF-1R can drive megakaryoblastic leukemia, which 
is characterized by growth of clonal hematopoietic progenitor cells (Gu et al., 2007). 
Mutations in proteins related to CSF-1R transcription factors lead to overexpression of the 
receptor, and are important in maintaining stem cells that generate and sustain acute myeloid 
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leukemia (Aikawa et al., 2010). B-cell-derived Hodgkin’s lymphoma and anaplastic large 
cell lymphoma aberrantly express the CSF-1R due to loss of expression of a repressor, 
CBFA2T3 (Lamprecht et al., 2010). 
However, a number of cancers outside the haematological system are also associated 
with CSF-1R or CSF-1 expression. CSF-1 is suggested to be a valuable biomarker for a great 
number of cancers, including pancreatic, colorectal, breast and ovarian cancers, and 
generally predicts prognosis more effectively than other commonly used biomarkers. Higher 
expression of CSF-1 or of its receptor is associated with worse outcomes, but in many cases 
it is not yet certain if high levels of this factor are the cause or the effect of neoplasia 
(Douglass et al., 2008; Khatami, 2007). The role of CSF-1 in cancer progression is best 
demonstrated by the fact that op/op mice have a 60 % reduction in malignant transformation 
when compared to normal mice, having much reduced mitotic index in carcinomas (Nowicki 
et al., 1996). 
In some tumours, high CSF-1 or CSF-1R expression is due to increased cancer cell 
production of these proteins. CSF-1R and CSF-1 can be associated with tumour growth via 
autocrine or paracrine pathways, therefore not requiring mutations in the receptor to elicit 
continuous signalling (Kluger, 2004; Lin et al., 2001; Patsialou et al., 2009). In mammary 
cells and in mammary cancers, CSF-1R and CSF-1 expression can be driven by lactogenic 
hormones, such as insulin, prolactin and glucocorticoids. Prolactin and glucocorticoids are 
linked to mammary tumours, presenting a possible explanation for the frequent increase of 
CSF-1R and CSF-1 in those cancers. In the lactating human breast, interestingly, the levels 
of CSF-1 and of its receptor are comparable with the levels observed in carcinomas 
(Chambers, 2009; Sapi, 2004).  
Examples of other tumour types in which the cancer cells express CSF-1R include 
prostatic, ovarian, lung, endometrial and trophoblastic cancers. In these cases, there is no or 
little expression of CSF-1R/CSF-1 in normal tissues, and these proteins are upregulated in 
malignancies. In prostatic cancers the overexpression of CSF-1 is such that there is a 
propensity to produce bone metastases with extensive bone resorption, likely due to 
osteoclast activation. In this type of cancer, CSF-1R is important for the survival of tumour-
initiating cells (Bauknecht et al., 1993; Chambers, 2009; Ide et al., 2002).  
The mechanisms driving CSF-1R/CSF-1 expression in non-haematological tumours 
are likely to be variable. A small cellular subpopulation within tenosynovial giant cell 
tumours (TGCT) and also within pigmented villonodular synovitis (PVNS) have a 
translocation resulting in fusion of COL6A3 and CSF1 genes, generating high levels of CSF-
1. The remaining cells of the tumour do not produce CSF-1, but do express its receptor, 
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stimulating the growth of the tumour mass (Cassier et al., 2014; Cupp et al., 2007; West et 
al., 2006). In renal clear cell carcinomas there are increased copies of the chromosomal 
CSF1R, offering an explanation for the increase of CSF-1R in that malignancy (Soares, 
2007). Gene regulation of CSF-1 and CSF-1R production in cancers is also likely to occur 
post-transcriptionally, where microRNAs (miRNAs) are known to play a role. In 
chemotherapy-resistant ovary cancer cells, several miRNA are downregulated, and in the 
case of miR-130a, this leads to increased production of CSF-1 (Chambers, 2009; Sorrentino 
et al., 2008). In ovarian cancer CSF1 transcripts also have prolonged stability with an 
extended half-life (Chambers and Kacinski, 1994). The increased levels of CSF1 transcripts 
in ovarian cancer lead to higher CSF-1 protein expression (Ramakrishnan et al., 1989). 
GAPDH is a RNA-binding protein that is upregulated in several ovarian cancer specimens. It 
has been shown to stabilize the mRNA of CSF-1 (Chambers, 2009). HuR, also an RNA-
binding protein, increases the expression of CSF-1R in breast cancer cells. HuR is necessary 
for glucocorticoid-induced CSF-1R overexpression by these cells (Woo et al., 2009). 
Accordingly, HuR expression is linked with metastasis and reduced survival (Chambers, 
2009). 
The phosphorylation pattern following CSF-1R activation varies in epithelial cells 
when compared to macrophages, indicating that the signal may be different between these 
cells (Kacinski, 1997; Welsch and Nagasawa, 1977). In breast carcinoma, the 
phosphorylation of Tyr809 in the CSF-1R kinase domain is associated with local 
invasiveness, while phosphorylation of Tyr723 leads to metastatic potential in both breast 
and ovary carcinomas (Toy et al., 2001). Following receptor phosphorylation, ERK1/2 is 
activated in breast cancer cells, leading to cell proliferation (Morandi et al., 2011). In these 
cells, CSF-1R can also be located in the nucleus, where it binds to the promoters of the 
proliferation-related genes CCND1, c-JUN, c-MYC and also to the promoter of CSF1, 
inducing its overexpression (Barbetti et al., 2014). 
Despite the roles that CSF-1R signalling has in inducing tumour growth by direct 
activation of receptors on the cancer cells, CSF-1R also has another important role in 
promoting cancer. Clinical data and experimental studies have determined the pro-
tumorigenic and metastatic potential of tumour-associated macrophages (TAMs), for which 
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1.4 Tumour-associated macrophages (TAMs) 
 
Cancer malignancy is determined by a progressive acquisition of characteristics that 
enable continuous tumour growth. Some of the traits that lead to such a phenotype are self-
sufficiency from external stimuli, resistance to apoptosis and to obstructive signals, evasion 
from immunity, neoangiogenesis to support growth, the capacity to invade surrounding 
tissues and to metastasize (Laoui et al., 2014). Monocyte and macrophage infiltration occurs 
throughout the development of a tumour, from early stage nodules to late-stage metastatic 
cancers. Thus, solid tumours contain a significant population of infiltrating myeloid cells. 
Migration of leucocytes into tumours was first interpreted as evidence of an immunological 
response of the host against the tumour. However, most cancers have been found to be non-
immunogenic, and even further, tumours incite macrophages to participate in every process 
implicated with cancer progression (Lewis and Pollard, 2006; Ohno et al., 2004).  
 
1.4.1 Entry of TAMs and their initial steps – neovascularization 
 
The production of inflammatory factors (cytokines, prostaglandins, among others) 
associated with tumour growth creates a microenvironment that is responsible for recruiting 
and activating leukocytes, particularly the cells of the myelomonocytic lineage. The 
angiogenic vascular endothelial growth factor (VEGF), produced by cancer cells, is also 
responsible for increased chemo-attraction of monocytes, both towards primary tumours and 
metastatic foci. However, macrophage infiltration can be independent of the local presence 
of neoangiogenesis. Foreign macrophages are derived from blood monocytes and can be 
recruited to the tumour site by the ‘CC’ chemokines CCL2, CCL3-5, CCL8, by VEGF, by 
stromal-derived factor-1 (SDF-1) and by CSF-1 (Sica et al., 2006; Wang et al., 2012). CSF-
1-deficient mice have impaired tumour vascularization, denoting the importance of this 
cytokine in this context (Nowicki et al., 1996).  
TAMs are correlated with high vascular grades in many tumour types, and 
macrophage infiltration precedes vigorous angiogenesis (Lin et al., 2006). Macrophages 
induce the production of angiogenic factors as an adaptation response to the hypoxia in the 
tumour environment. Hypoxic areas of the tumours appear when the cell mass outgrows 
neoangiogenesis. Rapid tumour growth leads to areas of low vascular supply and attraction 
of TAMs due to the necrotic debris emanating from these areas; TAMs are debris-
scavengers. Therefore, spots of low pH and higher lactate concentrations stimulate 
proangiogenic gene expression in TAMs. Hypoxia induces the expression of hypoxia-
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inducible factors (HIF-1 and HIF-2) in TAMs, which in their turn drive upregulation of 
genes encoding angiogenic proteins (Doedens et al., 2010; Lewis and Murdoch, 2005; 
Ramanathan et al., 2007).  
These newly arrived leukocytes promote, therefore, further angiogenesis. Blood 
vessels produced in the absence of macrophages are fragile and not fully formed. 
Macrophages stabilize and physically participate in the endothelial lining of new vessels. 
Monocytes and macrophages can show endothelial and myofibroblast phenotypes and allow 
the formation of vessels that withstand higher shear forces (Ito and Khmelevski, 2003; Jabs 
et al., 2005; Okazaki et al., 2005; Pujol et al., 2000; Saba, 1970; Schmeisser et al., 2001). 
The production of new blood vessels by macrophages can rely on or be independent of 
VEGF. In women with endometriosis, macrophages are capable of eliciting further 
endothelial cell proliferation through VEGF. Macrophages can be sensitive to oestrogen and 
progesterone signalling to enhance the production of VEGF in these patients (McLaren et al., 
1996). Other pro-angiogenic factors produced by macrophages include angiopoietins (Ang1 
and Ang2), CCL2, thymidine phosphorylase, CXCL8 and COX-2. Interestingly, TAMs that 
express the angiopoietin receptor Tie2 are more aggressive modulators of tumour behaviour 
than Tie2
-
 TAMs (Sica et al., 2012). The expression of MMP may also support angiogenesis 
by stimulating endothelial cell proliferation and migration (Lewis and Pollard, 2006; 
Polverini and Leibovich, 1984). siRNA targeted to CSF-1 or CSF-1R reduces human 
mammary cancer xenografts in mice through a reduction of recruitment of macrophages to 
tumours and down-regulation of MMP-2 and MMP-12. In this siRNA model, CSF-1R-
mediated reduction of MMP in the tumour is one explanation for slower progression of the 
cancer, since it contributes to tissue remodelling and angiogenic activity (Aharinejad et al., 
2004). Because of the capacity of macrophages to induce blood vessel formation through a 
wide set of signals, after treatment of tumours with inhibitors of VEGF signalling there 
follows a period of renewed vascular formation (Priceman et al., 2010).  
Macrophages are capable of not only neoangiogenesis at the tumoural site, but also 
of lymphangiogenesis, offering another route for cancer metastasis. CD11b
+
 macrophages 
are capable of forming tubular structures that express several markers of lymphatic 
endothelium. Lymphangiogenesis may normally be induced by VEGF and IL-1β, whose 
production is stimulated by CSF-1 (Maruyama et al., 2005). 
The formation of a high-density vessel network is associated with the cancer 
progression to malignancy, and infiltrating macrophages in primary mammary tumours 
regulate both vessel formation and subsequent malignancy traits, such as loss of tissue 
architecture. Very importantly, the size of a tumour is not a determinant of the formation of 
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new vessels and malignancy, whereas the presence of macrophages is (Lin et al., 2006; 
Mantovani et al., 2008; Priceman et al., 2010).  
There is still some debate on the mechanics that drive macrophage-induced 
angiogenesis. While the consensus is that hypoxia attracts TAMs, as presented above, 
another group suggested that hypoxia reduces the expression of CSF-1, and that 
macrophages tend to localize in the invasive zones of the tumour, where oxygen 
concentration is higher. Murine macrophages also show reduced ability to migrate under 
hypoxic conditions, which corroborates the hypothesis that TAM function would be more 
pronounced in the oxygenated tumour margins (Green et al., 2009). It is known that the 
localization within a tumour affects the response of macrophages. Just as low pH and 
necrosis attract TAMs, these, and other factors, influence TAMs to collaborate further with 
tumour growth.  
 
1.4.2 Not all TAMs are made the same – the M1 and M2 phenotypes 
 
TAMs can have varying localizations within a tumour and possess different 
characteristics in each. TAMs along the invasive tumour margin or near necrotic foci, in 
hypoxic areas, produce angiogenic factors which lead to poor prognosis, as described above. 
In contrast, TAMs in strict contact with cancer cells may produce cytotoxic mediators 
leading to cancer cell death (Ohno et al., 2004). In endometrial cancer, TAMs are 
preferentially positioned along the invasive margins, in necrotic foci and in the tumour 
stroma, but can also be found within the tumour nest (embedded between cancer cells). 
While presence of TAMs in the nest reduces tumour relapse, being thus correlated with good 
prognosis, TAMs in the hot-spots (the necrotic foci) are associated with tumour 
aggressiveness and relapse, and TAMs in the margin are linked to immunosuppression. 
Therefore, localization of the macrophages inside a tumour is relevant for determining their 
roles (Lewis and Pollard, 2006; Ohno et al., 2005, 2004; Sica et al., 2006).   
Even the sites of CSF-1 production within the tumour have been associated with 
different outcomes (Chambers et al., 1997). Curiously, macrophages appear to possess 
cytotoxic effects against tumours which have the membrane isoform of CSF-1 (mCSF-1), 
but not the secreted isoform (Jadus et al., 1996). The cytotoxic activity of macrophages 
against mCSF-1
+
 tumour cells might corroborate the finding that TAMs in close contact with 
cancer cells are able to eliminate them, instead of contributing to tumour growth (Jadus et 
al., 1996; Lewis and Pollard, 2006). Also, the balance of the CSF-1 isoforms by the tumour 
could affect the response created against the malignancy (Chitu and Stanley, 2006). 
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Therefore, it is clear that in the appropriate environment macrophages can show anti-
tumour activity (Baldwin et al., 1993). However, to achieve anti-tumour effects, 
macrophages must be stimulated into what is called the M1 classical phenotype, which is 
activated by microbial products and IL-12, TNF, GM-CSF or interferon-γ, most of which are 
not found in the tumour hot-spots (Chitu and Stanley, 2006).  
The cellular phenotype of tumour-associated macrophages is commonly 
denominated as “M2”. The M2 phenotype is stimulated by signals coming from regulatory T 
cells or from the tumour cells, which secrete CSF-1 with other cytokines that lead to 
inhibition of the cytotoxicity of TAMs. Some of the cytokines involved in M2 cell 
formation, besides CSF-1, are IL-10, IL-4, IL-6, MDF, TGF-β1 and prostaglandin E2 (PGE2) 
(Hagemann et al., 2009; Lewis and Pollard, 2006; Sica et al., 2006). CSF-1R signalling itself 
is capable of inducing higher sensitivity to IL-4, an M2 driver (Caescu et al., 2015). Whereas 
M1-activated macrophages would lead to cancer cell killing, the M2-type of activation leads 
to angiogenesis, tissue remodelling and an immune suppressing phenotype (Sica et al., 
2006).  
More specifically, M2 macrophages can be subdivided into M2a cells, differentiated 
under the influence of IL-4/IL-13, especially in parasitic diseases; M2b, formed with 
immune complexes; and M2c cells, an anergic state, prompted by IL-10; this cytokine 
induces a process of apoptosis of macrophages before they can ever be activated and 
cytotoxic. It is evident that in the tumour site these cytokines that drive M2 subtypes are not 
found in isolation and, indeed, their interactions are important for many biological effects. 
Thus, macrophages grown in the presence of tumour-secreted factors express M2 
characteristics which interpolate between the three M2 subsets: TAMs are stimulated by IL-4 
and produce IL-10, with the capacity of carrying out Fc-dependent antitumour functions. 
Because of this varied phenotype, a new name for the TAM activation state has also been 
proposed, M2d, although it is not commonly used (Duluc et al., 2009). Because the 
formation of M1 and M2 characteristics in uneven throughout the tumour, some 
macrophages are also likely to receive conflicting signals, displaying pro- and anti-tumoural 
characteristics in rapid succession (Grugan et al., 2012; Jenkins et al., 2013; Joimel et al., 
2010; Kataki et al., 2002). The M1-M2 cellular characteristics are illustrated in Figure 3.1, 
Chapter 3. 
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Therefore, inside tumours and in the presence of M2-inducing characteristics, such 
as CSF-1 signalling, TAMs can have immunosuppressive roles which are otherwise 
physiologically important for wound repair and injury resolution. Interleukin-4, IL-10, IL-
13, glucocorticoids and transforming growth factor (TGF)–β upregulate the expression of a 
set of molecules in macrophages that enables them to take part in the resolution of 
inflammatory reaction, tolerance induction and “organ formation”, such as during 
placentation (Biswas and Mantovani, 2010; Bronte et al., 2001). Indeed, many of the 
mechanisms used by TAMs in assisting tumour progression are reflected by “repair 
macrophages”, such as the production of VEGF, nitric oxide (NO) and TNF (Park and 
Barbul, 2004). However, although beneficial in other contexts, these mechanisms have a role 
in tumour development (Erreni et al., 2011). The characteristics are presented in Figure 1.7. 
 
 
Figure 1.7 – Effects of TAM distribution inside tumours. The tumour compartments are named in bold 
caption. The effect of TAMs in each compartment and the tumoural factors modulating TAMs are 
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1.4.3 TAMs and cancer growth  
 
Once inside the tumour and under its influence, TAMs can contribute to cancer cell 
proliferation and the creation of new hypoxic areas, perpetuating of a circle of formation of 
more M2 TAMs and further cancer growth. Cancer cell mitotic genes are promoted through 
the macrophage-induced production of several factors, among which EGF, platelet-derived 
growth factor (PDGF), TGF-β1, hepatocyte growth factor and basic fibroblast growth factor 
(bFGF) (Lewis and Pollard, 2006). Another important factor for direct cancer proliferation is 
CSF-1R, as discussed in section 1.3. In breast cancers, CSF-1R expression is associated with 
larger tumour size and decreased patient survival (Kluger, 2004). Placenta-derived growth 
factor (PlGF), produced in breast cancers, can promote the survival of TAM, which will, in 
their turn, induce more CSF-1R production by cancer cells (Król et al., 2012; Sica et al., 
2006).  
 
1.4.4 TAMs and metastases  
 
Metastasis has been demonstrated to require autocrine and paracrine signalling 
through CSF-1R, and requires macrophages for optimal invasion. A paracrine loop occurs 
between macrophages and cancer cells. Macrophages secrete epidermal growth factor 
(EGF), which acts on the EGF receptor (EGFR), expressed by carcinoma cells. The cancer 
cell, in its turn, secretes CSF-1, which acts both on CSF-1R on its own surface as well as on 
receptors on the macrophages. This signalling then drives tissue invasion through increased 
carcinoma mobility. Eighty percent of cancer cell movements occur near macrophages, 
reflecting the biological significance of the paracrine interaction between these cells 
(Patsialou et al., 2009; Wyckoff et al., 2007).  
Intravasation (movement of cancer cells into blood vessels) occurs preferentially in 
sites where macrophages are found. Many macrophages are found in association with tumour 
blood vessels and decreasingly throughout the stroma. The invading macrophages are 
associated with a vessel either as isolated motile cells or in clusters of around 3 
macrophages. Cancer cells migrate towards perivascular macrophages, which contribute with 
intravasation of cancer cells (Wyckoff et al., 2007). Targeting neoangiogenesis may be in 
itself an interesting approach to cancer therapy, as the expression of angiogenic factors has 
been associated with prognosis in several tumours (Bamias and Dimopoulos, 2003). 
However, the number of tumour perivascular macrophages is more important for 
intravasation than the number of vessels (Wyckoff et al., 2007). The physical interaction 
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between carcinoma cells, macrophages and endothelial cells predicts the development of 
systemic haematogenous metastases in breast cancer (Robinson et al., 2009).  
Naturally occurring breast cancers confirm the experimental data linking 
macrophages to metastases. The presence of CSF-1 and infiltration of macrophages into the 
primary tumour accelerates the malignant transformation to the late carcinoma stages. The 
absence of CSF-1, on the other hand, delays the development of invasive, metastatic 
carcinomas (Lin et al., 2001). As is common in the literature involving CSF-1, its 
responsibility in metastasis is also not unanimous. It has been seen that in vivo administration 
of CSF-1 to mice with metastatic murine melanoma increased the number of macrophages 
and that metastatic lesions were reduced (Hume et al., 1989). 
Macrophages contribute to cancer spread not only through circulatory dissemination. 
Normal tissue invasion may also be facilitated by presence of TAMs and stimulation through 
CSF-1R. Activation of this receptor in macrophages and the subsequent IL-1β production 
induces high expression of MMP-2 and MMP-9 as well as of urinary plasminogen activator 
(uPA), which in brief terms generates plasmin; MMPs and plasmin are extracellular 
proteases (Lewis and Pollard, 2006; Michel and Quertermous, 1989). These proteases break 
the basement membrane of the tumour, thereby prompting their escape into the surrounding 
tissue and promoting deregulated growth. In cervical cancer, CSF-1R is linked with 
invasiveness and severity, alongside VEGF and COX-2 (Hammes et al., 2008). CSF-1 is 
capable of inducing more protease activity and tumour invasiveness of surrounding tissue 
than GM-CSF or G-CSF (Lewis and Pollard, 2006; Pei et al., 1999). 
TAMs can also induce cancer cells to directly produce proteases. TGF-β1 produced 
by the TAMs stimulates the production of MMP-9 by glioma cells with stem-cell properties, 
which then can promote tissue invasion (Ye et al., 2012). TGF-β1 is a known regulator of 
cancer epithelial-mesenchymal transition (EMT). The interaction between CSF-1R and TGF-
β1 controls a switch between proliferation and invasion in some breast cancer cells. Through 
EMT, epithelial cells de-differentiate, acquiring stem cell-like characteristics and motility. 
These de-differentiated cancer cells have better abilities to metastasize and to invade 
(Katsuno et al., 2013; Patsialou et al., 2015). Thus, through the production of TGF-β1, 
TAMs simultaneously assist in breaking tumour barriers and in the formation of an invasive 
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1.4.5 TAMs and immunosuppression – effects over lymphocytes 
 
Contrarily to TAMs, tumour-infiltrating lymphocytes are usually linked to better 
immune responses against the cancer and, therefore, to improved prognosis. As an example, 
a low lymphocyte to macrophage ratio is linked with poorer prognosis in Hodgkin’s 
lymphoma (Koh et al., 2012). In their “wound-repair” M2 mode, macrophages limit 
lymphocyte survival and function within the tumour (Park and Barbul, 2004). Some of the 
mechanisms used by TAMs to limit lymphocyte action are listed here. 
Suppressor macrophages found on tumour-bearing hosts are down-regulated for 
MHC II molecules. The increase in immature MHC II
-
 macrophages results in reduced 
antigen-presenting capacity, which favours tumour progression through decreased 
lymphocyte activation. More than that, MHC II
-
 macrophages exert a direct cytotoxic and 
suppressor activity against T lymphocytes, as a result of increased secretion of PGE2, NO, 
H2O2, reactive oxygen intermediates, arginase-1 and TNFα (Bak et al., 2008; Bronte et al., 
2001).  
Upon contact with activated lymphocytes, but not when in contact with inactivated 
cells, TAMs induce T cell death through the production of NO. IFNγ and TNF produced by 
the activated T-lymphocytes cooperate to induce macrophage killing of T cells (Saio et al., 
2001). The production of IFNγ and TNF by lymphocytes is, in fact, a stimulus to create M1 
macrophages (Duluc et al., 2009). For some reason, within the tumour these cytokines 
activate the inflammatory potential against the lymphocytes themselves. The outcome of NF-
κB activation in macrophages (which controls IFNγ responses, for instance) can be quite 
different depending on the context in which it is being activated. NF-κB stimulation during 
the onset of inflammation is associated with the expression of inflammatory genes (e.g. 
NOS2), while NF-κB activation during the resolution phase of inflammation results in the 
expression of anti-inflammatory genes (e.g. TGF-β1) and a M2 activation state. The vast 
variety of signals (from necrotic cell debris to hypoxia) derived from tumours may act on 
regulating macrophages through NF-κB to eliminate lymphocytes (Hagemann et al., 2009). 
NF-κB activity is reduced in TAMs due to defective nuclear translocation of its 
subunits; this transcription factor is important for the production of inflammatory signals, for 
instance. Following an inflammatory stimulus, M2 cells favour the signal transducer and 
activator of transcription 1 (STAT1) transcription factor, leading to the preferential 
expression of immunosuppressing cytokines. In the same situation, M1 macrophages 
produce inflammatory cytokines through NF-κB (Biswas et al., 2006; Saccani et al., 2006). 
In follicular lymphoma, it is suggested that the expression of the STAT1 is involved in the 
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inhibition of T cell function; indeed, the expression of STAT1 was shown to reduce the 
survival rate (Álvaro et al., 2006). 
Myeloid-derived suppressor cells (MDSC) are immature myeloid precursors that 
also affect host immunity during cancer. These cells are M2-differentiated and accumulate in 
lymphoid tissues, instead of the tumour itself. Their roles and the mechanisms they use for 
reducing immune responses against the tumour are very similar to those of TAMs. In these 
cells, mouse paired immunoglobulin-like receptors (PIRs) have been found to be important 
for STAT and NF-κB signalling pathways. Myeloid cells ablated for PIR-B tend to develop 
into M1 cells, leading to reduction of T-regulatory lymphocytes (Treg), reduced tumour 
growth and metastases (Ma et al., 2011). In PIR-B-deficient animals, the growth of Lewis 
lung carcinoma is diminished, implying an important role for this molecule in cancer 
immunosuppression (Sica et al., 2012). 
Prostaglandins are highly produced in TAMs as a consequence of the abnormal 
metabolism of arachidonic acid. TAMs have high activity of 15-lipoxygenase-2 (15-LOX2), 
involved in the arachidonic acid pathway. Interestingly, production of IL-10 by TAMs is 
dependent on the activity of 15-LOX2. IL-10, which is anti-inflammatory, is also responsible 
for suppression of adaptive immunity and antitumor responses. In this way, TAMs stimulate 
the creation of Treg, inducing the T-regulatory cell transcription factor forkhead box P3 
(FOXP3) and the co-inhibitory cytotoxic T-lymphocyte antigen 4 (CTLA-4) (Daurkin et al., 
2011). In turn, Tregs are capable of feedback reinforcement of the transformation of 
macrophages into the M2 phenotype, therefore creating more immunosuppressive TAMs 
(Biswas and Mantovani, 2010). 
CSF-1 plays a direct role in immunosuppression. As cited before, this cytokine is 
seen as the counterbalance to GM-CSF (Sierra-Filardi et al., 2014). CSF-1-conditioned 
monocytes inhibit mitogen- and antigen-stimulated T cell proliferation through a mechanism 
involving T cell starvation of tryptophan caused by the enzyme indoleamine 2,3-dioxygenase 
(IDO) (Biswas et al., 2006; Bronte et al., 2001; Sica et al., 2006; Sweet and Hume, 2003). 
Although CSF-1R can increase immune responses against pathogens by stimulation of 
macrophages, it can also reduce antigen-specific and mitogen-induced T lymphocyte 
proliferation or macrophage stimulation of T lymphocytes (Sakurai et al., 1996; Sester et al., 
1999). Unfortunately, CSF-1R blockade also upregulates T cell inhibitory molecules such as 
CTLA-4, reducing beneficial effects of this form of therapy. Therefore, there is a synergistic 
effect in blocking both CSF-1R and CTLA-4 (Zhu et al., 2014). 
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1.4.6 TAMs and immunosuppression – effects over dendritic cells 
 
Most dendritic cells in tumours are not in a fully differentiated state, which occurs 
after M1 activation (Sica et al., 2006). Mature dendritic cells seem to be limited to 
peritumoral areas in breast carcinomas, while immature dendritic cells are found infiltrating 





lymphocytes to produce IL-10, which is a driver of M2 phenotypes (Bronte et al., 2001). 
Imiquimod, a TLR7 agonist, is currently being tested for cancer treatment by selective 
stimulation of the innate immune response, which enhances the maturation of dendritic cells 
(Sternberg et al., 2011).  
 
1.4.7 TAMs and resistance to therapy 
 
Macrophages have been shown to increase cancer resistance to several treatment 
modalities. In prostate cancer models, inhibition of CSF-1R enhances the response to 
radiation therapy. Irradiation recruits the DNA damage-induced kinase ABL1; it binds to the 
Csf1 promoter and induces protein expression, which then counteracts the treatment by 
increasing cancer growth through the mechanisms discussed above in the presence of TAMs 
(Laoui et al., 2014; Xu et al., 2013). A similar effect has been seen also following 
chemotherapy treatment (DeNardo et al., 2011). Chemotherapy resistance in prostate cancer 
can be predicted by high circulating levels of IL-4, IL-6 and macrophage inhibitory cytokine 
1 (MIC1), which recruit and alter the phenotype of TAMs into M2 characteristics (Mahon et 
al., 2015). Inhibiting CSF-1R and CCR2 improves chemotherapy results in prostate cancer 
not only by the direct effect of decreasing TAMs, but also by inhibiting the effects of TAMs 
on the survival of stem-like tumour-initiating cells through STAT3 activation (Mitchem et 
al., 2013). Macrophage-derived STAT3 and IL-6 have also been incriminated in pancreatic 
ductal adenocarcinoma, promoting the survival of stem cells following chemotherapy 
(Jinushi et al., 2011; Ruffell and Coussens, 2015).  
Following chemotherapy treatment of breast cancer, there is macrophage infiltration 
and cathepsin protease production by the TAMs. Cathepsin increases cancer cell resistance 
to several chemotherapeutics (Shree et al., 2011). Cathepsins are produced by TAMs in 
response to IL-4 stimulation in several tumour types, such as pancreatic islet cancers, 
mammary tumours, and lung metastases (Gocheva et al., 2010). Chemotherapy-driven 
cathepsin release stimulates IL-1β production by macrophages and the consequent 
generation of a regulatory immune response through T lymphocyte-derived IL-17 (Bruchard 
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et al., 2013).  Because IL-17 and IL-1β also drive IL-6 production in several cancer cell 
lines, cathepsin could also be associated with STAT-3 activation (Ruffell and Coussens, 
2015). Cathepsin also regulates the trafficking of vesicles containing TNF-α. Production of 
TNF-α by TAMs can occur from NF-κB or STAT3 activation. TNF-α has been correlated 
with cancer resistance to MAPK pathway inhibitors (Ruffell and Coussens, 2015; Smith et 
al., 2014). 
Other general effects of TAMs which may promote treatment resistance include 
extracellular matrix deposition and remodelling, and cell-cell interactions (Ruffell and 
Coussens, 2015). 
A positive factor of the presence of TAMs is the improvement of outcomes 
following antibody treatment. While IL-10 suppresses the expression of MHC II on the 
surface of macrophages, it also stimulates the presence of CD16. An increase in CD16 is also 
caused by CSF-1. The expression of CSF-1 is highly increased in the recovery phase of bone 
marrow hypoplasia induced by chemotherapy (Kimura et al., 1992). Accordingly, human 
patients recovering from myelosuppressive chemotherapy show also an increase in the 
expression of CD16, with a reduced expression of CD14 (MacEwen and Kurzman, 1996). 
The role of CD16 is to send survival signals to macrophages when coupled to IgG. In this 
way, IL-10 suppresses macrophages in healthy tissues, but favours accumulation and 
activation of macrophages when in the presence of antibodies (Wang et al., 2001). This may 
justify why after combined treatment with rituximab (an anti-CD20 mAb) and 
chemotherapy, high TAM content was linked with better prognosis, while TAM content 
predicted poor prognosis in untreated patients (Taskinen et al., 2007). Other works have 
confirmed the capacity of M2 TAMs to induce antibody-dependent cell cytotoxicity against 
cancer cells (Grugan et al., 2012). 
 
An overview of the effects of TAMs on the cancer hallmarks of malignancy is 
shown in Figure 1.8. 





Figure 1.8 – Tumour-promoting effects of TAMs. The cancer hallmarks of malignancy influenced by 
TAMs are denoted in bold caption. The factors mediating the effect of TAMs in each hallmark is 
shown inside the boxes. References: (Allavena et al., 2008; Bonde et al., 2012; Gocheva et al., 2010; 
Grugan et al., 2012; Lewis and Pollard, 2006; Mitchem et al., 2013; Shree et al., 2011; Sica et al., 
2006; Wyckoff et al., 2007). Chemotherapy is represented by the molecular structure of doxorubicin 
("Doxorubicin2DCSD" by Fuse809 (talk)). Licensed under Public Domain. 
 
 
1.5 CSF-1R as a target 
 
The abundant evidences that macrophages are required for tumour growth in cancer 
patients and in experimental models suggests that depleting this cellular population could 
generate clinical benefit. Because of the crucial roles of CSF-1R in the survival and function 
development of cells of the mononuclear phagocytic system and of cancer cells themselves, 
this receptor is a candidate target for a new anti-tumour drug (Hume and MacDonald, 2012). 




Chapter 1 - Introduction   39 
 
1.5.1 CSF-1R as a target – receptor tyrosine kinase inhibitors 
 
Small-molecule inhibitors of receptor tyrosine kinases (RTKi) are currently one of 
the most pursued anticancer therapeutics (J. G. Moffat et al., 2014). RTK are related to 
carcinogenesis and cancer progression in three different ways: firstly, many kinases can 
become directly involved in cancer transformation. Through the occurrence of mutation or 
translocation, kinases develop into an oncogenic form, essential for tumour survival and/or 
proliferation, such as is seen in feline fibrosarcomas induced by the v-fms form of mutated 
CSF-1R (Wheeler et al., 1986); secondly, kinases can be located in signalling pathways 
downstream of oncogenes or be activated by other oncogenes, and even though not in 
themselves oncogenic, they become necessary for cancer survival. This is seen in acute 
myeloid leukaemia due to deregulation of CSF-1R transcription factors (Aikawa et al., 
2010); thirdly, the kinase can be expressed in tissues that are peripheral to the tumour, and 
may be required for tumour formation or maintenance in the host. For the latter, examples 
would be receptors important for the development of blood supply to the tumour, such as 
VEGFR or again CSF-1R (Zhang et al., 2009).  
Toceranib phosphate (Palladia, Pfizer), one of such RTK inhibitors, has been used in 
veterinary medicine with some success in treating several tumour types (London et al., 
2009). Toceranib is a non-specific inhibitor of vascular endothelial growth factor receptor, 
platelet derived growth factor receptor (PDGFR), c-Kit and other kinases. In clinical trials, 
toceranib phosphate has shown clinical relevance mainly in dogs with mast cell tumours 
which contain a driving mutation in the c-Kit receptor (London et al., 2009; Yancey et al., 
2010). In this case, toceranib falls into the category of acting on kinases directly involved in 
cancer through oncogenic mutations. However, the inhibitor still seems to possess activity 
against tumours which are negative for the c-Kit mutations. Clinical response can also be 
observed in several other tumours, such as thyroid carcinoma and osteosarcoma, especially 
when in combination with other treatment modalities (Carlsten et al., 2012; Chon et al., 
2011; London et al., 2012, 2009, 2003). 
Mast cells and monocytes are derived from the same early precursor cells 
(Kirshenbaum et al., 1999), and c-Kit is also a RTK of known similarities to CSF-1R, 
especially in the tyrosine kinase region; PDGFR is, as has already been described in this text, 
from the same family of receptors as CSF-1R (Qiu et al., 1988; Yeung and Stanley, 2003). 
Therefore, at least part of the response of toceranib is derived from inhibiting kinases that 
help to support the tumour growth, such as CSF-1R. Other inhibitors of c-Kit are also known 
to inhibit CSF-1R (Mashkani et al., 2010).  
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Several other RTKi are being currently developed or tested for oncologic treatment. 
Masitinib mesytilate, for instance, has also been used in veterinary medicine, with relative 
success in oncologic therapy, both in dogs and cats, also in various cancer types. Special 
interest in using this drug is also given for mast cell tumours, or in investigations of VEGF 
inhibition (Conway et al., 2008; Marech et al., 2014).  
The inhibitor effects of 3-amido-4-anilinoquinolines, of 3-amido-4-anilinocinnolines 
and of bisamides, among others, have just recently been identified, all with highly selective 
activity against CSF-1R. The anilinoquinoline inhibitor has had success in reducing TAM in 
a breast cancer xenograft model (El-Gamal et al., 2010; Scott et al., 2009, 2011; Wall et al., 
2008).  
GW2580 is one of the most specific kinase inhibitors for CSF-1R. It can inhibit 
CSF-1-induced expression of IL-6 by monocytes and macrophages (Conway et al., 2005; 
Kitagawa et al., 2012). By affecting TAMs, GW2580 could reduce tumour evasion of 
chemotherapy, avoid metastasis and immunosuppression (Mitchem et al., 2013; Priceman et 
al., 2010).  
Advantages of kinase inhibition of CSF-1R include the fact that it does not interfere 
with the clearance of CSF-1, since the uptake of the ligand and receptor internalization does 
not require the kinase function. Most antibodies blocking CSF-1R interfere with this process 
(see more below); increased circulating CSF-1 causes a rebound effect when inhibitory 
antibody treatment is discontinued. Also, kinases are more likely to block autocrine 
signalling through CSF-1R, which are less accessible to antibodies (Hume and MacDonald, 
2012). 
However, a disadvantage of RTKi is the occurrence of adverse effects. These can 
derive from cross reactivity between kinases, since inhibitors can have variable selectivity to 
a specific kinase. Most inhibitors block the ATP-binding sites on the kinases, and since these 
sites are well conserved among several receptors, even inhibitors with considerate selectivity 
can block various kinases at the same time. Some of the reported side-effects are 
neutropenia, proteinuria, increase in serum creatinine concentration, myocardial 
degeneration, and with the greatest number of reports, gastrointestinal disorders (Aguirre et 
al., 2010; Daly et al., 2011; London et al., 2009). Curiously, it has been found that inhibition 
of c-Kit with small-molecules in human gastric sarcomas induces M2 macrophage 
polarization (Cavnar et al., 2013). Therefore, if using a RTKi against CSF-1R that cross-
reacts with c-Kit, this adverse effect can be generated.  
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1.5.2 CSF-1R as a target – TLR agonists 
 
The down-regulation of CSF-1R on the cell membrane after contact with LPS or 
other TLR agonists could be an alternative to impede macrophages from exerting the 
immunosuppressive effects of CSF-1R signalling (Sester et al., 1999). TAMs are mostly 
incapable of producing IL-12, a pro-inflammatory cytokine, even after LPS activation. 
Instead, the cytokines produced by tumour macrophages tend to create T regulatory cells 
(Treg) which suppress effector T cells and monocytes (Porta et al., 2009; Ruffell and 
Coussens, 2015). It is reported that defective activation of NF-κB in TAMs correlate with the 
impaired expression of M1 cytokines, and so restoration of the NF-κB would therefore 
impact on the cellular profile that is activated (Biswas et al., 2006; Sica et al., 2006). A 
combination of an IL-10R blocking antibody and of TLR9 agonists (which are NF-κB 
activators) switches infiltrating macrophages from M2 to an M1 phenotype, and the innate 
response triggered is capable of debulking large tumours within 16 hours (Kawai and Akira, 
2007; Sica et al., 2006). TLR4 and TLR7 agonists have also been tested as anti-cancer 
agents, inducing higher IL-12 production from macrophages and demonstrating usefulness in 
combination with chemotherapy. It is believed that LPS increases the cytotoxicity of 
macrophages in close contact with cancer cells (in the tumour “nest”) (Hirota et al., 2010; 
Sawachi et al., 2010; Sternberg et al., 2011). 
Even though LPS or other TLR agonists reduce CSF-1R expression, they are able to 
maintain cell viability probably by activation of ERK1/2, while obviously impeding cell 
signalling through CSF-1R. TLR agonists are reported to increase the time macrophages 
remain in secondary lymphoid organs, raising the probability of a macrophage activating 
circulating T cells. In summary, the presence of pathogen-associated molecular patterns such 
as LPS and other TLR agonists may contribute towards more efficient antigen-presenting 
cells (an M1 activation state), instead of the immunosuppressive macrophages that result 
from CSF-1 signalling (an M2 activation state). These M1 activated cells are potent effector 
cells, capable of killing tumours (Sester et al., 1999). Confirming this prediction, LPS is 
capable of inducing the maturation of dendritic cells, which are potent antigen presenters 
(Palucka et al., 1998).  
The interaction between CSF-1R and TLR agonists is not simple, however. Cells 
pre-stimulated with CSF-1 produce more IL-6, IL-12 and TNF-α (mostly M1 markers) when 
in contact with LPS, a TLR4 agonist, but suppressed the same response to CpG DNA, a 
TLR9 agonist. As stated before, CSF-1 suppresses the expression of various TLRs, except 
for TLR4 (Sweet and Hume, 2003). Also, IL-6 produced by CSF-1 can have pro- or anti-
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inflammatory effects, depending on the activity of suppressor of cytokine signalling 3 
(SOCS3) (Yasukawa et al., 2003), adding more levels of control over the final phenotype 
after TLR regulation. Therefore, using TLR agonists can have conflicting effects over 
macrophage activation in several different situations, depending on other factors. Indeed, the 
use of a TLR agonist in bladder cancer can have various outcomes, being subject to the 
tumour microenvironment. BCG, a TLR agonist, has long been used as an adjuvant in the 
therapy of bladder cancer. However, instead of BCG modulating the phenotype of the 
TAMs, an extensive infiltrate of M2 macrophages seems to limit the therapeutic potential of 
BCG (Suriano et al., 2013). 
 
1.5.3 CSF-1R as a target – antibodies 
  
Several antibodies have been tested against CSF-1R and its ligands. The use of 
antibodies against the receptor is especially relevant because of the existence of two ligands 
for CSF-1R (Chihara et al., 2010). Targeting the receptor instead of its ligand also has the 
advantage of avoiding the issue of the short half-life of the ligands (10 min for CSF-1). 
When blocking CSF-1, constant high levels of blocking antibody need to be maintained in 
the circulation to suppress its functions (Wei et al., 2005). However, anti-CSF-1R antibodies 
have been found that are able to inhibit only CSF-1 or IL-34 binding to the receptor, due to 
variations in the contact residues on the surface of CSF-1R between the ligands (Chihara et 
al., 2010). 
Despite the disadvantages of blocking the ligands, an anti-CSF-1 monoclonal 
antibody (mAb) is capable of retarding tumour growth by 40 %. In combination with CMF 
chemotherapy (cyclophosphamide, methotrexate, 5-fluorouracil), the growth of a breast 
cancer xenograft was retarded by 56 %. Angiogenesis, MMP expression and macrophage 
recruitment are all down-regulated by this treatment (Paulus et al., 2006). 
The evaluation of mice treated with anti-CSF-1R antibodies reinforces the idea of 
the functional heterogeneity of the monocytes/macrophages and provides a unique treatment 
option in which tissue populations of macrophages can be selectively depleted. Animals that 
received anti-CSF-1R antibodies are healthy throughout the experiments, and circulating 
monocytes are mostly kept at stable levels during the period. Some anti-CSF-1R antibodies 
are capable of depleting resident subsets of macrophages without affecting inflammation, 
while still preventing lesions that were derived from the selective accumulation of 
macrophages, including tumours. Thus, at least in the state of developmental maturity of an 
individual, there is markedly little impact on the use of antibodies over the animal, and this 
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may represent an optimal approach to modulate macrophage responses within tumours in 
vivo (Haegel et al., 2013; MacDonald et al., 2010; Murayama et al., 1999; Sauter et al., 
2014). 
Side effects of CSF-1R signalling inhibition with antibodies are usually seen only 
during the embryonic period or soon after birth. When an antibody against CSF-1 was 
administered to mice in the immediate post-natal period, osteopetrosis was induced, as well 
as depletion of macrophages, reduced growth rate, among other signs that indicate blocking 
of the CSF-1 function, similarly to what is seen in the knockout animals. Osteoclast 
suppression was not maintained as animals grew older, possibly because of the action of IL-
34 (Wei et al., 2010, 2005). In op/op mice, tooth eruption is completely annulled due to the 
absence of osteoclasts, which reabsorb alveolar bones around developing teeth. To produce 
the same effect by injection of antibodies specific to CSF-1R, the drug has to be 
administered from embryonic day 15.5 until postnatal day 12.5 (Yoshino et al., 2003).  
In adult animals, it has also been reported that immunity against a Listeria 
monocytogenes infection could be annulled when an antibody against CSF-1R was 
administered (Gregory et al., 1992). However, blockade of CSF-1R signalling does not 
necessarily block macrophage tissue function because tissue resident cells are able to 
proliferate in the presence of IL-4, independently from CSF-1R (Jenkins et al., 2013). Also, 
some predecessor dendritic cell populations do not express CSF-1R and are able to replenish 
all dendritic cell subsets subsequently (Araki et al., 2004; MacDonald et al., 2005; Palucka et 
al., 1998). 
A possible setback of antibody blockade of CSF-1R is the accumulation of 
circulating ligands, since their clearance occurs after binding to the receptor. With the 
receptor competitively bound by the antibody, CSF-1 accumulates in the circulation, and 
when antibody concentration decreases, a rebound effect might occur (Hume and 
MacDonald, 2012). To circumvent this, an antibody has been identified that is capable of 
blocking CSF-1R while still allowing the internalization of the receptor and removal of the 
ligand from the circulation (Haegel et al., 2013). 
 
The main characteristics of the CSF-1R-modulating therapies cited here are shown 
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Figure 1.9 – Advantages () and disadvantages () of CSF-1R-modulating therapies. The modulators 
shown are TLR agonists, receptor tyrosine kinase inhibitors (RTKi) and antibodies. References: 
(Haegel et al., 2013; Hume and MacDonald, 2012; Jenkins et al., 2013; Sester et al., 1999; Sica et al., 
2006; Yasukawa et al., 2003). 
 
 
1.6 The dog as a model to study cancer 
 
Not only in human malignancies have macrophages been associated with poor 
prognosis. Malignant canine mammary tumours have more macrophages than benign 
masses. When considering only canine malignant tumours, macrophages also associate with 
more aggressive phenotypes. Presence of TAMs correlates with skin ulceration and 
histological types, for example (Król et al., 2011; Raposo et al., 2012). 
Research on cancers of veterinary interest does not only regard the better care of 
animal patients, but also serves as a model for human diseases (Reichert and Dhimolea, 
2012). Despite the large investments for the development of new therapeutic monoclonal 
antibodies, few have been produced for use in the treatment of cancer in dogs. The first ever 
monoclonal antibody against cancer was targeted against canine lymphoma, in 1996, but was 
withdrawn from the market a few years later for lack of efficacy (Jeglum, 2009). More 
recently, anti-CD20, anti-EGFR and anti-CD52 monoclonals have been produced against 
canine targets (Acharya et al., 2015), but this is only a small fraction of the work being 
conducted against human cancer targets (Killick et al., 2015). 
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There are many characteristics in canine cancer that make it amenable for use as a 
model in the study of human cancer. Dogs possess the closest telomere biology compared to 
humans: they have similar telomere size and telomerase activity (Nasir et al., 2001); 
spontaneously arising canine cancer shows many genetic similarities to human cancers; the 
cancer-associated genes in dogs show great similarities to those of humans; there are greater 
similarities between canine and human proteins than between murine and human; cancer 
develops in canine patients with a functional immune system, as in humans and in opposition 
to many mouse models; there is great genetic diversity between animals and breeds, which 
can be useful in translational medicine, as drugs act differently in different genetic 
backgrounds; dogs and humans share the same environment and also some of carcinogens in 
these spaces, such as cigarette smoke; dogs are kept until old age and frequently treated with 
a high level of medical care (Rowell et al., 2011). Indeed, clinical studies in dogs have 
shown that they serve as good predictors of both clinical toxicity and response to therapy 
(London et al., 2009; Paoloni and Khanna, 2008). 
It is consequently expected that dogs will become increasingly important as models 
in the study of human cancer, hopefully decreasing the costs, the attrition rates and the 
disappointing results when drugs reach human trials (Paoloni and Khanna, 2007; Riccardo et 
al., 2014). Also, the increasing restrictions in the use of laboratory animals (RCUK, 2015) 
may turn the attention of researchers towards naturally-occurring disease models – such as 




CSF-1R is important for the dissemination and progression of cancer. Blocking this 
receptor impedes macrophage tumoural invasion and phenotypic alteration into M2 cells. It 
is also likely to affect the CSF-1R autocrine-mediated malignant transformation of cancer 
cells. Therefore, the aim of this project was to generate antibodies that blocked signalling of 
the canine CSF-1R with the purpose of treating cancer.  
The specific objectives of this project were: 
1) To analyse the interaction of cancer cells and macrophages in vitro and to 
characterize the importance of CSF-1R signalling for the cross-talk between 
these cells in the context of canine cancer. 
2) To generate monoclonal antibodies against the canine CSF-1R by immunization 
of mice with recombinant proteins. It was intended that several IgG clones 
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against CSF-1R would be created by hybridoma fusions to ensure that blocking 
antibodies could be identified. 
3) To test the capacity of the monoclonal antibodies in affecting CSF-1R 
signalling, as well as to test other parameters of antibody binding. The 
antibodies were expected to block CSF-1R-dependent cell survival with high 
specificity and affinity. 
4) To produce speciated antibodies that could potentially be used for clinical 
testing in dogs. These speciated mAbs should maintain antibody blocking 
properties when compared to the mouse antibodies while preventing 
immunogenic reactions by increasing the level of caninisation of the molecule.  
 
These objectives are explored in the following chapters.  








Reagents specific for a method are detailed in the method section of each chapter. 
Names of kits, equipment and other supplies are registered trademarks of the respective 
companies. Details of manufacturers are shown below. 
Agilent, Santa Clara, US; Amersham, a GE Healthcare company; Becton Dickinson (BD), 
Franklin Lakes, US; Biochrom, Cambridge, UK; Bioline, London, UK; Cole-Parmer, 
Vernon Hills, US; Corning Life Sciences, Acton, US; Dako, Fort Collins, US; eBioscience, 
San Diego, US; Eppendorf, Hamburg, Germany; Fisher, Hampton, US; Fluka, a Sigma-
Aldrich company; Gibco, a ThermoFisher Scientific company; Grant, Cambridge, UK; 
GraphPad Software, San Diego, US; Greiner, Kremsmünster, Austria; Invitrogen, a 
ThermoFisher Scientific company; Life Technologies, Paisley, UK; Miltenyi Biotec, 
Cologne, Germany; New Brunswick, an Eppendorf company; New England Biolabs, 
Beverly, US; Peprotech, Rocky Hill, US; Pfizer Animal Health, New York, US; Progen 
Biotchnik GmbH, Heidelberg, Germany; R&D Systems, Minneapolis, US; Roche, Basel, 
Switzerland; Sigma-Aldrich, St. Louis, US; SLS, Hessle, UK; Sorvall, a Thermo Scientific 
company; Southern Biotech, Birmingham, US; Starlab, Milton Keynes, UK; Stemcell, 
Vancouver, Canada; Sterilin, a ThermoFisher Scientific company; ThermoFisher Scientific, 
Waltham, US; TreeStar, Ashland, US; Vector Laboratories, Burlingame, US. 
 
Unless stated otherwise, 15 and 50 ml plastic tubes were from Greiner. Small (0.5 
and 1.5 ml) tubes were from Eppendorf. Pipette tips were from Starlab. In most instances, 
centrifugations of 0.5 and 1.5 ml tubes were done using the centrifuge 5415R (Eppendorf); 
15 ml and 50 ml tubes were centrifuged using 5810R (Eppendorf). Larger (250 ml) flasks 
were centrifuged using RC6 floor centrifuge (Sorvall). Reagents were weighed using 
L2200S+ or BP210D (Sartorius) balances. 
Throughout the thesis, basic chemicals used were: NaCl, KCl, Na2CO3, H2SO4, SDS, 
ethanol, methanol, isopropanol, xylene, glycerol, urea, glacial acetic acid, Tris base, 
Chapter 2 - Materials and Methods   48 
 
NaH2PO4, glucose (Fisher); Hepes, BSA, H2O2, Na2S2O3, Na3PO4, NaHCO3, NH4Cl, EDTA, 
KH2PO4, acetone, formaldehyde, paraformaldehyde, glycine, skimmed milk powder, DTT, 
NP-40, DOC, PMSF, Tris-HCl, MgCl2 (Sigma); Tween 20 (SIS); Tryptone, yeast extract, 
peptone, sucrose (Fluka); PEG6000 (Millipore); BactoAgar (BD); Triton X-100 (Thermo 
Scientific); AgNO3 (VWR). 
 
2.2 General use solutions 
 
All solutions were made with distilled water. The potential hydrogen (pH) of 
solutions was measured using a 7-easy pH meter (Mettler Toledo). The pH meter was 
calibrated using three solutions of standard pH (10, 7 and 4). 
PBS: NaCl (137 mM), KCl (2.7 mM), Na2HPO4 (10 mM), KH2PO4 (1.8 mM), pH 
7.2. This was prepared by the Central Service Unit at the Roslin Institute. 
PBST: PBS containing Tween 20 (0.05 %). 
  
2.3 Microbiological techniques 
 
All techniques were carried out using sterile plastic consumables under aseptic 
conditions. Bacterial plates, plastic universal tubes by Sterilin. Plate spreaders and 
inoculation loops by VWR. Bacterial shakers were usually Innova 4330 or Innova 4000 
(New Brunswick). Autoclaving was performed by the Central Service Unit at the Roslin 
Institute.  
 
2.3.1 Bacterial media  
 
Luria-Bertani (LB): tryptone (1 %), NaCl (1 %), yeast extract (0.5 %). For agar 
plates, agar was added at 1.5 %. The mixture was sterilized by autoclaving. This was 
prepared by the Central Service Unit at the Roslin Institute. 
2xTY: peptone (1.6 %), yeast extract (1 %), NaCl (5 %). For agar plates, agar was 
added at 1.5 %. The mixture was sterilized by autoclaving.  
SOC medium: tryptone (2 %), yeast extract (0.5 %), NaCl (10 mM), KCl (2.5 mM), 
The mixture was sterilized by autoclaving. Sterile glucose (at 20 mM final concentration) 
and MgCl2 (at 10 mM) were added aseptically to the autoclaved solution. This was prepared 
by the Central Service Unit at the Roslin Institute. 
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Top agar: 2xTY medium containing 7.5 g of agar/litre.  
Antibiotics (Sigma) for bacterial selection were ampicillin (used at 100 µg/ml), 
carbenicillin (75 µg/ml), tetracycline (12 µg/ml) and kanamycin (25 µg/ml). Stocks at 1000 
× the working concentration were made by diluting the powder in 50 % glycerol and filter-
sterilizing (0.22 µm) the solution. Stocks were kept at – 20
o
C and were added to media 




2.3.2 Transformation of bacterial chemically competent cells 
 
Two microliters of plasmid (either ligation or cloning product) were added to the 
bottom of a 15 ml plastic tube (Greiner). Chemically competent cells E. coli Bronze 
Efficiency (Bioline), Top10 (Invitrogen), JM109 or BL21 (DE3) (Agilent) were thawed on 
ice from – 80
o
C and 100 µl were added to the tube on top of the plasmid drop. The contents 
were gently mixed by agitation and kept on ice for 45 min. The tube was heat-shocked at 
42
o
C in a water bath for 45 sec and placed back on ice for 2 min. SOC medium (900 µl) at 
room temperature was added to the bacterial cells. The mixture was placed in an orbital 
incubator at 37
o
C, agitating at 200 rpm, for 1 h. One hundred microliters were plated with 
disposable plastic spreaders onto agar plates containing the appropriate antibiotics for 
selection. The remaining 900 µl were spun at 1000 × g for 5 min. The supernatant was 
discarded and the bacterial pellet was plated in a second agar plate with 100 µl of media. The 




2.3.3 Bacterial glycerol stocks 
 
Overnight bacterial cultures containing plasmids of interest were diluted 1:1 in LB 
medium containing 20 % sterile glycerol. The stock was maintained at – 80
o
C. When 
needed, the stock was stabbed with a sterile microbial loop, which was streaked on an agar 
plate containing the necessary antibiotic. The plate was then incubated overnight at 37
o
C and 
individual colonies were picked for liquid growth. 
 
2.3.4 Bacterial liquid cultures 
 
Single bacterial colonies were grown overnight at 37
o
C with shaking at 225 rpm in a 
25 ml plastic tube containing 5 ml of the necessary medium with antibiotic. High copy 
plasmids were grown in LB medium and low copy plasmids were grown in 2xTY medium. 
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For larger culture volumes, the initial culture was diluted 1:50 to the larger volume of media. 
Flasks had at least 4 times the volume of the liquid contents to permit aeration of the culture. 
 
2.3.5 Measuring optical density 
 
Optical density of bacterial cultures was measured by adding 1 ml of the culture into 
transparent disposable cuvettes. A blank control was made by adding 1 ml of sterile culture 
media into another cuvette. These were inserted in the spectrophotometer (WPA Biowave, 
Biochrom) and the light transmittance was measured at 600 nm.  
 
2.3.6 Electrocompetent XL-1blue 
 
Protocol from (Martineau, 2010). XL-1blue was picked from a commercial stock 
(Agilent) and grown overnight on LB agar containing tetracycline at 37
o
C. A single colony 
was picked and grown overnight in 10 ml of 2xTY with tetracycline. The contents of this 
initial inoculum were poured into a 5 l flask containing 1 l of 2xTY and tetracycline. The 
culture was grown shaking at 200 rpm until OD600nm = 0.7. The culture was poured into 4 × 
250 ml centrifuge flasks and cooled down on ice for 30 min, regularly mixing the bottles. 
These were centrifuged at 5000 × g for 5 min at 2
o
C. The supernatant was discarded. A cold 
and sterile magnetic bar was added to each bottle. The bottles were filled with 250 ml of cold 
de-ionized water with Hepes (1 mM). The pellet was resuspended using the magnetic stirrer. 
After all pellets were broken, the tubes were centrifuged as above for 10 min. The 
supernatant was discarded and water with Hepes was added again, repeating the steps above. 
The pellet was then resuspended 25 ml in cold glycerol (0.1 %) with Hepes (1 mM). The 
contents of the 4 bottles were collected into a new bottle without the magnetic stirrer. This 
was centrifuged as above for 15 min and the supernatant was discarded. The pellet was 
resuspended in 1 ml of cold glycerol with Hepes using a 10 ml pipette. If not used, the 
bacteria were aliquoted, snap frozen in dry ice and stored at – 80
o




Bacterial cultures were sonicated either in 15 ml or 50 ml plastic tubes using a 
microtip ultrasonic processor (Misonix). Amplitude of sonication was regulated to allow the 
formation of visible cavitation bubbles while avoiding foaming. The microtip did not touch 
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the sides of the tubes. The bursts of sonication were followed by maintaining the samples for 
at least 10 sec on ice. 
 
2.4 Molecular biology techniques 
 
Thermal cycling was performed using G-Storm (Labtech). Electrophoresis of 
proteins or genetic material was performed using equipment from Bio-Rad.  
 
2.4.1 Plasmid preparations 
 
For plasmid minipreparations, 5 ml (10 ml for low copy plasmids) of bacterial liquid 
cultures containing the desired plasmid were centrifuged at 3000 × g for 5 min. The 
supernatant was discarded. The plasmid was then purified using QIAprep Spin Miniprep Kit 
(Qiagen). Briefly, the protocol consists of 1) alkaline lysis of bacterial cells; 2) lysate 
clearing by rapidly neutralizing the alkaline buffer and centrifugation of precipitates; 3) 
adsorption of plasmid DNA on a silica membrane with high salt concentrations; 3) washing 
with ethanol to remove non-specifically bound DNA; 4) eluting plasmid from membrane 
with Tris-Cl (10 mM), pH 8.0.  
For larger scale plasmid maxipreparations, 150 ml cultures were grown overnight 
and the plasmids were purified using the HiSpeed Plasmid Kit (Qiagen). 
Plasmid concentration in the elution fraction was quantified using a Nanodrop 




2.4.2 mRNA extraction and reverse transcription (RT) 
 
Messenger RNA (mRNA) from cultured cells was extracted from the cells using 
QIAshredder columns (Qiagen), spinning 10
7
 cells at full speed for 2 min in the RLT lysis 
buffer from RNeasy Mini Kit (Qiagen). Animal tissues were stored in RNAlater (Life 
Technologies) at room temperature for 6 h and then at – 20
o
C. For RNA extaction, the 
tissues were placed in RLT buffer and disrupted with the Lysis Matrix plastic beads (MPBio) 
in a FastPrep FP120 machine (Thermo Scientific). The protocol of RNA extraction from this 
kit consists of: 1) lysis of the samples in a highly denaturing buffer, as described above; 2) 
addition of ethanol to increase binding to the silica membrane; 3) binding to the silica 
membrane after spinning the samples through the column; 4) on-column digestion of 
contaminant DNA (using the DNase Free Set, Qiagen); 5) removal of contaminants by 
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washing; 6) elution of mRNA with 30 µl of RNase-free water. mRNA concentration was 




Reverse transcription was performed using either Omniscript RT Kit (Qiagen) or M-
MLV RT Kit (Promega). Omniscript RT was carried out by mixing the following reagents: 
10 x Buffer RT; dNTP (to 0.5 mM of each dNTP, Promega); Specific primers (to 0.5 
µM)/Random nonamers (to 10 µM, Sigma); RNase inhibitor (10 units, Promega); 
Omniscript reverse transcriptase (4 units); template RNA (1 µg); water to 20 µl. Unless 




2.4.3 Polymerase chain reaction (PCR) 
 
PCR primers are mentioned in each chapter separately. In primer design, it was 
attempted to maintain the Tm temperature among the pair and to avoid primer hairpins, self-
dimers and heterodimers that involved the 3’-end of the sequence. When not obtained from 
the literature, primers were designed manually and the parameters mentioned were 
quantified using the IDT OligoAnalyzer online program 
(https://www.idtdna.com/calc/analyzer). Primers were produced by Eurofins Genomics.  
 
2.4.4 Agarose gels 
 
Gel concentration varied according to the size of the product to be resolved. 
Products up to 300 bp were resolved in 2 % agarose. From 300 bp to 1500 bp gel 
concentration was 1.5 %. Bigger products were resolved in 1 % agarose. Gels were made by 
dissolving the agarose powder (UltraPure Agarose, Invitrogen) at the stated concentrations in 
TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA). The mixture was heated in 
a microwave until gel was completely dissolved. Gel Red (Biotium) was added from 10000 
× stock. Gel was then poured into mould and left to set. Samples were prepared by mixing 
with 6 × Loading Dye (to 1 ×, Promega). Ladders with bands of known size were 100 bp 
DNA ladder or 1.5 Kb DNA ladder (Promega). Five microliters of the DNA ladders were 
mixed with loading dye. Ladder and samples were loaded into the gel and ran at 80 V until 
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2.4.5 Gel extraction and PCR clean-up 
 
Gel extractions were carried out using QIAquick Gel Extraction Kit (Qiagen). Bands 
were visualized in the gel using a Safe Imager Transilluminator (Invitrogen). Bands were cut 
using disposable scalpel blades. Weight was reduced to 0.4 g/purification. Followed 
manufacturer’s protocol for gel extraction of the DNA. PCR clean-ups were carried out 




Product was diluted to 600 ng of plasmid in 30 µl of nuclease-free water or between 
20 – 2000 ng of PCR product in 30 µl of water, depending on the product size. Primer was 
diluted to 3.2 µM. Samples and primers were sent to Dundee DNA Sequencing and Services, 
University of Dundee, Dundee, Scotland. 
 
2.4.7 DNA digest and ligations 
 
Digests are described individually in each chapter. After digests of PCR products 
destined for ligations, samples were cleaned-up to remove the unwanted digested fragments. 
Plasmids were gel purified for the same purpose. Clean-up was performed as described 
elsewhere in this chapter. Ligation concentrations were calculated with the formula below. 
Vector mass was usually 50 ng.  
 
𝑰𝒏𝒔𝒆𝒓𝒕 𝒎𝒂𝒔𝒔 (𝒏𝒈) = 𝟑 ×
𝒊𝒏𝒔𝒆𝒓𝒕 𝒍𝒆𝒏𝒈𝒕𝒉  (𝒃𝒑)
𝒗𝒆𝒄𝒕𝒐𝒓 𝒍𝒆𝒏𝒈𝒕𝒉 (𝒃𝒑)
× 𝒗𝒆𝒄𝒕𝒐𝒓 𝒎𝒂𝒔𝒔 (𝒏𝒈) 
 
Ligation reaction was: Vector (50 ng), insert (as calculated above), ligase buffer (to 
1 ×), T4 DNA ligase (1 U), nuclease-free water (to 10 µl). Reagents from Promega. 
 
2.5 Tissue culture techniques  
 
2.5.1 Cell lines  
 
The cell lines used throughout the work are described in Table 2.1. 
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Table 2.1 – Cell lines used throughout the thesis. 
Cell name Description 
Ba/F3 Murine bone marrow pro-B cell  
CHO-K1 Chinese hamster ovary 
CHO-K1-S Suspension adaptation of CHO-K1 
DH82 Canine histiocytic sarcoma 
HEK293T Human embryonic kidney 
Lilly Canine inflammatory mammary carcinoma 
MCF-7 Human mammary carcinoma 
NIH/3T3 Mouse fibroblast 
RAW264.7 Mouse macrophage 
REM134 Canine mammary carcinoma 
 
2.5.2 Maintenance of cell lines 
 
Cells were maintained in an incubator (HERA cell 150i, Thermo Scientific) at 37
o
C 
and 5 % CO2 in a humidified atmosphere. Unless stated otherwise, cells were grown in tissue 
culture treated disposable plates (Thermo Scientific). Disposable plastic pipettes were used 
for cell culture (Corning). Cell culture manipulations were performed within a BioMat 2 
Class 2 Biological Safety cabinet (CAS). Media were stored at 4
o
C and were warmed to 
37
o
C before use in JB Aqua18 Plus waterbath (Grant). 
All cell media were supplemented with 10 % fetal bovine serum (FBS, Gibco), 
penicillin/streptomycin (100 U/ml, Gibco) and L-glutamine (2 mM, Gibco) unless stated 
otherwise. REM134 (Else et al., 1982), MCF-7 (European Collection of Cell Cultures, 
86012803), Lilly (a gift from Dr R. de Maria, University of Turin, Italy), RAW264.7, 
Human embryonic kidney (HEK) 293T, Chinese Hamster Ovary (CHO)-K1 (American Type 
Culture Collection) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
media (Gibco). DMEM contained 4 mM l-glutamine, 4.5 g/L glucose, 1.0 mM sodium 
pyruvate.  
Bone marrow-derived macrophages (BMDMs), osteoclasts and Ba/F3 cells were 
maintained in Roswell Park Memorial Institute medium (RPMI). RPMI contained 2 mM l-
glutamine, 4.5 g/l glucose, 10 mM HEPES [N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic 
acid], 1.0 mM sodium pyruvate. Culture supplements were as above with the addition of 
amphotericin B (2.05 µg/ml, Fungizone, Invitrogen).  
Cell subculture of adherent cells was made by trypsinization, with the exception of 
the BMDMs. At 80 – 90 % confluence, the culture supernatant was removed by aspiration. 
Cells were then washed by PBS, added slowly to the culture. This was removed by aspiration 
and Trypsin-EDTA (0.25 %, Gibco) was added to the cells (around 1 ml was added to 75 
cm
2
 plates. Volume was adjusted accordingly to other culture sizes). Cells were placed in the 
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incubator for 2 min (10 min for RAW264.7 cells). Adherent cells and clumps were broken 
by repetitive pipetting with 5 ml of media. Cells were plated at the desired densities and 
media was added to the required volume. 
BMDM were resuspended by repeated vigorous jets of media using a 10 ml syringe 
and a 20 gauge needle (Becton Dickinson). 
RAW264.7 cells used for flow cytometry were resuspended by scraping the plate 
with a disposable plastic cell scraper (Becton Dickinson). The scraper was gently moved 
along the plate until all cells were detached. 
Suspension CHO-K1-S cells were passaged by transferring the desired amount of 
cells into fresh media. When media needed to be replaced (assessed by colour and cell 
survival), the necessary volume of culture was spun at 100 × g for 10 min and the 
supernatant was replaced for fresh media. 
 
2.5.3 Determination of cell viability 
 
Detached or suspension cells were diluted 1:1 with Trypan blue dye (Gibco). The 
mixture was visualized in a Neubauer counting chamber (SLS). The live cells (not stained by 




𝒎𝒍⁄ = 𝑪𝒆𝒍𝒍𝒔 𝒊𝒏 𝒄𝒆𝒏𝒕𝒓𝒂𝒍 𝒔𝒒𝒖𝒂𝒓𝒆 × 𝟐 (𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓) × 𝟏𝟎
𝟒 
 
2.5.4 Freezing and thawing cells 
 
Cells were frozen by resuspending 2 x 10
6
 cells in 500 µl of ice-cold FBS (Gibco). A 
solution of FBS + DMSO (20 %) was then added dropwise to the cells, to a final volume of 1 
ml. Cells were placed in cryovials (Corning) and placed on ice. The vials were frozen 
overnight in a – 80
o
C freezer, inside a Mr. Frosty Freezing Container containing isopropanol 
(Thermo Scientific). The following day the cells were transferred to a – 150
o
C freezer for 
prolonged stock. 
To revive frozen cells, the vials were placed in a water bath at 37
o
C until most of the 
contents were defrosted. The cells were transferred to a 15 ml tube and warm media was 
added dropwise (to 10 ml). This was centrifuged at 300 × g for 5 min, the supernatant was 
removed and cells were plated in a 20 cm
2
 bottle with 5 ml of media.  
 




Lipofection was performed with Lipofectamine 2000 (Invitrogen). For this, cells 
were grown overnight in antibiotic-free medium with 10 % FBS (Gibco). For transfection of 
a single well from a 24-well plate, cells were grown in 500 µl of media to 90 % confluence. 
OptiMEM (Gibco) was used for diluting the lipofection complexes. Lipofectamine 2000 
(1.75 µl) was added to 25 µl of OptiMEM. The plasmid DNA (0.5 µg) was added to another 
tube with 25 µl of OptiMEM. These were kept at room temperature for 5 min, after which 
both volumes were mixed and incubated for 20 min. The Lipofectamine/plasmid mixture 
was gently pipetted into the cell culture media. Unless stated otherwise, the cells were 
maintained with the lipofection complex until cells or medium were used.  
 
2.5.6 Bone marrow derived macrophages (BMDM)/osteoclasts 
 
Canine or feline bone marrows were isolated from animals euthanized at the Royal 
(Dick) School Small Animal Veterinary Hospital. Samples were collected from animals from 
the Edinburgh Dog and Cat home euthanized for humane reasons. Femur was collected and 
kept on ice. In a tissue culture hood, the epiphyses of the bone were removed by sawing and 
the marrow was flushed several times using 20 ml of RPMI medium + EDTA (5 mM). This 
was centrifuged for 400 × g for 10 min, the supernatant was removed and red blood cell lysis 
buffer was added (KHCO3 (10 mM), NH4Cl (155 mM), EDTA (0.1 M), filter sterilized). This 
was left for 5 min on ice, then 45 ml of PBS were added and the tube was centrifuged. 
Twenty-four millilitres of RPMI were added to the cell pellet. Cells were grown in culture 
with the addition of rhCSF1 (20 ng/ml, Invitrogen) in three bacterial 100 mm plates/bone 
marrow (non-culture treated) (Sterilin). For the formation of osteoclasts, cells were cultured 
in normal tissue culture plates with rhCSF-1 (10 ng/ml, R&D Systems) and rhRANKL (30 
ng/ml, R&D Systems). Macrophages were expected to survive on non-bacterial plastic 
(Sasmono et al., 2003). After two days, the culture media from the initial 3 plates was 
passaged on to new plates to allow space for floating cells to adhere. All plates were cultured 
until the macrophage phenotype had developed (around 10 days).   
 
2.5.7 Endpoint cellular proliferation 
 
Cell viability was assessed using CellTiter-Glo kit (Promega) following the 
manufacturer’s recommendations. Briefly, the cell culture plate and the kit reagents were 
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allowed to stabilize to room temperature for 1 h. The two kit reagents were mixed and 100 µl 
were added to each well. The plate was inserted into the Victor3 plate reader (Perkin Elmer). 
The plate was shaken for 10 min, and the luminescence was allowed to stabilize for 2 min. 
The luminescence was read at 1 sec/well. 
 
2.6 Protein methods 
 
2.6.1 Nickel affinity purification 
 
Ni-NTA affinity was performed by adding the resin (Qiagen) to plastic 12 ml Poly-
Prep columns (Bio-Rad). The storage buffer was allowed to drain and the resin was washed 
with Binding buffer (Hepes (100 mM), imidazole (10 mM), NaCl (500 mM), pH 7.75). The 
solution containing the His-tagged protein was then mixed with the resin and incubated at 
4
o
C for 1 h. The solution was allowed to drain through the column containing proteins that 
did not bind to the resin. The unbound fraction was collected for analysis. Non-specific 
binders were removed by washing the column thrice with 20 × the column volume of 
washing buffer (Hepes (100 mM), imidazole (50 mM), NaCl (500 mM), pH 7.75). The 
desired protein was then eluted from the column in four fractions of 1 × column volume of 
elution buffer (Hepes (100 mM), imidazole (500 mM), pH 7.75). 
 
2.6.2 Protein quantification 
 
For protein quantification using the Bradford assay, 200 µl of the ready-made 
reagent (QuickStart Bradford reagent, Bio-Rad) were added to 18 wells of a transparent 96-
well plate for the standard curve + the necessary amount of wells for the samples (done in 
triplicates). BSA was added as the standard protein in increasing concentrations, in 
triplicates: 0, 0.42, 0.85, 1.27, 1.7 and 2.12 mg/ml. The wells containing the BSA were 
mixed to allow the development of the blue colour. The sample proteins were added and 
mixed im their respective wells in concentrations that were within the standard range. The 
plate was then read in a Victor3 plate reader (Perkin Elmer) at 595 nm.  
 
2.6.3 Western blots and gel stains 
 
Gels were made using the recipes in (Gallagher, 2001). Briefly, the protocol was as 
follows: 30 % acrylamide/0.8 % bisacrylamide solution (National Diagnostics) (at 8 – 15 % 
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final acrylamide concentration); 1.5 M Tris-Cl with 0.4 % SDS, pH 8.8 (3.75 ml); distilled 
water to 15 ml; 10 % ammonium persulfate (50 µl, Bio-Rad); TEMED (10 µl, Bio-Rad). 
These were mixed and poured to 2/3 of the height of Mini-Protean glass plates of either 1 – 
1.5 mm, depending on the sample volumes (Bio-Rad). The gel was covered with distilled 
water and allowed to set. After setting, the water was removed and the stacking gel was 
added to the plates (30 % acrylamide/0.8 % bisacrylamide solution (0.65 ml), 0.5 M Tris-
HCl with 0.4 % SDS, pH 6.8 (1.25 ml), distilled water (3.05 ml), 10 % ammonium persulfate 
(25 µl), TEMED (5 µl)). The plastic comb was added into the poured stacking gel to shape 
the wells. The gel was allowed to set.  
Bis-Tris 4 – 12 % acrylamide gels (Invitrogen) were used to separate the peptide of 
the His-tagged dimerization region of CSF-1R. 
The samples were prepared by the addition of 6 × sample buffer (Tris-Cl/SDS, pH 
6.8 as above (7 ml), glycerol (3.8 g or ∼ 3 ml), SDS (1 g), DTT (0.93 g), bromphenol blue 
(1.2 mg), water (to 10 ml if needed)). DTT was omitted from the sample buffer in non-
reducing conditions. Unless stated otherwise, samples were heated at 95
o
C for 5 min after the 
addition of the sample buffer. The samples were pipetted into the wells of the gel. The size 
standard used was Precision Plus Protein Dual Colour (5 µl, Bio-Rad). The gel was run at 17 
mA/gel until the samples reached the running gel, when current was increased to 23 mA/gel.  
For Coomassie staining of the gel, it was removed from the glass and immersed in 
the staining solution (methanol (50 %), Coomassie brilliant blue R-250 (0.05 %), acetic acid 
(10 %), water (40 %)). Coomassie brilliant blue R was dissolved in methanol before adding 
acetic acid and water. When the gel was thoroughly blue, it was washed with the destaining 
buffer in 5 min incubation steps: methanol (5 %); acetic acid (7 %); distilled water (88 %). 
Washing was repeated until the bands were clearly visible. 
For silver staining, the gel was incubated in the following solutions: Fixing solution 
(methanol (50 %), acetic acid (10 %)) for 30 min; methanol (5 %) for 15 min; 3 washes of 5 
min with deionized water; Na2S2O3.5H2O (0.02 %) for 2 min; 3 washes of 30 sec with water; 
AgNO3 (0.2 %) for 25 min; 3 washes of 1 min with water; up to 10 min developing in 
developing solution (Na2CO3 (3 %), formaldehyde (0.018 %), Na2S2O3.5H2O (0.0004 %)). 
The development reaction was stopped with EDTA (1.4 %) for 10 min. 
For western blots, when running was complete, gel was removed from glass plates 
and the stacking gel was cut off. The gel was used for transfer of proteins to a nitrocellulose 
membrane. The transfer cassette (Bio-Rad) was assembled in the following order, from the 
anode (white) to the cathode (black) side: sponge, filter paper, nitrocellulose membrane (GE 
Healthcare), gel, filter paper, sponge. The cassette was placed in a transfer apparatus with 
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transfer buffer (Tris base (18.2 g), glycine (86.5 g), methanol (1200 ml), distilled water (to 6 
l)). Transfer was performed at either 100 V for 1 h or 25 V overnight, both at 4
o
C. 
If necessary, the membrane was stained using Ponceau red (Ponceau S (Sigma), 0.5 
g dissolved in 1 ml glacial acetic acid. Water was added to 100 ml). The staining solution 
was placed on the nitrocellulose membrane and incubated for 30 sec mixing. The stain was 
returned to the container for reuse. The membrane was washed with distilled water until the 
bands were visible.  
The membrane was blocked with PBST + skimmed milk (5 %) for 3 h at room 
temperature or overnight at 4
o
C. The primary and secondary antibodies, diluted in blocking 
buffer, were added sequentially, with 3 washing steps with PBST after each antibody. 
 
2.6.4 Dot blots 
 
Dot blots were performed by pipetting 1 µl of the samples onto nitrocellulose 
membranes (GE Healthcare). The samples dotted on the membrane were allowed to dry (2 – 
5 min). Membrane blocking and antibody incubations were as for western blots. 
 
2.6.5 Chemoluminescent detection 
 
Western and dot blots were developed by a luminescence reaction with the HRP 
conjugated with the secondary antibodies. The enhanced chemoluminescence reagents (GE 
Healthcare) were mixed 1:1 (total of 1 ml for an average western blot membrane) and added 
onto the membranes after washing the secondary antibody. The reagent was kept for 1 min 
on the membrane, after which it was drained. The membrane was covered in plastic film 
(Saran) and exposed to radiograph films (GE Healthcare) in a dark room. Exposure times 
varied from 15 sec to 4 min depending on signal strength. The film was developed by 
immersion in developer solution, water, fixer solution and water, in this order. The molecular 






Methods for staining are described separately in each chapter. Normal goat serum 
(Gibco) was commonly used for blocking binding sites (10 % in PBS). A secondary antibody 
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control was commonly used. The control samples received only blocking buffer in 
substitution for the primary antibody, and received the same concentration of secondary 
antibodies as the test samples. Images were obtained using a Leica DM LB fluorescence 
microscope. When necessary colour channels were joined using the ImageJ 1.46 software 
(open source). 
 
2.7.2 Flow cytometry 
 
FACSCalibur or FACSAria flow cytometers were used. Specific protocols and 
antibodies are detailed in each chapter. Cells were gated by adjusting the size (forward 
scatter/FSC) and granularity or complexity (side scatter/SSC) of the cells to the middle of a 
FSC × SSC graph. The fluorescent antibodies were excited by a blue argon-ion laser. Green 
fluorescence emission (FITC or Alexa 488 fluorochromes) was captured in FL1, yellow 
fluorescence emission (PE) was captured in the FL2 channel and red fluorescence emission 
(7-AAD) was captured in the FL3 channel. A secondary antibody control was added, when 
pertinent, as a negative control. Isotype controls were added when mentioned. Dual-colour 
cytometry was performed by using single-stained controls to set the fluorescence intensity of 
each channel. Results were analysed after setting the gate on the cellular population, 
eliminating debris. The percentage of positive cells was determined by comparison to the 
negative (secondary antibody or isotype) control level, which was set to 1 %. 
 
 





CSF-1 is an important mediator in the 





 Canine mammary carcinoma cells reduced the activation of macrophages in response to 
LPS. 
 The effect of cancer cells on macrophages was partially dependent on CSF-1R signalling. 
 CSF-1 had a dual effect on macrophages, inducing cellular activation but reducing 
inflammatory responses. 





Tumour-associated macrophages (TAMs) can constitute a large proportion of the cellular 
mass of solid tumours. Within tumours, macrophages can be in an alternative state of 
activation that acts in favour of carcinogenesis, instead of counteracting it. Consequently, 
TAMs can lead to poorer clinical prognosis, as they assist in cancer progression such as local 
tissue invasion and immunosuppression. In this chapter, it is demonstrated that canine 
mammary carcinoma cells reduced macrophage responses to LPS stimulation. CSF-1 is an 
important factor for macrophage survival and is highly expressed in several cancers. 
Blocking CSF-1 reduced the effect of cancer cells on macrophages, indicating that this is an 
important factor in the interaction between these cells. Independently, this cytokine induced 
macrophage activation, but it reduced LPS-induced activation. Macrophages also exerted an 
effect on cancer cells, inducing canine mammary carcinoma cells to up-regulate CSF-1R and 
glucose uptake. Canine mammary cancer cells showed increased proliferation in the 
presence of CSF-1 and were sensitive to a CSF-1R tyrosine kinase inhibitor. Overall, these 
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data support the significance of the collaboration between macrophages and canine cancer 




 The macrophage content of solid tumours is variable, but these cells have been 
found to compose up to 30 % of the cellular mass of naturally occurring human cancers and 
up to 83 % of syngeneic tumours of mice of both epithelial and mesenchymal origins (Gauci 
and Alexander, 1975; Milas et al., 1987).  
For many years, it was believed that the presence of macrophages within tumours 
indicated that the immune system was developing a response against the neoplasms (Lauder 
et al., 1977; Morantz et al., 1979). However, over time the paradigm of the role of 
macrophages within tumours shifted, and macrophages are currently linked with a myriad of 
events that lead to malignant transformation (Mantovani et al., 2002; Milas et al., 1987). The 
shift in our understanding of the significance of macrophages within cancer changed due to 
consistent findings that the presence of these cells within tumours correlated with poorer 
clinical outcomes (Lewis and Pollard, 2006; Richardsen et al., 2015). 
The term “tumour-associated macrophages” is consequently now widely used to 
report the negative effects of macrophage function within tumours. From 1960 to 1980, only 
one paper could be found in the PubMed database that contained the words “TAM”, 
“macrophage” and “cancer”. In the following twenty years, 88 papers associated with those 
three terms were indexed in that database. From 2000 to the time of writing, 506 articles 
were added to that list (http://www.ncbi.nlm.nih.gov/pubmed). The expansion of the 
literature on TAMs is a reflection of the protagonist role now being attributed to 
macrophages in cancer malignancy. For this reason, much attention is being given to 
therapeutic modalities that may target TAMs (Aharinejad et al., 2004; Hume and 
MacDonald, 2012; Paulus et al., 2006).  
 The “new” role of macrophages within cancer is justified by the concept that there 
are, in fact, differently polarized macrophage phenotypes – named M1 and M2 – which are 
anti- or pro-tumoural, respectively (Sica et al., 2006). The current understanding of TAMs is 
evolving into a more complex picture whereby the tumour microenvironment alters how 
macrophages react to the cancer cells. The idea of extremely polarized TAMs, either killing 
or assisting cancer cells, is being replaced by a more nuanced concept where several factors 
influence the activity of macrophages, such as the tumour sites where they are inserted 
(Grugan et al., 2012; Lewis and Pollard, 2006; Quatromoni and Eruslanov, 2012).  
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3.1.1 M1 and M2 
 
 The M1 and M2 classification was first generated to explain the different 
macrophage activation pathways following anti-microbial and anti-parasitic responses. The 
M2 was then further subdivided into three categories to denote other alternative activation 
routes: M2a (generated by parasitic responses, dependent on IL-4 and IL-13); M2b (induced 
by Fc receptors and immune-complexes); M2c (anergic state, promoted by IL-10) (Martinez 
and Gordon, 2014). The factors inducing the different macrophage activation pathways and 
the corresponding cellular markers are depicted in Figure 3.1. 
 
 
Figure 3.1 – The stimuli and markers of M1/M2 macrophage activation. The stimuli, promoters, 
markers and functions cited are examples and are not exhaustive of the whole literature. References: 
(Bouhlel et al., 2007; Lawrence and Natoli, 2011; Mantovani et al., 2002; Martinez and Gordon, 2014; 
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3.1.2 Tumour sites 
 
The tumour sites in which macrophages are embedded seem crucial in determining 
the fate of these cells. Areas of varying oxygen levels form within tumours due to the growth 
patterns of the neoplasms. Hypoxic regions form within tumours due to the rapid expansion 
of the cancerous tissue, overloading the capacity of new blood vessel formation. As the 
distance between the provisioning capillaries and the cancer cells increase, the intra-
tumoural oxygen levels decrease. Also, emboli and the high pressure from the tumour mass 
on the capillaries can inhibit perfusion. Hypoxic sites therefore lead to apoptosis of the 
cancer cells, accumulating cellular debris and stimulating the tumoural production of 
chemokines such as the vascular endothelial growth factor (VEGF) in response to the low 
oxygen concentration (Jögi, 2015; Lewis and Pollard, 2006).  
TAM density is higher in hypoxic and necrotic foci within tumours, areas that are 
denominated as “hot-spots”. The cellular debris and chemokines may be important to lead 
macrophages into the necrotic sites within the tumour mass. Hypoxic tumoural tissue also 
produces anti-inflammatory factors, such as IL-10 and prostaglandin E2 (PGE2); these may 
reduce the reactivity of macrophages against the cancer cells, reducing MHC II expression, 
for instance (Wiemer et al., 2011). 
In those tumoural areas, macrophages assume an “organ building” function, 
scavenging the necrotic foci (Murdoch et al., 2004) and increasing oxygenation by 
promoting blood vessel formation. The low oxygen concentration and reactive oxygen 
species within the tumour induce macrophages to express hypoxia-inducible transcription 
factors (HIFs) and NF-κB (Jögi, 2015). Abnormal expression of the p50 portion of NF-κB 
leads macrophages to become insensitive to inflammatory signals, a characteristic of TAMs 
(Saccani et al., 2006). In the tumour environment, macrophage HIFs act through NF-κB to 
express the pro-angiogenic factor VEGF (Eubank et al., 2011). The rapid neovascularization 
that follows is associated with malignant transformation of the tumour and further 
macrophage recruitment (Lewis and Pollard, 2006).  
As an endorsement of the great variability of macrophage functions, if these cells are 
under pro-inflammatory signals, they can be either pro- or anti-angiogenic, depending on 
which agonist or culture condition is used (Eubank et al., 2011; Ramanathan et al., 2007). 
The presence of macrophages in different tumour sites is therefore correlated to 
different biologic effects. Macrophage numbers in the hypoxic foci are more relevant for 
determining poor prognosis than TAMs in other tumour sites (Murdoch et al., 2004). TAMs 
away from the hot-spots but in the tumour stroma are linked to greater lymph node 
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metastasis. In contrast, TAMs in close contact with cancer cells are more likely to show anti-
tumour properties, leading to better clinical outcomes (Ohno et al., 2004, 2002).  
 
3.1.3 Effects of TAMs 
 
Pro-tumoural and other non-inflammatory macrophages share several features, such 
as nuclear accumulation of the inhibitory p50 NF-κB homodimer (Mantovani and Sica, 
2010). Indeed, many of the characteristics of TAMs occur due to an upregulation of genes 
which occur in non-inflammatory macrophages associated with physiological tissue 
development. Wnt-signalling is one of such organ development pathways that have increased 
activity in cancer macrophages, driving MMP and TNF-α overexpression. The same Wnt 
signals have a role in the vasculogenesis of the developing eye, for instance (Ojalvo et al., 
2010; Pukrop et al., 2006). These anti-inflammatory and tissue-remodelling characteristics of 
TAMs lead to several of the pro-tumoural effects of these macrophages, such as invasion of 
surrounding tissues, immunosuppression, intravasation and neovascularization (Van 
Ginderachter et al., 2006). 
As discussed above, TAMs are important drivers of neovascularization through the 
expression of VEGF. These cells also circumvent anti-VEGF therapies by increasing blood 
vessel formation through other signals when VEGF is blocked. Matrix metalloproteinase-9 
(MMP-9), secreted by macrophages in response to CSF-1, is one of the factors that 
contribute to enhancement of neovascularization (Lewis and Pollard, 2006; Priceman et al., 
2010). MMP-9 modifies the extracellular matrix and attracts endothelial cells, organizing 
newly formed blood vessels (Vu et al., 1998). The blood supply provided by the 
macrophages allows the expansion of the tumour by removing waste products and increasing 
the oxygen concentration. It also provides cancer cells access to the circulation for metastasis 
(Jögi, 2015). Along with an increase in vascularization, perivascular macrophages assist 
cancer cells to infiltrate into the blood vessels, leading to haematogenous metastasis 
(Wyckoff et al., 2007). Transforming growth factor-β1 (TGF-β1) produced by the TAMs 
influences epithelial cancer cells to acquire motility through the process of epithelial-
mesenchymal transition (EMT), another step towards metastasis formation (Jögi, 2015; Ye et 
al., 2012). 
Another cancer hallmark which can be stimulated by TAMs is the invasion of 
surrounding tissues. Stimulation of cancer cells with EGF produced by macrophages is 
required by some breast carcinoma cells to demonstrate invasive properties, moving into 
surrounding tissues in the presence of this factor (Goswami et al., 2005). Surrounding tissue 
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invasion also depends on MMP expression by the macrophages in response to TNF-α 
(Pukrop et al., 2006). TAMs secrete TGF-β1 that can also increase cancer invasion through 
cancer cell production of MMP-9 (Ye et al., 2012). 
The immunosuppressive characteristics of TAMs are enhanced by the tumour 
environment. Low oxygen concentration induces macrophages to express HIF-1α; hypoxia 
and HIF-1α production are sufficient to induce macrophages to suppress T-lymphocytes 
(Doedens et al., 2010). Tumour-derived anti-inflammatory cytokines (such as IL-10 and 
PGE2) also lead TAMs to express IL-10, for instance (Sica et al., 2000), and mediate lysis of 
CD8
+
 T-cells (Mitchem et al., 2013). Another cytokine which is produced by several tumour 
types is CSF-1 (Sapi, 2004). CSF-1-conditioned macrophages have increased activity of 
STAT1, a transcription regulator. In its turn, STAT1 promotes NO and arginase expression, 
which are necessary to induce apoptosis of T-lymphocytes by TAMs (Kusmartsev and 
Gabrilovich, 2005). Much is still not understood about the biology of immune evasion of 
tumours. Some regulators, such as STAT1, have even been implied in both M1 and M2 
formation (Mantovani and Sica, 2010). This regulator is connected with macrophage killing 
of lymphocytes but is also important for IFN-γ expression, a cytokine capable of inhibiting 
cancer growth (Dunn et al., 2002). 
 Despite the extensive incrimination of TAMs in assisting cancer progression, 
macrophages are in some circumstances capable of exerting anti-tumoural effects. TAMs 
showing pro-tumoural characteristics – such as promoting tumour cell invasion – are still 
capable of performing antibody-mediated cancer cell lysis, for instance (Grugan et al., 2012). 
This has been confirmed in a clinical trial with rituximab (anti-CD20), where high TAM 
counts were correlated to better treatment responses (Taskinen et al., 2007). As mentioned 
previously, depending on the localization within a tumour, some macrophages are also 
capable of phagocytic activity against the cancer cells (Ohno et al., 2004). 
  
3.1.4 CSF-1R signalling 
  
 As discussed above, the presence of TAMs does not necessarily correlate with 
malignancy, since these cells can perform different functions depending on the tumoural site 
where they are embedded. It has also been shown that altering the phenotype displayed by 
the “hot-spot” macrophages can be sufficient to impede pro-tumorigenic action. CSF-1 
secretion by the cancer cells attracts blood monocytes to the tumoural bed. The monocytes 
mature into TAMs inside the tumour and again CSF-1 seems important in directing 
macrophages towards tumour-promoting characteristics (Grugan et al., 2012). However, 
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depending on the inhibitor used, blocking CSF-1R does not reduce TAM counts. Although 
the number of macrophages may remain stable after blocking this receptor, improvements in 
the clinical outcome can still derive. This occurs because inhibiting CSF-1R can alter the 
phenotype of certain macrophage subsets. Thus, macrophages can be turned away from the 
tumour-promoting phenotype without affecting macrophage survival. In the event of CSF-1R 
blockade, the number of TAMs is maintained by other cytokines, such as GM-CSF and 
interferon-γ (Haegel et al., 2013; Louis et al., 2015; Pyonteck et al., 2013). 
 Transgenic mice with altered expression of CSF-1 or CSF-1R demonstrate the 
importance of this signalling pathway for tumour progression. The CSF-1 knockout (op/op) 
has unchanged incidence and growth rate of primary tumours, but exhibits delayed 
metastasis formation when compared to the wild-type (Lin et al., 2001). Overexpression of 
CSF-1 and its receptor leads to mammary hyperplasia and tumour formation, with increased 
cellular proliferation markers and macrophage infiltration (Kirma et al., 2004). On the other 
hand, the GM-CSF + IFN-γ knockout – both are cytokines associated with inflammatory 
macrophages – has the opposite effect, leading to spontaneous formation of a variety of 
tumours (Smyth et al., 2006). 
 CSF-1 is believed to be an important mediator in the paracrine signalling between 
cancer cells and macrophages. There is a loop of activation between these cells where CSF-1 
produced by cancer cells recruits macrophages and leads them to express epidermal growth 
factor (EGF), which in its turn has proliferative action on the cancer cells (Escamilla et al., 
2015; Wyckoff et al., 2004). For cancer cells that express the CSF-1R, production of CSF-1 
also drives an autocrine activation pathway that is important for tumoural tissue invasion 
(Patsialou et al., 2009).  
 
Because of the subtleties of macrophage functions within tumours, it is important to 
understand the mechanisms which drive each of these roles (Martinez and Gordon, 2014). In 
this chapter, co-cultures and cell-conditioned media were used to model the cancer cell and 
macrophage interaction. A canine mammary cancer cell line, REM134, had the effect of 
impeding LPS-induced activation of a murine macrophage cell line, RAW264.7. Activation 
was measured by MHC II and TLR 2 expression and cellular granularity. CSF-1 was an 
important mediator of the TAM/cancer cell interaction. Blocking this cytokine abrogated the 
effect of the cancer cells on the macrophages. Although CSF-1 was capable of inducing 
macrophage activation, it prevented LPS stimulation of these cells. Cancer cells were also 
sensitive to CSF-1, and macrophages increased CSF-1R expression on cancer cells. These 
data illustrate the importance of TAMs and of CSF-1R signalling to cancer progression. 
Chapter 3 - CSF-1 in macrophage/cancer interaction    68 
 
3.2 Materials and Methods 
 
Basic methodological descriptions and brands not stated here are presented in 
Chapter 2. 
 
3.2.1 Effect of cancer cells on macrophage activation by LPS 
 
RAW264.7 macrophages and REM134 canine mammary carcinoma cells were 
grown in co-cultures or in the presence of conditioned medium in 6-well tissue culture 
plates. Cells were kept in subconfluent conditions for the experiments.  
REM134-conditioned medium (CM) was collected after culturing these cells from 
60 % confluence for 72 h. Supernatant was removed from the culture, was centrifuged in 50 
ml tubes for 400 × g and was filtered through a 0.45 µm syringe filter (Cole-Parmer). The 
conditioned medium was stored at 4
o
C until used. 
For co-culture experimentation, RAW264.7 macrophages were stained with CFSE 
(eBioscience) in order to separate macrophages from cancer cells in flow cytometry. For this, 
cells were suspended in FBS-free DMEM medium (Gibco). CFSE was added to the cells at 
10 µM for 15 min at room temperature, protected from light. Cells were then washed twice 
with complete medium. This was performed for the first experiment only, since it was found 
that REM134 and RAW264.7 cells could easily be discriminated based on the forward 
scatter by flow cytometry. 
When in co-culture, cells were grown at a ratio of 2:1 of REM:RAW. Co-cultures 
and RAW264.7 cells with REM-conditioned medium were grown for 3 days, when 
Escherichia coli O111:B4 LPS (1 µg/ml, Sigma) was added (when stated in the text) and 
incubated with cells for 48 h. Cells were removed from the plate by scraping and were 
assessed by flow cytometry. 
 
3.2.2 Effect of CSF-1 on REM134 and RAW264.7 proliferation 
 
For cell proliferation assays, 7 × 10
3
 cells were grown in black opaque 96-well plates 
(Corning). Cells were treated with the indicated concentrations of rhCSF-1 (Invitrogen) for 
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3.2.3 Blocking CSF-1 by competitive inhibition 
 
Cancer cells and macrophages were co-cultured for 3 days in the presence or absence 
of recombinant canine CSF-1R extracellular region (1 µg/ml). RAW264.7 cells in isolation 
also received the CSF-1R as a control. The recombinant receptor was cloned, expressed and 
purified as is detailed in Chapter 7. rhCSF-1 (50 ng/ml, Invitrogen) was used when stated 
during the same period. LPS (1 µg/ml, Sigma) was then added for 48 h. Cells were scraped 
and analysed by flow cytometry. 
 
3.2.4 Effect of CSF-1 on MHC II expression by RAW cells 
 
Macrophages in 6-well plates at 60 % confluence were incubated with increasing 
concentrations of rhCSF-1 (Invitrogen) for 48 h. When stated, LPS (1 µg/ml, Sigma) was 
added and cells were incubated for another 48 h. Cells were harvested by scraping and MHC 
II expression was analysed by flow cytometry.  
 
3.2.5 Flow cytometry of RAW264.7 cells 
 
One million cells were used for each analysis. Cells were scraped from culture 
plates. To differentiate RAW264.7 and REM134 cells by flow cytometry in co-culture 
experiments, RAW cells were stained with CFSE, as described in 3.2.1, above. 
Macrophages in 100 µl of complete DMEM medium were stained with the primary 
antibody for 20 min at 4
o
C: anti-mouse MHC II I-A/I-E, PE-conjugated (0.125 µg/test, 
eBiosciences), anti-mouse TLR2, FITC-conjugated (0.5 µg/test, eBiosciences). Cells were 
then washed with PBS thrice at 4
o
C and centrifuged between washes at 400 × g for 5 min to 
remove the supernatant. Unstained cells and RAW264.7 macrophages unstimulated with 
LPS were used in flow cytometry as controls. 
Samples were analysed using a FACScalibur flow cytometer (Becton Dickinson). 
Cells in the macrophage gate were assessed. Results were analysed using the Summit 4.1 
software (Dako), assessing the percentage of positive cells and the mean fluorescence 
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3.2.6 Immunofluorescent staining of cancer cells 
 
Lilly cells (2.5 × 10
4
) were grown on tissue culture treated chamber slides (Nunc 
Lab-Tek II Chamber Slide System, Thermo Scientific) overnight in the presence or absence 
of conditioned medium from macrophages (conditioned medium was added to 20 % of total 
culture volume). RAW264.7 macrophage-conditioned medium was collected after culturing 
these cells from 60 % confluence for 48 h. Lilly cells were fixed with ice cold acetone for 20 
min at – 20
o
C and blocked with PBS + goat serum (10 %) for 1 h at room temperature. 
Rabbit anti-human C-terminal CSF-1R (1:100, Abcam) was diluted in blocking buffer. 
Slides were incubated overnight at 4
o
C. After 3 washes in PBS for 5 min, secondary goat 
anti-rabbit Alexa 488 (1:200, Invitrogen) in blocking buffer was used for 1 h at room 
temperature. The secondary antibody was washed with PBS as before. DAPI (4',6-
diamidino-2-phenylindole) nuclear staining was included in the mounting medium 
(Vectashield Mounting Media with DAPI, Vector Labs). A coverslip (Thermo Scientific) 
was placed on top of the section with a drop of mounting medium. The section was isolated 
using nail polish. 
  
3.2.7 Sequencing of CSF-1R from a canine cancer cell line 
 
mRNA was extracted from the Lilly inflammatory canine mammary carcinoma cell 
line using RNeasy Mini Kit (Qiagen). cDNA was synthesized using random nonamers 
(Sigma) and the Omniscript RT Kit (Qiagen). The receptor was amplified using the primers 
shown on Table 3.1 using Phusion High-fidelity polymerase (Thermo Scientific) and the 
protocol in Chapter 7 for the cloning of the full CSF-1R receptor. The product was cloned 
into the pCR4-TOPO vector (Invitrogen) following the same protocol as in Chapter 7. The 
plasmid was sequenced using the T3 and T7 primers (provided by the sequencing service), 
and also the primers shown in Table 3.1, which are specific for the canine CSF-1R. 
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Table 3.1 – Primers used to sequence the CSF-1R from Lilly cells. Primers shown as 5` to 3`. 







T3 primer: Chapter 7 
T7 primer: Chapter 7 
 
3.2.8 Effect of RAW264.7-conditioned medium on cancer cell 
proliferation 
 
The xCELLigence Real-Time Cell Analyzer (Roche) was standardized with 50 µl of 
DMEM medium before adding cells. REM134 cells (10
4
 or 3 × 10
4
 cells) were plated on a 
16-well xCelligence plate (Roche). The plate was scanned to measure the initial numbers of 
cells in each well, and then treatment was added. RAW264.7 macrophage-conditioned 
medium was collected after culturing these cells from 60 % confluence for 48 h. This 
conditioned medium was added to the REM134 cells (20 % of final culture volume). Where 
stated, rhCSF-1 (Invitrogen) was also added (100 ng/ml). Cells were then maintained at the 
usual culture conditions for the duration of the experiment. The amount of cells attached to 
the bottom of each well was measured by the equipment through assessment of the 
interference with the electrical impedance of the sensor on the plate. Cell proliferation was 
assessed every 15 min for 21 h (3 × 10
4




3.2.9 PCR for the CSF-1R in REM134 cells 
 
cDNA from REM134 cells was generated as presented above for the Lilly cells. PCR 
was performed to assess the expression of CSF-1R mRNA by REM cells. PCR conditions 
and primers were as for the His-tagged dimerization domain (Chapter 7). The positive 
control was cDNA from canine spleen, produced as shown in Chapter 7. A no-template 
reaction was added as a negative control. 
 
3.2.10 Glucose uptake 
 
REM134 cells were pre-incubated with RAW264.7 macrophage-conditioned 
medium for 72 h. Glucose uptake by cancer cells was assessed using 2NBDG fluorescent 
glucose (50 µM, Invitrogen). The reagent was added to the cells for 30 min at 37
o
C or on ice 
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(as a negative metabolic control).  Ethanol was used as a vehicle control (VC) for the 
glucose. After glucose uptake, the cells were resuspended by trypsinization, washed with 10 
ml of cold PBS thrice (400 × g centrifugations) and were analysed by flow cytometry. 
Samples were analysed using a FACScalibur flow cytometer (Becton Dickinson). Cells in 
the REM134 cell gate were assessed. Results were analysed using the Summit 4.1 software 
(Dako), assessing the percentage of positive cells in comparison to cells that did not receive 
2NBDG fluorescent glucose. 
 
3.2.11 Effect of small molecule inhibitors 
 
For cell proliferation assays, 7 × 10
3
 cells were grown in black opaque 96-well plates 
(Corning). GW2580 (Cayman Chemical), toceranib phosphate (Palladia, Pfizer) or 
RS102895 hydrochloride (Sigma) were added at the stated concentrations. Concentrations of 
inhibitors differ between cells because they were increased from previous assays until an 
effect was seen or until the volume of vehicle became toxic to cells. All the inhibitors were 
dissolved in dimethyl sulfoxide (DMSO) Hybri-Max (Sigma) to create the stock solution. 
Toceranib phosphate was supplied as a tablet. It was crushed manually to create the stock 
solution. DMSO Hybri-Max (Sigma) was added at the same volumes as the inhibitors as a 
vehicle control. Cell proliferation was analysed with CellTiter-Glo (Promega). 
 
3.2.12 Statistical analyses 
 
Assumption tests were performed using Minitab 16 software (MiniTab Inc). 
Kruskal-Wallis, Student’s t-test, ANOVA statistical analyses (P < 0.05, unless indicated) and 




3.3.1 Effects of cancer cells on macrophages – reduced inflammatory 
activation 
 
 Activation of RAW264.7 macrophages in response to LPS was impeded by the 
presence of mammary cancer cells. Size, granularity and MHC II expression were increased 
in macrophages after LPS stimulation, indicating inflammatory activation of these cells. Co-
culture with canine and human mammary cancer cells (REM134 and MCF7, respectively) 
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hindered macrophage activation as measured by these parameters. The presence of a control 
cell line (HEK293T) had a minor effect on LPS-induced macrophage activation (Figure 3.2). 
RAW264.7 do not normally express MHC II (Saxena et al., 2003), so LPS activation as 
measured by MHC II could be quantified as the percentage of positive cells and the mean 























Figure 3.2 – Mammary cancer cells inhibited LPS-induced RAW 267.7 macrophage activation. 
Macrophages were cultured for 72 h in the presence or absence of two mammary cancer cell lines 
(REM134 and MCF-7) or a control cell line (HEK293T). E.coli O111:B4 LPS (1 µg/ml, Sigma) was 
added for 48 h. Notice how co-culture with cancer cells reduced macrophage activation by LPS. (A) 
Bright-field images of macrophages cultures. (B) Size (FSC) × granularity (SSC) flow cytometry plots 
of different treatments. Macrophages are marked inside the gate. (C) Quantification of macrophage 
granularity (SSC). (D) Macrophage MHC II, percentage of positive cells. Cells were stained with anti-
mouse MHC II I-A/I-E PE (0.125 µg/test, eBiosciences). (E) Macrophage MHC II, mean fluorescence 
intensity quantification. Results represent the means of 4 replicates ± SD. Asterisks represent 
statistical difference by ANOVA from the “RAW+LPS” group. “ns”, non-significant difference from 
the “RAW+LPS” group. 
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The effect of cancer cells on macrophages was not dependent on cell-cell interaction. 
The suppressive effects of REM134 cells over macrophages could be replicated by adding 
only conditioned medium (CM) from the cancer cells into the RAW264.7 macrophage 
culture. In the presence of conditioned medium, macrophages had reduced granularity and 
expression of MHC II after LPS exposure. TLR2, a second membrane cellular activation 
marker (Saccani et al., 2006), was also evaluated to confirm the analysis with MHC II. TLR2 
presented a similar pattern to MHC II (Figure 3.3). 
 
Figure 3.3 – The effects of cancer cells over macrophages were not dependent on cell-cell 
interactions. RAW264.7 macrophages cultured for 72 h in the presence or absence of conditioned 
medium (CM) from REM134 cells and then another 48 h with E.coli O111:B4 LPS (1 µg/ml). Cancer 
cell-conditioned medium reduced macrophage activation by LPS. (A) Macrophage granularity (SSC). 
(B) Macrophage MHC II, mean fluorescence intensity quantification. (C) Macrophage TLR2, mean 
fluorescence intensity quantification. Cells were stained with anti-mouse TLR2, FITC-conjugated (0.5 
µg/test, eBiosciences). Results represent the means of 3 replicates ± SD. Asterisks represent statistical 




3.3.2 CSF-1-induced proliferation 
 
Since CSF-1 is known to be relevant for progression of several types of cancer (Lin 
et al., 2001), the effect of this cytokine was analysed on the REM134 canine mammary 
cancer cells and the RAW264.7 macrophages. Both cell types were analysed with regards to 
their proliferation capacity in response to recombinant human (rh) CSF-1. Cancer cells and 
macrophages proliferated in response to rhCSF-1. The proliferation of the cells was dose-
dependent (Figure 3.4). The presence of CSF-1R in REM134 cells was confirmed by PCR 
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(not shown). The CSF-1R from another canine mammary cancer cell line (Lilly) was 













Figure 3.4 – Mammary cancer cells and macrophages proliferated in response to CSF-1. (A) 
Proliferative response of RAW264.7 macrophages 48 h after addition of rhCSF-1 (Invitrogen). (B) 
Proliferative responses of REM134 canine mammary cancer cells 48 h after addition of rhCSF-1. 
Proliferation results as measured by luciferase activity (CellTiter-Glo, Promega). Results represent the 
means of 6 replicates ± SD. Asterisks indicate statistically significant difference by ANOVA in 
relation to the control (0 ng/ml). “ns”, non-significant difference from the control group.  
 
 
3.3.3 CSF-1 as a mediator in the cancer cell/macrophage cross-talk 
 
Work from other groups had suggested that CSF-1 signalling could not only promote 
cancer proliferation, as confirmed in Figure 3.4, but also induce the M2 phenotype of TAMs 
(Grugan et al., 2012). To assess if CSF-1 played such a role in the interaction between canine 
mammary cancer cells and macrophages, this growth factor was blocked by the addition of 
recombinant canine (rc) CSF-1R. The recombinant receptor is able to actively bind to CSF-1 
(Chapter 7), thus competitively inhibiting its functions on cells within the cell culture 
system.  
Macrophages were co-cultured with cancer cells with the addition of rcCSF-1R. LPS 
was added to induce macrophage inflammatory stimulation. As expected (based in Figure 
3.2), the co-culture of macrophages with cancer cells impeded macrophage activation after 
LPS stimulation – as measured by cellular granularity and MHC II expression. However, the 
addition of rcCSF-1R allowed a marked stimulation of macrophages after LPS addition, 
apparently circumventing the effect that cancer cells had on macrophages. The receptor itself 
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had only a small effect on macrophages. Addition of CSF-1 to the co-culture marginally 
enhanced the suppression of macrophages. The marked stimulation of macrophages by LPS 
in the presence of cancer cells indicates that this growth factor is important in the cross-talk 
between these cells (Figure 3.5). 
 
Figure 3.5 – Blockade of CSF-1 circumvented cancer inhibition of macrophages. RAW macrophages 
were grown for 72 h in co-culture with REM134 cancer cells with/out rhCSF-1 (50 ng/ml) or rcCSF-
1R (1 µg/ml). E.coli O111:B4 LPS (1 µg/ml) was then added for 48 h. CSF-1R-treated cells were 
activated by LPS even in the presence of cancer cells. (A) Macrophage granularity (SSC). (B) 
Macrophage MHC II, mean fluorescence intensity quantification. Results represent the means of 3 
replicates ± SD. Asterisks represent statistical difference by ANOVA from the “RAW+LPS” group. 
“ns”, non-significant difference from the “RAW+LPS” group. 
 
 
3.3.4 The role of CSF-1 in macrophage activation 
 
To further evaluate the effects of CSF-1 on macrophages, these cells were cultured 
with increasing concentrations of rhCSF-1. In isolation, CSF-1 induced macrophage 
activation, as measured by MHC II expression. However, LPS-induced activation was 
reduced after cells were grown with CSF-1; this effect seemed to be dose-dependent, 
although statistically significant differences were only apparent between the control group 
and the highest dose of CSF-1. The differences are more evident when considering the 
percentage of MHC II
+
 macrophages than when assessing the mean fluorescence intensity, 
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so both graphs are shown (Figure 3.6). These results indicate that CSF-1 has the potential to 
promote macrophage activation while impeding inflammatory stimulation. 
 
 
Figure 3.6 – CSF-1 prompted macrophage activation but impeded LPS-induced stimulation. (A) 
RAW264.7 macrophages were grown in the presence of increasing concentrations of rhCSF-1 for 48 
h, and MHC II expression (measured as the percentage of positive cells and mean fluorescence 
intensity) was assessed after 48 h. Macrophages were activated with increasing concentrations of 
CSF-1. (B) RAW264.7 macrophages were grown with increasing concentrations of rhCSF-1 for 48 h. 
E.coli O111:B4 LPS (1 µg/ml) was added to the culture for another 48 h. MHC II expression was then 
evaluated. Macrophage activation was reduced in the presence of increasing concentrations of CSF-1. 
Results represent the means of 3 replicates ± SD. Different letters above the bars indicate statistically 
significant differences. 
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3.3.5 Effects of macrophages on cancer cells 
 
After being stimulated into the TAM phenotype, macrophages provide feedback to 
the cancer cells and intensify malignant progression of the tumour (Wyckoff et al., 2004). 
The effect of RAW264.7 macrophages on canine mammary carcinoma cells was therefore 
analysed to assess the counter-effects of the macrophages over the cancer cells. Macrophage-
conditioned medium increased the expression of CSF-1R in Lilly cells, a canine 



















Figure 3.7 – Macrophage-conditioned medium induced CSF-1R expression in canine mammary 
inflammatory carcinoma cells. (A) Lilly cancer cells were grown in the absence of conditioned 
medium from macrophages. (B) Lilly cancer cells were incubated overnight with conditioned medium 
from RAW264.7 macrophages (CM was 20 % of culture volume). Notice higher CSF-1R expression. 
Cells were stained with rabbit anti-human CSF-1R C-terminus (1:100, Abcam). Secondary antibody 
was goat anti-rabbit, Alexa 488-conjugated (1:200, Invitrogen). The negative control was stained only 
with the secondary antibody. Nuclear stain is in blue (DAPI). “40 ×” indicates the magnification used 
to acquire the images. 
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The biological relevance of the macrophage conditioned medium over cancer cells 
was analysed next. Addition of RAW264.7-conditioned medium to REM134 cells increased 
the proliferation rate of the cancer cells, irrespective of the initial REM134 cell density (10
4
 
or 3 × 10
4
 cells/well). Addition of rhCSF-1 did not increment the proliferative effect of the 
macrophage-conditioned medium over the cancer cells. (Figure 3.8 A, only higher cell 
concentration shown). Results were statistically significant (two-way ANOVA). Addition of 
macrophage-conditioned medium also increased glucose uptake by the cancer cells (Figure 
3.8 B). These results indicate that macrophage-conditioned medium can increase the 
metabolic activity of the cancer cells.  
Figure 3.8 – RAW264.7 macrophage-conditioned medium increased REM134 cell proliferation and 
glucose uptake. (A) REM134 cells received conditioned medium (CM) from macrophages at 20 % of 
culture volume (and 100ng/ml rhCSF-1, where stated) at plating. Cell proliferation was measured 
every 15 min. Representative result showing an initial plating of 3 × 10
4
 REM134 cells. Lower cell 
concentration not shown. Cell index (y-axis) is correlated to cell number. Each point represents the 
average of 4 wells ± SD. Statistical analysis by two-way ANOVA. Where P < 0.05 is indicated in the 
graph, the points containing CM or CM + CSF-1 were statistically superior to the control group 
containing only REM134 cells. (B) REM134 cells were cultured with/out macrophage-conditioned 
medium (20 % culture volume). Cells received 2NBDG fluorescent glucose (50 µM, Invitrogen). 
After washing out extracellular glucose, cells were analysed by flow cytometry. REM cells were kept 
at 4
o
C during glucose uptake as a negative control. “VC” is the vehicle control for the glucose, 
ethanol. Each point represents the average of 3 wells ± SD. Statistical analysis by one-way ANOVA. 
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3.3.6 Cancer cells and CSF-1R signalling 
 
The CSF-1R dependence of two canine mammary carcinoma cell lines was tested. 
REM134 and Lilly cells were evaluated for their susceptibility to three small molecule 
inhibitors. CSF-1R was targeted by GW2580, CCR2 was affected by RS102895 (CCR2i). A 
multi-tyrosine kinase inhibitor was also used (toceranib). Among other kinases, it is known 
to target c-Kit (Conway et al., 2005; Liao et al., 2002; Tang and Tsai, 2012). Both cell lines 
were susceptible to GW2580, but the Lilly line was resistant to the other small molecule 
inhibitors tested. This indicates that dependence on CSF-1R may be a common occurrence in 
canine mammary carcinomas, in comparison to other receptors commonly implicated in 
malignancy (Cavnar et al., 2013; Mitchem et al., 2013) (Figure 3.9).  
 
 
Figure 3.9 – CSF-1R dependence was a common feature in two canine mammary cancer cell lines. 
Lilly and REM134 mammary carcinoma cells were grown in 96-well plates and were cultured for 48 h 
with different concentrations of inhibitors: (A) RS102895 hydrochloride, a CCR2 small molecule 
inhibitor; (B) toceranib phosphate, a c-Kit tyrosine kinase inhibitor; (C) GW2580, a CSF-1R tyrosine 
kinase inhibitor. Notice the different response of both cell lines to the treatments in (A) and (B). Each 
point represents the average of 3 wells ± SD. Asterisks indicate statistically significant differences to 








 Infiltration of tumours by macrophages has been associated with metastasis and poor 
prognosis. Under the influence of the cancer cells and in the presence of low oxygen levels 
and necrosis, macrophages are differentially activated into a non-inflammatory state. This 
macrophage phenotype is denominated “M2”, in contrast to the classically activated “M1” 
inflammatory cells stimulated by microbial pathogens. M2 macrophages are dependent on 
the localized tumoural production of CSF-1 and other factors, such as IL-10 and TGF-β1. 
These alternatively activated macrophages can be immunosuppressive and can drive tumour 
neoangiogenesis, tumour intravasation and assist cancers in invading surrounding tissues 
(Allavena et al., 2008; Biswas et al., 2013).  
This chapter aimed to explore the mechanisms involved in the cross-talk between 
canine cancer cells and macrophages and the role played by CSF-1R signalling in this 
process. 
The canine REM134 and the human MCF-7 mammary carcinoma cell lines inhibited 
lipopolysaccharide (LPS) activation of RAW264.7 macrophages. The addition of LPS is 
known to induce dendritic-like morphology and MHC II expression in RAW264.7 
macrophages, which are otherwise MHC II
-
 (Saxena et al., 2003). MHC II expression and 
increased macrophage granularity indicate inflammatory (M1) cellular maturation 
(Michelsen et al., 2001; Saxena et al., 2003). Tumour associated macrophages (TAMs) are 
normally directed into an activation phenotype that shows low antigen-presenting capacities 
(Lewis and Murdoch, 2005), for which MHC II is essential (Lin et al., 1996).  
As cited above, the influence of cancer cells over macrophages and the consequent 
transformation of these cells into M2 TAMs is due largely to the cytokine 
microenvironment. The expression of anti-inflammatory cytokines, such as prostaglandin E2 
(PGE2), IL-10, transforming growth factor-β1 (TGF-β1) and IL-4 leads macrophages into a 
“wound-healing” and “tissue remodelling” phenotype, which characterizes M2 cells (Lewis 
and Pollard, 2006).  
Within tumours, the localization of TAMs is also believed to be important for the 
phenotypic transformation of the macrophages. The low oxygen concentration and high 
necrotic content of tumour hot-spots can alter the gene expression of macrophages to a non-
inflammatory phenotype, with increased characteristics of scavenger and “organ building” 
cells (De Villiers et al., 1994; Murdoch et al., 2004). Macrophages outside these necrotic 
“hot-spots” are believed to be more inflammatory and even capable of phagocytic activity 
against the cancer cells (Ohno et al., 2004). However, one of the characteristics of TAMs, 
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reduced inflammatory activation, could be induced in the present study in 2-dimensional co-
cultures and even without cellular contact, exclusively through conditioned medium. This 
shows that positioning of the macrophages inside the tumours is not necessary for 
macrophage phenotype alteration. Cell culture was carried out at common oxygen levels, far 
from the 1 % oxygen level needed to induce hypoxia in culture (Jögi, 2015); this 
demonstrates that hypoxia is also not a necessary condition for at least partial alternative 
macrophage activation. The soluble factors produced by the cancer cells are sufficient for 
induction of at least part of the M2 characteristics. The results shown here confirmed the 
findings of another work studying canine macrophages which also used soluble factors from 
cancer cells to suppress macrophage activation and MHC II expression (Wasserman et al., 
2012). Whether the RAW264.7 macrophages carried out phagocytosis of the cancer cells, as 
expected of TAMs outside the hot-spots, was not assessed (Ohno et al., 2004). 
Another study analysing the effect of MCF-7 cells on RAW264.7 macrophages 
found that the co-culture induced the macrophages to form osteoclasts via a RANKL 
pathway. The authors suggested that osteoclast formation from TAMs is correlated with 
increased bone metastases and mineral resorption. As expected from osteoclasts, these cells 
were larger and more granular than the original RAW macrophages (Nicolin et al., 2008), a 
finding that is similar to the results presented in this chapter. Thirty percent of RAW 
macrophages present osteoclast phenotype within 48 h of co-culture with MCF-7 (Nicolin et 
al., 2008). Although osteoclast formation was not evaluated in the present study, the similar 
methodology and time course in relation to the cited work indicate that comparable findings 
may have occurred here. 
LPS-non-responsive macrophages share characteristics with TAMs, such as nuclear 
accumulation of the inhibitory p50 NF-κB homodimer (Mantovani and Sica, 2010) and 
changes to STAT1 phosphorylation (Porta et al., 2009). Normally, p50 is translocated to the 
nucleus after LPS stimulation, where it dimerizes with p65 to regulate transcription activity. 
In TAMs, nuclear overexpression of p50 with inhibition of p65 prevents the production of 
IL-12, an inflammatory cytokine. After LPS or LPS/IFNγ [inflammatory] stimulation, cells 
overexpressing p50 produce IL-10 – which is anti-inflammatory –, in contrast to resting 
macrophages. IL-10, PGE2 and TGF-β, which are known to be produced by cancer cells, are 
factors capable of inducing overexpression and nuclear translocation of the p50 homodimer. 
The excessive nuclear p50 also is correlated to a reduction of surface expression of TLR2 by 
the macrophages (Bellone et al., 1999; Saccani et al., 2006). This mechanism of p50 nuclear 
expression may explain the findings of the present work with relation to LPS stimulation of 
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the RAW264.7 macrophages and cell surface MHC II/TLR2 expression following exposure 
to cancer cells. 
Another group showed that co-culture between canine cancer cells and macrophages 
reduced the transcription of TLR2 and TLR4 by macrophages (Król et al., 2012). LPS 
activation is dependent on the expression of its receptor, TLR4 (Hirschfeld et al., 2000). 
Therefore, LPS activation of the RAW264.7 cells after co-culture with REM134 cells or 
MCF-7 cells could have been impaired because of the absence of the receptor to recognize 
the ligand.  
CSF-1 was identified as an important mediator of the cross-talk between the cancer 
cells and macrophages. Free recombinant CSF-1R was used to competitively inhibit CSF-1 
present in the cell culture system. The same strategy of competitive inhibition by the free 
recombinant receptor is used in the drug VEGF-trap, in which the vascular endothelial 
growth factor binds to a decoy receptor, therefore having its action inhibited (Holash et al., 
2002). Blocking CSF-1 signalling resulted in increased activation of RAW264.7 
macrophages by LPS, as measured by cellular granularity and MHC II expression. The 
expression of MHC II molecules on macrophages has been shown to be regulated by colony 
stimulating factors. CSF-1 inhibits MHC II expression while IFNγ and the granulocyte-
macrophage colony-stimulating factor (GM-CSF) stimulate it. CSF-1 is also able to 
overcome the effects of IFNγ and GM-CSF over MHC II (Rey-Giraud et al., 2012; Willman 
et al., 1989). Importantly, it has been suggested that the role of CSF-1 in generating M2 
macrophages in vitro is reduced when cells are in serum-containing medium, due to 
unknown factors in the FBS (Rey-Giraud et al., 2012). Therefore, cultivation of 
macrophages in serum-free conditions could have enhanced the effects seen in the present 
study. However, CSF-1 must not have been responsible for all the effect of cancer cells over 
the macrophages. The human breast cancer MCF-7 cells do not express CSF-1, but were still 
able to reduce LPS activation of the macrophages (Lee et al., 1999).  
CSF-1 can prime macrophage activation or suppress inflammatory responses, 
depending on what co-signals are present (Sweet and Hume, 2003). Other studies have 
indicated that pre-treatment with CSF-1 increased macrophage sensitivity to LPS while 
reducing stimulation through other bacterial molecular patterns, such as CpG DNA. CSF-1 
can enhance LPS-induced IL-6, TNF-α and PGE2 expression. It is believed that CSF-1 
increases macrophage sensitivity to LPS by inducing autocrine stimulation by GM-CSF 
(Conway et al., 2005; Sweet and Hume, 2003). In RAW264.7 macrophages, LPS stimulates 
the expression of the GM-CSF receptor (Rosas et al., 2007).  
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This is in apparent disagreement with the findings of the present study, where CSF-1 
stimulation of RAW264.7 macrophages reduced LPS-induced MHC II expression. Another 
group also found reduced LPS activation of CSF-1-conditioned macrophages, corroborating 
the results shown here. They demonstrated that CSF-1 reduced the expression of Activin A, 
an inflammatory differentiation factor. Through the reduction of Activin A, CSF-1-
macrophages produced more IL-10 and less IL-6 following LPS stimulation. In their study, 
CSF-1 also emulated cancer-conditioned medium in reducing macrophage activation (Sierra-
Filardi et al., 2014, 2011).  
However, it is also possible that the results shown here after stimulation with CSF-1 
are derived from reduced activation through non-LPS dependent pathways. CSF-1 down-
regulates the expression of TLR2, but not TLR4 (Sweet et al., 2002). Purified LPS is 
exclusively able to signal in the extracellular compartment through TLR4, but contaminants 
in LPS preparations can activate cells through different pathways. The LPS used in this 
study, E. coli O111:B4, from Sigma, has been shown to contain contaminants – probably 
bacterial lipoproteins – that are able to signal through TLR2 (Hirschfeld et al., 2000; 
Rutledge et al., 2012). Therefore, down-regulation of TLR2 by CSF-1 may have prevented 
RAW264.7 macrophage stimulation by the LPS preparation with contaminants. Regardless 
of the molecular route affected, the results of the present study indicate that cancer cells and 
CSF-1 reduced inflammatory activation of macrophages. 
CSF-1 could have reduced LPS activation through receptors other than TLR4/TLR2. 
LPS is known to be able to act in a TLR4-independent pathway. Intracellularly, LPS can 
activate caspase-11 independently of TLR4 and lead to inflammatory activation of 
macrophages. Another group used ultrapure O111:B4 E. coli LPS – O111:B4 LPS was also 
used in the present work – to elicit caspase-11 activation (Kayagaki et al., 2013). Aberrant 
intracellular LPS localization and signalling occur at very high concentrations of LPS, 
activating the caspase-11 pathway (Hagar et al., 2013). CSF-1 may have altered the STAT1 
pathway, which is relevant for LPS reactivity of macrophages through caspase-11. Mice 
knocked out for STAT1 have reduced levels of caspase-11 (Ramana et al., 2000). LPS-
irresponsive M2 macrophages show reduced activation of STAT1 (Porta et al., 2009). 
However, CSF-1 can increase STAT1 activation (Novak et al., 1995), and both TLR4 and 
caspase-11 are up/down-regulated in similar conditions, raising the possibility that if CSF-1 
did not act through TLR4 it also would not reduce LPS activation through caspase-11 (Jung 
et al., 2005).  
LPS can counter-regulate CSF-1 by modulating the expression of its receptor. LPS 
can induce the production of both CSF-1 and GM-CSF by macrophages. However, one of 
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the effects of LPS is the down-regulation of the CSF-1R. Therefore, CSF-1-conditioned 
macrophages have reduced proliferation when LPS is added (Sester et al., 1999; Yeung and 
Stanley, 2003).  
Modulation of cellular activity occurs both ways in the TAM/cancer cell interaction. 
Canine mammary adenocarcinomas are known to express CSF-1R, and this is linked to 
malignancy and ability to metastasize (Król et al., 2011). Also, co-culture with macrophages 
increases transcription of the mRNA for CSF-1R in canine tumours (Król et al., 2012). Here, 
it is shown that macrophage-conditioned medium increased cancer cell proliferation and 
expression of CSF-1R. Since cancer cells could replicate in response to CSF-1, it is likely 
that the interaction with the macrophage-conditioned medium lead to higher cancer cell 
proliferation through increased CSF-1R signalling. Sequencing of the CSF-1R from the Lilly 
cell line showed that the receptor had no mutations, which could lead to constitutive 
activation of the receptor (Heisterkamp et al., 1983). Therefore, signalling through CSF-1R 
in the cancer cells must occur through binding of ligand to the receptor. Cancer cells are 
capable of autocrine stimulation with CSF-1 (Patsialou et al., 2009). A large number, if not 
the majority, of breast tumours express the CSF-1R, indicating that this is an important 
pathway for this cancer (Lee et al., 1999). CSF-1R signalling in epithelial cancer cells can 
induce radiotherapy resistance, for instance. CSF1 is a target gene for p53, and CSF-1R 
signalling feeds back to p53 to decrease apoptosis. In cancer, radiotherapy resistance is 
induced by CSF-1R signalling in a p53-dependent manner (Azzam et al., 2013). 
The importance of CSF-1R to canine mammary cancer cells was confirmed using 
small molecule inhibitors of three receptors. GW2580 is a tyrosine kinase inhibitor of CSF-
1R (Conway et al., 2005). Toceranib phosphate is a pan-tyrosine kinase inhibitor that is 
currently licensed for treatment of cancer in dogs (Bernabe et al., 2013; Liao et al., 2002). 
RS102895 hydrochloride is an inhibitor of the CCR2 (CCR2i). These inhibitors were chosen 
for the significance of the respective targets in cancer development. Of these, only GW2580 
was able to effectively target both canine mammary carcinoma cell lines tested, indicating 
that dependence on CSF-1R signalling is a common trait among canine mammary 
carcinomas. As stated before, not all mammary cancer cell lines/tumours rely on CSF-1R for 
survival or proliferation. CSF-1 leads to arrest of insulin or estradiol-induced proliferation of 
hormone-dependent cancer cells, such as MCF-7. This is mediated by upregulation of p21, 
which induces a G1 arrest in these cells (Lee et al., 1999). The REM134 cell line is not 
hormone-dependent (Else et al., 1982); that information is not available for the Lilly cell 
line. 
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The Lilly cell line was originated from a canine inflammatory mammary carcinoma 
(R. de Maria, University of Turin, Italy), an aggressive form of the disease with very poor 
prognosis (Alenza et al., 2001; Peña et al., 2003). The canine inflammatory mammary 
carcinoma shows several similarities to the human inflammatory breast cancer (Lerebours et 
al., 2008). Among the genes overexpressed in inflammatory breast cancers in relation to 
other forms of breast cancer, are those encoding CCL2 and CSF-1 (Lerebours et al., 2008). It 
was shown here that Lilly cells express the CSF-1R, and may therefore involve CSF-1 in an 
autocrine stimulation pathway. If these cells express CCL2, as do inflammatory breast 
cancers, this chemokine is probably connected with factors other than the autocrine 
stimulation of the cancer cells – such as recruitment of macrophages – since the Lilly cell 
line was not inhibited by the CCR2i. CCL2 function in breast cancers is believed to be 
mainly associated to cancer migration and metastasis, not direct proliferation (Soria and Ben-
Baruch, 2008). Nevertheless, the REM134 cell line was successfully inhibited by the CCR2i. 
In experiments conducted by other members of the group, CCL2 demonstrated some 
capacity to induce REM134 proliferation (Teresa Raposo, Roslin Institute/Universidade de 
Trás-os-Montes e Alto D’Ouro, personal communication). 
Toceranib was first licensed for use against mast cell tumours, but has been shown to 
be reactive against canine mammary cancers (Ranieri et al., 2013). However, as seen for the 
CCR2i, toceranib was only able to target REM134 cells, but not Lilly cells in the present 
study. The effectiveness of toceranib against different forms of canine mammary carcinomas 
has not yet been established (Chon et al., 2012). 
Macrophages also influenced mammary cancer cells to increase glucose uptake. 
Tumoural consumption of glucose is a marker of cellular metabolism that is associated with 
cancer grade and prognosis. However, the association of higher glucose uptake and presence 
of TAMs is not certain in clinical samples (Bos et al., 2002; Brown et al., 1999). Increased 
CSF-1R expression due to macrophage conditioned medium and autocrine CSF-1 signalling 
may have increased proliferation and metabolism of the cancer cells.   
The general interactions evidenced in this chapter and proposed mechanisms are 
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Figure 3.10 – Summary of the results and proposed mechanisms. Cancer cells affected LPS-induced 
increases in macrophage MHC II, TLR2 and granularity possibly due to the production of CSF-1. 
Mammary carcinoma cells also depended on CSF-1R signalling for proliferation and survival, 
suggesting that these cells may rely on autocrine CSF-1R stimulation. The expression of this receptor 





These results underline the importance of CSF-1R-inhibiting therapies in cancer, 
which would block TAMs and cancer cells expressing this receptor. The cancer cells seem to 
have reduced inflammatory responses of macrophages partially through CSF-1 mediation. 
The mechanism through which CSF-1 affects LPS stimulation is not fully clarified, but is 
likely to involve regulation of the receptors that recognize LPS. Both cancer cell lines 
studied in this chapter expressed the CSF-1R and at least one of the cancer lines proliferated 
in response to CSF-1. Although not studied directly here, evidence from the literature 
indicates that CSF-1R autocrine stimulation of cancer cells is a common event. Macrophages 
may enhance this event, since cultivation of cancer cells with macrophage-conditioned 
medium increased carcinoma CSF-1R expression and cellular metabolism, indicating that 




















Characterization of murine monoclonal 




 Several monoclonal antibody candidates were tested for the capacity to bind to CSF-1R 
and block macrophage proliferation. 
 mAb 3.1, raised against the dimerization domain of CSF-1R, emerged as the most 
promising clone, effectively binding to macrophages in tissues and blocking cellular 
proliferation. 
 However, mAb 3.1 seemed to have moderate specificity for CSF-1R, requiring 




In Chapter 3, it was shown that CSF-1R signalling is relevant in the context of tumour 
progression. The receptor induces tumour promoting phenotypes both in tumour-associated 
macrophages and in the cancer cells themselves. Therefore, blocking CSF-1R could be 
beneficial to cancer patients. With this purpose, monoclonal antibodies (mAbs) were raised 
against the canine CSF-1R using the hybridoma technology. This chapter describes the 
validation of the antibodies generated by hybridoma in Chapter 7. Several antibodies were 
produced, of which mAb 3.1 showed the greatest potential, having been used successfully in 
immunostaining assays and to block macrophage proliferation. However, the results also 
indicate that this mAb only binds to CSF-1R with moderate affinity and specificity. mAb 3.1 
seemed to only stain cells with high CSF-1R expression, and, by ELISA, presented a degree 
of non-specific binding. Inhibition of macrophage proliferation was only achievable at high 
antibody concentrations. In conclusion, it was functionally validated that mAb 3.1 binds to 
its target, but improvements in its binding characteristics are required before it can be 
indicated for clinical uses. 
 




CSF-1R and tumour associated macrophages (TAMs) are known causes of poor 
prognosis in several cancer types (Chambers et al., 1997; Raposo et al., 2012). The presence 
of TAMs has been correlated with increased proteinase expression, which leads to tissue 
invasion (Paulus et al., 2006); TAMs assist cancer cells in penetrating blood vessels 
(Wyckoff et al., 2007); they are linked to tumoural immunosuppression; and are associated 
with reduced chemotherapeutic responses (Mitchem et al., 2013). Cancer cells recruit TAMs 
and establish a paracrine loop of stimulation where the tumour secretes CSF-1, which acts on 
the macrophages, and in response TAMs produce EGF, which induces cancer cell growth 
(Wyckoff et al., 2004). Furthermore, the cancer cells can be stimulated by CSF-1 in an 
autocrine manner, reinforcing the importance of this receptor for cancer progression 
(Patsialou et al., 2009). Because of its significance in the pathogenic progression of cancer, 
CSF-1R is an attractive target for drug development.  
Several antibodies have been raised against human and murine CSF-1R (Haegel et 
al., 2013; MacDonald et al., 2010; Murayama et al., 1999) or against the CSF-1 (Paulus et 
al., 2006). Clinical trials for breast and prostatic human cancer are currently in progress with 
an inhibitory anti-CSF-1R (https://www.clinicaltrials.gov/ct2/show/study/NCT02265536). 
However, none of the previously described antibodies targets the canine receptor. 
Conversely, antibodies which were designed to identify canine macrophages through other 
receptors have been raised, although none have been assessed for their ability to block 
macrophage function or survival (Aguiar et al., 2004; Yamate et al., 2000). 
As a clinical tool, antibodies that target the CSF-1R are more suitable than antibodies 
that target the ligands, since these have short circulation half-lives. Also, CSF-1R has two 
ligands, CSF-1 and IL-34, which are structurally unrelated, therefore requiring different 
antibodies to block both (Bartocci et al., 1987; Liu et al., 2012). Additionally, both of these 
cytokines have dissimilar spatiotemporal expression patterns, making the targeting of both 
difficult (Wei et al., 2010).  
 
4.1.1 Approaches for targeting TAMs 
 
Macrophage depletion within tumours has been explored using alternative methods 
to monoclonal antibody treatment, such as liposome clodronate therapy and small molecule 
inhibitors of CSF-1R (Guth et al., 2013; Mashkani et al., 2010; Zeisberger et al., 2006). 
Small molecule inhibitors of CSF-1R affect the tyrosine kinase function of this receptor. 
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However, a common disadvantage of this method is the off-target binding, whereby the 
drug indiscriminately affects other tyrosine kinase receptors, leading to a range of 
unanticipated side-effects (Zhang et al., 2009). Antibody therapy would have greater 
selectivity, limiting the off-target effects. Liposome clodronate therapy involves the 
employment of a bisphosphonate drug, clodronate, to inhibit osteoclast and macrophage 
survival. Bisphosphonates are commonly used in medical practice to inhibit osteoclast 
function in diseases such as osteoporosis (Coxon et al., 2006). Liposome is used as a 
delivery agent to improve the pharmacokinetic properties of the bisphosphonate. This form 
of therapy has shown promising results as an anti-cancer agent. One disadvantage of 
clodronate therapy is a complete depletion of macrophages. It has been shown, for instance, 
that following clodronate treatment there is rapid reduction of circulating monocytes, loss of 
inflammatory mediators and reduced inflammatory cell recruitment. This could potentially 
permit infections in patients which are already immunocompromised due to the cancer 
(Davies et al., 2013; Ono, 2008; Zeisberger et al., 2006). Targeted anti-CSF-1R therapy has 
the advantageous effect of limiting only certain subpopulations of macrophages such as 
TAMs, while allowing for the function of cells with inflammatory phenotypes (Haegel et 
al., 2013; MacDonald et al., 2010). 
Among the unconjugated mAbs approved for clinical use, antibodies with capacity 
to block the function of the target are the most common. This characteristic improves the 
efficacy of the drug, even if other mechanisms of action are present, such as antibody-
dependent cellular cytotoxicity (ADCC) (Adams and Weiner, 2005; Iannello and Ahmad, 
2005). However, another possible antibody approach to depleting tumour macrophages 
could be to couple anti-CSF-1R antibodies to toxins or radioactive compounds. In this case, 
the mAb would not need to have receptor-blocking capacity and would overcome the 
difficulties in finding a suitable blocking antibody. Nevertheless, the technology of 
conjugated antibodies also presents some hurdles of its own, such as immunogenicity of the 
coupled drug/toxin; increased side effects due to non-specific targeting; and increased cost 
of production, which is very relevant in the veterinary practice (Teicher and Chari, 2011). 
Also, as stated above, CSF-1R-blocking mAbs have the advantage of sparing inflammatory 
macrophages, which are CSF-1R
+
 but are being stimulated by other cytokines. A drug-
conjugated antibody would completely remove CSF-1R
+
 cells, irrespective of the cytokine 
stimulation background. Therefore, both TAMs and macrophage protective responses 
would be lost (MacDonald et al., 2010). Due to these considerations, the aim of the work 
presented here was to identify a CSF-1R-blocking mAb. 
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Two major strategies were identified for blocking CSF-1R using a mAb. The 
antibody could either inhibit ligand binding to the receptor or it could inhibit receptor 
dimerization. These effects could be performed by direct binding of the antibody to the 
receptor regions responsible for ligand recognition/dimerization or through stabilization of a 
folded conformation of the receptor (Bradbury et al., 2011). Stable dimerization is essential 
for CSF-1R signalling (Li and Stanley, 1991). Blocking dimerization would impede 
signalling through both IL-34 and CSF-1, and should fully stop CSF-1R signalling. 
Although both IL-34 and CSF-1 share a binding site on the surface of CSF-1R, there are 
differences on the receptor contact points for binding both ligands; these overlap, but are 
not identical (Liu et al., 2012; Ma et al., 2012). Indeed, while an antibody has been 
identified that can block the binding of CSF-1R to both ligands, another mAb was only 
capable of blocking the interaction of the receptor with CSF-1, but not IL-34 (Chihara et al., 
2010).  
Given the different possible mechanisms to block receptor function using antibodies, 
two strategies of antibody production were used in the present work. Antibodies were 
generated against either the full extracellular portion of the receptor (expressed in 
mammalian cells) or the dimerization domain only (produced in bacteria). 
 
4.1.2 Published CSF-1R-blocking antibodies 
 
There is a considerably extensive literature on CSF-1R blocking antibodies. The 
knowledge acquired with those mAbs presents important arguments regarding the usefulness 
of anti-CSF-1R therapies. Also, a comparison can be drawn between these published clones 
and the antibodies discussed in the present work. Therefore, the main findings in the 
literature on the anti-CSF-1R are presented here. 
M279 is a mAb against the mouse CSF-1R. When administered in vivo for short 
periods (3 weeks), it causes mononuclear cell depletion of peritoneal macrophages (the 
antibody was injected in the peritoneal cavity) and of most tissue-resident macrophages and 




), but has little effect on bone marrow, blood, 
lymph node and spleen macrophages. Over long treatment protocols (6 weeks), osteoclasts, 
Kupffer cells, Ly6C
Low
 monocytes in the bone marrow and testis macrophages are depleted. 







). This translates in no effect of M279 treatment on induced inflammation models of 
lung and peritoneum, and no effect on wound healing and graft-versus-host disease. This 
mAb is capable of reducing the burden of tumour-associated macrophages on a murine 
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model of mesothelioma, but not of macrophages present in the tumour growth front. The 
mAb does not reduce tumour growth, maybe because of the short test period (3 weeks) or the 
presence of surrounding macrophages which were not eliminated. Notably, not even with a 
long treatment protocol, which reduced several tissue macrophage subsets, did this antibody 
induce toxicity or side-effects (MacDonald et al., 2010; Sauter et al., 2014).  
AFS98 is also a mAb against murine CSF-1R and, like M279, has little effect on 
bone marrow macrophages (Sudo et al., 1995). This antibody is capable, however, of 
depleting tumour-associated macrophages in murine tumour models. This is sufficient to 
delay tumour appearance, reduce its growth and increase survival and chemotherapy 
sensitivity (Fend et al., 2013). Although AFS98 does not reduce all macrophages within the 
bone marrow, it does deplete nonclassical (Ly6C
-
) monocyte subsets from the bone marrow 
and circulation. AFS98 also reduces Ly6C
-
 resident peritoneal, alveolar and splenic 
macrophages by reducing cellular viability, not by affecting proliferation. This antibody also 
strongly reduces inflammatory recruitment of macrophages in peritoneal inflammation 
models (Louis et al., 2015) and after muscular lesion; in the latter model, less macrophages 
resulted in reduced proliferation of muscular satellite cells and increased fibrosis (Segawa et 
al., 2008). Interestingly, the antibody not only depletes most CSF-1R
+
 but also CSF-1R
-
 cells 
in peritoneal inflammation models. The authors believed that the reduction of CSF-1R
-
 cells 
in inflammation following mAb treatment was due to reduced governing signals from the 
depleted CSF-1R
+
 cells. The effects of AFS98 on inflammation are in disagreement with 
other anti-CSF-1R mAbs, such as M279, described above, which do not seem to affect 
inflammatory function. It had been suggested that AFS98 only reduced inflammation 
because it acted though ADCC via its IgG2a heavy chain to kill monocytes. It was later 
confirmed that AFS98 reduces inflammation due to neutralization of CSF-1R signalling, not 
through ADCC (Louis et al., 2015).  
mAb 2-4A5 is an anti-murine CSF-1R. It inhibits bone marrow-derived macrophage 
and monocyte survival, without inducing internalization or degradation of the receptors 
(Haegel et al., 2013; Sherr et al., 1989).  
RG7155 is a mAb against the human CSF-1R. It binds to the fourth extracellular 
region of the receptor, inhibiting macrophage survival by impeding receptor dimerization. 
The mAb depletes CSF-1 and tumour-conditioned macrophages, but not GM-CSF-




monocytes from peripheral 
blood. Kupffer cells and colonic macrophages are depleted, but the effect is lesser against 
lung macrophages. CSF-1R inhibition by mAb 2G2, an anti-murine CSF-1R described 
together with RG7155, decreases TAM counts, which is followed by a concomitant increase 
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in neutrophil and lymphocyte infiltration of the tumour. When RG7155 was administered to 
human patients with diffuse-type Giant Cell tumours, clinical improvements could be seen, 
reducing tumour burden. In several other human tumour types, RG7155 reduced TAM 
counts (Ries et al., 2014). In human patients with tenosynovial giant cell tumours, which 





 monocytes and the presence of TAMs, which was correlated with rapid 
clinical improvement (Cassier et al., 2014). 
H27K15 is a somewhat different monoclonal antibody in that it does not block CSF-
1 binding to CSF-1R and their removal from the cell surface, unlike the previously described 
antibodies. It is an intermediate-affinity clone and its function is mainly dependent on Fc 
binding. It does not kill monocytes, but impedes their activation into the M2 state, 
suppressing CCL2 and IL-6 expression by these cells (Haegel et al., 2013). 
 
4.1.3 Targeting TAMs in dogs 
 
Targeting canine cancer offers the evident benefit of providing better care for these 
patients. However, targeting naturally occurring canine cancers in a clinical setting also 
generates information for the study of human diseases. There are many characteristics in 
canine cancer that make it amenable for use as a model in the study of human cancer, such as 
genetic similarities, shared environmental risk factors, similar responses to treatment and 
spontaneous occurrence of several cancer types (Rowell et al., 2011). Drug trials in dogs can 
be valuable in predicting the clinical value of new pharmaceuticals when these are tested in 
humans. A high rate of human clinical trials end in failure following encouraging results in 
mice (Gordon et al., 2009; Natanson, 2011). As an example, while mouse experiments 
indicated very positive outcomes after TAM depletion using clodronate therapy (Zeisberger 
et al., 2006), initial results in dogs showed little effect (Guth et al., 2013), reflecting the more 
conservative results seen in early human tests (Diel et al., 1998; Paterson et al., 1993; Saarto 
et al., 2001).   
 
The goal of this work was to identify an antibody that could block the function of 
canine CSF-1R with the intent of treating cancer patients. This chapter describes the 
validation tests for several monoclonal antibodies raised against the canine CSF-1R. 
Although numerous clones were tested in some of the assays shown here, greater emphasis is 
given to mAb 3.1, which was analysed through a large array of tests. This antibody could 
bind to bone marrow macrophages and CSF-1R
+
 canine mammary cancer cells. It also 
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presented staining patterns in canine tissues that were in accordance with the expected 
distribution of macrophages. However, this antibody also presented issues with specificity 
and affinity, as it could not bind to canine peripheral blood monocytes and cross-reacted with 
control proteins in ELISA. 
 
4.2 Materials and Methods 
 





For cellular stains, cells were grown on tissue culture-treated glass slides (between 
10
3
 – 5 × 10
3
 cells per chamber) (Nunc Lab-Tek II Chamber Slide System, Thermo 
Scientific). Canine bone marrow-derived macrophages (BMDM) were allowed to adhere to 
the slide overnight and were fixed with ice cold acetone at – 20
o
C for 20 min, washed with 
PBS and blocked for 60 min with PBS + normal goat serum (10 %) at room temperature.  
For histological stains, tissue samples were fixed in PBS + paraformaldehyde (4 %, 
agitated for 1 h at 60
o
C for solubilisation) for 3 h. The tissue was then immersed in 20 % and 
then 40 % sucrose, until sunk in each solution. The samples were embedded in OCT 
compound (Fisher) and snap-frozen by submersion in liquid nitrogen. Sections of 6 µm were 
obtained using an OTF5000 cryostat (Bright) and these were placed on SuperFrost glass 
slides (Thermo Scientific). The sections were stored at – 80
o
C until used. After removing 
from the freezer, the slides were washed with PBS and blocked as for the cellular stains. 
Sections were permeabilized by addition of PBS + Triton X-100 (0.2 %) for 10 min at room 
temperature. Slides were rinsed with PBS after permeabilization.  
Cells or sections were incubated overnight at 4
o
C with hybridoma cell culture 
supernatants. Mouse anti-human CD163 AM3K (1:75, TransGenic Inc.), mouse anti-canine 
CD11b (1:10, AbD Serotec) and rabbit anti-human c-Kit (1:100, Dako) were also used for 
comparison where stated. Isotype control was mouse IgG1 (20 µg/test, Abcam). Antibodies 
were diluted in blocking buffer.  
For assessment of competitive inhibition of staining, DH82 cells were stained with 
the hybridoma supernatant of mAb 3.1 or anti-CD11b adding increasing concentrations of 
purified recombinant His-tagged dimerization domain of CSF-1R (produced as shown in 
Chapter 7). 
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Goat anti-mouse Alexa 488 or goat anti-rabbit Alexa 647 fluorescent secondary 
antibody (Invitrogen) was diluted 1:300 in blocking buffer and cell staining was performed 
at room temperature for 2 h. Slides were washed with PBS thrice for 5 min after the antibody 
incubation steps. DAPI (4',6-diamidino-2-phenylindole) nuclear stain was included in the 
mounting medium (Vectashield Mounting Media with DAPI, Vector Labs). A coverslip was 
placed on top of the section with a drop of mounting medium. The section was isolated using 
nail polish. 
 
4.2.2 Dot blot 
 
For determination of the concentration of mAb 3.1 in the hybridoma supernatant, it 
was compared to an isotype control by dot blot. Mouse IgG1 isotype control (Abcam) at 20, 
40, 80 and 160 µg/ml was diluted in PBS in 1:2 steps until 1:2048. This was compared to a 
similar dilution of the supernatant containing mAb 3.1. The dilutions were dotted on a 
nitrocellulose membrane (1 µl). The membrane was blocked with PBST + milk (5 %). 
Bound antibodies were detected with rabbit anti-mouse immunoglobulins, HRP-conjugated 
(1:1000, Dako) diluted in blocking buffer. HRP activity was detected using ECL reagent (GE 
Healthcare). The concentration of antibody in the supernatant was determined by visual 
comparison against the different concentrations of the isotype control. The isotype control 
used for staining canine duodenum (see 4.2.1, above) was adjusted according to the 




Cancer samples were obtained from Teresa Raposo (Universidade de Trás-os-
Montes e Alto Douro, Portugal and The Roslin Institute). Samples were collected from 
clinical cases with owner’s consent. Paraffin wax-embedded mammary cancer samples were 
cut in 4 µm sections with a microtome (RM2235, Leica). The sections were placed on glass 
slides (Thermo Scientific) and rehydrated by dipping the slides successively in solutions 
with higher water content:  
1. Xylene: 2 × 3 min;  
2. Xylene 1:1 with 100 % ethanol: 3 min;  
3. 100 % ethanol: 2 × 3 min;  
4. 95 % ethanol: 3 min;  
5. 70 % ethanol: 3 min;  
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6. 50 % ethanol: 3 min;  
7. Running cold tap water to rinse. 
Antigens were retrieved by Proteinase K treatment (Promega) for 20 min at 37
o
C. 
Sections were blocked with H2O2 (0.3 %) for endogenous peroxidase activity. Peroxide was 
removed by rinsing with PBS. Non-specific binding sites were blocked with PBS + goat 
serum (10 %). Mouse hybridoma supernatants were used to probe the slides. These were 
incubated overnight at 4
o
C. Goat anti-mouse Ig, HRP-conjugated secondary antibody 
(1:1000 in blocking buffer, Dako) detected the bound mAbs by incubation at room 
temperature for 1 h. Slides were washed with PBS thrice for 5 min after both antibody 
incubation steps. 
HRP activity was detected using NovaRed substrate (Vector Labs). The reagents 
were mixed and placed on the sections. When colour had developed, slides were rinsed with 
water. Slides were counterstained with Mayer’s haematoxylin solution (Sigma) for 30 s and 
washed twice in water for 5 min. The sections were dehydrated by following the rehydration 
protocol above in reverse. DPX mountant (Fluka) and the coverslips were placed covering 
the sections. 
 
4.2.4 Flow cytometry 
 
For all cell types, 10
6
 cells were used for flow cytometry. For REM134 staining, 
cells were centrifuged at 400 × g and the supernatant was discarded. Cells were fixed with 
PBS + formaldehyde (0.01 %) for 10 min at room temperature and permeabilized with PBST 
for 15 min at room temperature (where stated). Cells were washed and stained with undiluted 
mAb supernatants containing Tween 20 (0.05 %), for 20 min at room temperature. After 
washing in PBST thrice, secondary antibody was added in blocking buffer + Tween 20 
(0.05%). 
Canine blood was collected from animals from the Edinburgh Dog and Cat Home, 
euthanized for humane reasons. Leucocytes were isolated from whole blood using ficoll 
density separation (Ficoll-Paque, density of 1.077, Sigma). Blood (3 ml) was diluted 1:1 with 
PBS at room temperature and layered slowly over the same volume of ficoll. Cells were 
separated by centrifugation (30 min, 400 × g, room temperature). The cloudy interface 
containing white cells was collected and washed with PBS (10 ml). The leucocytes were 
centrifuged again. This was followed by lysis of remaining red blood cells in the pellet for 5 
min on ice (lysis buffer: NH4Cl (150 mM), NaHCO3 (10 mM), EDTA (0.1 mM), pH 7.2). 
PBMCs were blocked with cold PBS + FBS (10 %) for the first attempt and then PBS + 
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human Fc Blocking Reagent (20 µl, Miltenyi Biotec) or PBS + canine serum (10 %) for the 
following trials. PBMCs were stained with purified mAbs or hybridoma supernatants for 30 
min, 2 h or overnight, at 4
o
C. For overnight stains, cells were fixed in PBS + 
paraformaldehyde (2 %). After washing thrice in cold PBS, secondary antibody was added. 
A mouse anti-swine CSF-1R mAb was used as positive control for the staining of PBMCs 
(produced by Lindsey Waddell, David Hume group, The Roslin Institute). For PBMCs, 
Sytox blue (Life Technologies) or 7-AAD (5 µl/sample, eBioscience) stains were added 5 
min before the analysis for assessment of cell viability by flow cytometry.  
To assess the differences in expression of CSF-1R in the presence or absence of 
CSF-1, BMDM were differentiated as explained in Chapter 2. Cells were FBS-starved 
overnight in the presence or absence of 100 ng/ml rhCSF-1 (Invitrogen). When stated, cells 
were fixed for 30 min at 4
o
C with PBS + paraformaldehyde (2 %). Cells were placed in 
round bottom 96-well plates (Greiner) and blocked with PBS + goat serum (10 %) for 30 
min, at 4
o
C. IgG1 isotype control (Abcam), anti-pig CSF-1R (Lindsey Waddell) (both at 25 
µg/ml in blocking buffer) or mAb 3.1 (hybridoma supernatant or 10 µg) were used for cell 
staining. After 3 washes in PBS (centrifugations at 400 × g), secondary antibody was added. 
When stated, cell viability was assessed using 7-AAD (5 µl/sample, eBioscience). To 
confirm the identity of BMDM in a separate experiment, cells were stained with a mouse 
anti-canine CD11b antibody (1:10, AbD Serotec) in blocking buffer, followed by a 
secondary antibody.  
For all cells, secondary antibody used was goat anti-mouse antibody, Alexa 488-
conjugated (Invitrogen). It was added at 1:800 in 100 µl blocking buffer /10
6
 cells for 30 min 
at 4
o
C. This was followed by three washes, as for the primary antibodies. 
Cells were analysed on a FACScalibur flow cytometer (Becton Dickinson). Data 
were analysed using Summit 4.1 software (Dako), assessing the percentage of positive cells 
as determined in relation to the secondary antibody control. The first result showing the flow 
cytometry of PBMCs was analysed on a FACSAria flow cytometer (Becton Dickinson) and 
was analysed on FlowJo (TreeStar). Cells in the BMDM or the leukocyte gate were assessed, 




mAbs (21 µg or supernatant from mAb 1C6) in sodium phosphate buffer (pH 7.0) 
were bound to 75 µl (dried volume) of Protein G beads (GE Healthcare) for 2 h at 4
o
C. 
Unbound mAbs were removed by centrifuging the beads at 1000 × g and washing once with 
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sodium phosphate buffer. HEK293T cells were transiently transfected to express the 
extracellular region of CSF-1R (Chapter 7). One millilitre of the supernatant was incubated 
overnight, at 4
o
C, with the Protein G + mAbs. The resin was washed 5 × with sodium 
phosphate buffer. The resin was incubated with 30 µl PBS + reducing sample buffer 
(considered the volume of the resin to calculate the sample buffer volume). This was 
incubated at 95
o
C for 5 min. Centrifuged to precipitate the resin. Loaded the supernatant into 
10 % SDS-PAGE gel. Probed western blot nitrocellulose membrane with mouse anti-His tag, 
1:500 (Invitrogen) and with goat anti-mouse, HRP-conjugated, 1:1000 (Dako). 
 






 REM134 or RAW264.7 cells were plated in 100 µl of DMEM 
medium (Gibco) in individual wells of black opaque 96-well plates (Greiner). Hybridoma 
supernatants (where stated) and/or rhCSF-1 (100 ng/ml, Invitrogen) were added to the 
culture at the same time as the cells. After 48 h, viable cells were quantified using CellTiter-
Glo, Promega. 
 
4.2.7 Real time cell proliferation assay 
 
The xCELLigence Real-Time Cell Analyzer (Roche) was standardized with 50 µl of 
DMEM medium (Gibco) before adding cells. Between 10
4
 and 3 × 10
4
 cells were used 
(either REM134 or canine bone marrow macrophages). Bone marrow macrophages and 
REM134 cells were grown in the presence of rhCSF-1 (50 ng/ml and 100 ng/ml, 
respectively, Invitrogen). Cells were placed on an xCelligence 16 or 96-well plate (Roche) in 
100 µl of culture medium. The plate was scanned to measure the initial numbers of cells in 
each well, and then treatment was added. Between 5 – 20 µl of hybridoma supernatant or 
purified mouse antibodies were used for each assay. Controls received equivalent volumes of 
vehicle (medium or PBS) or the equivalent concentration of murine serum IgG (Sigma). 
Cells received rhCSF-1 and antibodies circa every 48 h during the experiment. Cells were 
then maintained at the usual culture conditions for the duration of the experiment. The 
amount of cells attached to the bottom of each well was measured by the equipment through 
assessment of the interference with the electrical impedance of the sensor on the plate. Cell 
proliferation was assessed every 15 min. 
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4.2.8 Chorioallantoic membrane (CAM) assay 
 
The biological effect of blocking CSF-1R in REM134 cells was studied by the CAM 
assay. These cancer cells were grafted onto the chick embryo CAM and blood vessel 
formation was quantified in the presence or absence of mAbs. The protocol of Ribatti et al., 
2006 was followed. The technique is illustrated in Figure 4.1. The use of chicken 
embryonated eggs is allowed by the Home Office until day 11 of incubation without the need 
for a licence. Briefly, chicken embryonated eggs (National Avian Research Facility, The 
Roslin Institute) were incubated rocking (Brinsea Octagon 40 OX incubator) at 37.5
o
C until 
day 4 of development in a horizontal position. At this date, circa 2 ml of egg albumin was 
removed with a syringe and a 24 gauge needle (Becton Dickinson). A 1 cm × 1 cm window 
was opened on the shell with a scissor, having the egg in the horizontal position. The embryo 
received 150 µl of 10 × tissue culture-grade penicillin/streptomycin (Gibco), pipetted slowly. 
The window was closed with a plastic adhesive tape and the egg was incubated statically at 
37.5
o
C (RCOM Maru Digital Incubator) until day 7. The window was reopened by removing 
the tape and the cancer cells were grafted onto the CAM. Cells were stained with CFSE 
(eBiosciences). For this, cells were suspended in FBS-free DMEM medium. CFSE was 
added to the cells at 10 µM for 15 min at room temperature protected from light. Cells were 
then washed twice with complete medium. The stained cells were absorbed in a 5 × 5 × 5 
mm gelatine sponge (Gelatamp, Roeko) (around 10
6
 cells/sponge), either in the presence of 
mAb 3.1 hybridoma supernatant or in control medium. After placing the sponge on the 
CAM, eggs were returned to the static incubator. On day 10, eggs were moved to 4
o
C for 30 
min before imaging. Images acquired using Axio ZoomV16 coupled with AxioCAM HRM 
camera (Zeiss). Blood vessel formation around the sponge graft was assessed. Blood vessel 
density and blood vessel branching near the graft were scored according to Ribatti et al., 
2006. Briefly, vessel density was given a score between 0 (no vessel convergence towards 
graft) and 5 (intense convergence of large vessels towards graft). Branching was given a 
score where distant branching from the implant was scored 2 points; near branches received 
1 point; and unbranched vessels reaching the sponge at an angle of less than 45
o
 were scored 
1 point. If doubtful about the score to be attributed for each picture, the lowest score was 
given to the control samples and the highest was given to the test samples. 




Figure 4.1 – The chicken chorioallantoic membrane assay. (1) On day 4 of egg incubation, 2 ml of egg 
white is removed with a syringe. (2) A 1 × 1 cm window is opened on the egg shell close to where the 
embryo is located. (3) Antibiotic is added. (4) The window is closed with an adhesive tape. (5) On day 
7, cancer cells are absorbed in a gelatine sponge, in the presence or absence of treatment. The sponge 
is placed on the CAM without touching the embryo. (6) On day 10, the sponge and its surroundings 
are imaged for quantification of blood vessel formation and branching. 
 
 
4.2.9 Inhibition of feline osteoclasts 
 
Feline bone marrow cells were differentiated for 10 days in rhRANKL (30 ng/ml, 
R&D Systems) and rhCSF-1 (10 ng/ml, R&D Systems) in low adherence tissue culture 
plates (Corning). Anti-CSF-1R mAb 3.1 hybridoma supernatant or an anti-CCR2 hybridoma 
supernatant (produced by Teresa Raposo, Universidade de Trás-os-Montes e Alto Douro, 
Portugal and The Roslin Institute) was added to the cells at 1/6 of the total culture volume. 
One control well received no CSF-1 after the beginning of the experiment. The culture 
medium and supplements were renewed at 48 h. Cells were lysed on day 4 using 1 ml/well 
of Lysis buffer 15 (R&D Systems, Apoptosis array kit) for 30 min at 4
o
C. Protein 
concentration was measured using a Bradford assay. The protein mixture was resolved on a 
10 % SDS-PAGE (20 µg of protein/lane) and transferred to nitrocellulose. The membranes 
were probed with anti-pAkt (Ser 473), total Akt and pMAPK, (all at 1:1000, Cell Signalling) 
in PBST + skimmed milk powder (5 %) for 2 h at room temperature. Antibodies were used 
sequentially on the same membrane, after stripping the nitrocellulose membrane using 
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Restore PLUS Western Blot Stripping Buffer (ThermoFisher Scientific) and blocking the 
membrane. Secondary antibody used was swine anti-rabbit HRP-conjugated (1:1700, Dako), 
in the same buffer as the primary antibody. 
 
4.2.10 ELISA assays 
 
Competition ELISA for the CSF-1R binding region 
 
An ELISA was used to test the ability of some mAbs to block the binding of CSF-1 
to CSF-1R. This methodology has been used previously for testing the effect of mAbs on the 
CSF-1/CSF-1R interaction (Haegel et al., 2013). This assay is based on the capacity of the 
recombinant canine CSF-1R to bind to rhCSF-1 (Chapter 7), which is in turn detected by a 
commercial antibody. If the mAb being tested is able to block the binding of ligand/receptor, 
CSF-1 is washed away and the signal is reduced (Figure 4.2). A Nunc Maxisorp 96-well 
plate (Thermo Scientific) was coated overnight at 4
o
C with 300 ng/well of canine 
recombinant CSF-1R extracellular region (Chapter 7) in 100 µl of carbonate buffer (Na2CO3 
(15 mM), NaHCO3 (35 mM), pH 9.6). The plate was rinsed with PBST and blocked with 
PBS + BSA (2 %) for 2 h at 37
o
C. After rinsing with PBST, the culture supernatants 
containing mAbs were added to the wells for 1 h at room temperature. Wells were washed 6 
× 2 min with PBST. rhCSF-1 (BioLegend) was added at 18 ng/well in blocking buffer and 
incubated for 2 h at room temperature. After washing the plate with PBST, the bound CSF-1 
was detected using an anti-CSF-1 antibody (Peprotech) at 1:75 in blocking buffer, at 4
o
C, 
overnight. Wells were washed and a goat anti-rabbit secondary, HRP-conjugated (1:10000, 
Life Technologies) in blocking buffer was added for 3 h at room temperature. After washing 
the plate, the reaction was developed using 100 µl of chemoluminescent substrate (GE 






















Figure 4.2 – Schematic representation of the ELISA to test the capacity of mAbs to block CSF-1/CSF-
1R interaction.  The cylinder represents a well in a 96-well plate. On the left half, CSF-1 is shown 
bound to the adsorbed rCSF-1R (represented by the vertical bar with five subunits). Bound CSF-1 is 
then quantified by a HRP system with commercial antibodies. On the right half, the anti-CSF-1R mAb 




ELISA for determination of non-specific mAb binding 
 
Maxisorp 96-well plates (Thermo Scientific) were coated with 400 ng/well of either 
canine recombinant CSF-1R extracellular region or BSA in 50 µl of PBS at 4
o
C, overnight. 
Plates were blocked with PBS + BSA (2 %) for 2 h at 37
o
C. Hybridoma supernatants 
containing mAb were added for 2 h at 37
o
C. Plate was washed with PBST for 6 × 2 min. 
Secondary rabbit anti-mouse HRP (1:2000, Dako) was added for 1 h at room temperature in 
blocking buffer. Reaction was developed with 50 µl TMB Ultra (Fisher) and was stopped 
with the same volume of H2SO4 (2 M). Absorbance at 450 nm was read using a Victor3 plate 
reader (Perkin Elmer). 
 
4.2.11 Antibody purification by protein G chromatography 
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4.2.12 Statistical analyses 
 
Blood vessel remodelling in the CAM assay was analysed using a Mann-Whitney 
test. The endpoint proliferation assay was analysed using one-way ANOVA with a 
Bonferroni post-test. The real-time proliferation assays were assessed using repeated-
measures two-way ANOVA with a Bonferroni post-test. For all tests, P < 0.05. Assumption 
tests were performed on Minitab 16 (Minitab Inc.). Statistical tests and graphs were made on 




Overall, four hybridoma fusions were performed for the production of anti-CSF-1R 
monoclonal antibodies, three using the extracellular fraction of CSF-1R as the immunogen 
and one using the dimerization domain of the receptor. Of the several antibodies selected in 
the initial phases of ELISA screenings (Chapter 7), two of the most promising clones were 
mAb 3.1 (using the dimerization antigen) and mAb 1C6 (using the extracellular region 
antigen), which are described in the results below. mAb 1C6 lost binding affinity over time, 
and for this reason work on it was discontinued.   
 
4.3.1 Cellular immunofluorescence 
 
REM134 (canine mammary cancer cells), Lilly (canine inflammatory mammary 
cancer cells), DH82 (canine histiocytic sarcoma), canine bone marrow-derived macrophages 
(BMDM) and RAW264.7 (mouse macrophages) were used for immunofluorescence assays 
with the mAbs (Figure 4.3). Several antibodies were tested as tissue culture supernatants in 
the immunofluorescences (not purified). mAb 3.1 showed the best results. These results 
show that mAb 3.1 stained cells that express the canine CSF-1R, but it did not stain a murine 
macrophage cell line, RAW264.7, that is also CSF-1R
+






































Figure 4.3 – mAb 3.1 stained canine but not murine CSF-1R-expressing cells. Canine mammary 
carcinoma cells REM134 and Lilly, canine histiocytic sarcoma DH82, canine BMDM and mouse 
macrophages RAW264.7 were stained with hybridoma culture supernatants containing mAb 3.1. 
Secondary antibody was goat anti-mouse Alexa 488 (1:300, Invitrogen). Negative controls were 
stained only with the secondary antibody. Nuclear stain is in blue (DAPI). “20 ×” or “40 ×” indicate 
the magnification used to acquire the images.  
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The specificity of mAb 3.1 was assessed by a “peptide competition” assay. DH82 
cells were stained with mAb 3.1 in the presence or absence of recombinant canine CSF-1R 
protein (His-tagged dimerization domain). If mAb 3.1 stained DH82 cells strictly by binding 
to CSF-1R, adding the recombinant protein would have the effect of blocking the staining. If 
mAb 3.1cross-reacted with other antigens, adding the recombinant protein would have no 
effect or little effect on cellular staining. An antibody against canine CD11b was used as a 
control. Adding the recombinant CSF-1R should not block the binding of the anti-CD11b 
antibody. 
As shown in Figure 4.4, the addition of increasing amounts of recombinant CSF-1R 
was able to block the staining of the cells by mAb 3.1, but not by the CD11b mAb (the same 
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Figure 4.4 – Recombinant CSF-1R was able to competitively inhibit the binding of mAb 3.1 to DH82 
cells. DH82 cells were stained with the hybridoma supernatant containing mAb 3.1 or with anti-
CD11b (1:10, AbD Serotec), as a control. The primary antibody was competitively inhibited by 
adding increasing concentrations of His-tagged recombinant dimerization domain of CSF-1R. The 
addition of CSF-1R did not affect CD11b staining. The concentration of the dimerization domain is 
shown above each figure. Secondary antibody was goat anti-mouse Alexa 488 (1:300, Invitrogen). 
Negative controls were stained only with the secondary antibody. Nuclear stain is in blue (DAPI). “20 
×” indicates the magnification used for acquiring the images. 
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4.3.2 Tissue immunofluorescence 
 
A range of canine tissues from healthy animals were stained with mAb 3.1 by 
immunofluorescence using the hybridoma supernatant. mAb 3.1 bound to cells in all tissues 
tested, duodenum, lymph node and spleen. Staining of these tissues with anti-CD163 and 
anti-CD11b antibodies showed patterns of staining similar to mAb 3.1. In the duodenum, 
mAb 3.1
+
 cells were present around the duodenal glands and within the villus lamina propria, 
as were CD163
+
 cells. Staining was stronger around the duodenal glands (Figure 4.5). In the 
spleen, mAb 3.1
+
 cells surrounded the white pulp, as did CD11b
+
 cells (Figure 4.6). In the 
lymph node, mAb 3.1
+
 cells were mostly seen in the medullary cords and in the paracortical 
areas, but also close to the subcapsular space and the trabeculae (Figure 4.7). 
Exclusively for the duodenal staining, the antibody concentration of the hybridoma 
supernatant was titrated in order to adjust the concentration of the isotype control used in 
immunofluorescence. To assess the concentration of mAb 3.1 in the hybridoma supernatant, 
a scale of isotype control was made by dot blotting several dilutions of the isotype. This 
allowed for the correct concentration of isotype to be used in the immunostaining. Using this 
assay, the concentration of mAb 3.1 in the hybridoma supernatant was estimated to be 








































Figure 4.5 – mAb 3.1 stained cells around the duodenal glands and in villi of canine duodenum. (A) 
Duodenal villi and (B) glands stained with anti-CD163 (1:75, TransGenic Inc), used as a positive 
control. (C) Duodenum stained with hybridoma supernatant containing mAb 3.1 showing villi in 
profile. (D) and (E), mAb 3.1 stain showing duodenal glands. (F) mAb 3.1 stain showing villus in 
cross section. (G) Mouse IgG1 isotype control (80 µg/ml, Abcam), showing duodenal glands. Notice 
the similar distribution of cells stained with the control (A) and mAb 3.1 (C-F). Secondary antibody 
was goat anti-mouse Alexa 488 (1:300, Invitrogen). Nuclear stain is in blue (DAPI). The white arrows 
indicate duodenal glands; the yellow arrows indicate the edges of villi. “20 ×” and “40 ×” indicate the 
magnification used to acquire the images. 
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Figure 4.6 – mAb 3.1 stained cells surrounding the white pulp in canine spleen. (A) CD11b (1:10, 
AbD Serotec) stained spleen, used as a positive control. (B) Spleen stained with hybridoma 
supernatant containing mAb 3.1. (C) Negative control was stained only with the secondary antibody. 
Notice the similar distribution of cells stained with the control (A) and mAb 3.1 (B). Secondary 
antibody was goat anti-mouse Alexa 488 (1:300, Invitrogen). Nuclear stain is in blue (DAPI). The 
white arrows indicate the central arteriole. The red arrows indicate the limits of the white pulp. “20 ×” 
and “40 ×” indicate the magnification used to acquire the images. 
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Figure 4.7 – mAb 3.1 stained cells throughout the canine lymph node. (A) Paracortical area showing 
staining with hybridoma supernatant containing mAb 3.1. (B) Medullary cords stained with mAb 3.1. 
(C) Subcapsular region stained with mAb 3.1. (D) Mouse IgG1 isotype (20 µg/ml, Abcam) stain of the 
medullary cord.  Secondary antibody was goat anti-mouse Alexa 488 (1:300, Invitrogen). Nuclear 







Figure 4.8 – Titration of mAb 3.1 in the hybridoma supernatant. Four concentrations of mouse IgG1 
isotype (Abcam) and the supernatant containing mAb 3.1 were sequentially diluted and dotted on a 
nitrocellulose membrane. After blocking, bound antibody was detected using rabbit anti-mouse Ig, 
HRP-conjugated (1:1000, Dako). The concentration of mAb 3.1 was estimated to be ~ 40 – 80 µg/ml 
by comparison with the isotype antibody scale. 
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To analyse the cross-reactivity of mAb 3.1 with c-Kit, a similar receptor to CSF-1R, 
normal canine thyroid tissue was double-stained with an anti-cKit and mAb 3.1. The C-cells 
of the thyroid stained positive for c-Kit, but no individual cell was double-stained with mAb 
3.1 and anti-c-Kit (Figure 4.9). This indicates that mAb 3.1 did not cross-react with c-Kit. 
 
 
Figure 4.9 – mAb 3.1 did not cross-react with c-Kit. Canine thyroid tissue was double-stained with 
hybridoma supernatant containing mAb 3.1 and rabbit anti-human c-Kit (1:100, Dako). No cells were 
double-stained with anti-cKit and mAb 3.1. Secondary antibodies were goat anti-mouse Alexa 488 
and goat anti-rabbit Alexa 647 (1:300, Invitrogen). Mouse IgG1 isotype (20 µg/ml, Abcam) was used 
as a negative control. Nuclear stain is in blue (DAPI). “20 ×” and “40 ×” indicate the magnification 





Canine mammary tumours were stained with mAb 3.1 to assess its binding in 
paraffin wax-embedded tissues. While mammary carcinoma epithelial cells stained with 
mAb 3.1, normal breast tissue showed only minimal background staining (Figure 4.10).  
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Figure 4.10 – mAb 3.1 stained canine epithelial mammary cancer cells but not cells of normal tissue. 
Formaldehyde-fixed paraffin wax-embedded samples of canine mammary tissue and carcinomas. 
Tissues were stained with hybridoma supernatants containing mAb 3.1. Negative control was stained 
only with the secondary antibody. Secondary antibody was rabbit anti-mouse, HRP-conjugated 
(1:1000, Dako).  “20 ×” indicates the magnification used to acquire the images. 
 
 
4.3.4 Flow cytometry 
 
 Three cell types were analysed by flow cytometry using the anti-CSF-1R antibodies: 
REM134 cells, bone marrow-derived macrophages (BMDM) and peripheral blood 
mononuclear cells (PBMCs). 
 
Flow cytometry using REM134 
 
To assess mAb 3.1 in flow cytometry, REM134 (canine mammary carcinomas) cells 
were evaluated using this technique. The first trial was performed on non-permeabilized, 
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non-fixed cells. This resulted on very low percentage of stained cells using mAbs against 
either the dimerization or the extracellular region (< 1 %). Subsequently the cells were fixed 
and then permeabilized using PBST before the antibody staining, showing increased 
positivity (Figure 4.11).  
 
 
Figure 4.11 – Permeabilized REM134 carcinoma cells were stained with mAbs. REM134 cells 
permeabilized with Tween 20 stained with two IgG hybridoma supernatants containing mAbs against 
the extracellular (1C6) or dimerization domain (3.1) of CSF-1R (200 µl/10
6
 cells). The y-axis shows 
the percentage of cells stained by each mAb. Negative control was stained only with the secondary 
antibody.  Secondary antibody was goat anti-mouse Alexa 488 (1:800, Invitrogen). 
 
 
Although permeabilization increased the number of REM134 cells stained with mAb 
3.1, the percentage of positive cells was still reduced when compared to the number of 
positive cells seen in some of the replicates of immunofluorescence (Figure 4.3, above). 
Therefore, the assay was repeated using permeabilized REM134 cells. In this replicate of the 
assay (Figure 4.12), the percentage of cells stained by mAb 3.1 was greatly increased when 










































Figure 4.12 – The percentage of cells stained by mAbs was variable between replicates. REM134 cells 
permeabilized with Tween 20 stained with various hybridoma supernatants containing mAbs (200 
µl/10
6
 cells). The y-axis shows the percentage of cells stained by each mAb. Negative control was 




In accordance with the flow cytometry findings on the expression of CSF-1R by 
REM134 cells, which showed great variation, these cells responded differently to CSF-1 in 
several assay replicates. Depending on the culture conditions, REM134 cells increased, did 
not respond or even reduced replication in the presence of CSF-1. It was determined that 
sensitivity of REM134 cells was density-dependant. High cell density before they were used 
in the proliferation assay reduced the sensitivity of REM134 to CSF-1. Whereas cells grown 
in low densities proliferated in response to the addition of CSF-1 to the culture, cells in 100 
% confluence before they were harvested for the assay did not respond or had reduced 
proliferation with the addition of the growth factor. Adding more or less cells to the assay 
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Figure 4.13 – High culture density reduced REM134 sensitivity to CSF-1. The assay measured the 
effect of culture density before and during proliferation assays on the sensitivity of REM134 cells to 
CSF-1. (A) Cells grown in either low or high densities were harvested and plated for the assay also in 
varying densities. On the graph, “Low” and “High” indicate the density of the cells in culture before 
they were harvested for the assay, and “1k”, “5k” and “10k” indicate the number of cells plated for the 
actual proliferation assay. “CSF-1” indicates the addition of rhCSF-1 (100 ng/ml, Invitrogen). The y-
axis indicates luminescence intensity, which is correlated to cell number. The results are the mean of 
at least 4 replicates ± SD. (B) Difference of proliferation with/without the addition of CSF-1. Cells 
from high-density plates showed reduced proliferation in the presence of CSF-1. The y-axis shows the 
difference between the results of cells coming from high or low densities. Cells were grown for 48 h 




REM134 cells grown at different densities were stained for CSF-1R using mAbs 
1C6 and 3.1. The cells were then analysed by flow cytometry. When grown at high density, 
fewer cells were CSF-1R
+ 
(as per mAb 1C6 or 3.1 staining) in comparison to cells at lower 
densities. This result was consistent using both antibodies tested, although there was 
significant difference in the percentage of cells bound by each mAb (Figure 4.14). Therefore, 
culture conditions that reduced REM134 responsiveness to CSF-1 also reduced CSF-1R 
expression on these cells. This suggests a mechanism where a decrease in receptor 















Figure 4.14 – High culture density decreased CSF-1R expression by REM134 cells. REM134 cells 
were permeabilized with Tween 20 and stained with hybridoma supernatants containing mAbs 1C6 
and 3.1 (200 µl/10
6
 cells). “Low density” and “high density” indicate the density of the cells in culture 
before they were harvested for the assay. The y-axis shows the percentage of cells stained by each 
mAb. Negative control was stained only with the secondary antibody. Secondary antibody was goat 
anti-mouse Alexa 488 (1:800, Invitrogen). 
 
 
Flow cytometry using BMDM 
 
Next, the capacity of mAbs to bind to BMDM in flow cytometry was assessed. This 
allowed for a direct comparison between the canine anti-CSF-1R described here and an anti-
porcine CSF-1R positive control, produced elsewhere (this antibody did not stain cells in 
tissues).  
mAb 3.1 and the anti-pig CSF-1R stained canine BMDM with similar patterns. CSF-
1-conditioned BMDM showed a low percentage of cell surface CSF-1R. mAb 3.1 stained 8.7 
% of cells in this condition, while the anti-swine CSF-1R stained 3.24 % of cells. (Figure 
4.15 A). When BMDM were starved of CSF-1 overnight, there was no significant difference 
in the staining patterns with both mAb 3.1 and the anti-swine CSF-1R (not shown). 
Therefore, in a subsequent assay, cells were starved of FBS overnight, with or without CSF-
1. Unexpectedly, serum starvation seemed to abolish the surface expression of CSF-1R on 
these cells, while 12 and 14 % of cells cultured without FBS but with rhCSF-1 were positive 
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Figure 4.15 – mAb 3.1 and anti-swine CSF-1R showed similar flow cytometry staining patterns of 
BMDM. (A) BMDM in complete medium with rhCSF-1 (100 ng/ml, Invitrogen). Live cells stained 
with hybridoma supernatant containing mAb 3.1 (200 µl/10
6
 cells) or pure mouse anti-swine CSF-1R 
(25 µg/ml, Lindsey Waddell). Cell viability was assessed for this assay only using 7-AAD 
(eBioscience). The line R3 indicates the positivity threshold determined in comparison with the mouse 
IgG1 isotype control (25 µg/ml, Abcam). (B) A second assay was performed comparing BMDM 
starved of FBS overnight. Negative control was stained only with the secondary antibody or with 
isotype antibody. (C) Staining patterns of serum-starved BMDM using mAb 3.1 and anti-swine CSF-
1R in the absence of rhCSF-1 or (D) presence of rhCSF-1. In serum-starved cells, CSF-1 increased the 
expression of the receptor. The line R4 indicates the positivity threshold. Cells in (B-D) were fixed in 
PFA (2 %) before staining. The y-axis shows the number of cells. The x-axis shows green 
fluorescence intensity. Secondary antibody was goat anti-mouse Alexa 488 (1:800, Invitrogen). 
 
 
In an independent assay, the identity of the BMDMs was confirmed by staining cells 
with an antibody against canine CD11b. These cells were not serum starved. This assay 
indicated that nearly all cells from canine bone marrow cultivated in rhCSF-1 and in 
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Figure 4.16 – Putative BMDM express CD11b. BMDM were grown in the presence of rhCSF-1 (100 
ng/ml, Invitrogen) for 10 days in bacterial plastic and were used for flow cytometry. Cells were 
stained with CD11b (1:10, AbD Serotec) for characterization of the cells. All BMDM expressed 
CD11b. The y-axis shows the number of cells. The x-axis shows green fluorescence intensity. 
Negative control was stained only with the secondary antibody. Secondary antibody was goat anti-
mouse Alexa 488 (1:800, Invitrogen). 
 
 
Flow cytometry using PBMCs  
 
When the monoclonal antibodies were used to stain peripheral blood mononuclear 
cells (PBMCs) from dogs, no specific binding to monocytes was obtained with any of the 
anti-canine CSF-1R mAbs, regardless of staining time (from 30 min to overnight) or whether 
purified antibodies or hybridoma supernatants were used. The positive control, anti-swine 
CSF-1R, bound almost exclusively to canine monocytes, showing little background staining 
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Figure 4.17 – mAb 3.1 did not stain canine PBMCs. (A) PBMCs discriminated by cell granularity 
(SSC) and size (FSC). The cells with granularity around 100 and 150 are monocytes. (B) Live cells 
stained with mAb 3.1 or 12.2 (10 µg/10
6
 cells) or mouse anti-swine CSF-1R (25 µg/ml, Lindsey 
Waddell). Notice the absence of positive monocytes in the gate P3 of mAb 3.1-stained cells. Notice 
the unspecific staining of lymphocytes with mAb 12.2. Cell viability was assessed using Sytox blue 
(Invitrogen). Fluorescence intensity is shown on the x-axis and cell granularity on the y-axis. The cells 
shown in (B) are inside the gate drawn in (A). Positive cells, as determined by the P3 gate in (B), were 
set in relation to the isotype control (not shown). Positive cells are depicted in blue in both graphs. 
Secondary antibody was goat anti-mouse Alexa 488 (1:800, Invitrogen). 
 
 
However, binding of the anti-swine CSF-1R antibody to the canine cells seems to 
have been at least partially mediated through Fc receptor activity. When these receptors were 
blocked using a high concentration of an Fc blocking reagent, binding of the anti-swine 
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antibody to the canine receptor was greatly reduced. Fc blocking had no effect on mAb 3.1, 
since it showed no staining of the monocytes (Figure 4.18). 
 
Figure 4.18 – Blocking the Fc receptor reduced anti-swine CSF-1R staining of canine PBMCs. Live 
cells stained with hybridoma supernatant containing mAb 3.1 (200 µl/10
6
 cells) or pure mouse anti-
swine CSF-1R (25 µg/ml, Lindsey Waddell). Fc receptor-block reduced the staining by the anti-swine 
antibody. Cell viability was assessed using 7-AAD (eBiosciences). The rectangle R4 indicates the 
positivity threshold determined in comparison with the mouse IgG1 isotype control (25 µg/ml, 
Abcam). The x-axis shows fluorescence intensity and the y-axis shows cell granularity (SSC). The 
results on the top row are of cells that received the Fc blocking reagent (20 µl, Miltenyi Biotec). The 
results on the lower row show cells that were not Fc-blocked. Secondary antibody was goat anti-





 The monoclonal antibodies were tested in an immunoprecipitation assay to further 
verify for specificity. Purified mAbs 3.1, 2H1 and 12.2 and the supernatant of mAb 1C6 
were bound to protein G. These were then incubated with culture supernatant from 
HEK293T cells that transiently expressed the CSF-1R extracellular region. After removing 
unspecific binders by washing, the immunoprecipitated proteins were detected by western 
blot with an anti-His tag monoclonal (this tag is coupled to CSF-1R). mAbs 3.1 and 12.2 
recovered proteins with the correct molecular weight of CSF-1R. mAb 3.1 seemed to only 
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bind to a narrow range of the glycoforms of CSF-1R, as seen by the tight band in the western 
blot assay. mAb 12.2 recognized a broader range of the glycoforms of CSF-1R. Since an 
anti-mouse HRP-conjugate was used to detect the anti-His antibody, the anti-CSF-1R mAbs 
also appeared on the western blot (Figure 4.19). 
 
Figure 4.19 – Immunoprecipitation with anti-canine CSF-1R murine mAbs. Purified murine mAbs (21 
µg) or hybridoma supernatant (mAb 1C6 only) were coupled to protein G beads (75µl, GE 
Healthcare). Unbound antibodies were removed by washing. Medium from transiently transfected 
HEK293T cells expressing CSF-1R extracellular region was added to the beads and incubated 
overnight at 4
o
C. Unbound proteins were removed by washing. The resin was incubated with reducing 
sample buffer at 95
o
C for 5 min. The mixture was centrifuged and the supernatant was resolved by 
SDS-PAGE. His-tagged proteins were identified by western blotting (anti-His at 1:500, Invitrogen). 
Secondary antibody was anti-mouse, HRP-conjugated (Dako, 1:1000). The arrow indicates the 
extracellular CSF-1R. Notice the positive results from mAbs 3.1 and 12.2. The arrowhead indicates 
the size of the antibody heavy chain. 
 
 
4.3.6 mAbs blocked REM134 proliferation 
 
REM134 cells express the CSF-1R receptor (Chapter 3) and are also capable of 
proliferating in response to CSF-1 (Figure 4.13, above, and Chapter 3). This cell model was 
therefore utilised to determine if inhibition of CSF-1R by the mAbs would decrease cancer 
cell proliferation. The anti-proliferative activity of mAbs generated in the first hybridoma 
against the extracellular CSF-1R was tested exclusively in this assay, with the exception of 
mAb 1C6, which was also tested by real time proliferation assay against REM134 cells. 
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The supernatant of 1C6 was capable of inhibiting REM134 proliferation, as tested in 
an endpoint proliferation assay (Figure 4.20). Several IgM clones were able to affect 
REM134 cell proliferation, such as mAbs 7G3 and 6C2 (not shown).  
 
Figure 4.20 – mAb 1C6 inhibited REM134 proliferation. Hybridoma supernatant containing mAb 1C6 
was used, with the addition of rhCSF-1 (100 ng/ml, Invitrogen) to the culture. The REM134 cells (in 
100 µl medium) received between 5 – 20 µl of the supernatant. Cells were grown for 48 h after 
addition of treatment. There is a dose-dependent effect of mAb 1C6 on REM134 survival. 
Proliferation results as measured by luciferase activity (CellTiter-Glo, Promega). Results shown as 
mean of at least 6 replicates. The asterisk indicates statistically significant difference from the Control 
group by ANOVA. 
 
 
To test if mAb 1C6 could inhibit proliferation of murine macrophages, this antibody 
was used in an assay with RAW264.7 cells (mouse macrophage cell line). Contrarily, mAb 
1C6 increased RAW264.7 cell proliferation (Figure 4.21). 
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Figure 4.21 – mAb 1C6 did not reduce proliferation of RAW264.7. The murine macrophages (in 100 
µl medium) were supplemented with rhCSF-1 (100 ng/ml, Invitrogen) and/or hybridoma supernatant 
containing mAb 1C6 (40 µl). Results shown as mean of at least 8 replicates. Asterisks indicate 
statistically significant difference from the “Control No CSF-1” group by ANOVA. 
 
 
mAbs originated from the hybridoma fusion against the dimerization domain were 
tested only in real time proliferation assays, as shown below in relation to the proliferation of 
REM134 (mammary carcinoma cells). Cells were maintained in the presence of CSF-1 and 
received two different concentrations of antibodies. Several antibody clones against the 
dimerization domain of CSF-1R demonstrated the capacity to reduce REM134 proliferation. 
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Figure 4.22 – Effect of mAb supernatants in the proliferation of canine REM134 mammary carcinoma 
cells. Cells (in 100 µl medium) were cultured with rhCSF-1 (100 ng/ml, Invitrogen) and treated with 
hybridoma culture supernatants containing the indicated antibodies (5 µl or 10 µl) or with 10 µl of 
DMEM (control). Notice that some mAbs reduced REM134 proliferation. A control without CSF-1 is 
shown. Data was collected every 15 min. The vertical line and arrowhead at around 1 h indicates 
when the treatments were added. The data was also normalized by subtraction (delta) from that point. 
Delta cell index (y-axis) is correlated to cell number. Results are shown as the mean of 4 wells ± SD 
for each time point. Results analysed by repeated measures two-way ANOVA with a Bonferroni post-
test. The coloured values next to mAb names indicate the time in hours when treatments were 
different from Control. 
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4.3.7 mAb 3.1 reduced blood vessel remodelling in the CAM assay 
 
To assess if the effect of antibody activity on cancer cells was sufficient to provide 
biologically relevant outcomes, mAb 3.1 was tested in a chorioallantoic membrane (CAM) 
assay, analysing blood vessel remodelling. A sponge containing REM134 cells was 
implanted onto the CAM of day-7 chick embryos. Four days after grafting the sponge, CAM 
blood vessels became strongly directed towards the graft. mAb 3.1 was able to reduce blood 
vessel growth towards the sponge containing REM134 cancer cells. Blood vessel 
remodelling towards the graft was quantified by two parameters, a score on blood vessel 
number and blood vessel branching counts.  
The REM134 cells were largely confined to the sponge throughout the experiment, 
as can be seen by the presence of the green fluorescent cells (Figure 4.23 A). Treatment with 
mAb 3.1 significantly reduced blood vessel branching surrounding the sponge graft (Figures 
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Figure 4.23 – mAb 3.1 reduced cancer cell-directed blood vessel remodelling in the chorioallantoic 
membrane (CAM) assay. (A) REM134 cells were stained with CFSE (green fluorescence), and cells 
were absorbed in a gelatine sponge (~ 10
6 
cells), which was placed on the CAM at embryonic day 7, 
in the presence or absence of hybridoma culture supernatant containing mAb 3.1. The sponges and 
surrounding vessels were imaged at embryonic day 11. The limits of the sponge are shown by the 
white arrows. (B) Representative picture of blood vessel formation towards the sponge graft (dark 
square) in the absence of treatment. (C) Blood vessel formation in the presence of mAb 3.1. Notice 
the reduced vascular reorientation surrounding the sponge compared to (B). The limits of the sponge 
are shown by the white arrows. (D) Blood vessel branching counts in control or mAb 3.1 treated cells. 
Horizontal bar represents the median. Results analysed by Mann-Whitney test.  
 
 
4.3.8 mAbs blocked macrophage proliferation 
 
The capacity of the anti-CSF1-1R mAbs to block the proliferation of canine 
macrophages was analysed by real time proliferation assay. Bone marrow-derived 
macrophages were harvested and plated onto the real time analysis plates, where cells were 
then treated with monoclonal antibodies in the presence of CSF-1. Five of the ten antibodies 
tested were able to inhibit macrophage survival in a dose-dependent manner (Figure 4.24), 
all of which had also shown at least partial response against REM134 cells in the same assay 
(Figure 4.22, above). mAb 2H1 was the only antibody that had shown evident activity 
against REM134 cells but did not inhibit macrophage proliferation in this test.  
Chapter 4 - Characterization of mAbs    128 
 
Figure 4.24 – Effect of mAb supernatants against CSF-1R in real time proliferation assay of canine 
BMDM. Cells (in 100 µl medium) were grown in rhCSF-1 (50 ng/ml, Invitrogen) and treated with 
hybridoma culture supernatants containing the indicated antibodies (10 µl or 20 µl) or with 20 µl of 
DMEM (control). Notice that some mAbs reduced BMDM proliferation. A control without CSF-1 is 
shown. Data was collected every 15 min. Antibodies were added in the first hour of the assay. The 
abrupt drops in the graphs indicate when the plate was removed from the xCelligence equipment for 
change of medium/treatment. Cell index (y-axis) is correlated to cell number. Results are shown as 
means of 4 wells ± SD for each time point. Results analysed by repeated measures two-way ANOVA 
with a Bonferroni post-test comparing all groups to the control. The coloured values next to mAb 
names indicate the time in hours when treatments were different from Control. 
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The proliferation assays shown previously used hybridoma supernatants as the 
source of antibodies. When purified antibodies were used for inhibition of BMDM 
proliferation, the lowest mAb concentration to exhibit significant biological activity in 
relation to the mouse antibody control was of 1.25 µg/well for mAbs 12.2 and 2H1. 
However, this was inconstant, and mAb 2H1 was not significantly different from the control 
antibody at higher concentrations. Also, mAb 12.2 was relatively more efficacious at the 
lowest dose, since statistically significant differences from the control occurred in earlier 
time points in the 1.25 µg/well dose compared to 3.75 and 7.5 µg/well. mAb 3.1 showed a 
trend of significant activity at 7.5 µg/well, when all mAbs yielded visibly lower cell 
proliferation than the control antibody. However, at that dose, only 2 wells were used as 
replicates for control and mAb-treated cells, and the differences seen with mAb 3.1 did not 
reach statistical significance (Figure 4.25). For clarity, antibody purification is shown in 
Chapter 7.  
mAb 3.1 hybridoma supernatant (SN) was used as a control for the purified antibody 
response, as it had previously been shown to affect macrophage proliferation. It showed a 
similar effect to 3.75 µg/well of purified mAb 3.1, indicating that the concentration of 
antibody in the supernatant estimated from Figure 4.8, above, was correct. Based on that 
figure, mAb 3.1 hybridoma supernatant had up to 80 µg/ml of antibody (= 3.2 µg per 40 µl, 
the volume of supernatant used).   
GW2580, a small-molecule inhibitor of CSF-1R, also showed dose-specific response 
and was able to reduce macrophage survival at 20 µM and 30 µM in relation to their DMSO 
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Figure 4.25 – Effect of purified mAbs in proliferation assay of canine BMDM. Cells (in 100 µl 
medium) were grown in rhCSF-1 (20 ng/ml, Invitrogen) and treated with one of three purified mAbs 
(at 1.2, 3.7 or 7.5 µg), the hybridoma supernatant of mAb 3.1 (40 µl) or GW2580 (10 – 30 µM), as 
indicated. Only mAb 12.2 consistently reduced BMDM proliferation. The controls received 
equivalent concentrations of mouse serum IgG antibody (Sigma), PBS (antibody vehicle control) or 
DMSO (GW2580 vehicle control). The untreated control is not shown on the first graph as its curve 
overlaps with that of the mouse IgG control. Data was collected every 15 min. The vertical line at 
around 17 h indicates when the treatments were added. Data were also normalized at that point. 
Normalized cell index (y-axis) is correlated to cell number. The abrupt drops in the graphs indicate 
when the plate was removed from the xCelligence equipment for change of medium/treatment. 
Results are shown as means of 4 wells (2 wells at 7.5 µg) ± SD for each time point. SD bars are not 
shown on the last graph for clarity. Results analysed by repeated measures two-way ANOVA with a 
Bonferroni post-test comparing all groups to the control. The coloured values next to mAb names 
indicate the time in hours when treatments were different from their respective controls (either ms 
IgG, DMEM or DMSO groups). 
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4.3.9 mAb 3.1 inhibited osteoclast survival 
 
Osteoclasts have a distinct morphology, forming a tight “tiled” structure in culture. 
Because of this, apoptosis is easy to identify in the cell culture, as this tiled pattern is then 
broken (Lacey et al., 2000). Feline osteoclasts were differentiated from the bone marrow and 
kindly provided by Seungmee Lee (Gura Bergkvist group, Roslin Institute). The feline and 
the canine CSF-1R have 82 % homology when only the extracellular region is considered 
(Chapter 7) – this is the region targeted by mAb 3.1. When mAb 3.1 was used on feline 
osteoclasts, it induced phenotypical alterations that indicate cellular contraction and 
membrane blebbing. The use of a control antibody (anti-CCR2 mAb) or the removal of CSF-
1 after the cells had differentiated had no effect on cellular morphology and in these cases 
the cells maintained a “tiled” pattern (Figure 4.26). Next, the CSF-1R signalling pathways 
were evaluated by western blotting. Osteoclasts were removed from the plates and were 
lysed for analysis by western blot. While total Akt was stable between treatments, pAkt was 
reduced in mAb 3.1 treated cells. The antibody treatment had no effect on pMAPK. This 
indicates that mAb 3.1 specifically induced apoptosis of feline osteoclasts, affecting survival 
pathways dependent on Akt phosphorylation (Figure 4.27). 
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Figure 4.26 – mAb 3.1 induced apoptosis of feline osteoclasts. Bright field images of feline 
osteoclasts grown with rhCSF-1 (10 ng/ml, R&D Systems) and rhRANKL (30 ng/ml, R&D Systems) 
treated with hybridoma culture supernatant containing mAb 3.1 (1/6 of medium volume in osteoclast 
culture) for 4 days and comparisons with anti-CCR2 hybridoma culture supernatant (similar dose, 
Teresa Raposo), untreated and no CSF-1 controls. (A) Cells at 0 h (beginning of the assay). (B) and (B 
(annotated)) Cells at 4 days of treatment. (B (annotated)) display the same images as (B), but the 
images were consistently digitally altered and the cellular membranes were manually outlined to 
highlight the differences between the groups. Notice the membrane retraction in mAb 3.1-treated 
osteoclasts, typical of apoptosis. Pictures are representative of two wells for the negative controls and 
mAb 3.1 treated cells, and of a single well for the anti-CCR2 treated cells. 
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Figure 4.27 – mAb 3.1 reduced pAkt in feline osteoclasts. Feline osteoclasts were grown with rhCSF-
1 (10 ng/ml, R&D Systems) and rhRANKL (30 ng/ml, R&D Systems) and were treated with 
hybridoma culture supernatant containing mAb 3.1 (1/6 of medium volume in osteoclast culture) for 4 
days. Controls were: anti-CCR2 hybridoma culture supernatant (similar dose, Teresa Raposo), 
labelled as “α CCR2” in the figure, untreated cells (“Control”) and no CSF-1 after cells had matured 
into osteoclasts (“-CSF-1”). Proteins from the lysed osteoclasts (20 µg/well) were resolved by SDS-
PAGE and transferred onto a nitrocellulose membrane. The same membrane was probed with anti-
pAkt, anti-total Akt and anti-pMAPK (all at 1:1000, Cell Signalling). Notice the reduced pAkt band in 




4.3.10 ELISA assays 
 
CSF-1 binding inhibition assay 
 
A selection of clones that showed promising results in the proliferation assays using 
the REM134 cells were analysed in their capacity to block CSF-1 binding to CSF-1R. This 
was tested by ELISA, where immobilized CSF-1R was used to capture CSF-1, which was 
detected with a commercial antibody. Anti-CSF-1R mAbs were tested for the ability to 
inhibit CSF-1R/CSF-1 binding. The IgG mAb 1C6 showed the best response, producing a 
signal lower than the control, indicating that less CSF-1 bound to the receptor (Figure 4.28). 
All other tested antibodies were IgM clones. However, in later assays, mAb 1C6 seemed to 
lose its capacity to bind to CSF-1R, as measured by ELISA. mAb 3.1 was not tested in this 
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assay since it was produced against the dimerization domain of the CSF-1R and was 












Figure 4.28 – mAb 1C6 reduced CSF-1/CSF-1R interaction. Competition ELISA for the CSF-1R 
ligand-binding region using hybridoma culture supernatants containing mAbs. Monoclonal antibodies 
were added to plates containing the immobilized canine CSF-1R (300 ng/well, Chapter 7). rhCSF-1 
(18 ng/well, Biolegend) was added subsequently, and the amount of bound CSF-1 was detected using 
anti-CSF-1 (1:75, Peprotech). Only mAb 1C6 reduced CSF-1 binding when compared to the control. 
Secondary antibody was anti-rabbit Ig, HRP-conjugated (Life Technologies). The negative control 
was stained only with the secondary antibody. The y-axis indicates the relative amount of CSF-1 
bound to CSF-1R. The result shown here is the difference in luminescence between the wells with 
mAb competing with CSF-1 and the wells with the mAb only. Results lower than the control suggest 
that the respective mAb supernatant reduced CSF-1 binding. The figure is representative of 4 wells in 
each of two independent assays. 
 
 
Cross reactivity of mAb 3.1 
 
All of the monoclonal antibodies were originally selected for the ability to bind CSF-
1R in dot-blots or ELISA assays (Chapter 7). However, when the antibodies were tested 
against unrelated control proteins, it became evident that many clones showed non-specific 
binding. mAb 3.1 bound strongly to the antigen against which it was raised, the dimerization 
domain of CSF-1R, produced in bacteria. However, it bound weakly to the full CSF-1R 
receptor, which was produced in mammalian cells, and also to a control protein, bovine 
serum albumin (BSA) (Figure 4.29). 
 
 















































Figure 4.29 – mAb 3.1 showed cross-reactivity with other proteins in ELISA. Plates were coated with 
either the extracellular region (EC) of canine CSF-1R (400 ng/well), with similar concentrations of 
BSA or with the dimerization domain of the CSF-1R with the respective tags (Dimer His/Dimer 
GST). mAb 3.1 bound similarly to the EC region and to the control protein, BSA. Secondary antibody 
was rabbit anti-mouse Ig, HRP-conjugated (1:2000, Dako). The negative control was stained only 





Several monoclonal antibodies exist for therapies against human cancer. Common 
targets, such as CD20, are overrepresented among the existing drugs as companies tend to 
follow the commercial success of preceding mAbs (Scott et al., 2012). The same is true for 
veterinary medicine, and CD20 is one of the two currently licensed (FDA) targets of mAbs 
for dogs (Acharya et al., 2015). To fully achieve the potential of mAbs in cancer therapy, 
there is a need to develop targeted treatments against a wider range of antigens (Zhao et al., 
2014). The tumour microenvironment and the infiltrated immune cells are believed to be 
potential targets. The immune components of the tumour bulk are not only tolerant to the 
cancer cells, but can in fact promote cancer growth (Bonde et al., 2012; Marabelle et al., 
2014). 
This chapter shows the characterization of antibodies with potential to inhibit 
macrophage survival and proliferation by blocking the CSF-1R. These antibodies were 
created with the intent of affecting the population of tumour-associated macrophages 
(TAMs). The two best candidates were described here: mAb 1C6 was produced against the 
full extracellular fraction of the CSF-1R; mAb 3.1 was generated against the dimerization 
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over time and was therefore not studied using the full complement of assays described here. 
The second antibody, mAb 3.1, was thoroughly characterized. 
Although not shown, none of the mAbs tested here reacted against the CSF-1R in 
western blots. Therefore, other assays were performed to determine mAb specificity, such as 
immunostaining of different cells and tissues. 
 
4.4.1 Immunostaining assays 
 
Bone marrow-derived macrophages express CSF-1R on the cell surface, as has been 
shown in cells from other species, such as pigs and chickens (Garcia-Morales et al., 2014; 
Moffat et al., 2014). mAb 3.1 was able to stain BMDM and a canine histiocytic sarcoma cell 
line (DH82) by immunofluorescence, although the staining was weak. BMDM were 
supplemented with rhCSF-1, which leads to receptor degradation (Garcia-Morales et al., 
2014). Also, cells that co-express CSF-1 and its receptor have a reduced number of copies of 
the receptor on the cell surface, due to an increased rate of turnover (Rettenmier et al., 1987). 
BMDM cells in culture are capable of expressing CSF-1 after an initial exogenous CSF-1 
stimulation (Temeles et al., 1993), and therefore low concentrations of the receptor were 
expected. However, because of the fixation method, intracellular receptor could be detected 
by immunofluorescence. For flow cytometry, BMDM were starved of CSF-1 in an attempt to 
increase CSF-1R expression on the cell surface, without effect, as measured using both the 
anti-swine CSF-1R (positive control antibody) and mAb 3.1 (not shown). This may be due to 
the long period of CSF-1 conditioning to which those cells had previously been subjected. In 
these conditions, as mentioned above, BMDM can produce CSF-1 (Temeles et al., 1993), 
rendering the CSF-1 starvation inefficacious. When cells were starved of FBS overnight, no 
CSF-1R expression could be detected with mAb 3.1 or the control antibody, probably due to 
forced cell cycle arrest (Rosner et al., 2013). If cells were supplemented with CSF-1 during 
serum starvation, CSF-1R could be detected in similar levels by both the control and 3.1 
antibodies. 
mAb 3.1 specifically bound to dog cells as no staining was detected in the murine 
macrophage cell line (RAW264.7). This is an important negative control, since staining 
cannot therefore be attributed to binding to the Fc receptors. The function of Fc receptors is 
illustrated in Figure 4.30. These receptors are present in several leukocytes and are 
responsible for binding to the Fc region of the antibodies (Fridman, 1991). RAW264.7 cells 
express Fc receptors (Rosa et al., 2007) and since mAb 3.1 is a murine antibody it would be 
possible for it bind to the receptors on the surface of RAW264.7 cells leading to non-specific 
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staining. However, it has been suggested elsewhere that Fc receptor binding during 










Figure 4.30 – Schematic representation of the role of Fc receptors. Cells expressing these receptors are 
activated upon binding to the Fc fraction of an antibody.   
 
 
Fc receptors are expressed throughout several leucocytes lineages (Fridman, 1991). 
If mAb staining was dependent on Fc receptors, immune tissues stained with mAb 3.1 
should demonstrate non-specific staining of several FcR
+
 cells, such as granulocytes or 
lymphocytes in the lymph node or spleen. On the contrary, mAb 3.1 could identify cells 
within normal canine tissues – lymph node, spleen and duodenum – that are compatible with 
the spatial distribution of macrophages (Sasmono et al., 2003). In the MacGreen mouse, 
which expresses a CSF-1R-GFP transgene, it is possible to recognize a subpopulation of 
especially bright CSF-1R
+
 cells surrounding the lymphoid follicles of the spleen 
(MacDonald et al., 2010) which could correspond to the cells stained by mAb 3.1. When the 
mAb was used to stain lymph nodes, the cells of the medullary cords were preferentially 
marked, with increased intensity compared to other areas of the organ. This subpopulation of 
cells is known to highly express the CSF-1R (Sasmono et al., 2003). Strong staining of cells 
throughout other regions of the lymph node only was obtained when cells were 
permeabilized, as shown in the Results, indicating that most receptors expressed by these 
cells were intracellular. These data indicate that mAb 3.1 binds to cells expressing high 
concentrations of CSF-1R. mAb 3.1 stained cells in the same tissue compartments as other 
markers such as CD163 and CD11b, which confirms that those cells are likely macrophages. 
CD163 is commonly expressed in macrophages in the intestine (Bain et al., 2013; Komohara 
et al., 2006). CD11b is a common myeloid cell marker, although it can be expressed by other 
leukocytes, such as neutrophils (Jämsä et al., 2015).  
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There does not seem to exist cross reactivity between the monoclonal antibody 3.1 
and receptors of similar structure to CSF-1R. The CSF-1R is structurally similar to other 
tyrosine kinase receptors, such as c-Kit and the platelet-derived growth factor receptor 
(PDGFR), although the canine amino acid sequences share only 29.18 % and 23.12 % 
identity in the extracellular portions, respectively (NCBI) (Qiu et al., 1988). A thyroid 
section was co-stained with c-Kit antibody and mAb 3.1. No cells were double-stained by 
these antibodies. It is suggested that the c-Kit
+
 cells within the thyroid are C cell precursors 
(Bosse et al., 1997). The distribution of c-Kit
+ 
staining in the current work is similar to what 
is expected for C cells (Islam, 2013). Few macrophages are present in the thyroid (Kimura et 
al., 2005), as was observed here with mAb 3.1. Antibody specificity was also confirmed by a 
competitive inhibition assay where increasing concentrations of recombinant CSF-1R was 
used to block the staining of DH82 cells by mAb 3.1. The same competition protocol could 
not reduce the staining by the control CD11b antibody. 
mAb 3.1 also was able to stain cancer cells. Two canine mammary cancer cell lines 
(REM134 and Lilly) and also epithelial cells in paraffin wax-embedded tumours were 
positive using mAb 3.1. Canine mammary tumour epithelial cells have previously been 
shown to express the CSF-1R (Król et al., 2011), and the expression pattern was confirmed 
here. As is shown in Chapter 3, both cancer cell lines transcribe CSF-1R mRNA and can be 
repressed by a CSF-1R small-molecule inhibitor. The expression of CSF-1R (as stained by 
mAbs 1C6 and 3.1) and the reliance on this receptor for cancer cell proliferation was 
variable and dependent on cell density, probably due to contact inhibition and cell cycle 
arrest (Rosner et al., 2013). This could justify some of the large differences in cell positivity 
seen in the replicates of flow cytometry staining of REM134 cells. 
mAb 3.1 could not stain peripheral blood monocytes from dogs, however. An anti-
mouse CSF-1R inhibiting antibody, mAb 2-4A5, has been found not to be able to stain CSF-
1R on the surface of a transfected cell line and the authors believed this was due to the 
proximity of the epitope to the cellular membrane (Haegel et al., 2013). The region used as 
the immunogen for mAb 3.1 spanned the amino acids 344 to 444 of the extracellular portion 
of the canine receptor. This is similar to the epitope of mAb 2-4A5, which is located between 
the amino acids 349 and 512 of the murine sequence (Sherr et al., 1989). Therefore, epitope 
unavailability of the soluble receptor could potentially inhibit the binding of mAb 3.1. 
It is possible that some of the monocytes express low levels of CSF-1R and were not 
detected by mAb 3.1. Other antibodies also selectively target some of the CSF-1R
+
 
monocytes. M279, a blocking anti-CSF-1R, only depletes GR-1
-





 cells from the blood of mice (MacDonald et al., 2010), leaving some of 




 monocytes unaffected. The number of CSF-1R copies on the cell surface is 
much smaller for blood monocytes than for tissue or activated macrophages (Byrne et al., 
1981). Additionally, in humans, CSF-1R is only highly expressed in the nonclassical 
monocyte subset, which represents less than 10 % of the circulating total of monocytes 
(Thomas et al., 2015; Wong et al., 2011). These CSF-1R
Low
 cells could potentially evade 
staining by mAb 3.1. As was seen when staining tissues, mAb 3.1 may not detect cells 
expressing low concentrations of CSF-1R, as it preferentially seems to bind to CSF-1R
High
 
populations such as medullary cord macrophages in the lymph nodes (Sasmono et al., 2003) 
and perifollicular macrophages in the spleen (MacDonald et al., 2010). 
The positive control used for staining of canine monocytes was an anti-swine CSF-
1R. It is interesting to note that some of its binding was dependent on the antibody Fc 
fraction. When a human Fc receptor block was used, binding of the control antibody to 
monocytes was greatly diminished. Human antibodies can bind to canine Fc receptors 
(Bergeron et al., 2014), and therefore the human Fc blocking reagent used – dependent on 
the presence of human antibodies to compete for Fc binding – was suitable for blocking dog 
cells. Mouse IgG1 antibodies can bind to the canine FcγRIII. Binding to this receptor only 
occurs when there is an antigen-antibody complex. It is possible that the Fc receptor could 
have served to strengthen the binding of the anti-swine mAb to CSF-1R on the same cell 









Figure 4.31 – Fc receptor binding can modulate the antibody contact with its antigen on the same cell 
(cis-interaction). This can alter the binding properties of the antibody to its target (Haegel et al., 2013). 
 
 
Lack of antibody specificity or affinity could also justify why mAb 3.1 did not bind 
to blood monocytes. This is supported by the ELISA assay of specificity, where mAb 3.1 
failed to bind to the extracellular fraction of CSF-1R. This antibody was raised against the 
dimerization domain of CSF-1R, a fraction which is contained within the extracellular 
region. However, while the extracellular region was produced in mammalian cells, therefore 
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being folded and glycosylated similarly to the wild-type protein, the dimerization domain 
was expressed in bacteria. Also, the recombinant antigen used for generating mAb 3.1 
formed aggregates. The different protein conformation due to bacterial origin and aggregate 
formation could explain the binding of mAb 3.1 to fixed tissues but not to the native soluble 
protein expressed on monocytes. Immunization with a non-conformational peptide is known 
to reduce the formation of antibodies that recognize the conformational epitopes (Beil et al., 
1973). 
 In immunoprecipitation, it could be verified that mAb 3.1 bound only to a narrow 
range of the glycoforms of CSF-1R, reinforcing the hypothesis that the bacterial origin of the 
antigen used for producing this antibody had an effect on its affinity. Surprisingly, mAb 12.2 
immunoprecipitated a large range of glycoforms, although it was originated from the same 
immunization as mAb 3.1.   
 
4.4.2 Proliferation assays 
 
The capacity of an antibody to interfere with signalling from a receptor can be 
derived from several separate mechanisms. Possible means include blockade of ligand-
receptor interaction, impediment of dimerization/aggregation of receptor units and alteration 
of receptor conformation (Bradbury et al., 2011). 
mAb 1C6 was raised against the extracellular portion of this receptor, and seemed to 
reduce canine mammary cancer cell survival based on the competitive inhibition of CSF-1 
binding, as shown by ELISA. Other antibodies could not affect CSF-1 binding to the 
receptor, and some seemed to increase this interaction possibly through cooperative binding 
(Lu et al., 2004) or allosteric control (Rizk et al., 2011). All other antibodies tested in the 
assay of CSF-1 binding inhibition were IgM, and could present some allosteric interaction 
with CSF-1, increasing its binding. However, over time the 1C6 hybridoma clone seemed to 
lose binding for the CSF-1R, as later assessed in confirmatory ELISAs. 
To increase the likelihood of finding an inhibitory antibody against this receptor, 
monoclonal antibodies were raised using the dimerization domain of CSF-1R as an antigen. 
Stable dimerization of the receptor monomers after ligand binding is essential for signal 
transduction via the CSF-1R (Li and Stanley, 1991). Blocking receptor dimerization has 
been shown to be an effective means to impede receptor function (Adams et al., 2006). The 
monoclonal antibody (mAb) 3.1, originated from this hybridoma production strategy, was 
capable of reducing BMDM survival, and it is therefore likely that this effect was mediated 
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by blocking the CSF-1R. Blocking the function of CSF-1R abrogates the growth of bone 
marrow macrophages (Dewar et al., 2005). 
It could be hypothesized that an effect on cell survival could also be derived from 
affecting the Fc receptors on the macrophage surface. The high affinity Fc receptor FcγRI is 
capable of binding free antibodies (not coupled to an antigen) and could have mediated some 
of the effects that the mAbs showed on the canine macrophages (van der Poel et al., 2011). 
However, murine IgG1, such as mAb 3.1, is not able to bind to the canine FcγRI (Bergeron et 
al., 2014), indicating that contact with this receptor could not have affected the canine 
BMDM. mAb 12.2 was of the IgG2b isotype, which also cannot interact with the canine 
FcγRI. This antibody showed a strong effect on macrophage proliferation in the dosing 
assays, but this effect was removed upon antibody chimerization (Chapter 5). This indicates 
that when Fc binding was added to mAb 12.2, its affinity towards CSF-1R was removed, 
perhaps as an effect of the obligatory cis-interaction between mAb and CSF-1R after 
chimerization (see Figure 4.31, above).  
If there is an interaction of mAb 3.1 with Fc receptors, it is more likely that Fc 
binding modulates, rather than substitutes, the CSF-1R binding effects. This could happen 
through FcγRIII, which requires the formation of an antibody-antigen complex for binding to 
the Fc region and which can interact with murine IgG1 (Bergeron et al., 2014; van der Poel et 
al., 2011). This interaction may have occurred with the anti-pig CSF-1R antibody, discussed 
above in the flow cytometry assays. Another anti-CSF-1R mAb has been described which 
depends largely on the Fc region for functional impairment of the CSF-1R signalling (Haegel 
et al., 2013). FcγRI and FcγRIII binding is believed to increase, rather than inhibit, 
macrophage proliferation (Luo et al., 2010). However, the stimulation through Fc receptors 
paradoxically can induce immunosuppression through the release of cytokines such as IL-10 
(Gerber and Mosser, 2001). In this way, mAb 3.1 could bind to CSF-1R through the variable 
regions and to the FcγRIII through the Fc fraction, leading to reduced cellular survival (see 
Figure 4.31, above). Again, the activity of mAb 12.2 must have been Fc-independent since 
the murine IgG2b does not bind to FcγRIII (Bergeron et al., 2014). 
The binding to Fc receptors may, however, explain the large influence of the control 
IgG used in the dose-dependent proliferation assay. The commercial control antibodies used 
in that assay are purified from mouse serum and therefore are comprised of all antibody 
isotypes. As such, no direct comparison can be made between IgG1 or IgG2b clones, such as 
mAb 3.1 and mAb 12.2, and the control antibody, which contains IgG2a, a strong binder of 
canine Fc receptors (Bergeron et al., 2014). Another group also found that the isotype control 
altered macrophage functionality. When mAb AFS98 (anti-murine CSF-1R) was used in a 
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tumour model, it was revealed that treatment of animals with rat isotype control could reduce 
CSF-1R
+
 cells within the tumours, although the mAb displayed superior results. Nonetheless, 
improved clinical outcomes could only be seen when using mAb AFS98 (Fend et al., 2013). 
Mammary cancer cells are not expected to express effector Fc receptors, and 
therefore this mechanism cannot be even considered to explain the cellular inhibition of 
these cells with the mAbs (Cianga et al., 1999; Dougherty et al., 1987; Kerbel and Dennis, 
1980). As stated above, these cells express the CSF-1R. Our results (Chapter 3) and other 
works from the literature suggest that CSF-1R can be relevant for cancer cell metabolic 
activity (Patsialou et al., 2009). Even if exogenous CSF-1 has only a small effect in cancer 
cell proliferation, autocrine expression of the ligand can activate the receptor (Patsialou et 
al., 2009). The effect of mAb 3.1 in reducing cancer cell survival also was translated as 
reduced vascular remodelling in the CAM assay even in the absence of macrophages, 
indicating that the effect of the mAb solely on the cancer cells could be biologically relevant. 
However, it was verified by flow cytometry that CSF-1R expression and proliferation by 
REM134 carcinoma cells was very sensitive to contact inhibition, as discussed above. This 
could have affected the screening of the first hybridoma fusion against the extracellular 
region of CSF-1R (Chapter 7). The anti-proliferative activity of these first antibodies was 
tested mainly against REM134 cells; for those assays, cellular confluence was not observed 
and potential clones may have been discarded due to weak anti-proliferative responses in 
cells that were overconfluent at the time of testing. 
The effects of mAb 3.1 on cellular proliferation were confirmed using feline 
osteoclasts. The inhibition assay with osteoclasts was performed because these cells have a 
distinct morphology, forming a tight “tiled” structure. When cells undergo apoptosis, they 
naturally retract. Detecting this occurrence on osteoclasts is simple because of the 
characteristic arrangement of the cells in culture (Lacey et al., 2000). Apoptosis was induced 
using mAb 3.1 but not a control anti-CCR2 monoclonal. When the molecular pathways were 
analysed, it could be seen that only mAb 3.1 induced a reduction in the phosphorylation of 
Akt, which is important for cell survival mediated through CSF-1R (Kelley et al., 1999).  
However, FcγRIIb is capable of inhibiting macrophage activation also by affecting 
the Akt phosphorylation (Tridandapani et al., 2002). Although the human FcγRII can bind to 
murine IgG1 and IgG2 (Warmerdam et al., 1993), it is not known to which murine isotypes 
the feline version of the receptor can bind. Against this hypothesis is the fact that IL-4 can 
induce the expression of FcγRIIb, and would therefore increase the inhibition of 
macrophages in the presence of mAbs. However, this did not happen when chimeric mAbs 
were used in the presence of IL-4 (Chapter 5) (Tridandapani et al., 2002). Analysis of CSF-
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1R phosphorylation would clarify the pathways involved in the osteoclast apoptosis, but 
there are no commercially available antibodies that detect this in feline or canine cells.  
Although mAb 3.1 seemed consistent in being able to affect cellular proliferation, 
only high concentrations of the mAb was able to reduce macrophage replication; because 
only two replicates were used at the relevant antibody dose, no statistical difference from the 
murine antibody control was found. Because the unpurified supernatants were compared 
initially, it is not possible to know if the concentration of antibodies being secreted by the 
hybridomas was the cause of the variation of the inhibitory ability of different mAbs in those 
assays. When the purified mAbs were compared, only doses of 7.5 µg/well (75 µg/ml) were 
able to (visually) reduce macrophage proliferation in comparison to the control antibody. 
mAb 12.2 had higher efficacy, and inhibited proliferation at 1.25 µg/well (~ 12.5 µg/ml). 
Published CSF-1R-blocking antibodies are effective in the range of 0.1 – 1 µg/ml (Haegel et 
al., 2013). This indicates that, if mAb 3.1 or the other mAbs tested here do bind to the CSF-
1R, the interaction is weak, which would probably affect the practical use of these 
antibodies.  
Because of the difficulties in studying macrophage proliferation – such as the 
responsiveness of these cells to a wide range of stimuli, among which the antibody Fc region 
– future studies with these and other CSF-1R-blocking antibodies should include assays with 
cells that rely on recombinant CSF-1R expression for survival (Gow et al., 2012; L. Moffat 
et al., 2014). This allows the comparison against similar cells that are not expressing the 




The monoclonal antibody 3.1 was able to reduce proliferation and survival of 
macrophages and canine mammary cancer cells. Based on the staining patterns of this 
antibody in tissues and cell lines, this effect appears to be mediated through CSF-1R. 
However, it is not possible to eliminate that non-specific binding to other proteins and Fc 
receptor interactions are responsible for some or all effects of the mAb, based on the results 
of the ELISA, staining of monocytes and the suppression of the Akt pathway in osteoclasts. 
For the practical use of this mAb, further specificity assays are needed. In vitro alterations of 
the CDRs of mAb 3.1 are an alternative to improve its binding characteristics, and this 
approach is explored in Chapter 6.  
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 Four anti-CSF-1R antibodies were subjected to chimerization by exchanging the Fc 
region of the murine mAbs for the canine equivalent. 
 Three of the four chimerized antibodies maintained the capacity to affect macrophage 
proliferation following CSF-1R stimulation. When macrophages were conditioned with 
IL-4 (which is CSF-1R-independent), the antibodies lost their effect. 





Chimerization and humanization of therapeutic antibodies has become the norm in the 
industry. This process offers the benefit of reducing antibody antigenicity when administered 
in vivo as well as increasing effector functions through the Fc fraction. This Chapter aimed 
to implement the process of chimerization and speciation of antibodies against the CSF-1R, 
developing a caninised version of these mAbs. Speciation should provide additional 
information on the efficacy of these antibodies and also offer an insight into the viability of 
these techniques for further studies. Antibody candidates from the mouse hybridomas were 
selected on their ability to inhibit macrophage proliferation. These clones were chimerized 
into a canine version by altering the Fc region. Three of the four clones that underwent 
chimerization maintained the ability to reduce macrophage proliferation when under the 
influence of CSF-1, and showed partial inhibition of cells in the presence of IL-34, the CSF-
1R ligands. The chimeric antibodies had no effect on IL-4-conditioned macrophages. mAb 
3.1 was further speciated into a fully caninised antibody. This was achieved by altering the 
framework regions of the variable fraction. Speciation offers the possibility to investigate the 
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importance of the Fc region for the effect of the anti-CSF-1R mAbs. In a review of the 





The presence of CSF-1R
+
 cells within tumours is related to poor clinical outcome 
(Chambers et al., 1997; Lin et al., 2001). These cells are usually infiltrates of myeloid-
derived cells, which are then differentiated into tumour-associated macrophages (TAMs) by 
factors within the tumour microenvironment. TAMs can contribute to almost every stage of 
tumour progression, such as neovascularization, tissue invasion, intravasation and increased 
cancer cell proliferation, among other attributes (Król et al., 2013, 2011; Mitchem et al., 
2013). However, the cancer cells themselves can express CSF-1R and also its ligand, CSF-1 
(Ide et al., 2002; Solinas et al., 2010), creating a loop of self-activation and macrophage 
recruitment and differentiation which is then fed back by the TAMs, as indicated by the 
results in Chapter 3. These pathogenic effects of CSF-1R make this receptor a prospective 
target for cancer treatment (Hume and MacDonald, 2012). 
The goal of this project was the production of monoclonal antibodies (mAbs) with 
the capacity to bind and block the CSF-1R in canine cancer patients. The formation of anti-
antibody responses during the administration of mAbs is a common occurrence and often 
represents an obstacle for the clinical usefulness of these biological products (Hwang and 
Foote, 2005). For this reason, the monoclonal antibodies originating from mice hybridomas 
should be expressed in a format that is less likely to induce canine anti-murine responses. 
There are three main reasons why antibody “speciation” is relevant: the formation of anti-
antibody responses; the importance of FcRn in antibody pharmacokinetics; and the 
importance of the Fc region for effector functions. (A/N: henceforth, “speciation”, 
“caninisation” and their derivatives will be written without quotes for clarity). 
Prevention of anti-antibody responses through speciation has for long been known to 
be important in the clinical setting; anti-antibody responses are deleterious to the efficacy 
and safety of the mAb. The first commercial monoclonals used for treatment of cancer were 
purified murine antibodies. These pioneering attempts ended with the withdrawal of the 
products due to efficacy concerns. Edrecolomab (Panorex), an anti-epithelial cell adhesion 
molecule (EpCAM) antibody, was the first anti-cancer mAb to be licensed for human use in 
the world, having been approved in Germany in 1996 for the treatment of colorectal tumours 
(Reichert, 2012). However, later tests proved that the antibody lacked efficacy. Human anti-
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mouse antibody responses were a common occurrence in patients receiving edrecolomab, 
and these were indicated as possible reasons for the clinical failure of this mAb (Punt et al., 
2002). The efficacy of mAbs is reduced in the presence of host responses because there is 
increased clearance from the circulation (Lobo et al., 2004). 
The importance of speciation of murine mAbs was also observed in canine patients. 
An anti-lymphoma murine monoclonal antibody, mAb 231, has been used in dogs. This was 
the first ever licensed monoclonal antibody for cancer therapy, preceding the drugs for 
human use (Jeglum, 2009). Although clinical benefit was encountered in the initial 
assessments, canine anti-mouse reactions were commonly seen and these were progressively 
increased with subsequent applications of the drug – as expected in secondary immune 
responses – therefore limiting its utility (Jeglum, 2009, 1996). As illustrated by these initial 
attempts with anti-cancer mAbs and later confirmed by antibody speciation experiments, 
murine antibodies are much more likely to induce marked anti-antibody responses. This 
adverse event has an incidence of over 80 % in humans receiving murine mAbs, and this is 
halved after antibody chimerization (Hwang and Foote, 2005).  
The ability of the antibody to bind to the neonatal Fc receptor (FcRn) is another 
reason why antibody speciation is relevant. This receptor is responsible for recovering IgG 
from degradation in the lysosomes, allowing for increased antibody serum half-life. 
However, binding to FcRn is dependent on species-specificity. The human receptor, for 
example, is strict in its binding partners, not being able to rescue the murine 
immunoglobulins from degradation (Ober et al., 2001). Therefore, murine antibodies have a 
half-life of only 2 – 3 days in humans, whereas natural human antibodies last in the 
circulation for about 23 days (Lobo et al., 2004). 
Besides its importance in increasing circulating time for antibodies, the Fc antibody 
fraction also mediates effector functions, such as antibody-dependent cell-mediated 
cytotoxicity (ADCC) through binding to receptor FcγRIIIa, and complement-dependent 
cytotoxicity (CDC) through binding to the complement protein C1q (Kubota et al., 2009) 
(Figure 5.1). Once more, these effects are largely, although not entirely, Fc species-specific, 
which makes speciation relevant (Bergeron et al., 2014). 
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Figure 5.1 – Speciation improves antibody function and reduces side-effects. The antibody Fc region 
is important for: effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), 
complement-dependent cytotoxicity (CDC); antibody “recycling” through the neonatal Fc receptor 
(FcRn), avoiding endosome degradation; reduction of anti-antibody responses, such as rapid clearance 
from the circulation and inflammatory reactions. 
 
 
In many cases the effector functions are significant for the clinical usefulness of the 
mAbs, and therefore inhibiting anti-mAb responses would not be sufficient to implement 
these antibodies in the clinic (Kubota et al., 2009). Immune suppression of the patient has 
been studied as an alternative to antibody speciation for the reduction of anti-mAb responses. 
Cyclosporin and other immunosuppressant drugs are capable of reducing the formation of 
anti-mAb immune responses – although the suppression is not complete (Dhingra et al., 
1995; Ledermann et al., 1988; Weiden et al., 1994). However, even if immunosuppression 
could fully inhibit anti-murine antibody responses, this strategy would still not enable the 
mAb effector functions, which depend on the Fc fraction.  
Consequently, because of anti-mAb responses, FcRn and Fc effector functions, not 
only the antibody binding properties through the variable regions determine the success of 
monoclonal antibodies in therapy. The antibody constant fraction is crucial for the 
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distribution and cellular functions of this biological drug, therefore affecting the clinical 
utility of the mAbs.  
The expression of the anti-CSF-1R antibodies in a canine framework was, therefore, 
an important step to achieve the goal of an anti-cancer drug. Several methods of antibody 
speciation exist, varying in the level of amino acid substitution from the murine sequence to 
that of the desired species. The levels of speciation are illustrated in Figure 5.2. 
Chimerization is the simplest form of species conversion of the antibody structure, in which 
the variable regions are originated from the mouse hybridomas and the constant regions are 
from the species of interest (dog, for instance). By genetic engineering, these fractions are 
then expressed as a chimeric protein. Full speciation of the antibody structure – such as 
humanization or caninisation – refers to the substitution of amino acids within the variable 
region, therefore further reducing the presence of murine sequences. Because full speciation 
alters amino acids near the antigen binding sites of the antibody, this process is more likely 
than chimerization to alter binding affinity. However, if full speciation is successful, it also 
leads to improved pharmacokinetics characteristics due to reduced formation of anti-mouse 
antibodies that may remove the mAb from circulation (Adams et al., 2006; Lobo et al., 
2004). The production of 100 % canine sequences (the last possible step in the speciation 
process, Figure 5.2) would only be possible starting with display techniques using libraries 
of canine antibodies. 
 
Figure 5.2 – Schematic representation of the different antibody formats with regard to their level of 
speciation. Green colour depicts canine sequences and blue represents murine. 
 
 
This chapter describes the construction of chimeric and caninised anti-CSF-1R 
antibodies with the goal of studying the feasibility of the technique and the functionality of 
the derived antibodies. The first step for the construction of the chimeric antibody was the 
isolation of the variable region from the hybridoma clones. For this, mRNA was isolated 
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from the hybridoma cells and the variable regions were amplified by a specialized technique, 
RACE-PCR. This structure was then coupled to a canine constant region, generating a 
chimeric molecule. The chimeric mAbs were expressed in mammalian cells and seemed to 
maintain function when compared to the parental antibodies. For further reduction of dog 
anti-mouse reactions, mAb 3.1, described previously, was caninised by altering the variable 
framework regions (Figure 5.3). Although chimerization and full speciation could be 
achieved, the vectors and host systems for expression of these antibodies require 
optimization to allow for higher production scales. 
  
 
Figure 5.3 – Overview of the speciation process used in this chapter. mRNA was obtained from the 
candidate hybridoma cells. The variable regions were sequenced and chimerized by inserting into a 
plasmid containing the canine constant regions. Full speciation was performed by altering the 
framework regions (FR). Immunization and hybridoma production are described in Chapter 7. 
 
 
5.2 Materials and Methods 
 
Basic methodological descriptions and brands not stated here are presented in 
Chapter 2. HotStarTaq polymerase kits are supplied by Qiagen. Phusion polymerase kits and 
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restriction enzyme kits are supplied by Thermo Scientific. dNTPs are supplied by Promega. 
 
5.2.1 Sequencing the antibody variable region 
 
The cloning of the antibody variable region was conducted according to the protocol 
from Bradbury, 2010 (Bradbury, 2010) for RACE amplification of variable regions. All 
primers are shown on Table 5.1.  
 
Table 5.1 – Primers for sequencing the antibody variable regions. Primers shown as 5` to 3`. 
Heavy chain reverse transcription primers 
RACEMOG1 (mouse IgG1) TATGCAAGGCTTACAACCACA 




Reverse transcription from mAb 6C2, an IgM, was done using 
random nonamers (Sigma) 
Light chain reverse transcription primers 
MOCKFOR (mouse κ) CTCATTCCTGTTGAAGCTCTTGACAAT 
CL1FOR (mouse λ 1) ACACTCAGCACGGGACAAACTCTTCTC 
CL2FOR (mouse λ 2) ACACTCTGCAGGAGACAGACTCTTTTC 
RACE PCR primers 
MOCG12FOR (mouse IgG1, IgG2a heavy) CTCAATTTTCTTGTCCACCTTGGTGC 
MOCG2bFOR (mouse IgG2b heavy) CTCAAGTTTTTTGTCCACCGTGGTGC 
MOCMFOR (mouse IgM heavy) TGGAATGGGCACATGCAGATCTCT 
CKMOsp (mouse κ light) CTCATTCCTGTTGAAGCTCTTGACAATGGG 
CL1FOR (mouse λ1 light) ACACTCAGCACGGGACAAACTCTTCTC 
CL2FOR (mouse λ2 light) ACACTCTGCAGGAGACAGACTCTTTTC 
XSCTnTag (anneals to the poly-A tail) GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT 
 
RNA was extracted (RNeasy Mini Kit, Qiagen) from the hybridoma monoclonal cell 
lines. cDNA was synthetized using MLV-V reverse transcriptase using one or two-steps 
approaches, for comparison (Table 5.2). 
 
Table 5.2 – Strategies tested for reverse transcription of the antibody variable regions (all reagents by 
Promega). 
One-step approach Two-steps approach 
mRNA (1 µg) was denatured at 65
o
C for 5 min and 
immediately transferred to ice 
mRNA (2 µg) was annealed to 7.93 µl of the primer 
RACEMOG1 or MOCKFOR (10 µM) at 70
o 
C for 5 
min and immediately cooled on ice 
The remaining reagents were added: 
5 × M-MLV transcriptase buffer (5 µl) 
dNTP (to 0.25 mM) 
M-MLV reverse transcriptase (10 U) 
RNAse inhibitor (10 U) 
water (to 25 µl) 
Incubated at 42
o
C for 60 min 
52
o
C for 30 min 42
o
C for 30 min 
95
o
C for 5 min 
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After cDNA synthesis, excess primer was removed using a Centricon 100 spin filter 
(Millipore), diluting the reaction to 500 µl with 0.1 × buffer TE (TE: Tris (10 mM), EDTA 
(1 mM), pH 8.0) and centrifuging at 300 × g until nearly all the volume passed through the 
filter, as determined visually. The volume was again brought to 500 µl with 0.1 × buffer TE. 
The solution was centrifuged again until concentrated to 10 µl, determined by pipetting. A 
poly-A overhang was added to the 5`-end of the cDNA sequence of the mAbs with the 
following reaction: terminal deoxynucleotidyl transferase (Promega) (10 U), dATP (to 0.3 
mM), tailing buffer (4 µl, supplied with enzyme). The reaction was incubated at 37
o
C for 5 
min and then 65
o
C for 5 min. The volume of the reaction was adjusted to 500 µl with 0.1 × 
buffer TE, and this was used as a template in subsequent PCR reactions at 10 % of the final 
volume. The variable light cDNA was unstable after freeze/thaw cycles, so it was divided in 
aliquots after this process. 
PCR was performed using primer XSCTnTag and a specific primer for the light or 
heavy chain (Table 5.1, above). Protocol for PCR was: 10 × HotStarTaq buffer (to 1 ×), 
dNTP (to 0.2 mM), forward and reverse primers (to 0.5 µM each), HotStarTaq polymerase 
(2.5 U), cDNA (10 µl), nuclease-free water (to 100 µl). Thermal cycling conditions were: 
95
o
C for 15 min, 60
o
C for 5 min, 72
o
C for 40 min; 40 × [95
o
C for 1 min, 60
o
C for 1 min, 
72
o
C for 3 min].  
An illustration of the PCR strategy is depicted in Figure 5.4: 
 
 
Figure 5.4 – Rapid amplification of cDNA ends (RACE) strategy for amplification of the hybridoma 
variable regions. Primers are indicated as arrows. UTR, unstranslated region. TdT, Terminal 
deoxynucleotidyl transferase. Fwd, forward primer. Rvs, reverse primer. 
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 After PCR amplification of the antibody sequences, the products were run on 1 % 
agarose and were gel extracted using QIAquick Gel Extraction Kit (Qiagen). The product 
was quantified by Nanodrop spectrometry (Thermo Scientific) at 260 nm, and sequenced 
using the reverse PCR primer as initiator (Dundee DNA Sequencing and Services).  
 
5.2.2 Construction of the chimeric antibodies 
 
Having identified the antibody variable sequences with the PCR strategy above, 
primers were designed for each individual variable heavy and variable light clones (Table 
5.3). The primer design strategy in relation to the antibody sequence is illustrated here for 
mAb 3.1 (Figure 5.5).  
The primers contained specific restriction digestion sites to insert the amplicons into 
the plasmids pVH (BssHII and BamHI) and pVL (ApaLI and XhoI). The forward primers 
had to contain the necessary sequence to maintain the translation of the leader within the 
plasmids after the enzymatic digestion (Figure 5.5). The cloning sites of the pVH and pVL 
plasmids are shown in Figure 5.6.  
  
Table 5.3 – Primers used for inserting the variable regions into the chimerization plasmids. EF-1α was 
the sequencing primer after chimerization. Primers shown as 5` to 3`. 
 
Antibody chain Primers 
1C6 D6 VL 
FWD – TATCCGTGCACTCCGACATTGTGCTGACCCAATC 
RVS – TTTGATCTCGAGCTTGGTG 
1C6 D6 VH 
FWD – TATCCGCGCGCACTCCCAGGTGCAACTGAAGGAG 
RVS – CGGGATCCTGAGGAGACTGTGAGAGTG 
3.1 VL 
FWD – TATCCGTGCACTCCAATATTGTGCTAACTCAGTCTCCAG  
RVS (same as 1C6 D6 VL) – TTTGATCTCGAGCTTGGTG 
3.1 VH 
FWD – TATCCGCGCGCACTCCGAAGTGAAGCTGGTGGAGTC 
RVS – CGGGATCCTGAGGAGACGGTGACTGAG 
2H1 VL 
FWD – TATCCGTGCACTCCGACATCCAGATGACTCAG 
RVS – TTTGATCTCGAGCTTGGTG 
2H1 VH 
FWD – TATCCGCGCGCACTCCCAGGTCCAACTGCAGCAG 
RVS – CGGGATCCTGAGGAGACTGTGAGAGTG 
6C2 D6 VL 
FWD – TATCCGTGCACTCCGACATCCCGATGACTCAG 
RVS – TTTGATCTCGAGCTTGGTG 
6C2 D6 VH 
FWD – TATCCGCGCGCACTCCGATGTGCAGCTTCAGGAGTC  
RVS – CGGGATCCTGAGGAGACGGTGACCGTGGTC  
12.2 VL 
FWD – TATCCGTGCACTCCGACATCCAGATGAACCAG 
RVS – TTTGATCTCGAGCTTGGTG 
12.2 VH 
FWD – TATCCGCGCGCACTCCGAGGTTCAGCTGCAGCAGTC 











 L  V  L  V  L  K  G  V  Q  C  E  V  K  L  V  E  S  G  G  D  
ttagtgaagcctggagggtccctgaaactctcctgtgcagtctctggattctctttcagt 
 L  V  K  P  G  G  S  L  K  L  S  C  A  V  S  G  F  S  F  S  
acctatgccatgtcttgggttcgccagactccagagaagaggctggagtgggtcgcatcc 
 T  Y  A  M  S  W  V  R  Q  T  P  E  K  R  L  E  W  V  A  S  
attagtagtggtggtagcatgtatcatttagacagtgtgaagggccgattcaccatctcc 
 I  S  S  G  G  S  M  Y  H  L  D  S  V  K  G  R  F  T  I  S  
agagataatgccaggaacatcctgtatctgcaaatgagaagtctgaggtctgaggacacg 
 R  D  N  A  R  N  I  L  Y  L  Q  M  R  S  L  R  S  E  D  T  
gccaggtattactgtgcaagagccattcattactacggccgctatgttatggactactgg 
 A  R  Y  Y  C  A  R  A  I  H  Y  Y  G  R  Y  V  M  D  Y  W  
ggtcaaggaacctcagtcaccgtctcctcagccaaaacgacacccccatctgtctatcca 
 G  Q  G  T  S  V  T  V  S  S  A  K  T  T  P  P  S  V  Y  P  
 
3.1VhFWD – 5’- tatccgcgcgcactccGAAGTGAAGCTGGTGGAGTC 




 P  Q  I  L  G  L  M  L  F  W  I  S  A  S  R  G  N  I  V  L  
actcagtctccagcctccctgtctgtgactccgggagatagcgtcagtctttcctgcagg 
 T  Q  S  P  A  S  L  S  V  T  P  G  D  S  V  S  L  S  C  R  
gccagccaaagtattagcaccaacctacactggtatcaacaaaaatcacatgagtctcca 
 A  S  Q  S  I  S  T  N  L  H  W  Y  Q  Q  K  S  H  E  S  P  
agacttctcatcaagtattcttcccagtccatctctgggatcccctccaggttcagtggc 
 R  L  L  I  K  Y  S  S  Q  S  I  S  G  I  P  S  R  F  S  G  
agtggatcagggacagatttcactctcagtatcaacagtgtggagactgaagattttgga 
 S  G  S  G  T  D  F  T  L  S  I  N  S  V  E  T  E  D  F  G  
atgtatttctgtcaacagagtatcagctggccgtggacgttcggtggaggcaccaagctg 
 M  Y  F  C  Q  Q  S  I  S  W  P  W  T  F  G  G  G  T  K  L  
gaaatcaaacgggctgatgctgcaccaactgtatccatcttcccaccatccagtgagcag 
 E  I  K  R  A  D  A  A  P  T  V  S  I  F  P  P  S  S  E  Q  
 
3.1VLkFWD – 5’ - tatccgtgcactccAATATTGTGCTAACTCAGTCTCCAG  
3.1VLkRVS – 5’ - TTTGATCTCGAGCTTGGTG 
 
 
Figure 5.5 – Design of primers for insertion of the variable heavy/light regions from monoclonal 
antibody 3.1 into pVH/pVL plasmids. The antibody variable region amino acids are highlighted in 
blue. Priming regions are outlined in green. The 5` to 3` sequence of the primers is shown under the 
variable regions, already containing the restriction sites, in lowercase lettering. The two bases 
highlighted in yellow in the 3.1VLkRVS primer were altered from the original antibody sequence to 
produce an XhoI site, although the amino acids encoded were not changed. Sequence translation 
performed using ExPASy translate (http://web.expasy.org/translate/). 
 
 
Using the antibody-specific primers, variable regions were amplified using Phusion 
high fidelity Taq polymerase. PCR reactions were as follows: Phusion HF buffer (to 1 ×), 
dNTP (to 0.2 mM), forward and reverse primers from Table 5.3 (to 0.5 µM), cDNA (2 µl), 
Phusion enzyme (0.008 U), nuclease-free water (to 20 µl). Samples were again ran on 1 % 
agarose and gel extracted for ligation with pVL and pVH.  
The pVL and pVH plasmids were built from the backbone described in (Persic et al., 
1997). The human constant regions were removed from the backbones and were substituted 
for canine constant regions, isotype B (Figure 5.6). The construction of these vectors was 
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performed by Jianguo Shi (Theodore Hupp Group, Edinburgh Cancer Research UK, 
University of Edinburgh).  
 
 
Figure 5.6 – Cloning sites of the pVH (upper) and pVL (lower) plasmids, adapted from (Persic et al., 
1997). The Vh sequence of the antibody was inserted into pVH using the BssHII and BamHI 
restriction sites. The VL sequence of the antibody was inserted into pVL using the ApaLI and XhoI 
sites. The Genbank accession numbers of the canine constant sequences are shown in the boxes. The 
sizes of each region are indicated in base pairs (bp) (drawing not to scale). The size of the inserts was 
inconstant because the variable regions of different antibodies differ in length. 
 
 
 Plasmid digestion was as follows: pVH: plasmid (1 µg), Buffer Tango (to 2 ×), 
twofold excess BamHI (10 U), PauI (5 U), nuclease-free water (to 20 µl). pVL: plasmid (1 
µg), Buffer R (to 1 ×), twofold excess Alw44I (10 U), XhoI (5 U), nuclease-free water (to 20 
µl). The reactions were incubated for 4 h at 37
o
C. Enzymes were inactivated at 80
o
C for 20 
min. Product digestion was as for the plasmids with the exception that digestion time was 
reduced to 1 h. Plasmids were run in 1 % agarose and were gel extracted to remove the 
digested product. A PCR clean-up kit (Wizard SV Gel and PCR Clean-Up System, Promega) 
was used for the ligands after restriction digest. 
 Ligation was as follows: pVH or pVL (50 ng), insert (25 ng), ligase buffer (to 1 ×), 
T4 DNA ligase (0.6 U), nuclease-free water (to 10 µl). This was incubated for 3 h at room 
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temperature and was transformed into chemocompetent Bronze Efficiency E. coli (Bioline). 
Three colonies from each construct (pVH/pVL) were purified by miniprep. 
 Once the antibody Vh and VL sequences had been ligated into pVH/pVL, 
respectively, their insertion was confirmed by sequencing the cloning site using the primer 
EF-1α (Table 5.3, above), which binds to the promoter upstream of that region.  
 
5.2.3 Expression of chimeric antibodies 
 
Chinese Hamster Ovary (CHO)-K1 cells were double-transfected by lipofection with 
the plasmids pVH and pVL containing the variable regions of mouse mAbs recognizing 
CSF-1R (Figure 5.7). The lipofection complexes were removed 4 h after transfection of the 
CHO-K1 cells and the medium was substituted for fresh complete DMEM. This had the aim 
of avoiding toxicity of Lipofectamine 2000 when the supernatant was subsequently used on 
the macrophages in the proliferation assays. Supernatant containing mAbs was collected 72 h 
after transfection.  
For the production of antibodies for subsequent purification, CHO-K1 cells were 
grown and transfected with Ultra-Low IgG FBS-supplemented medium (Life Technologies). 
Alternatively, suspension CHO-K1-S cells in serum-free medium were transfected by 
lipofection. Suspension CHO cells (denominated as CHO-K1-S) were selected from adherent 
CHO-K1 cells by successive passages in CHO-S-SFM II medium (Invitrogen) in 125 ml 
spinner bottles (Sigma) at 125 rpm, reducing the percentage of FBS by 2 % every two 
passages. Once cells were completely adapted in suspension and serum-free conditions, they 
were transfected following previously published protocols (Rosser et al., 2005) using 
Lipofectamine 2000 (Invitrogen). Briefly, Lipofectamine 2000 (120 µl) and plasmids (20 µg 
each) were mixed in CHO-S-SFM II medium (2.5 ml) and incubated at room temperature for 
20 min. Cells were counted and 2.5 x 10
7
 cells were centrifuged at 100 × g for 10 min. Cells 
were resuspended in fresh medium (47.5 ml). The mixture of Lipofectamine and plasmids 
was added to the cells. Cells were incubated in the spinner flask for 3 d. Supernatant was 






















Figure 5.7 – Production strategy of recombinant chimeric canine mAbs. The mouse variable heavy 
and light chains were cloned into the pVH and pVL plasmids, which contained the canine constant 
regions. These plasmids were transfected into CHO cells for recombinant expression and assembly of 
the full antibody protein. 
 
 
5.2.4 Selection of stable transfectants 
 
After transfection of CHO-K1 cells, stable transfectants were selected using a 
combination of mycophenolic acid (20 µg/ml, Sigma) and G418 (400 µg/ml, Sigma) added 
to the DMEM medium. These were added every two days, when the medium was changed. 
Cells were kept in subconfluent densities to ensure antibiotic effectiveness. After two weeks 
in the selection medium, cells were subcloned by limiting dilution. Cells were trypsinized 
and diluted to 0.5 cells/100 µl in selection medium. Then, 100 µl were plated into each well 
of a 96-well plate. Cells were grown until colonies were observable. The supernatants were 
then collected and assessed by dot blot for antibody expression. 
 
5.2.5 Antibody purification 
 
To assess antibody production, the canine immunoglobulins were purified from the 
transfected medium using protein A and G affinity chromatography. Protein A sepharose 4B 
(Sigma) and Protein G sepharose 4 fast flow (GE Healthcare) were used to bind the 
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antibodies from serum free (CHO-S-SFM II medium) or low IgG FBS-containing media 
(Life Technologies). The protocol for purification is described in Chapter 7.  
 
5.2.6 Western blot, dot blot and silver staining 
 
Tissue culture supernatants containing the chimeric antibodies were loaded at 30 
μl/well in a 10 % SDS-PAGE gel in non-reducing buffer, without heating samples. After 
resolving the proteins, they were transferred onto nitrocellulose membranes and probed with 
a 1:500 dilution of anti-dog H+L immunoglobulins (Alpha Biotechnology) in PBST + 
skimmed milk powder (5 %) for 2 h at room temperature. Secondary swine anti-rabbit, HRP-
conjugated antibody was used in the same buffer as the primary antibody (1:1700, Dako). 
The assessment of the purity of the chimeric antibodies after affinity 
chromatography was made by resolving the proteins using a 10 % SDS-PAGE gel with non-
reducing sample buffer and staining the gel using a silver stain protocol. 
 
5.2.7 Caninisation of the variable regions of mAb 3.1 
 
mAb 3.1 was assessed for similarities to a group of canine sequences. Only the 
frameworks of the variable regions were considered (the complementarity-determining 
regions were not included in this analysis). Where the murine antibody sequences 
corresponded to the canine matrix, no changes were made to the murine antibody; where 
they differed, the most similar amino acid (by charge, size, polarity) found in the canine 
matrix was used, even if it only occurred in a single sequence of the matrix; if no similar 
amino acid was available, the most abundant canine residue was chosen (Gearing et al., 
2013). Amino acid similarity was determined using the algorithm from Clustal Omega 
(www.ebi.ac.uk/Tools/msa/clustalo/). 
The matrix of canine Vh cDNA sequences (112 sequences) is described in (Bao et 
al., 2010). The VL kappa sequences (41 sequences) were from NCBI (accession numbers 
EU295719.1 to EU295758 and EU305402.1). Variable light kappa chain was chosen in 
detriment of lambda – despite this being the most common in dogs (Arun et al., 1996) – 
because that corresponds to the original mouse monoclonal isotype chain, meaning that 
fewer amino acid substitutions were necessary to achieve caninisation. 
The determination of what the framework regions consisted of was made by 
comparison with other murine antibodies (resource available from www.bioinf.org.uk). 
Comparison between canine and murine antibodies was done by aligning the sequences 
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using BioEdit 7.2.5 (Ibis Biosciences) and by analysing the amino acid “logo” of the canine 
matrix. The amino acid logos were built using the online application available at 
weblogo.berkley.edu. Sequence alignment between the caninised and murine sequences was 
done using Clustal Omega. 
Three-dimensional analysis of the caninised structures was performed by modelling 
the antibody structures on The Rosetta Online Server That Includes Everyone (ROSIE) 
(http://rosie.rosettacommons.org/antibody) (Lyskov et al., 2013). The variable regions of the 
antibodies were submitted to the website and the relaxed structure models were used for 
comparisons. Comparisons between mutated and the original mAb 3.1 sequences and root-
mean-square deviation of atomic positions (RMSD) measurements were made using UCSF 
Chimera 1.8.1 (University of California).  
Gene synthesis of the caninised mAb 3.1 was performed by Eurofins Genomics. 
  
5.2.8 Real time cell proliferation assay 
 
The xCELLigence Real-Time Cell Analyzer (Roche) was standardized with 50 µl of 
DMEM medium before adding cells. Between 10
4
 and 3 × 10
4
 canine bone marrow 
macrophages were used. Bone marrow macrophages were grown in the presence of 
recombinant human CSF-1 (20 ng/ml, Invitrogen), rhIL-34 (R&D Systems, 70 ng/ml) or 
recombinant canine (rc) IL-4 (R&D Systems, 70 ng/ml) for at least 48 h after initial cell 
differentiation from bone marrow in rhCSF-1. Cells were placed in an xCelligence 16-well 
plate (Roche) in 100 µl of medium. The plate was scanned to measure the initial numbers of 
cells in each well, and then treatment was added. Forty microliters of CHO-K1 transiently 
transfected supernatants containing chimeric antibodies were used for each assay. Controls 
received similar amounts of either regular medium, of mock-transfected CHO cell medium 
or of hybridoma supernatant of murine mAb 3.1. Cells received CSF-1, IL-4 or IL-34 and 
antibody-containing supernatants circa every 48 h during the experiment. Cells were then 
maintained at the usual culture conditions for the duration of the experiment. The amount of 
cells attached to the bottom of each well was measured by the equipment through assessment 
of the interference with the electrical impedance of the sensor on the plate. Plate readings 
were made every 15 min. 
The results of the proliferation assays were statistically evaluated by repeated-
measures two-way analysis of variance (ANOVA) using the software package GraphPad 
Prism 5 (GraphPad Software). The graphs shown for these assays were made using the 
accompanying software for the xCelligence system (Acea Biosciences). 




 5.3.1 Chimerization of the monoclonal antibodies 
 
Anti-canine CSF-1R mAbs were selected based on their capacity to block 
macrophage and REM134 cancer cell proliferation (Chapter 4). Clones 3.1, 12.2, 2H1 (IgG) 
and 6C2 (IgM) were then selected for chimerization. The first antibody clone to be amplified 
by rapid amplification of cDNA ends (RACE) PCR was 1C6. This clone was therefore used 
to optimise the PCR technique for amplification of the antibody chains, testing two different 
reverse transcription protocols. The two-step protocol of reverse transcription yielded the 
best results and was then used for all antibodies subsequently. The variable light isotypes 
were not known beforehand, so when amplifying the variable light regions, primers for both 
the VL κ and λ chains were tested. All antibodies expressed the κ light chain. The variable 
heavy and light were amplified and sequenced. The products contained the full length 






























































  Leader            CDR 1 
1c6       MAVLALLLCLVAFPGCTLSQVQL-KESGPGLVAPSQSLSITCTVSGFSLFSYD--ISWIR 
1aag      -------------------EVML-VESGGGLVQPGGSLRLSCAASGFTFSRYA--MSWVR 
1acy      -------------------QVKL-QESGPAVIKPSQSLSLTCIVSGFSITRTNYCWHWIR 
1afv      -------------------QVQL-QQPGSVLVRPGASVKLSCKASGYTFTSSW--IHWAK 
                              * **   *     *  *    *  **           *   
        CDR 2 
1c6       QPPGKGLEWLGIIW---TGGGTNYNSAFMSRLIISKDNSKGQVFLKMNSLVTDDTAVYYC 
1aag      QPPGKRLEWVATIS--SGGSHTFHPDSVKGRFIISRDNAKNTLYLQMNALRAEDTAIYYC 
1acy      QAPGKGLEWMGRIC---YEGSIYYSPSIKSRSTISRDTSLNKFFIQLISVTNEDTAMYYC 
1afv      QRPGQGLEWIGEIH--PNSGNTNYNEKFKGKATLTVDTSSSTAYVDLSSLTSEDSAVYYC 
          * **  ***   * **                    *                * * *** 
        CDR 3    Constant region 
1c6       VREGLRRG--F-------------DFWGQGTTLTVSSAKTTPPSVYPLAPGSAAQTNSMV 
1aag      ARPPLISLVADYAM----------DYWGAGTTVTVSS----------------------- 
1acy      SRENHMYETYF-------------DVWGQGTTVTVSS----------------------- 
1afv      ARWRYGSPYYF-------------DYWGQGTTLTVSS----------------------- 
           *            *********** ** *** ****                        
 
                                                                       
 
Figure 5.8 – RACE PCR amplification and sequencing of the mAb variable regions. (A) 
Amplification of the variable heavy region. mAb 1C6 D6 shown as example. Two protocols for 
reverse-transcription were tested (labelled as “cDNA protocol” in the figure). From these, the variable 
heavy region of IgG1 mAbs was amplified using primers MOCG12FOR and XSCTnTag. (B) 
Amplification of the variable light region. Since the subisotype was unknown, primers were used for 
the κ and λ regions (CKMOsp, CL1FOR or CL2FOR with XSCTnTag) after cDNA production using 
the two-steps approach, which was selected from the results in (A). In this case, the VL κ chain was 
amplified. The arrows indicate the correct product size. Neg, no template control. “100 bp” indicates 
the molecular weight marker (Promega). (C) Sequencing of the variable heavy region, after translation 
and alignment to three other murine antibody sequences for identification of the antibody regions, 
shown in different colours in the figure with the respective annotation (sequences available at 
www.bioinf.org.uk). Alignment performed using Clustal Omega. Asterisks indicate complete 
alignment at the respective positions. 
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For canine chimerization, the pVL and pVH plasmids were constructed and kindly 
gifted by Jianguo Shi (Edinburgh Cancer Research UK). The plasmids were constructed 
based on backbones obtained from Persic and colleagues (Persic et al., 1997). The human 
constant regions present on the plasmid were removed and substituted for canine constant 
regions. These were named pVL (containing the canine constant light lambda region) and 
pVH (containing the canine constant heavy region of isotype IgG B). Expression in 
mammalian cells was driven by a constitutive EF-1α promoter. To chimerize antibodies, the 
variable light and heavy domains (shown in Figure 5.8, above) were inserted into pVL and 
pVH, respectively (one plasmid for each of the heavy and the light chains) (Figure 5.6, 
above). 
Both plasmids were transfected into CHO cells and the production of the full 
antibody structure was confirmed by western blotting, as seen by the molecular size (Figure 
5.9 A). Both adherent CHO-K1 cells and suspension and serum-free adapted CHO cells 
(CHO-K1-S) were transfected. Production levels in CHO-K1-S after transient antibody 
expression and later purification by Protein G affinity were around 200 ng/10
6
 cells/day. 
Because expression was low, only small antibody quantities could be purified using transient 
transfections (Figure 5.9 B). Stable transfectants of CHO-K1 were created by selection with 
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Figure 5.9 – The chimeric antibodies were correctly expressed and purified from cell culture. (A) 
Antibodies were transiently expressed by CHO-K1 cells. The presence of antibodies in supernatants of 
CHO-K1 cell culture (30 µl) transiently transfected with pVL/pVH containing the chimeric versions 
of anti-CSF-1R antibodies was confirmed by non-reducing SDS-PAGE resolution of the proteins and 
Western blot with anti-dog H+L Ig, HRP-conjugated (1:500, Alpha Biotechnology). The hybridoma 
culture supernatants containing the murine versions of the same mAbs were used as species negative 
controls. The mock-transfected CHO-K1 supernatant was used as an expression negative control. (B) 
Silver staining of SDS-PAGE-resolved, non-reduced samples of Protein G affinity-purified chimeric 
mAb, presenting the four elution steps used to remove the protein from the resin (30 µl). The proteins 
were detected by silver staining. Notice the low yield of antibodies.  
 
 
 5.3.2 Most antibodies conserved inhibitory function after chimerization 
 
 The canine chimeric antibodies were tested for their ability to block bone marrow-
derived macrophage proliferation. The results demonstrate that the chimeric antibodies 3.1, 
2H1 and 6C2 preserved the macrophage-blocking function from the parent mouse 
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Figure 5.10 – Chimerization did not affect the efficacy of mAbs 3.1, 2H1 and 6C2 in inhibiting the 
proliferation of canine bone marrow-derived macrophages. Cells (in 100 µl medium) were grown with 
rhCSF-1 (20 ng/ml, Invitrogen) and treated with CHO-K1 transfected supernatant containing chimeric 
mAbs against CSF-1R or the hybridoma supernatant containing murine mAb 3.1, for comparison (40 
µl). All antibodies shown reduced BMDM proliferation. Control received mock-transfected medium 
(40 µl). Data was collected every 15 min. Cell index (y-axis) is correlated to cell number. The abrupt 
drops in the graphs indicate when the plate was removed from the xCelligence equipment for change 
of medium/treatment. Results are shown as mean of 3 wells ± SD for each time point. Results 
analysed by repeated measures two-way ANOVA with a Bonferroni post-test comparing all groups to 
the control. The coloured values at the top of the figure indicate the time in hours when treatments 
were different from Control. 
 
 
 In contrast to the other chimeric antibodies tested, mAb 12.2 (originally a mouse 
IgG2b isotype) lost its inhibitory activity against macrophages after chimerization. Two 
proliferation assays were conducted using this chimerized mAb. In both it showed no 
inhibition of macrophage proliferation. In the second trial, chimeric mAb 12.2 was compared 
to chimeric mAb 3.1 (which was shown to be effective in Figure 5.10, above), and while 
mAb 3.1 reduced macrophage proliferation, mAb 12.2 did not (Figure 5.11). As shown 
above in Figure 5.9, transfection of CHO-K1 cells with the plasmids for mAb 12.2 lead to 
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Figure 5.11 – Chimerization altered the efficacy of mAb 12.2 in inhibiting the proliferation of canine 
bone marrow-derived macrophages. (A) Cells (in 100 µl medium) were grown with rhCSF-1 (20 
ng/ml, Invitrogen) and treated with CHO-K1 transfected supernatant containing chimeric mAb 12.2 
against CSF-1R (40 µl). Control received mock-transfected medium (40 µl). Results are shown as 
mean of 3 wells ± SD for each time point. (B) Cells were grown with CSF-1 and treated with CHO-
K1 transfected supernatant containing chimeric mAbs 12.2 or 3.1 against CSF-1R compared to the 
supernatant of mock-transfected cells. Results are shown as mean of 8 wells ± SD for each time point 
(4 wells for the mock control). Data was collected every 15 min. The vertical black line at the 
beginning of the graphs indicates the point where the antibodies were added. The data were also 
normalized at that point. Cell index (y-axis) is correlated to cell number. The abrupt drops in the 
graphs indicate when the plate was removed from the xCelligence equipment for change of 
medium/treatment. The coloured value at the top of the figure indicates the time in hours when 
treatment was different from control. 
 
 
The capacity of the chimeric mAbs in blocking IL-34-induced proliferation was also 
tested. This cytokine is a ligand of CSF-1R (Chihara et al., 2010). The chimeric antibodies 
showed a trend of reducing the proliferation of the canine cells in the presence of IL-34 
(Figure 5.12), although the differences were less pronounced than when CSF-1 was used 
(Figure 5.10, above). In the direct comparison of all groups against the control group, only 
mAb 2H1 showed statistically significant differences. 
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Figure 5.12 – Chimeric mAbs affected IL-34-conditioned macrophage proliferation. Cells (in 100 µl 
medium) were grown with rhIL-34 (70 ng/ml, R&D Systems) and treated with CHO-K1 transfected 
supernatant containing chimeric mAbs against CSF-1R (40 µl). One group did not receive IL-34. 
Although all mAbs showed a trend of reduction in proliferation, only mAb 2H1 had a significant 
effect. The control received an equivalent volume of mock-transfected medium. Data was collected 
every 15 min. The vertical black line around 3 h indicates the point where the antibodies were added. 
The curves were also normalized at that point. The y-axis indicates cell index (correlated to cell 
number). The abrupt drops in the graphs indicate when the plate was removed from the xCelligence 
equipment for change of medium/treatment. Results are shown as mean of 3 wells ± SD for each time 
point. Results analysed by repeated measures two-way ANOVA with a Bonferroni post-test 
comparing all groups to the control. The coloured value at the top of the figure indicates the time in 
hours when treatment was different from control. 
 
 
 To assess the effect of the antibodies on macrophages stimulated by a CSF-1R-
independent growth factor (Jenkins et al., 2013), IL-4-conditioned macrophages were treated 
with the chimeric mAbs. BMDMs were differentiated from the bone marrow precursors in 
the presence of CSF-1, as had been done for the cells used in the previous proliferation 
assays. However, for the present analysis, BMDM were further conditioned with IL-4 and 
without CSF-1 for 48 h. No reduction of macrophage viability by the addition of mAbs was 
seen in the presence of IL-4. On the contrary, chimeric mAb 3.1 induced higher cell 
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Figure 5.13 – The chimerized mAbs did not reduce IL-4-conditioned BMDM proliferation. Cells (in 
100 µl medium) were treated with CHO-K1 transfected supernatant containing chimeric mAbs against 
CSF-1R (40 µl) in the presence or absence of recombinant canine IL-4 (70 ng/ml, R&D Systems). The 
control received mock-transfected medium (40 µl). Data was collected every 15 min. The vertical 
black line around 3 h indicates the point where the antibodies were added. The curves were also 
normalized at that point. The y-axis indicates cell index (correlated to cell number). The abrupt drops 
in the graphs indicate when the plate was removed from the xCelligence equipment for change of 
medium/treatment. Results are shown as mean of 3 wells ± SD for each time point. Results analysed 
by repeated measures two-way ANOVA with a Bonferroni post-test comparing all groups to the 
control. The coloured value at the top of the figure indicates the time in hours when treatment was 
different from control. 
 
 
5.3.3 Caninisation of the variable regions of mAb 3.1 
 
To achieve full speciation of the monoclonal antibody structure, amino acid residues 
from the variable framework regions were changed to allow for optimum similarity 
compared to canine antibodies, following a protocol described previously (Gearing et al., 
2013). As a part of this protocol, a matrix of canine antibody cDNA was compiled and the 
most common amino acids were determined by drawing a “logo” of the primary structure of 
the framework regions of the antibodies (Figure 5.14). The complimentary determining 
regions (CDRs) were not included in this analysis and were not changed in an attempt to 
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Figure 5.14 – Logo representation of the amino acids of a series of canine framework regions of Vh 
and VLκ antibody chains. For this, 112 Vh and 41 VLκ sequences were used to compose the logos 
(NCBI). Each framework region is represented separately, in a total of 8 regions (4 Vh and 4 VLκ). 
The most common amino acid in each position is shown as a letter of larger height, the size being 
proportional to the representativeness of that amino acid in that position. The maximum “bit” value 
for each position (y-axis) is 4.3. The x-axis indicates the residue number of each amino acid starting 
from 1 for each individual framework region (does not follow any antibody numbering scheme). The 
colours represent the physicochemical properties of the amino acids: polar amino acids 
(G,S,T,Y,C,Q,N) are green, basic (K,R,H) are blue, acidic (D,E) are red and hydrophobic 




 The murine and canine framework sequences were compared, and where the 
sequences did not match, amino acid substitutions were made in the murine sequence. In 
general, where changes had to be made, the amino acid residue in the canine matrix with 
most similar properties to the murine sequence was used. If no conserved substitutions could 
be made, the most frequent canine amino acid was used (based on Figure 5.14, above). For 
the Vh, 6 amino acid changes were made, of which 3 are conservative; for the VL, 14 amino 
acid changes were made, 8 of which are conservative. The caninised sequence that resulted 





Chapter 5 - Antibody speciation    169 
 
Caninized3.1Vh      EVRLVESGGDLVKPGGSLKLSCAVSGFSFSTY 
Natural3.1Vh        EVKLVESGGDLVKPGGSLKLSCAVSGFSFSTY 
                    **:***************************** 
 
Caninized3.1Vh      AMSWVRQTPEKGLDWVASISSGGSMYHLDSVKGRFTISRDNARNALYLQMNSLRSEDTAV 
Natural3.1Vh        AMSWVRQTPEKRLEWVASISSGGSMYHLDSVKGRFTISRDNARNILYLQMRSLRSEDTAR 
                    *********** *:****************************** *****.********  
 
Caninized3.1Vh      YYCARAIHYYGRYVMDYWGQGTSVTVSS 
Natural3.1Vh        YYCARAIHYYGRYVMDYWGQGTSVTVSS 
                    ****************************                                 
 
Caninized3.1VLk      DIVLTQTPLSLSVTPGESASISCRASQSISTNLHWYQQKSGQSPRLLIKY 
Natural3.1Vh         NIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKY 
                     :*****:* *******:*.*:******************* :******** 
 
Caninized3.1VLk      SSQSISGVPDRFSGSGSGTDFTLSINSVETEDAGVYYCQQSISWPWTFGQGTKLEIK 
Natural3.1Vh         SSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGGGTKLEIK 
                     *******:*.********************** *:*:************ ******* 
 
 
Figure 5.15 – Caninised variable regions of mAb3.1 compared to the natural sequence. An asterisk 
below the alignment indicates a position where no amino acid changes were made. A “:” (colon) 
indicates amino acid substitutions between groups of strongly similar properties, as per the algorithm 




To assess the probability of the alterations made to the primary structure of mAb 3.1 
changing antibody affinity, the 3-dimensional structures of the variable regions were 
analysed. A verification was made as to whether the amino acid substitutions affected the 
positioning of the complementarity-determining regions (CDRs); none of the changes 
affected CDR structure, as root-mean-square deviation of atomic positions (RMSD) was less 
than 1 for all six CDRs, when analysed pair-by-pair between the canine and murine 
structures. This is a measurement of atomic deviation between two structures, and is 
considered to be insignificant when lower than 1 (Zhang et al., 2013). A single amino acid 
change to the variable heavy framework region 2 led to a major conformation change 
(RMSD > 1) but because this structure is placed opposite to the binding sites, this did not 
affect the overall layout of the CDRs (Figure 5.16).  
Since the caninisation process seemed not to affect the structure of the CDRs, the 
caninised antibody variable regions were synthesized and were inserted into pVL/pVH. This 
fully caninised version of the antibody 3.1 has yet to be tested in functional assays. 
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Figure 5.16 – Caninisation did not affect the CDR regions of mAb 3.1. Three-dimensional analysis of 
conformation changes after the caninisation process of the variable regions of mAb 3.1. (A) 
Homology model of the variable regions. Left: Conformation change to the framework regions, 
indicated by the arrow, caused by a single amino acid substitution. The antibody binding sites are 
shown in grey in the second plane of the image. Original antibody (mouse) is shown in blue; caninised 
is shown in black. Where the line traces differ there is change in conformation. Right: Variations of 
CDR loops of the variable heavy region (shown on the first plane of the image) after caninisation, as 
exemplified by the position indicated by the arrow. (B) Space-filling model of the variable regions. 
The CDRs are identified in the figure. Changes to the structural conformation are exemplified in the 





 Biological drugs have been described as the new frontier of drug development for a 
range of diseases including auto-immune syndromes, neurological conditions and cancer 
(Singh et al., 2011). Inside this class of drugs, monoclonal antibodies have become 
increasingly important in the clinical setting in recent years, with special relevance for 
cancer (Ecker et al., 2014). Although several antibodies exist for human clinical use, very 
few have been developed for use in dogs (Acharya et al., 2015; Jeglum, 2009; Scott et al., 
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2012). Carry-over of drugs developed for humans to the veterinary practice, which has been 
common with other therapeutics, is not usually feasible for biologics; the efficacy of 
monoclonals is dependent not only on the specificity of the variable regions but also on the 
interaction of the immune system of the host with the antibody structure. The antibody 
framework is important for its antigenicity, pharmacokinetics and effector roles, and these 
effects are generally species-specific (Scott et al., 2012).  
Improvements in the biodistribution and effector mechanisms of mAbs have been 
identified as crucial factors for achieving the full potential of monoclonal antibody therapies. 
Both factors are greatly dependent on the Fc regions of antibodies (Yan et al., 2009). 
Reducing the antigenicity of biological drugs is the single most relevant step to improve the 
pharmacokinetic properties and therefore the efficacy of these therapeutics (Lobo et al., 
2004). For monoclonal antibodies, in many circumstances chimerization is sufficient to 
allow for clinical use of the mAb. Rituximab is an example of this. It is a human chimeric 
antibody; it was the first anti-cancer monoclonal licensed by the United States Food and 
Drug Administration (FDA) and one of the highest grossing anti-cancer drugs, which is still 
in the market after 17 years (Ziegelbauer and Light, 2008). 
In this chapter it was demonstrated that the monoclonal antibodies of interest were 
successfully sequenced and cloned into a canine constant region, therefore generating canine 
chimeric monoclonals. The production of the chimeric antibodies was also performed 
effectively in adherent and suspension CHO-K1 cells, leading to the expression of fully 
formed molecules, composed of two heavy and two light chains joined by disulphide 
bridges, and probably containing other posttranslational modifications such as glycosylation, 
as shown by the apparent size on western blots (Braren et al., 2007). The absence of isolated 
heavy or light chains in non-reducing western blot indicates that all the antibody secreted by 
the cells are assembled into fully formed molecules (Dodev et al., 2014). However, 
expression of the heavy and light chains in separate plasmids and the consequent need for 
co-transfection with both plasmids may have been one of the factors limiting protein yield by 
the transiently transfected cells.  
The level of antibody production after CHO-K1 cell transfection was low (200ng/10
6
 
cells/day), as assessed after affinity purification of the antibodies. This is in accordance with 
the original paper that described the plasmids pVH and pVL (Persic et al., 1997). Although 
this was assessed in the transient batch-transfected cells, instead of the stable transfectants, 
this laboratory scale of production still represents a hurdle for the progression of the 
antibodies to clinical trials. Improvements in the vector (promoter region, for instance), the 
use of a single vector containing both heavy and light chains, and improvements in the 
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process of production (cell type, media, suspension vs. attached cells) can significantly 
promote expression levels of antibodies (Jäger et al., 2013), and will be necessary as a next 
step in this project. 
Canine IgG isotype B was used in the present work as the constant region into which 
the murine variable regions were inserted. Canine IgG isotypes are named from A to D 
following their relative quantities within the body (Tang et al., 2001). Isotype B is capable of 
strongly binding CD64 and of activating the complement cascade, therefore showing the 
greatest similarities to the human IgG1 (Bergeron et al., 2014; Gearing et al., 2013). The 
circulation half-life of canine IgG B chimeric antibodies is of 14 days (Rue et al., 2015). The 
constant light chain used for chimerization was lambda. Contrarily to mouse and human 
antibodies, the lambda chain is the most common light constant chain in the dog (91 % of all 
antibodies in circulation) (Arun et al., 1996). 
The activity of all antibodies was maintained after chimerization, with the exception 
of mAb 12.2, which lost the ability to decrease macrophage proliferation. Among the 
chimerized antibodies, this was the only one that originated from an IgG2b mouse mAb. 
Mouse antibodies are capable of inducing effector functions on canine macrophages 
through Fc receptors. The murine isotype subclasses IgG2a and IgG3 can promote antibody-
dependent cell cytotoxicity (ADCC) having dog macrophages as effectors (Rosales et al., 
1988). Murine IgG2b, however, cannot bind to canine FcγRI or FcγRIII (Bergeron et al., 
2014). When the antibodies were chimerized using the canine IgG B as the recipient constant 
region, all mAbs should have become able to bind to canine Fc receptors. Chimerization may 
have affected the binding of mAb 12.2 because of FcR affinity to canine IgG B (Bergeron et 
al., 2014). Just as Fc receptor affinity has been shown to increase CSF-1R binding for a 
previously published mAb (Haegel et al., 2013), it is possible that Fc binding of the chimeric 
12.2 obstructed the coupling site of this mAb on the CSF-1R. Acting in a “cis” conformation 
may have impeded correct binding of this antibody (see Figure 4.31, Chapter 4). This could 
be further clarified by testing this chimeric antibody using cells transfected with CSF-1R, 
such as Ba/F3 cells. These cells can be induced to survive in the presence of CSF-1 after 
being transfected with the receptor (Gow et al., 2012). If Fc binding was the cause of the 
disruption of the activity of mAb 12.2 after chimerization, it should still be active against the 
Ba/F3 cells, which do not express Fc receptors.  
It is also possible that the loss of activity of mAb 12.2 was due to the reduction in 
antibody concentration after chimerization. Its inhibitory function may have been dependent 
on high antibody concentrations; the chimerized antibodies were present in much lower 
concentrations in the supernatants than the murine mAbs. However, the murine mAb 12.2 
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was the most effective antibody at low concentrations in reducing BMDM proliferation 
(Figure 4.24, Chapter 4). Since the concentration of other chimeric mAbs was sufficient to 
inhibit BMDM proliferation, antibody concentration is unlikely to have been the most 
prominent factor affecting chimeric mAb 12.2.  
Given that the CSF-1R is able to bind both CSF-1 and IL-34 (Chihara et al., 2010), it 
was expected that the antibodies would also be able to block CSF-1R signalling following 
IL-34 stimulation. One of the three chimeric antibodies tested with IL-34-macrophages was 
raised against the dimerization domain of the receptor (mAb 3.1), and should block CSF-1R 
dimerization irrespective of the ligand. Stable dimerization of two CSF-1R monomers after 
ligand binding is essential for signal transduction (Li and Stanley, 1991). All the tested 
mAbs seemed to reduce IL-34-conditioned macrophage proliferation, although the 
antibodies did not fully block cell survival as was seen with CSF-1-conditioned cells. Indeed, 
statistical significance against the control group only occurred for mAb 2H1. IL-34 and CSF-
1 have mostly overlapping signals in macrophages, but IL-34 seems to induce a more mild 
cellular activation of some pathways when compared to CSF-1 (Barve et al., 2013). The 
results found here following IL-34 activation may be due to lower stimulation of the control 
group rather than reduced antibody effect. If the proliferative signal in the control group was 
driving slow cellular proliferation, it would take longer for treated and untreated cells to 
differ.  
When CSF-1, IL-34 or CSF-1R is blocked in vivo, not all macrophage activity is 
hindered. Inflammatory responses are still seen after CSF-1R signalling blockade 
(MacDonald et al., 2010). Indeed, even in the CSF-1 knockout, the op/op mouse, some 
macrophages remain, such as in the lymphoid tissues or in the skin (Stanley et al., 1997). 
Local self-renewal of macrophages is at least in some cases dependent on IL-4. Because IL-4 
acts on its own specific receptor (IL-4R) and its function is independent of CSF-1R (Sieweke 
and Allen, 2013), the anti-CSF1R mAbs being studied here were not expected to block IL-4-
associated macrophage proliferation. This cytokine drives macrophages into what is 
described as an anti-inflammatory phenotype that is typical of the response against 
helminthic infection. In these situations, as the levels of IL-4 increase, this cytokine takes 
over from CSF-1 in maintaining macrophage proliferation. It not only drives tissue 
macrophage survival but may also have an effect on monocyte-derived macrophages. 
Although IL-4 has little capacity to induce macrophage proliferation in vitro, it is still able to 
affect the cellular phenotype (Jenkins et al., 2013; Sieweke and Allen, 2013; te Velde et al., 
1992). IL-4 treatment reduces CSF-1R expression by macrophages, reducing the need for 
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CSF-1 by individual cells (Jenkins et al., 2013), and is known to block CSF-1 dependent 
proliferation (Arpa et al., 2009). 
Therefore, the results of the present work confirmed that hypothesis, and the use of 
chimeric anti-CSF-1R had no impact on the survival of IL-4 conditioned macrophages. This 
also supports the demonstration of the specificity of the antibodies. It could be expected that 
if the effect of the antibodies on the macrophages were due to off-target binding, these 
effects would also be present when the mAbs were used against IL-4-conditioned 
macrophages. However, in human macrophages IL-4 decreases the expression of the FcγRI 
(te Velde et al., 1992). If the activity of the chimeric mAbs was mediated through these 
receptors, then it would be expected that the mAbs would have no effect on IL-4-conditioned 
macrophages. Therefore, it cannot be ruled out that IL-4 conditioning of macrophages 
reduced Fc receptor expression, and, with it, the effect of the mAbs through Fc receptors. 
Conversely, if all activity of the mAbs was mediated through FcγRI, chimeric mAb 12.2 also 
would have inhibited the proliferation of CSF-1-conditioned macrophages, which did not 
occur.  
No literature could be found to provide explanation as to the apparent proliferative 
effect of mAb 3.1 on IL-4-conditioned macrophages. All antibodies tested possessed the 
same Fc fraction and IL-4 decreases FcγRI expression (te Velde et al., 1992), therefore the 
differences cannot have derived from FcR-binding. All antibodies were also expressed at 
approximately similar concentrations (as assessed by western blot), and therefore differences 
in effect related to varying chimeric antibody concentrations are unlikely. Whether mAb 3.1 
non-specifically activated the IL-4 receptor or other receptors to drive proliferation was not 
tested. 
The recent trend in the development of monoclonal antibodies is towards full 
speciation of these biologicals (Modjtahedi et al., 2012). The mouse monoclonal antibody 
3.1 was selected for full caninisation based on its cellular staining and macrophage 
proliferation inhibition capacities (Chapter 4). However, it is known that speciation of the 
variable regions can alter antibody affinity since the loop conformation given by the 
framework regions, which are altered during the speciation process, are relevant towards the 
antibody binding characteristics (Kettleborough et al., 1991). The issue of loss of affinity is 
usually only circumvented by maintaining or returning to a structure which has to be similar 
to the original murine antibody, therefore not really reducing the overall immunogenicity of 
the protein (Clark, 2000). The caninisation technique used here has an advantage over other 
speciation techniques, such as CDR grafting, in that only some framework amino acids are 
altered from the original sequence, therefore reducing the likelihood of lowering the 
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antibody affinity (Gearing et al., 2013; Safdari et al., 2013). The process used in the present 
study is similar to that of “resurfacing”, previously used for the humanization of antibodies. 
Both methods alter only some of the amino acids in the framework region to achieve 
speciation, but in the technique of resurfacing only those residues close to the surface of the 
molecule are considered for alterations. This is because it is believed that the amino acid 
residues turned toward the centre of the antibody cannot be reached by the immune system 
of the host and are therefore not immunogenic (Safdari et al., 2013). Since resurfacing is 
usually done using the germline antibody sequences as models for choosing which amino 
acids should be substituted, it tends to require more alterations than the process used here, 
where the cDNA of fully functional circulating antibodies are used as the frames of reference 
(Gearing et al., 2013). 
The method used here for speciation had the drawback that it did not consider the 
Vernier zones in the process of changing the amino acids. The Vernier zones are areas within 
the variable framework regions of the antibodies which are relevant for antibody affinity, 
although these areas do not contact the antigen. The Vernier zones are important for the 
maintenance of the structural conformation of the variable region, supporting the CDRs in 
the optimal configuration for binding. Therefore, antibody speciation strategies that do not 
contemplate the Vernier zones risk reducing or losing the binding affinity not by altering the 
contact areas themselves, but by changes in the conformation of the entire variable region 
(Makabe et al., 2008; Safdari et al., 2013). 
 Speciation in itself does not guarantee low anti-antibody responses, and cautious 
and selective speciation procedures such as the one used in the present work are probably 
even less likely to fully prevent host immune reactions (Clark, 2000; Hwang and Foote, 
2005). The main effect of full antibody speciation seems to be in reducing “marked” anti-
antibody responses, while chimeric and fully humanized are similar in the amount of 
“tolerable” and “negligible” anti-antibody responses elicited (Hwang and Foote, 2005). It is 
also recognized that even fully speciated protein sequences may be immunogenic due to 
several factors, such as differences in the normal glycosylation pattern of the protein (Singh 
et al., 2012; van Meer et al., 2013). 
 The value of full speciation has also been disputed since the idiotype will, by 
definition, always be variable and therefore susceptible to the formation of anti-idiotype 



















Figure 5.17 – The anti-idiotype cascade. The recognition of the mAb by the host immune system leads 
to the production of antibodies (Ab2) against the variable region of the mAb; the variable regions of 
Ab2 are the mirrored image of the mAb variable regions. Ab2 also serves as an antigen for the 
production of a third antibody (Ab3), whose variable region is the mirrored image of the variable 
region of Ab2. Therefore, the original mAb and Ab3 are equal with regard to their variable regions. 
 
 
It is known, for instance, that some fully humanized antibodies can still elicit 
significant anti-mAb responses (Clark, 2000; Waldmann, 2014). It can be also argued that 
the humanization process may not necessarily produce antibodies that resemble those that 
are naturally in the circulation. Humanization is commonly done using human germline 
sequences as templates for the modification of the murine sequences. These may not 
correctly represent the most common amino acid composition found in circulating 
antibodies, since many modifications occur from the germline sequence, such as somatic 
hypermutation, which increase the variability of the antibodies. The use of germline 
sequences as template may create regions in the humanized antibody which have an amino 
acid repertoire bias that is different to that of circulating antibodies (Ackerman et al., 2011; 
Briney et al., 2012). Some researchers suggest, however, that immunogenicity in humanized 
mAbs arises only against the CDRs but not the framework regions, implicating that, whereas 
humanization is successful in reducing anti-antibody responses against the framework 
regions, the presence of anti-idiotypes cannot be fully avoided unless laborious alterations of 
the CDRs are performed (Harding et al., 2010).  
However, even fully human antibodies (not only humanized but from human origin) 
can induce anti-antibody responses, illustrating the unavoidable possibility of anti-idiotype 
immune reactions. Adalimumab is such an example. It is a human antibody (thus containing 
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100 % of human sequences) against TNF-α that shows marked human-anti human antibody 
responses in 89 % of the patients (Berdougo et al., 2011).  
To circumvent the problem of anti-idiotype immune responses, one alternative 
would be the induction of immune tolerance against the antibody. It has been argued that the 
clustering of several mAb molecules on their binding site is a strong inducer of anti-antibody 
responses. Monomeric forms of the mAbs are reportedly tolerogenic, and it has been 
proposed that a pre-treatment administration of a mAb with low binding affinity – therefore 
preventing the formation of immune complexes – should induce immune tolerance towards 
the high-affinity binding version of the same mAb, when it is administered later (Gilliland et 




Three monoclonal antibodies were successfully chimerized and maintained the same 
activity as the parent hybridomas in inhibiting macrophage proliferation. Because of possible 
specificity issues with these antibodies, discussed in Chapter 4, further work is necessary 
before they can be used in the clinical setting.  
However, the chimerization process assisted in understanding the mode of action of 
the monoclonal antibodies tested. The comparison of the results of the murine and the 
chimerized mAb 12.2 contributed in the comprehension of the role of Fc receptor binding in 
macrophage proliferation, for instance. It is possible that the activity of the chimeric mAb 
12.2 was hindered by Fc receptor binding after chimerization. This is a relevant finding for 
the discussion of the activity of murine mAbs in Chapter 4.  
Finally, the development and application of the technology of chimerization and 
caninisation may prove useful in future projects. Some of the difficulties within this protocol 
of chimeric antibody production, such as low expression levels, have been acknowledged 
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Phage display screening of a semi-synthetic 





 mAb 3.1, described in Chapter 4, contained only a few mutations from the germline 
sequence, indicating that the antibody did not undergo profound affinity maturation. 
 Two complementarity-determining regions (CDRs) of mAb 3.1 were mutated by PCR 
using degenerate primers, in an attempt to alter the antibody binding characteristics. 
 This library of mutated variations of mAb 3.1 was screened by phage display and clones 
with lower non-specific binding were selected. 
 The technique of CDR mutation proved successful in the generation of antibody clones 
with different binding characteristics. Shuffling of the mutated VL and Vh chains will 




Although mAb 3.1 was shown to bind to macrophages by immunostaining and to inhibit 
CSF-1R-dependent proliferation, it demonstrated low binding to the native form of the CSF-
1R. When compared to mouse immunoglobulin germline sequences, mAb 3.1 presented only 
a few mutations at the complementarity determining regions (CDRs), which indicate a low 
level of affinity maturation. Therefore, two CDRs within the sequence of mAb 3.1 were 
mutated with the intention of identifying new clones with improved binding characteristics 
when compared to the original antibody. Two semi-synthetic antibody libraries were created 
by PCR site-directed mutagenesis of the CDRs of mAb 3.1. Each library contained either a 
mutated version of the variable light chain or of the variable heavy chain of mAb 3.1. These 
libraries were then screened by phage display for binding to the extracellular region of 
canine CSF-1R. Several clones were identified which successfully bound to CSF-1R with 
reduced interaction to unrelated proteins, which represents an increment in relation to the 
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characteristics of mAb 3.1. Several clones were further expressed as soluble proteins in the 
absence of phage for assessment of their characteristics. In conclusion, by introducing small 
mutations within the CDRs, it was possible to create antibody variants with improved 




Inhibition of tumour-associated macrophages (TAMs) is a potential therapeutic 
pathway against cancers (Król et al., 2011). Among the possible strategies to reduce the 
influence of TAMs within tumours is the inhibition of CSF-1R, a crucial receptor for 
macrophage survival and polarization into the TAM phenotype (Pyonteck et al., 2013). CSF-
1R inhibitory antibodies have been described in the literature which exert anti-proliferative 
activity over macrophages at concentrations as low as 0.1 – 1 µg/ml (Haegel et al., 2013). In 
Chapter 4, antibodies were described which were also able to inhibit macrophage 
proliferation, although at concentrations tens of times higher than those referred in the 
literature. Of these antibodies, monoclonal antibody (mAb) 3.1 was identified as one of the 
most promising anti-canine CSF-1R clones, since it was able to bind to macrophages by 
immunostaining and to inhibit cellular proliferation. However, this mAb also showed cross-
reactivity with other antigens by ELISA, and seemed unable to immunostain cells expressing 
low levels of CSF-1R. 
Therefore, it was theorized that, by generating and screening mutant variations of 
mAb 3.1, it would be possible to identify clones with improved binding properties. The 
initial step in this process was the creation of variants of mAb 3.1. 
 
6.1.1 The generation of antibody variability 
 
The natural production of antibodies by the immune system is dependent on a range 
of events that lead to variations of the germline antibody sequences. In the bone marrow, the 
antibody variable (V), joining (J) and diversity (D) genes undergo rearrangements in an 
initial step to create variability. At the junctional points of rearrangements, nucleotide 
insertions and deletions also occur, adding diversification to the germline variable sequences. 
In the secondary immune organs, these genes are altered by somatic hypermutation followed 
by positive selection of the high affinity-binding antibody clones through the process of 
affinity maturation (Teng and Papavasiliou, 2007). Hypermutation occurs preferentially at 
specific positions of the antibody variable regions. These positions are appropriately named 
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hypervariable regions or complementarity-determining regions (CDRs). The parts of the 
variable region which are less mutated are named the framework regions (Figure 6.1). The 
alterations induced by hypermutation amount to 1 – 2 mutations per cellular generation, 
which is much higher than the average rate in other cells. High variability within the CDRs is 
important because these are the points of contact between the antibody and the epitopes on 
the antigens (Mirsky et al., 2015). 
 
 
Figure 6.1 – The structure of the antibody variable regions. There are two variable regions in each 
antibody “arm”, termed heavy (VH) and light (VL) variable regions. Within the mature variable 
region genes, diversity is created through hypermutation of the CDRs. When the protein is expressed 
and folded, the CDRs form the points of contact of the antibody with the epitope. The CDRs of the 
VL and VH chains must combine to form the antigen binding site. Therefore, each antibody arm will 
have 6 CDRs which will determine binding affinity and specificity. 
 
 
6.1.2 Semi-synthetic libraries 
 
Semi-synthetic antibody libraries are composed of mutational derivations from an 
original antibody clone. Since the original clone is usually resultant of mouse immunizations 
(a “natural” antibody) and the mutations are purposefully generated in the laboratory 
(“synthetic”, therefore), these libraries are called semi-synthetic. By mutating the antibody 
variable regions, mimicking somatic hypermutation, it is possible to create new antibodies 
that have either improved or reduced binding properties in relation to the original clone. If 
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the mutations in the antibody variable regions are extensive enough, antibodies with affinity 
for entirely different antigens can be found, therefore circumventing the necessity for new 
mouse immunizations for production of antibodies against these targets (Chen and Sidhu, 
2014).  
As is also the case with the natural process of generating antibody variations, the site 
where mutations are inserted is extremely relevant to the creation of semi-synthetic libraries. 
Methods that create random alterations to the entire variable region will equally change the 
framework regions (FR) and the CDRs. These methods include error-prone PCR and mutator 
E. coli strains. However, changes to the FR are less likely to generate large improvements to 
the antibody affinity, therefore restricting their relevance in finding improved antibody 
clones (Gram et al., 1992). Random mutations spread throughout the variable regions require 
larger antibody libraries to be screened in order to find useful clones. Large library sizes 
represent a technical hurdle in the antibody display technologies, since they require 
improved transformation/transfection efficiencies of the host organism and more intensive 
selection processes to enrich the best clones (Ponsel et al., 2011).    
Therefore, in vitro affinity alterations of antibodies have more commonly been 
directed to the CDRs (Bradbury et al., 2011). Since alterations of the CDRs are much more 
efficient in producing active antibody conformations than changes to the framework regions, 
reduced library sizes are adequate to find clones of interest. Few mutations in a single CDR 
are sufficient to completely alter the binding affinity of an antibody (Gilliland et al., 1999). 
Since each CDR is crucial to the binding characteristics of an antibody, semi-synthetic 
libraries have been generated by altering one or just a few CDRs. For example, by mutating 
exclusively the CDR3 of the variable heavy chain, it is possible to generate a library that is 
able to bind to a large number of unrelated antigens (Mahon et al., 2013).  
 
6.1.3 Antibody display 
 
After generating a semi-synthetic or another form of an antibody library, the 
challenge rests in finding which of the clones contained within the library are suitable for the 
desired purposes. The technology of antibody display has the purpose of selecting specific 
monoclonal antibodies within a combinatorial library. Although it is a time-consuming 
method, it poses some benefits in comparison to the hybridoma approach for antibody 
production. It permits selection from synthetic libraries without the need for animal 
immunization, easily allows negative selection of unwanted binders, does not require 
laborious tissue culture work and is easily accessible for molecular biology alterations of the 
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antibody structure, such as chimerization and affinity maturation (Frenzel et al., 2013; 
Hammers and Stanley, 2014; Thie et al., 2008). These advantages of the technique have been 
translated into increased contribution of the display methods for newly approved clinical 
antibodies. Phage display, for instance, has been used in the development of the best-selling 
monoclonal antibody adalimumab (Humira), used for autoimmune conditions (King, 2013; 
Thie et al., 2008). 
Several antibody display platforms are available, such as mammalian cell and yeast 
display; of these, phage display is the most widespread. It consists of the expression of scFv 
antibody fractions on the surface of a bacteriophage virus, commonly on the pIII coat protein 
(Figure 6.2). This is accomplished by introducing into host bacteria a phagemid containing 
the scFv fraction coupled to the pIII-coding gene (gIII). When these bacteria are infected 
with a phage (called helper phage), the virus packages the phagemid-coded pIII protein 













Figure 6.2 – Antibody fractions and the phage display system. (A) Three antibody fractions. The black 
lines represent linkers between the chains. (B) Schematic representation of the bacteriophage virus 
and the displayed scFv fraction on the pIII protein. Structures not to scale. 
 
 
Since each bacteriophage will contain a scFv copy on its surface and the 
corresponding phagemid, the best scFv can then be selected and enriched from the original 
library, which can potentially contain billions of different clones. Selection is done by a 
process called biopanning, where specific phages are enriched from the original pool by 
selecting for binding affinity to an immobilized antigen. This is repeated for several rounds 
and the enriched pool is examined for its binding capacity (in an ELISA, for instance). If 
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positive, individual clones are picked, the phagemid are sequenced and the scFv is tested in a 
monoclonal ELISA and in further desired assays (Figure 6.3). 
 
 
Figure 6.3 – Phage display biopanning for selection of scFv. The phagemid library is packaged by 
helper phages. The newly formed phage particles express the scFv with the pIII protein, and are 
selected and enriched based on binding affinity to a specific antigen. 
 
 
The goal in this chapter was to generate and test a library of semi-synthetic 
antibodies based on mAb 3.1, a monoclonal antibody raised against the canine CSF-1R. As 
demonstrated in Chapter 4, despite initial promising results, mAb 3.1 showed specificity 
issues and weak affinity for the correctly folded CSF-1R. Since mAb 3.1 was raised using a 
misfolded bacterially produced antigen, it did not react against CSF-1R protein produced by 
mammalian cells, which displayed the correct conformation. To create novel antibodies 
starting from mAb 3.1 as a template, two CDRs from this antibody were altered, namely 
CDR2 from the heavy chain and CDR3 from the light chain. These mutated versions were 
tested in parallel in two separate libraries. Phage display was used to screen the two libraries 
for binders to the native form of CSF-1R. Antibodies with improved binding properties in 
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relation to mAb 3.1 could be isolated. These mutated variants bound to CSF-1R and had 





Figure 6.4 – Overview of the method used in the present chapter. mAb 3.1 was generated by 
hybridoma, as described in Chapter 7. The variable regions of mAb 3.1 were mutated and two 
libraries were constructed by insertion into phagemid vectors. The mutated libraries were then 
screened by phage display. The best candidates were expressed in the pOPE101 plasmid in E. coli, 
independently from the phage. 
 
 
6.2 Materials and Methods 
 
Basic methodological descriptions and brands not stated here are presented in 
Chapter 2. QIAprep Spin Miniprep Kit and QIAquick Gel Extraction Kit are supplied by 
Qiagen. Phusion polymerase kits and restriction digest kits are supplied by Thermo 
Scientific. dNTPs, DNA ligase kits and Wizard SV Gel and PCR Clean-Up System are 
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supplied by Promega. The protocol for the construction of the semi-synthetic antibodies and 
library construction was obtained from Martineau, 2010. 
 
6.2.1 Comparison to germline 
 
The level of antibody hypermutation was estimated by comparing the sequence of 
mAb 3.1 to murine germline genes. This was performed on IMGT/V-QUEST 
(http://www.imgt.org/IMGT_vquest/share/textes/) using the nucleotide sequence of mAb 3.1 
(Giudicelli et al., 2004). 
 
6.2.2 Site-directed CDR mutagenesis 
 
CDR mutagenesis was performed by PCR using specific oligonucleotides. Two 
CDRs of mAb 3.1 were mutated, CDR3 of the variable light chain and CDR2 of the variable 
heavy chain. The sequence of mAb 3.1 was determined in Chapter 5. Mutagenesis primers 
were designed to bind to the regions around the aforementioned CDRs. Within the CDRs the 
mutagenesis primers contained areas of degenerate sequences that coded for all possible 
amino acids and one stop codon (amber codon, TAG). The primers contained restriction sites 
for insertion into the plasmid pSEX81 (Progen). 
The PCR strategy for the production of the mutated regions of mAb 3.1 is outlined 
in Figure 6.5. The primers are shown in Table 6.1.  
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Figure 6.5 – PCR strategy for the mutagenesis of mAb 3.1. (A) Mutagenesis strategy for the variable 
light region. (B) Mutagenesis strategy for the variable heavy region.  The arrows represent primers, as 
respectively named. The PCR product sizes are indicated in base pairs (bp). The figure is not to scale. 
The boxes within primers 3.1VLrvsCDR3 and 3.1VhRvsCDR2 show the points where mutations were 
inserted in each region. Several PCR steps were required for the full assembly of each of the variable 
regions, shown as PCR 1, PCR 2 and PCR 3. The lines in PCR 2 of the VH indicate the products from 
PCR 1.  
 
 
Table 6.1 – Primers for site-directed mutagenesis of mAb 3.1. The degenerate sites for inserting 
mutations into the CDRs are highlighted. Primer 3.1VhFWDNcoI contained 2 bp after the NcoI site to 

















PCR was performed using the following protocols (Table 6.2). Schematic 
representations of the reactions are shown in Figure 6.5, above. 
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Table 6.2 – Protocol for the PCR-directed mutagenesis of CDRs. Primers are shown in Table 6.1 and 
in Figure 6.5.  
Vh chain VL chain 
PCR 1 
Reaction: 5 × HF buffer (to 1 ×); dNTP mix (to 0.2 mM); 
forward and reverse primers (to 0.5 µM); template (0.2 
µl of pVH containing mAb 3.1, Chapter 5); Phusion 
enzyme (0.4 U); nuclease-free water (to 20 µl). 
 
Thermal cycling protocol: VH chain: 98
o
C for 30 sec, 35 
× [98
o
C for 10 sec, 72
o
C for 15 sec, 72
o
C for 10 sec], 
72
o
C for 10 min. 
Reaction: 5 × HF buffer (to 1 ×); dNTP mix (to 0.2 mM); 
forward and reverse primers (to 0.5 µM); template (0.2 
µl of pVL plasmid containing mAb 3.1, Chapter 5); 
Phusion enzyme (0.4 U); nuclease-free water (to 20 µl). 
 
Thermal cycling protocol: 98
o





C for 15 sec, 72
o
C for 10 sec], 72
o
C for 10 
min.  
 
The products from PCR 1 were run on 1.5 % agarose and were gel extracted. 
PCR 2 
Reaction: Gel extracted 5`-fraction of Vh chain (200 ng); 
gel extracted 3`-fraction of Vh chain (200 ng); 5 × HF 
buffer (to 1 ×); dNTP (to 0.2 mM); Phusion enzyme (0.4 
U), nuclease-free water (to 20 µl).  
 
Thermal cycling protocol: 98
o





C for 20 sec, 72
o
C for 15 sec], 72
o
C for 5 
min. 
Reaction: 5 × HF buffer (to 1 ×); dNTP mix (to 0.2 mM); 
forward and reverse primers (to 0.5 µM); template (0.1 
µl of gel purified PCR 1 product); Phusion enzyme (0.8 
U); nuclease-free water (to 40 µl). 
 
Thermal cycling protocol: 98
o





C for 25 sec], 72
o
C for 10 min. 
The products from PCR 2 were run on 1 % agarose and were gel extracted. 
PCR 3 (Vh only). The assembled Vh region was 
further amplified with a third PCR. 
Reaction: HF buffer (to 1 ×); dNTP (to 0.2 mM); forward 
and reverse primers (to 0.5 µM); gel purified assembled 
Vh (1 µl); Phusion enzyme (0.8 U); nuclease-free water 
(to 40 µl). 
 
Thermal cycling protocol: 98
o





C for 15 sec, 72
o
C for 25 sec], 72
o
C for 10 
min. 
The products from PCR 3 were run on 1 % agarose and 
were gel extracted. 
 
6.2.3 Amplification of non-mutated Vh and VL chains of mAb 3.1 with 
restriction sites for pSEX81 
 
 The non-mutated mAb 3.1 Vh and VL chains were also amplified using the primers 
above to append the restriction sites at the ends of the products, allowing the insertion of the 
non-mutated chains into pSEX81 (Progen). 
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PCR for non-mutated variable chains of mAb 3.1: 5 × HF buffer (to 1 ×); dNTP (to 
0.2 mM); primers 3.1VHfwdNcoI/3.1VHConRvsHind for Vh region or 
3.1VLfwdMluI/3.1VLrvsNotI for VL region (to 0.5 µM); template (3.1 pVH/pVL plasmids, 
0.1 µl, Chapter 5); Phusion enzyme (0.8 U); nuclease-free water (to 40 µl). 
Cycling temperature for non-mutated variable chain PCR: 98
o
C for 30 sec, 35 × 
[98
o
C for 10 sec, 65
o
C for 15 sec [Vh] or 72
o
C for 15 sec [VL], 72
o
C for 25 sec], 72
o
C for 7 
min. The products from non-mutated mAb 3.1 regions were run on a 1.5 % agarose gel and 
were gel extracted using a commercial kit. 
 
6.2.4 Restriction digests of pSEX81 and ligation products 
 
VL (or pSEX81 to receive VL): DNA (1 µg); MluI (20 U); NotI (10 U); Buffer O (to 
1 ×), nuclease-free water (to 20 µl). 
Vh (or pSEX81 to receive Vh): DNA (1 µg); NcoI (20 U); HindIII (10 U); Buffer R 
(to 1 ×), nuclease-free water (to 20 µl). 
pSEX81 was digested for 4 h at 37
o
C. The inserts Vh and VL were digested for 1 h 
at 37
o
C. Enzymes were inactivated at 80
o
C for 20 min. The digested fragments were 
removed from the insert using PCR clean-up kit. The fragments were removed from pSEX81 
by running the digestion in a 0.8 % gel and gel-extracting the plasmid using a gel extraction 
kit. 
 
6.2.5 Ligation of non-mutated VL/Vh mAb 3.1 and pSEX81 
 
Reaction was as follows: pSEX81 vector (50 ng); digested VL/Vh inserts (10.75 ng); 
ligase buffer (to 1 ×); T4 ligase (1 U); nuclease-free water (to 10 µl). Reaction was incubated 
overnight at 4
o
C. Next day it was inactivated at 65
o
C for 15 min. In preparation for 
electroporation, the ligation had salts removed using a PCR clean-up kit. The reaction was 
eluted in 15 µl of nuclease-free water. 
 
6.2.6 Transformation of XL-1blue E. coli with pSEX81 + non-mutated 
Vh/VL 
 
 pSEX81 containing non-mutated VL or Vh were added (5 µl) to 100 µl of 
electrocompetent XL-1blue. Bacteria were transformed with a 2500 V pulse (CellJect Basic 
Electroporator) using a 2 mm-gap cuvette (VWR). Cells were incubated with 900 µl of SOC 
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medium for 1 h at 37
o
C and plated on LB agar plates containing ampicillin. Plates were 




6.2.7 Construction of the mutated libraries 
 
pSEX81 containing the non-mutated Vh/VL sequences of mAb 3.1 were digested as 
above (increasing concentrations tenfold). The plasmids that contained non-mutated Vh were 
digested with MluI and NotI to receive the mutated VL. The digested plasmids were gel-
purified in a 0.8 % agarose gel. 
The mutated Vh/VL inserts were also digested as above (increasing concentrations 
fivefold). The digested fragments were removed from the inserts with a PCR clean-up kit. 
Plasmids and inserts were ligated: Digested pSEX81 containing non-mutated Vh/VL 
(5 µg); digested insert (1 µg); ligase buffer (to 1 ×), ligase (50 U); nuclease-free water (to 
500 µl). The ligation reaction was incubated overnight at 4
o
C and 2 h at room temperature. It 
was inactivated at 65
o
C for 10 min. Salts were removed using a PCR clean-up kit, eluting the 
products in 80 µl of nuclease-free water. 
 The ligation was then transformed into XL-1blue. Freshly made electrocompetent 
cells (300 µl) received the purified ligation products (20 µl) and were electroporated. This 
process was repeated until all ligation was used (4 times in total). The transformed bacteria 
were recovered with SOC medium. The bacteria were removed from the cuvette with 1 ml of 
SOC, and were placed into an Erlenmeyer flask containing 25 ml of SOC. This was 
incubated for 1 h at 37
o





) on LB plates containing glucose (1 %) and carbenicillin. The four 
Erlenmeyer flasks for each library were pooled and centrifuged at 5000 × g for 10 min at 
8
o
C. The supernatant was discarded and the pellet was resuspended in 4 ml SOC. This was 
then placed on 15 LB plates containing glucose (1 %) and carbenicillin. Plates were 
incubated overnight at 37
o
C. 
 The following day, the contents from each plate was scraped using scalpel blades 
and 2 ml of 2xTY/glycerol (7.5 ml of 2xTY + 2.5 ml of glycerol (40 %)). The contents of all 
plates were pooled. To calculate the bacterial density, a 1:200 dilution was measured at 
OD600nm using a S2100 spectrophotometer (Biowave). An OD600nm = 1 = 5.10
8
 cell/ml. The 
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6.2.8 Sequencing of library products 
 
Colonies from each of the Vh/VL mutated libraries were picked from the plates 
using for titration of the library size and sent for sequencing. Primers were 3.1VHfwdNcoI 
(for pSEX81 + mutated VL) or 3.1VLrvsNotI (for pSEX81 + mutated Vh). The composition 











Figure 6.6 – Phagemid architecture of the two semi-synthetic libraries. Libraries were constructed 
using mAb 3.1 as a backbone, containing either a VL or Vh region with inserted mutations. The 
library was inserted into pSEX81, which expresses the scFv antibody with a leader sequence for 
periplasmic localization, a linker between the Vh and VL regions and the coupled phage gIII, which 
expresses a viral coat protein. 
 
 
6.2.9 Phage display – preparation of helper phage 
 
Protocols described below were obtained from Kontermann, 2010 and Clackson and 
Lowman, 2004. Top agar was melted and cooled down to 50
o
C. Commercially available 





). The dilutions were mixed with 100 µl of log-phase XL-1blue (OD600nm = 0.5) 
and incubated at 37
o
C for 15 min. Bacteria and phage were mixed with 3 ml of top agar. The 
mixture was plated on 2xTY agar plates and incubated overnight at 37
o
C. A single small 
plaque of bacteriophage was picked by touching with a pipette tip. The tip was placed inside 
a tube with XL-1blue at an OD600nm = 0.5 in 3 ml of 2xTY. The tube was incubated at 37
o
C 
for 3 h. The grown plaque was added to 500 ml of 2xTY. The flask was incubated for 1 h 
shaking at 37
o
C, and then kanamycin was added. The flask was incubated overnight shaking 
at 200 rpm and at 37
o
C. The culture was centrifuged at 4000 × g for 30 min at room 
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temperature. The supernatant, containing the helper phage, was filtered through a 0.45 µm 
filter (Nalgene) using a 50 ml syringe (Becton Dickinson). Phage was titrated using the same 
dilutions and protocol as was done with the commercial M13KO7. The helper phage solution 




6.2.10 Phage display – packaging the phage library 
 
XL-1blue bacteria containing the pSEX81 + mutated antibodies were added to 2 l 
culture flasks containing 250 ml of 2xTY with ampicillin and glucose (2 %). For the mutated 
variable heavy library, 10
10
 bacteria were added to 500 ml. 
The culture was grown at 37
o
C with shaking (250 rpm) to an OD600nm = 0.5 (approximately 2 
h). The helper phage was added to the bacteria in a ratio of 20:1, following the formula 
below. 
 
𝐻𝑒𝑙𝑝𝑒𝑟 𝑝ℎ𝑎𝑔𝑒 𝑎𝑑𝑑𝑒𝑑 (𝑚𝑙) =  20 ×
0.5 𝑂𝐷 (2.5 × 108 𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎) × 250 𝑚𝑙






The mutated VL library was packaged using the M13KO7 helper phage, expanded 
as explained in section 6.2.9, above. The Vh was packaged separately with two different 
helper phages, the M13KO7 (prepared as shown above) and Hyperphage, obtained 
commercially (Progen). 
After adding the helper phage, the culture was incubated at 37
o
C for 30 min standing 
to allow the helper phage to infect the cells, followed by 30 min shaking (200 rpm). To 
assess the efficiency of helper phage infection, 1 µl was removed from each flask and diluted 
in 1 ml of 2xTY. One and 10 µl of the dilution were plated on 2xTY agar plates containing 
either ampicillin + glucose (1 %) or kanamycin + glucose. The proportion of kanamycin 
resistant clones should be at least 10 % of the number of ampicillin resistant clones. 
The bacterial cultures were centrifuged at 1520 × g. The supernatant was removed; 
the pellet was resuspended in 500 ml of 2xTY with ampicillin and kanamycin. This was 
grown in two 2 l flasks overnight at 30
o
C, shaking. The following day the bacteria were 
centrifuged at 14000 × g for 30 min. The supernatant was added to a new flask. PEG solution 
(polyethyleneglycol 6000 (20 %), NaCl (2.5 M)) was added to the supernatant, which was 
incubated on ice for 1 h. The phage precipitates were removed from the solution by 
centrifuging at 3000 × g for 15 min at 4
o
C. The supernatant was discarded. The pellet was 
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dried by centrifuging again for 30 sec. The remaining liquid was pipetted out and the phage 
pellet was resuspended in 5 ml of PBS. The phage was stored at – 80
o
C until used. 
 
6.2.11 Phage display – phage library biopanning 
 
 For the identification of the most suitable clones from the phage libraries, these were 
screened against the extracellular region of the canine CSF-1R. Immunotubes (Greiner) were 
coated overnight at 4
o
C with 0.5 ml of PBS containing 25 µg (rounds 1 and 2 of panning) or 
12.5 µg (further rounds) of the CSF-1R protein. A fresh colony of XL-1blue was grown 
overnight in 5 ml of 2xTY with tetracycline. The following day, the immunotube was rinsed 
thrice with PBS and blocked with PBS + milk (2 %) for 2 h at room temperature. During this 
time, the packaged phage library or the outputs from previous rounds of selection were 
blocked for 30 min at room temperature with 1 ml of PBS + milk. After blocking, the 
immunotube was emptied and the pre-blocked phage was added. This was incubated for 2 h 
at room temperature with occasional shaking. 
 At this point, 12 ml of 2xTY with tetracycline were inoculated with 100 µl of 
overnight XL-1blue culture. The culture was grown to OD600nm = 0.5 shaking (200 rpm) at 
37
o
C. In rounds 1 and 2 of panning, the immunotubes were rinsed 10 × with PBS + Tween 
20 (0.1 %) followed by 10 × with PBS only.  In the further rounds of panning, washings 
were increased to 20 × for each buffer. The tubes were blotted after each rinse to remove 
excess washing buffer. 
 The bound viruses were eluted either by trypsin elution or direct infection. Trypsin 
elution was done by adding 0.5 ml of trypsin (10 mg/ml diluted in PBS, Gibco) for 15 min at 
room temperature followed by 10 × pipetting up and down. Direct infection of the bacteria 
was done by adding 2 ml of the log-phase XL-1blue in the immunotube for 30 min at room 
temperature. 
 The eluted phage was then added to 10 ml of the log-phase XL-1blue. The flasks 
were incubated for 30 min at 37
o
C standing and then 30 min shaking (200 rpm). Serial 
tenfold dilutions of the cultures were made in 2xTY and 100 µl of each was plated in 2xTY 
agar plates with ampicillin and glucose (1 %). Plates were incubated overnight at 37
o
C. 
These were used to determine the number of eluted phage. This was the “phage output”. The 
remaining culture was spun at 2000 × g for 10 min. The pellet was resuspended in 0.5 ml of 
2xTY and was plated onto 6 × 2xTY plates with ampicillin and glucose. These plates were 
named “stock plates” and were incubated at 30
o
C. 
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 The following day 1 ml of 2xTY was added to each of the stock plates, and these 
were scraped with L-scrapers. The contents were transferred to a 15 ml tube. A glycerol 
stock was made from 1 ml of the bacteria. Approximately 2 – 3 ml of the bacteria was added 
to 50 ml of 2xTY with ampicillin and 2 % glucose to get a starting OD600nm = 0.1. This was 
incubated at 37
o
C shaking (200 rpm) until OD600nm = 0.5 (around 2 h). Tenfold excess of 
helper phage was added to the bacteria. The flask was incubated at 37
o
C for 30 min standing 
and then 30 min shaking.  
 The culture was centrifuged for 10 min at 2000 × g and 40 ml of the supernatant was 
transferred to a new 50 ml tube. PEG solution was added (8 ml) and mixed; the tube was 
incubated on ice for 1 h. The phage was removed by centrifugation at 3500 × g for 30 min. 
Supernatant was discarded. The pellet was resuspended in 1 ml of PBS. This was spun twice 
at 10000 × g to remove remaining bacteria. This was termed the “rescued phage”. 
 To determine the phage titre, serial dilutions of the phage were made (up to 10
-12
) 
and these were incubated with 1 ml of log-phase XL-1blue, as described previously. The 
bacteria (100 µl) was plated on 2xTY with ampicillin and glucose, grown overnight at 37
o
C. 
The colonies were counted to determine phage titre. Phage was then used for the following 




6.2.12 Phage display – polyclonal phage ELISA 
 
 Plates were coated overnight at 4
o
C with 400 ng/well of the extracellular fraction of 
the canine CSF-1R in 50 µl of PBS. As a control protein for coating the ELISA plate, BSA 
was used at the same concentration. The plate was rinsed with PBS and wells were blocked 
with PBS + milk (2%) for 2 h at room temperature. Blocking buffer was removed. The 
rescued phage (10 – 20 µl) was added to PBS + milk (to 50 µl) into the wells, and was 
incubated for 1 h at room temperature. The plate was washed at least 6 times with PBS, 
blotting the plate against paper to completely remove the washing buffer each time. Mouse 
anti-M13 antibody (1:1000, GE Healthcare) was used to detect phage particles bound to the 
plate. A tertiary antibody was added, rabbit anti-mouse IgG, HRP-conjugated (1:2000, 
Dako). Secondary and tertiary antibodies were diluted in PBS + 2 % milk and were 
incubated for 1 h at room temperature. HRP activity was detected using 50 µl of TMB 
substrate (Millipore). The reaction was stopped with the same volume of H2SO4 (2 M). 
Positive control was serum from mice immunized with the CSF-1R protein for hybridoma 
production (1:4000 in blocking buffer). Negative control wells received only the secondary 
and tertiary antibodies. 
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6.2.13 Phage display – monoclonal phage ELISA 
 
 Bacterial colonies on plates were directly screened to detect individual phage clones 
with binding activity. The phage selection rounds with enriched binding were identified 
using the polyclonal phage ELISA (6.2.12, above). Bacterial colonies in the output titration 
plates were individually picked using pipette tips. As a positive control, several colonies 
were picked together, therefore generating again a polyclonal pool. The colonies were 
transferred to 100 µl of 2xTY + ampicillin + glucose (1 %) in deep-well 96-well plates 
(VWR). The plate was sealed and incubated at 37
o
C for 5 h, shaking (200 rpm). M13KO7 
helper phage was added into each well (10 µl of 10
10
 cfu/ml, from the commercial stock, 
New England Biolabs). The plate was incubated for 30 min standing and then 30 min 
shaking (200 rpm) at 37
o
C. The plate was centrifuged for 10 min at 2000 × g. The 
supernatant was discarded and 150 µl of 2xTY + ampicillin + kanamycin (NO glucose) was 
added to the bacterial pellets. The plate was sealed again and incubated at 37
o
C overnight. 
The plate was spun as previously. The supernatant was used for ELISA.  
ELISA was performed as for the polyclonal phages in 6.2.12. The bacterial 
supernatant containing the phage (50 µl) was diluted into the same volume of PBS + milk (2 
%). Serum from mice immunized with the CSF-1R protein for hybridoma production was 
also used as a positive control (1:4000 in PBS + milk (2 %)). Negative control wells received 
only the secondary and tertiary antibodies. 
 The positive clones were picked from the deep-well plates and grown overnight in 5 
ml of 2xTY with ampicillin. The phagemids were purified by miniprep and sequenced using 
the pSEXfwdSignal primer (5` - TACCTATTGCCTACGGCAG). 
 
6.2.14 Testing the phage scFv – western blot 
 
 The extracellular portion of the canine CSF-1R was expressed in HEK293T cells as 
detailed in Chapter 7. The supernatant of the transfected HEK293T culture (30 µl) was 
prepared in reducing sample buffer and was run in a 10 % SDS acrylamide gel and 
transferred to a nitrocellulose membrane. After blocking the membrane, PEG-concentrated 
phage expressing the scFv was overlaid on the membrane (between 1:4 to 1:1000). The 
membrane was washed and probed with the anti-M13 (1:1000, GE Healthcare) followed by 
the anti-mouse, HRP-conjugated (1:1000, Dako). All antibodies were diluted in PBST + 
milk (5 %). 
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6.2.15 Testing the phage scFv – immunofluorescence  
 
 HEK293T cells or BMDM were grown on tissue culture-treated glass slides (Nunc 
Lab-Tek II Chamber Slide System, Thermo Scientific). No CSF-1 was added to the BMDM 
culture. HEK293T cells were transfected using Lipofectamine 2000 (Invitrogen) with the full 
canine CSF-1R receptor. The following day, cells were fixed with ice cold acetone at – 20
o
C 
for 20 min, washed with PBS and blocked for 60 min with PBS + normal goat serum (10 %) 
at room temperature. Staining was performed using murine immune serum against CSF-1R 
extracellular region (1:4000) as a positive control or purified phage expressing the scFv 
(between 1:2 and 1:1000 dilutions). Antibodies were incubated overnight at 4
o
C. Bound 
phage was detected using the mouse anti-M13 antibody (1:1000) followed by a goat anti-
mouse IgG, Alexa 488-conjugated (1:400, Invitrogen) for 1 h at room temperature. Slides 
were washed with PBS thrice for 5 min after the antibody incubation steps. Antibodies were 
diluted in blocking buffer. DAPI (4',6-diamidino-2-phenylindole) nuclear stain was included 
in the mounting medium (Vectashield Mounting Media with DAPI, Vector Labs). A 
coverslip was placed on top of the section with a drop of mounting medium. The section was 
isolated using nail polish. 
 
6.2.16 Testing the phage scFv – BMDM proliferation assay 
 
 Canine bone marrow-derived macrophages (BMDM) were added to 96-well tissue 
culture plates. The cells were left to adhere to the plate for 3 h with rhCSF-1 (20 ng/ml, 
Invitrogen) and then received 10 µl of either: PBS (vehicle control for the purified phage); 
PEG-precipitated phage containing the scFv, monoclonal or polyclonal; M13KO7 helper 
phage, produced as detailed in section 6.2.9. The cells were then incubated for 60 h in tissue 
culture. Live cells were detected using CellTiter-Glo (Promega). The amount of phage 
present in the monoclonal, polyclonal and helper phage solutions were estimated by dot blot. 
The phage solutions were serially diluted 1:10 in PBS and 1 µl of each was dotted on a 
nitrocellulose membrane. Bound phage was detected using the anti-M13 antibody and anti-
mouse HRP as for the western blot (section 6.2.14). 
 
6.2.17 Expressing the scFv in a new system – ligation into pOPE101 
 
 The variable regions of the monoclonal antibodies identified from the mutated 
library were amplified by PCR to allow the ligation into pOPE101. The PCR for mAbs from 
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both the VL and Vh mutated libraries was as follows. 5 × HF buffer (to 1 ×); dNTP (to 0.2 
mM); primers 3.1VHfwdNcoI/3.1VLrvsNotI (to 0.5 µM); pSEX81 miniprep of the desired 
clone (0.1 µl); Phusion enzyme (0.4 U); nuclease-free water (to 20 µl). Cycling 
temperatures: 98
o
C for 30 sec, 35 × [98
o
C for 10 sec, 72
o
C for 20 sec], 72
o
C for 10 min. The 
PCR products were run on 1.5 % agarose gel and were gel-purified using a gel extraction kit.  
The pOPE101 vector and the PCR products were digested before ligation. Vector 
digestion was: vector (1.6 µg); NcoI (80 U); NotI (20 U); Buffer O (to 1 ×); nuclease-free 
water (to 100 µl). The reaction was kept for 4 h at 37
o
C and then run on a gel and the band 
was gel extracted. The antibody PCR products were digested with the same reaction but to a 
final volume of 50 µl. The digestion was performed for 1 h and the products were cleaned 
using a PCR clean-up kit. 
Products and plasmid were ligated as follows: Digested pOPE101 vector (50 ng); 
insert (29 ng); ligase buffer (to 1 ×); T4 DNA ligase (1 U); nuclease-free water (to 10 µl). 
The reaction was kept for 1 h at room temperature and at 4
o
C overnight. Salts were removed 
from the ligation with a PCR clean-up kit and the reaction was eluted in 10 µl of water. Two 
microliters were used to electroporate XL-1blue E. coli. The resulting colonies were 
expanded in 10 ml of 2xTY media with ampicillin, the plasmids were purified using a 
miniprep kit. Confirmation of ligation was obtained by sequencing using the primers 
3.1VhConRvsHind and pSEXfwdSignal. 
 
6.2.18 Expressing the scFv in a new system – expression of the scFv 
 
Expression of soluble scFv by XL-1blue was tested under several conditions. 
Glycerol stocks of the transformed bacteria were picked to grow in a starter culture overnight 
in 2xTY (10 ml) with ampicillin. The starter culture was then added to a larger volume of 
medium (1:50). The bacteria were grown at 37
o
C shaking at 200 rpm until the OD600nm = 0.7 
and were induced to express the scFv with IPTG (200 or 500 µM, Sigma). Induction was 






C in the presence or absence of sucrose (0.4 M). 
The duration of induction was tested between 1 h, 4h and overnight. 
 
6.2.19 Expressing the scFv in a new system – purification of the single-
chain fraction variable (scFv) 
 
 Soluble scFv were purified from the periplasm of XL-1blue bacteria using a mild 
lysis buffer (Tris-HCl (200 mM); sucrose (20 %); EDTA (1 mM), pH 8.0). Lysozyme was 
Chapter 6 - Semi-synthetic library    198 
 
added just before using the buffer (0.1 mg/ml, Thermo Scientific). The bacterial culture was 
centrifuged at 5000 × g for 15 min. The supernatant was removed and the bacterial pellet 
was lysed with the buffer above (added at 5 % of the initial culture volume). The bacteria 
were incubated in the lysis buffer for 1 h on ice. Insoluble proteins were removed by 
centrifugation at 14000 × g for 40 min. The supernatant was then filtered using a 0.45 µm 
syringe filter (Nalgene). The solution was dialyzed against a dialysis buffer (Tris-HCl 
(200mM), NaCl (200mM), pH 8.0) using a 3000 molecular weight cut-off (MWCO) 
cellulose ester membrane (Spectrum Labs). The following day, the dialyzed scFv solution 
was affinity purified. 
 For the production of insoluble scFv, the bacterial culture was induced with 500 µM 
of IPTG (Sigma) at OD600nm = 0.5 – 0.6, at 37
o
C, shaking at 200 rpm overnight. The soluble 
protein fraction was removed by lysing the bacteria as above. The insoluble remaining pellet 
was then resuspended (in 5 % of the initial culture volume) in a denaturing buffer (Tris-HCl 
(50 mM), NaCl (50 mM), EDTA (1 mM), urea (8 M), pH 8.0; DTT (10 mM) was added 
immediately before using the buffer). The pellet was solubilized in this buffer overnight at 
4
o
C. The scFv were then refolded by dialysis with stepwise reduction in the concentration of 
urea in 1.5 l of the same buffer. Urea was reduced to 6 M, 4 M, 2 M, 1 M, 0.5 M and no 
urea. The dialysis steps were performed stirring overnight using a 10000 MWCO membrane 
(Spectrum Labs). After all urea had been removed, the soluble scFv was affinity purified. 
 
6.2.20 Expressing the scFv in a new system – affinity purification of 
scFv 
 
Ni-NTA resin (Qiagen) was used for affinity purification of scFv, as described in the 
section 2.6.1, Chapter 2, using 200 µl of resin. When stated, after affinity purification 
refolded scFv G3 was dialysed thrice against PBS (1 l) to remove impurities. Dialysis 
membrane had a 3000 MWCO (Spectrum Labs). Protein concentration was later measured 
with a Nanodrop spectrophotometer (Thermo Scientific) at 280 nm. 
  
6.2.21 Expressing the scFv in a new system – testing the pure scFv 
 
 BMDM inhibition was performed as for the phage-bound scFv, above, section 
6.2.16. Staining of the duodenal tissue was performed as in Chapter 4, using the scFv either 
neat or diluted 1:2, 1:5, 1:10 in blocking buffer. The secondary antibody was unlabelled 
mouse anti-c-Myc tag (1:3000, Cell Signalling) diluted in blocking buffer. The tertiary 
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antibody was goat anti-mouse Ig, Alexa 488-conjugated (1:300, Invitrogen). Coomassie 
staining and western blot were performed using a 12 % SDS acrylamide gel. Ten microliters 
of the eluates were resolved on the gel in reducing sample buffer. scFv was detected using an 
HRP-conjugated anti-c-Myc tag (1:10000, Bethyl Laboratories) diluted in blocking buffer. 
 Flow cytometry was performed with live or fixed cells, obtained from canine 
peripheral blood as described in Chapter 4. Cells were fixed with 1 % paraformaldehyde in 
PBS for 20 min at 4
o
C. Cells were stained with 50 µl of pure scFv H8 for 40 min in ice. 
Secondary antibody was anti-His (1:700, Invitrogen). Tertiary antibody was goat anti-mouse, 
Alexa 488-conjugated (1:800, Invitrogen). 
 For ELISAs, the scFv were tested as for the phage monoclonal ELISAs, above, 
section 6.2.13. Soybean trypsin inhibitor (Sigma) was also used as a negative control for 
coating plates, in parallel to BSA. The secondary antibody was an HRP-conjugated anti-c-
Myc tag (1:10000, Bethyl Laboratories), diluted in blocking buffer.  
 
6.2.22 Statistical analyses 
 
The BMDM proliferation assay using phage-coupled antibodies was analysed using 
Kruskal-Wallis test comparing all groups against the “Helper phage” group. The 
proliferation assay using purified scFv was analysed using one-way ANOVA (P < 0.05). The 
assumption tests were performed on Minitab 16 (Minitab Inc.). The statistical tests and 




6.3.1 mAb 3.1 showed few mutations compared to the germline 
 
 mAb 3.1 was shown to cross-react with other antigens apart from CSF-1R (Chapter 
4), indicating that it may have undergone low affinity maturation. The level of 
hypermutation undergone by mAb 3.1 (an anti-canine CSF-1R) was estimated by comparing 
its sequence to germline murine antibody genes using the database available on IMGT/V-
QUEST (Giudicelli et al., 2004). This database finds the closest murine germline sequence to 
the input mAb. A low level of amino acid changes was present between mAb 3.1 and the 
closest germline genes, especially for the variable light chain. For this chain, only 3 amino 
acid variations were identified within the three CDRs (Figure 6.7). The “diversity” (D) gene 
could not be identified, and therefore only the first two CDRs of the Vh are shown. For these 
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two Vh CDRs, also only three mutations were present compared to the germline. This 





                                              FR1-IMGT          CDR1-IMGT       FR2-IMGT     CD 
                                               (1-26)            (27-38)        (39-55)       ( 
                                   __________________________ ____________ _________________ __ 
                                   1       10        20         30         40        50         
                                   .........|.........|...... ...|........ .|.........|..... .. 
3.1VL                              NIVLTQSPASLSVTPGDSVSLSCRAS QSI......STN LHWYQQKSHESPRLLIK YS 
AJ235973 Musmus IGKV5-43*01 F      DIVLTQSPATLSVTPGDSVSLSCRAS QSI......SNN LHWYQQKSHESPRLLIK YA 
                                   N        S                           T                     S 
 
                                   R2-IMGT                 FR3-IMGT                 
                                   56-65)                  (66-104)                 
                                   ________ _______________________________________ 
                                    60         70        80        90        100      
                                   ..|..... ....|.........|.........|.........|....  
3.1VL                              .......S QSISGIP.SRFSGSG..SGTDFTLSINSVETEDFGMYFC QQSISW 
AJ235973 Musmus IGKV5-43*01 F      .......S QSISGIP.SRFSGSG..SGTDFTLSINSVETEDFGMYFC QQSNSWP 
                                                                                       I   
 
 J-REGION 
                                     Identity 
V00777 Musmus IGKJ1*01 F             100.00% (37/37 nt) 
 
Alignment 
3.1VL                               gtggacgttcggtggaggcaccaagctggaaatcaaa 




                                              FR1-IMGT          CDR1-IMGT       FR2-IMGT     CD 
                                               (1-26)            (27-38)        (39-55)       ( 
                                   __________________________ ____________ _________________ __ 
                                   1       10        20         30         40        50         
                                   .........|.........|...... ...|........ .|.........|..... .. 
3.1Vh                              EVKLVESGG.DLVKPGGSLKLSCAVS GFSF....STYA MSWVRQTPEKRLEWVAS IS 
AJ851868 Musmus IGHV5-6-5*01 F     EVKLVESGG.GLVKPGGSLKLSCAAS GFTF....SSYA MSWVRQTPEKRLEWVAS IS 
                                             D             V    S      T                        
 
                                   R2-IMGT                 FR3-IMGT                 
                                   56-65)                  (66-104)                 
                                   ________ _______________________________________ 
                                    60         70        80        90        100      
                                   ..|..... ....|.........|.........|.........|....  
3.1Vh                              SG...GSM YHLDSVK.GRFTISRDNARNILYLQMRSLRSEDTARYYC AR 
AJ851868 Musmus IGHV5-6-5*01 F     SG...GST YYPDSVK.GRFTISRDNARNILYLQMSSLRSEDTAMYYC AR 
                                          M  HL                       R        R       
 
J-REGION 
                                   Identity 
V00770 Musmus IGHJ4*01 F           90.57% (48/53 nt) 
 
Alignment 
3.1Vh                               ccattcattactacggccgctatgttatggactactggggtcaaggaacctcagtcaccg 
V00770 Musmus IGHJ4*01 F            ...............atta-----c----------------------------------- 
 
Figure 6.7 – A limited number of mutations differentiate mAb 3.1 from the closest murine germline 
sequence. The sequence of mAb 3.1 (Chapter 5) was inserted into IMGT/V-QUEST, which identified 
the closest murine germline antibody genes, named on the left column. The genes are displayed 
separately for the variable heavy and light chains, showing the V and J-regions for each. The 
framework regions (FR) and the complementarity-determining regions (CDR) are annotated. The 
differences between mAb 3.1 and the germline are highlighted. Notice the reduced number of 
mutations, especially in the light chain. 
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6.3.2 Construction of mutated mAb 3.1 libraries 
 
  Due to the low apparent level of maturation and affinity of mAb 3.1, this antibody 
was mutated with the intention of creating variant clones with different – perhaps improved 
– binding properties. To generate mutations in mAb 3.1 and create a semi-synthetic antibody 
library, the sequences for the variable regions of this antibody were amplified using primers 
containing degenerate sites within two of the CDRs (Figure 6.5, above). These mutated PCR 
products were then ligated into the pSEX81 phagemid, which codes the antibody variable 
regions in the format of a scFv antibody coupled to the pIII bacteriophage coat protein 
(Figure 6.6, above). After ligation and transformation of the libraries into XL-1blue E. coli, 
individual colonies were picked and their plasmid contents were purified by miniprep. These 
were then sequenced, showing that the library constructs were correct and contained 
mutations in the desired sites. The mutated VL library contained the non-mutated mAb 3.1 
Vh chain and an array of mutations was present in the VL CDR 3. The mutated Vh library 
contained the non-mutated mAb 3.1 VL chain and an array of mutations was present in the 
Vh CDR 2 (Figure 6.8). 
 By counting the colonies in the plate dilutions after library electroporation, the size 
of the mutated Vh library was estimated to be of 6 × 10
8 
clones and the size of the mutated 
VL library was estimated to be of 1.6 × 10
10
. These library sizes were significantly higher 
than the quantity of necessary clones, since the number of possible mutations for Vh was of 
3.2 × 10
6
 (possible amino acids
Number of mutated sites 
= 20
5
 = 3.2 × 10
6
) and for VL it was of only 
8000 mutations (= 20
3
).  
The insertion of the mutated antibodies into the pSEX81 phagemid allowed for the 
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                          Leader sequence          Mutated VH 
3.1VhKnown      -------------------------------EVKLVESGGDLVKPGGSLKLSCAVSGFSF 
3.1VhMut3       ---------MKYLLPTAAAGLLLLAAQPAMAEVKLVESGGDLVKPGGSLKLSCAVSGFSF 
3.1VhMut1       ---------MKYLLPTAAAGLLLLAAQPAMAEVKLVESGGDLVKPGGSLKLSCAVSGFSF 
3.1VhMut2       ---------MKYLLPTAAAGLLLLAAQPAMAEVKLVESGGDLVKPGGSLKLSCAVSGFSF 
                                               ***************************** 
                         Mutation site 
3.1VhKnown      STYAMSWVRQTPEKRLEWVASISSGGSMYHLDSVKGRFTISRDNARNILYLQMRSLRSED 
3.1VhMut3       STYAMSWVRQTPEKRLEWVASILRSGMLYHLDSVKGRFTISRDNARNILYLQMRSLRSED 
3.1VhMut1       STYAMSWVRQTPEKRLEWVASIAQRGGRYHLDSVKGRFTISRDNARNILYLQMRSLRSED 
3.1VhMut2       STYAMSWVRQTPEKRLEWVASISPDGLAYHLDSVKGRFTISRDNARNILYLQMRSLRSED 
                **********************   *  ******************************** 
                                                 Linker seq.     Non-mutated VL 
3.1VhKnown      TARYYCARAIHYYGRYVMDYWGQGTSVTVSS-------------------------- 
3.1VhMut3       TARYYCARAIHYYGRYVMDYWGQGTSVTVSSGSASTTKLEEGEFSEARVNIVLTQSP 
3.1VhMut1       TARYYCARAIHYYGRYVMDYWGQGTSVTVSSGSASTTKLEEGEFSEARVNIVLTQSP 
3.1VhMut2       TARYYCARAIHYYGRYVMDYWGQGTSVTVSSGSASTTKLEEGEFSEARVNIVLTQSP 
                ******************************* 
 
 
                                                                             
                   Non-mutated Vh              Linker seq.      Mutated VL 
3.1VLmut1       YCARAIHYYGRYVMDYWGQGTSVTVSSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTP 
3.1VLmut2       YCARAIHYYGRYVMDYWGQGTSVTVSSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTP 
3.1VLknown      ---------------------------------------------NIVLTQSPASLSVTP 
                                                             *************** 
 
3.1VLmut1       GDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSI 
3.1VLmut2       GDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSI 
3.1VLknown      GDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSI 
                ************************************************************ 
                            Mutation site            Phage coat pIII 
3.1VLmut1       NSVETEDFGMYFCQQTQRWPWTFGGGTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTN 
3.1VLmut2       NSVETEDFGMYFCQQSLTWPWTFGGGTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTN 
3.1VLknown      NSVETEDFGMYFCQQSISWPWTFGGGTKLEIK---------------------------- 
                ***************   **************                             
 
 
Figure 6.8 – The mutated scFv libraries displayed the expected modifications. Single colonies were 
picked after library electroporation into XL-1blue bacteria. The phagemids were purified and sent for 
sequencing. The mutated Vh and VL libraries are shown respectively, compared to the known mAb 
3.1 parental sequences (named in the figure as “3.1V_Known”). The yellow highlights show the 
mutation sites, compared to the parental mAb 3.1, in green. Other plasmid hallmarks are highlighted 
and identified. “Linker seq.”, linker sequence between Vh and VL. The asterisks under the sequence 
identify where the parental antibody and the mutated libraries coincide. 
 
 
6.3.3 The mutated VL phage display 
 
The mutated VL library was the first to be screened. Since the VL library was very 
small (8000 possible clones), only 3 rounds of biopanning were performed. The library was 
screened against CSF-1R extracellular region, immobilized in immunotubes. The original 
mAb 3.1 was raised against the dimerization region of CSF-1R, produced in bacteria, so it 
was desired to find clones with increased binding towards the CSF-1R produced in 
mammalian cells, which possessed correct folding and conformation.  
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Two protocols were compared side-by-side for the elution of the bacteriophage from 
the immunotubes. Adding the bacteria to the immunotube after washing (direct infection 
elution method) was not capable of eluting the bound phage, as shown by the output number 
of bacterial colonies after biopanning (Figure 6.9). Trypsin could successfully elute the 












Figure 6.9 – Trypsin efficiently eluted phage and allowed for increasing bacterial outputs after 
selection. Two methods of phage elution were tested after panning the mutated VL library against 
CSF-1R extracellular region immobilized in an immunotube. After washing out non-specific binders 
from the immunotube, bacteriophage attached to the antigen were removed by adding either 0.5 ml 
trypsin for 15 min (10 mg/ml, Gibco) or by adding 2 ml of log-phase XL-1blue for 30 min. Both 
elution conditions were incubated at room temperature. After incubation, the contents (outputs) were 
removed from the immunotube and used to infect XL-1blue. Only trypsin effectively eluted the phage. 
The y-axis shows the total estimated resulting colony number by titration of the outputs after each 
round of biopanning.  
 
 
 The phage mixture selected in each round by biopanning was then used in a 
polyclonal ELISA to determine binding to CSF-1R. The ELISA test is termed polyclonal at 
this stage because several different phages with diverse mutated sequences are tested 
together. The most significant results by ELISA were seen after two rounds of biopanning 
the VL library using trypsin for phage elution. The activity of the phage was significantly 
increased from the first to the second round of selection, but it was again reduced in the third 
round. Phage eluted by direct infection showed no enrichment after the first round. 
Biopanning selected phage with specific binding affinity to CSF-1R, since there was no 
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Figure 6.10 – Trypsin-eluted VL phage had enriched activity after two rounds of selection. Phage was 
eluted from immunotube either with trypsin (A) or by direct infection of the bacteria (B). The eluted 
phages were then expanded in XL-1blue and precipitated by the addition of PEG. The precipitated 
polyclonal phages expressing scFv were then tested by ELISA for binding to canine CSF-1R. Plates 
were coated with either CSF-1R extracellular region (400 ng/well in 50 µl of PBS) or BSA (same 
concentration), as a control. R.1, R.2 and R.3 refer to the rounds of biopanning. Secondary antibody 
was mouse anti-M13 (1:1000, GE Healthcare). Tertiary antibody was rabbit anti-mouse Ig, HRP-




To test the activity of mutated antibodies separately, colonies were individually 
picked from the output titration plates from the VL library biopanning and were induced to 
express their monoclonal phage. These were then tested by ELISA, thus termed monoclonal. 
All three rounds of VL biopanning were tested in monoclonal ELISA, but more clones were 
screened from round 2 of trypsin-eluted phage and from round 1 of direct infection elution, 
since these yielded the best results in the polyclonal ELISA. As a control, several colonies 
were scraped together from round 2 of trypsin-eluted phage. This composed a polyclonal 
pool.  
Only colonies originated from round 2 of the trypsin elution produced phages that 
bound to CSF-1R in the monoclonal ELISA. BSA was used as a control protein in ELISA, 
but no clones cross-reacted with BSA. A representative ELISA result, presenting trypsin 
eluted clones from round 2 is shown in Figure 6.11. 
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Figure 6.11 – Monoclonal phage from the VL-mutated library bound specifically to CSF-1R. 
Individual XL-1blue colonies containing bacteriophage were expanded separately in deep-well 96-
well plates and expressed the phage containing scFv. The culture supernatant was then used for 
ELISA (50 µl + 50 µl of PBS/milk (2 %)). Plates were coated with either CSF-1R extracellular region 
(400 ng/well in 50 µl of PBS) or BSA (same concentration), as a control. Each bar represents a well 
with a single clone in a 96-well plate. An individual clone is shown in the same position in both 
graphs. The dark blue bar is the positive control, using serum from mice immunized with CSF-1R 
extracellular region (1:4000). The dark green bar is the phage positive control, where several bacterial 
colonies were scraped together, thus producing polyclonal antibodies. Secondary antibody was mouse 
anti-M13 (1:1000, GE Healthcare). Tertiary antibody was rabbit anti-mouse Ig, HRP-conjugated 




 Colonies A11 and C2 (respectively called scFv 11 and 24) from Figure 6.11 and also 
scFv E9 from another plate were picked and expanded overnight. Their phagemids were 
purified by miniprep and sequenced to identify the mutations each clone contained. Each of 
the three monoclonal scFv had unique mutations in the CDR 3 of VL (Figure 6.12 A). The 
sequencing chromatograms confirm the monoclonality of the newly identified mAbs, in 
contrast with the polyclonal positive control used in the ELISA in Figure 6.11, which was 
comprised of several colonies grown together (Figure 6.12 B). 




Phage11           NIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPS 
3.1pVL            NIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPS 
                  ************************************************************ 
 
Phage11           RFSGSGSGTDFTLSINSVETEDFGMYFCQQSCQWPWTFGGGTKLEIK 
3.1pVL            RFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGGGTKLEIK 
                  ******************************* .************** 
 
 
Phage24           NIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPS 
3.1pVL            NIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPS 
                  ************************************************************ 
 
Phage24           RFSGSGSGTDFTLSINSVETEDFGMYFCQQFLSWPWTFGGGTKLEIK 
3.1pVL            RFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGGGTKLEIK 
                  ****************************** :*************** 
 
 
PhageE9           NIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPS 
3.1pVL            NIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKSHESPRLLIKYSSQSISGIPS 
                  ************************************************************ 
 
PhageE9           RFSGSGSGTDFTLSINSVETEDFGMYFCQQPGIWPWTFGGGTKLEIK 
3.1pVL            RFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGGGTKLEIK 




Figure 6.12 – Sequence of the monoclonal VL-mutated scFv 11, 24 and E9. The best clones found by 
monoclonal ELISA of the mutated VL library were sequenced. (A) Amino acid sequences of the 
mutated clones compared to the parental mAb 3.1 (shown as “3.1pVL”). The yellow highlights show 
the mutation sites, compared to the parental mAb 3.1, in green. The asterisks under the sequence 
identify where the parental antibody and the mutated libraries coincide. Alignment made using Clustal 
Omega. (B) Sequencing chromatogram of the VL CDR3 of the polyclonal positive control, comprised 
of several individual phage-containing XL-1blue colonies grown together. The mutation sites are 
inside the highlighted area, demonstrating the variability. Lower and mixed peaks demonstrate that 
more than one sequence was present in the sample sent for sequencing. (C) Sequencing chromatogram 
of the CDR3 of the monoclonal scFv 24. The mutation sites are inside the highlighted area. Higher 
discrete peaks indicate where the antibody sequence is unanimous within a sample. Chromatograms 
made using ApE 2.0.47 (M. Wayne Davis). 
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6.3.4 The mutated Vh phage display 
 
The Vh-mutated library was considerably larger than the VL library, presented 
above. Therefore, four rounds of biopanning were performed to enrich the clones that bound 
to the extracellular CSF-1R region protein. Two packaging strategies were tested for the Vh 
library. Packaging is the capture of the phagemid vectors containing the scFv by the 
bacteriophages, which will then express the scFv on the viral surface. The phagemids were 
packaged either with the M13KO7 helper phage, which was also used for the VL library, or 
with Hyperphage. After the first round of biopanning, however, the phage eluates from both 
packaging formats were re-packaged using M13KO7 (see Figure 6.3 above for packaging 
and re-packaging of phage). The phages were eluted from the immunotube using trypsin, 
since the best results for the VL mutated library were obtained using this elution method. 
The bacterial colony counts in the outputs of biopanning were enriched to a level 
200 × higher in round 3 for the Hyperphage packaged Vh library compared to the M13KO7 
Vh library. However, by round 4 the output for the Hyperphage Vh was zero, while it 
continued to grow for the M13KO7 Vh library (Figure 6.13). 
 
Figure 6.13 – Hyperphage packaging yielded higher bacterial outputs after selection until round 3. 
Two helper phages (M13KO7, New England Biolabs or Hyperphage, Progen) were tested for 
packaging the phagemids containing mutated Vh. After the first biopanning round, both phagemids 
were packaged using M13KO7. (A) Bacterial outputs of the M13KO7-packaged Vh mutated library 
after each round of biopanning. (B) Outputs of the Hyperphage-packaged Vh mutated library after 
each round of biopanning. The y-axis shows the total resulting colony number estimated by titration 
of the outputs. 
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 However, the increased output of phage after the biopanning did not translate into 
enrichment of phage containing active scFv. In the polyclonal ELISA evaluating the eluted 
phage after each round, the M13KO7 packaged Vh library showed a significant enrichment 
after four rounds, while the Hyperphage Vh library demonstrated a modest result (Figure 
6.14). 
 
Figure 6.14 – The M13KO7-packaged mutated Vh library had enriched activity after four rounds of 
selection. The mutated Vh phagemid library was packaged either with (A) M13KO7 (New England 
Biolabs) or (B) Hyperphage (Progen). After each biopanning round, the eluted phages were then 
expanded in XL-1blue and precipitated by the addition of PEG. The precipitated polyclonal phages 
expressing scFv were then tested by ELISA for binding to canine CSF-1R. Plates were coated with 
either CSF-1R extracellular region (400 ng/well in 50 µl of PBS) or BSA (same concentration), as a 
control. R1, R2 and R3 refer to the rounds of biopanning. Binding was strongest at R.4 for the 
M13KO7-packaged library (A). Secondary antibody was mouse anti-M13 (1:1000, GE Healthcare). 
Tertiary antibody was rabbit anti-mouse Ig, HRP-conjugated (1:2000, Dako). Negative controls 
received only the tertiary or secondary + tertiary antibodies. 
 
 
Individual colonies were picked from the M13KO7 packaged Vh mutated library. 
These were grown individually and induced to express the phage containing the monoclonal 
scFv. The bacterial supernatant was used in an ELISA.  
Several clones displayed strong reactions in ELISA, which surpassed the mouse 
immune serum positive control. There was no cross-reactive binding with BSA in a second 
plate coated with this protein (Figure 6.15).  
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Figure 6.15 – Monoclonal phage from the Vh-mutated library bound specifically to CSF-1R. 
Individual XL-1blue colonies containing bacteriophage were expanded separately in deep-well 96-
well plates. The colonies were allowed to express the phage containing scFv. The culture supernatant 
was then used for ELISA (50 µl + 50 µl of PBS + milk (2 %)). Plates were coated with either CSF-1R 
extracellular region (400 ng/well in 50 µl of PBS) or BSA (same concentration) as a control. Each bar 
represents a well with a single clone in a 96-well plate. An individual clone is shown in the same 
position in both graphs. The H12 position is the positive control, using serum from mice immunized 
with CSF-1R extracellular region (1:4000). The F12 bar shows the phage positive control, where 
several bacterial colonies were scraped together, thus producing polyclonal antibodies. Secondary 
antibody was mouse anti-M13 (1:1000, GE Healthcare). Tertiary antibody was rabbit anti-mouse Ig, 




Fifteen clones were selected based on the Vh monoclonal ELISA results (Figure 
6.15). These were B8, C4, C8, D5, D8, E2, E4, E10, E11, F3, F10, F12, G3, G7 and H8. The 
bacteria harbouring these phagemids were grown and the vectors were extracted by 
miniprep. These were then sent for sequencing to identify the mutations present in each. Five 
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of these clones had the same sequence, containing the same mutations in the Vh CDR 2. 
Surprisingly, for these 5 clones the VL chain was not the expected non-mutated sequence 
originated from mAb 3.1, but was the insert present in the plasmid before restriction digest, 
indicating that digest had not been complete and some clones still retained the plasmid insert 
(Figure 6.16 A).  
The other 9 clones contained the correct mAb 3.1 VL. Each of these 9 clones 
contained a different mutation in the CDR 2 (Figure 6.16 A). All of these clones had an 




   Vh sequence     Mutation site 
D8       -----LVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIRRRGHAY 
F10      MAEVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIRRRGHAY 
E11      MAEVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIRRRGHAY 
C8       --EVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIRRRGHAY 
E4       MAEVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIRRRGHAY 
              ******************************************************* 
 
D8       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
F10      HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
E11      HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
C8       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
E4       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
         ************************************************************ 
    Linker seq.       Plasmid VL 
D8       SSGSASTTKLEEGEFSEARVQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYVQL 
F10      SSGSASTTKLEEGEFSEARVQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYVQL 
E11      SSGSASTTKLEEGEFSEARVQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYVQL 
C8       SSGSASTTKLEEGEFSEARVQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYVQL 
E4       SSGSASTTKLEEGEFSEARVQSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYVQL 
         ************************************************************ 
 
D8       PGTAPKLLIYDNNKRFSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDGSLREAV 
F10      PGTAPKLLIYDNNKRFSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDGSLREAV 
E11      PGTAPKLLIYDNNKRFSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDGSLREAV 
C8       PGTAPKLLIYDNNKRFSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGA--------- 
E4       PGTAPKLLIYDNNKRFSGVPDRFSGSKSGTSATLGITGLQTGDEADYYCGAWDGSLREAV 
         ***************************************************          
   Phage pIII 
D8       FGGGTKVTVLGAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNA 
F10      FGGGTKVTVLGAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNA 
E11      FGGGTKVTVLGAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNA 
C8       ------------------------------------------------------------ 
E4       FGGGTKVTVLGAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNA 
 
   Vh sequence                Mutation site 
B8       --EVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIQ-PGAQY 
D5       ---VKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIAL-GESY 
G7       MAEVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASINCPG-RY 
E10      MAEVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASI-TKGSTY 
C4       ------VESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASI-PNGAQY 
H8       MAEVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIAP-GPGY 
F3       ---VKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASI-TRGPRY 
E2       ---VKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIPH-GTCY 
G3       MAEVKLVESGGDLVKPGGSLKLSCAVSGFSFSTYAMSWVRQTPEKRLEWVASIH-RGRVY 
               ***********************************************   *  * 
 
B8       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
D5       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
G7       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
E10      HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
C4       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
H8       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
F3       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
E2       QLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
G3       HLDSVKGRFTISRDNARNILYLQMRSLRSEDTARYYCARAIHYYGRYVMDYWGQGTSVTV 
         :*********************************************************** 
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               Linker seq.        Non-mutated mAb 3.1 VL 
B8       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
D5       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
G7       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
E10      SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
C4       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
H8       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
F3       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
E2       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
G3       SSGSASTTKLEEGEFSEARVNIVLTQSPASLSVTPGDSVSLSCRASQSISTNLHWYQQKS 
         ************************************************************ 
 
B8       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFVE 
D5       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFVE 
G7       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGG 
E10      HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGG 
C4       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGG 
H8       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGG 
F3       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGG 
E2       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGG 
G3       HESPRLLIKYSSQSISGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQSISWPWTFGG 
         **********************************************************   
                    Phage pIII 
B8       APSSR------------------------------------------------------- 
D5       APSSR------------------------------------------------------- 
G7       GTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVV 
E10      GTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVV 
C4       GTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVV 
H8       GTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVV 
F3       GTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVV 
E2       GTKLEIKAAAGSKDIRAETVESCLAKSHTENSFTNVWKDDKTLDRYANYEGCLWNATGVV 




 G  G  S  L  K  L  S  C  A  V  S  G  F  S  F  S  T  Y  A  M  
tcttgggttcgccagactccagagaagaggctggagtgggtcgcatccattcagtagcct 
 S  W  V  R  Q  T  P  E  K  R  L  E  W  V  A  S  I  Q  -  P  
ggtgcgcagtatcatttagacagtgtgaagggccgattcaccatctccagagataatgcc 
 G  A  Q  Y  H  L  D  S  V  K  G  R  F  T  I  S  R  D  N  A  
 
 
Figure 6.16 – Sequencing the monoclonal Vh-mutated scFv. The best 14 clones found by monoclonal 
ELISA of the mutated Vh library were sequenced. (A) Amino acid sequences of the mutated clones, 
grouped based on the correct expression of the non-mutated VL chain from mAb 3.1 (found in 9 
scFv). Five clones showed the same sequence (top) but expressed the “wrong” VL, while other 9 
selected scFv had unrelated mutations, but expressed the VL from mAb 3.1. The VL chains are 
highlighted in grey. “Plasmid VL” refers to a VL sequence that was already present in the pSEX81 
vector before the library was inserted (found in 5 scFv). The red highlights show the expected 
mutation sites in CDR2. The asterisks under the sequence identify where the mutated antibodies 
coincide. The column on the left indicate the names of the individual clones. Alignment made using 
Clustal Omega. (B) Paired base pair/amino acid sequence of scFv B8, demonstrating the amber stop 
codon, highlighted in yellow. Protein translation made using ExPASy.  
 
 
6.3.5 Testing the phage-conjugated scFv 
 
The scFv, still coupled to the phage particle, were tested in other assays beyond 
ELISA to assess their functionality. No binding was seen when the phage scFv (all relevant 
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monoclonal and polyclonal outputs) were used to probe for the recombinant extracellular 
CSF-1R by western blot, regardless of the dilution of the phage, from 1:4 to 1:1000 (not 
shown). 
The monoclonal phages and the M13KO7 Vh round 4 polyclonal phages were used 
to stain BMDM or cells transfected with the full CSF-1R. All monoclonal phages from the 
Vh library were tested in the staining of canine BMDM, and only scFv G3 (also from the Vh 
library) was tested in the staining of transfected HEK293T cells. No cellular staining was 
seen at lower concentrations (phage diluted 1:300), and phage precipitates formed at higher 
concentrations, which affected image quality (Figure 6.17).  
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Figure 6.17 – Phage-conjugated scFv from the Vh library did not stain CSF-1R
+
 cells. (A) Canine 
BMDM was grown overnight without CSF-1 and was stained with undiluted monoclonal phage H8. 
(B) CSF-1R-transfected and mock-transfected HEK293T were stained with phage expressing scFv 
(polyclonal from round 4 of the Vh biopanning or phage G3) (both diluted at 1:2). Notice the intense 
background precipitates on phage-stained images. The positive control was serum from mice 
immunized with CSF-1R extracellular region (1:4000). Secondary antibody was mouse anti-M13 
(1:1000, GE Healthcare). Tertiary antibody was goat anti-mouse, Alexa 488-conjugated (1:400, 
Invitrogen). Negative controls received only the secondary + tertiary antibodies. 40 × refers to the 
magnification used to acquire the images. 
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 The phage-conjugated scFv were also tested for the capacity to affect the 
proliferation and survival of canine BMDM. The addition of the control helper phage was 
sufficient to reduce BMDM survival, but the phage expressing scFv had a more prominent 
effect. The polyclonal phage from the M13KO7 output from round 4 showed a trend of 
reducing BMDM survival, an effect which was diminished if the amount of phage added was 
also reduced. The monoclonal phage G3 had the most evident effect, completely killing all 
BMDM (Figure 6.18 A). The phage solutions were titrated to assess if their effects in the 
proliferation assay were merely dependent on the number of particles instead of relying on 
scFv binding. On the contrary, scFv G3 contained the lowest concentration of phage particles 
of the three samples used, although it showed the strongest effect on BMDM (6.18 B). 
 
 
Figure 6.18 – The scFv-expressing phage reduced BMDM survival. (A) BMDMs were maintained 
with rhCSF-1 (20 ng/ml, Invitrogen) and were treated with 5 – 10 µl of the phage expressing scFv 
(polyclonal from round 4 of the Vh biopanning or phage G3, originated from the M13KO7 Vh 
library). The helper phage (M13KO7) was used as a control for the presence of the virus. PBS was the 
vehicle control for the scFv-expressing phage (shown in the figure as “Control”). Cells were incubated 
for 60 h with the treatments, and Phage G3 inhibited BMDM survival compared to its control. The 
horizontal bar within each group indicates the median. Statistical analysis (Kruskal-Wallis) comparing 
all groups against the “Helper phage” group. Proliferation results as measured by luciferase activity 
(CellTiter-Glo, Promega). (B) Titration of the phage contents from the solutions used in the assay. 
The three solutions were serially diluted and phage content was analysed by detecting the M13 
antigen on the membrane. Based on this result, the effect seen in (A) cannot be attributed to different 
viral quantities. Detection antibody was mouse anti-M13 (1:1000, GE Healthcare). Secondary 
antibody was rabbit anti-mouse Ig, HRP-conjugated (1:2000, Dako). 
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6.3.6 Testing purified scFv 
 
Testing the scFv still conjutated to the phage particle has several drawbacks, such as 
the low scFv expression levels, the confounding presence of the virus when used in tissue 
culture assays and the higher background staining in immunoassays. Therefore, it was 
necessary to express the scFv antibody fractions independently of the bacteriophage. To 
achieve this, the variable regions of the mutated antibodies of interest were ligated into a 
new vector, pOPE101, which allows the soluble expression of the scFv independently of the 
phage particle. The scFv D8, E9, H8 and G3 from the Vh library and the scFv 24 from the 
VL library were inserted into this vector.  
Induction conditions for the production of soluble scFv in the bacterial periplasmic 
space were initially standardized using scFv G3. Shorter induction times were more adequate 
for the production of soluble protein. Bacteria induced overnight accumulated the protein as 
insoluble aggregates (Figure 6.19 A). Induction intensity was relevant to the yield of soluble 
protein. Lower concentrations of the inducing agent IPTG (and therefore slower inductions) 
produced more soluble proteins. Lower temperatures, which reduce bacterial metabolism, 
also increased protein solubility. Sucrose, which is reported to increase production of soluble 
recombinant protein (Kipriyanov et al., 1997), negatively affected solubility of the scFv 



















Figure 6.19 – Shorter and slower induction conditions increased scFv G3 solubility. XL-1blue were 
transfected with pOPE101 containing the scFv fractions selected by phage display. (A) Expression of 
soluble and total scFv protein before or after 1 h, 2 h or overnight (O/N) induction of expression (500 
µM IPTG). Soluble protein was removed from the bacterial periplasmic space using a mild lysis 
buffer and was detected by western blot. Protein became insoluble after overnight induction. (B) Dot 
blot presenting the effect of different induction protocols for scFv expression. Soluble proteins were 
released from the bacterial periplasmic space and quantified by dotting the resulting solution on a 
nitrocellulose membrane. Higher solubility occurred at lower temperatures and with less IPTG. For 




 The scFv antibodies were expressed using the optimized protocol established as 
shown in Figure 6.19 above, using 200 µM of IPTG, at 30
o
C for 4 h induction. scFv 24 was 
more soluble than scFv G3 (not shown), and was expressed using a different protocol, using 
500 µM of IPTG at 30
o
C. After bacterial lysis and nickel affinity purification of the scFv, 
these were tested in an ELISA. However, the soluble scFv bound more avidly to a control 
protein than to CSF-1R in ELISA. The only exception was scFv 24, which showed increased 
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Figure 6.20 – The scFv expressed in the bacterial periplasm generally showed no specificity for CSF-
1R. Soluble scFv expressed in XL-1blue was removed from the bacterial periplasm using a mild lysis 
buffer. Binding properties were tested against two antigens, a control protein (soybean trypsin 
inhibitor, STI, Sigma), represented by the black columns, or CSF-1R, coated onto ELISA plates (400 
ng/well in 50 µl of PBS), represented by the white columns. Each column shows one of the elution 
fractions after Ni-NTA purification of each of the scFv clones (D8, E9, H8, G3, 24). Notice that 
binding to STI was generally higher than binding to CSF-1R. The arrows indicate the only elution 
fraction (n
o
 3), of scFv 24, which showed specific binding for CSF-1R. scFv were detected with an 
anti-c-Myc tag, HRP-conjugated (1:10000, Bethyl Laboratories). 
 
 
 The scFv G3 was also expressed as an insoluble protein, as it has been previously 
reported that levels of expression are significantly higher when scFv are produced as 
insoluble aggregates and then refolded by dialysis (Sun et al., 2014). Therefore, production 
of scFv G3 was induced by adding a high concentration of IPTG (500 µM) at a high 
temperature (37
o
C) for 4 h. This induction protocol lead to a strong production of insoluble 
protein, which was dissolved in a buffer with 8 M urea. The scFv was then refolded to the 
correct conformation by reducing the urea by stepwise dialysis. The antibody was then 
purified by affinity chromatography (Figure 6.21 A).  
 The majority of the refolded antibody was presented in the expected size of around 
30 kD. However, some aggregation occurred probably during refolding, as larger bands of 
circa 75 kD could be seen by western blot after scFv affinity purification (Figure 6.21 B). 
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Figure 6.21 – Refolding of scFv G3 produced some scFv aggregation. scFv G3 was expressed by XL-
1blue with high IPTG concentration (500 µM) and temperature (37
o
C). The protein was extracted 
under denaturing conditions with urea and was refolded by dialysis removal of the urea. The protein 
was then purified by affinity chromatography. (A) Purity was assessed after affinity chromatography 
with Coomassie staining of the eluates from the purification after SDS-PAGE. (B) The aggregation of 
the eluates was assessed by western blot. The scFv expected size is shown by the arrow. scFv were 
detected with an anti-c-Myc tag, HRP-conjugated (1:10000, Bethyl Laboratories). 
 
 
The refolded format of scFv G3 showed improved properties in ELISA, when 
compared to the originally soluble format shown in Figure 6.20, above. Whereas the soluble 
scFv G3 extracted from the periplasmic space showed strong cross-reactivity with the 
control protein in ELISA, the scFv G3 produced as an insoluble protein and then refolded by 
dialysis bound preferentially to CSF-1R. When compared to the original mAb 3.1, from 
which the mutated semi-synthetic antibody libraries were originated, scFv G3 demonstrated 
improved binding characteristics, with reduced binding to two control proteins, BSA and 






















Figure 6.22 – The refolded scFv G3 displayed improved binding characteristics when compared to the 
parent mAb 3.1. The purified and refolded scFv G3 and the murine mAb 3.1 were tested by ELISA in 
wells coated either with the canine extracellular region of CSF-1R, BSA or soybean trypsin inhibitor 
(Sigma) (all at 400 ng/well in 50 µl of PBS). scFv G3 had reduced binding to the control proteins 
when compared to mAb 3.1. scFv G3 was detected with an anti-c-Myc tag, HRP-conjugated (1:10000, 
Bethyl Laboratories). mAb 3.1 was detected with an anti-mouse Ig HRP-conjugated antibody (1:2000, 
Dako). Negative controls received only the secondary anti-mouse or anti-cMyc antibodies. Result 
representative of three independent assays. 
 
 
Refolding was then tested for other scFvs, as performed for scFv G3 (Figure 6.22, 
above). The clones scFv 24 (VL mutated), D8 and H8 (Vh mutated) were refolded in urea 
after insoluble expression. The activity of these scFv was then tested by ELISA. scFv H8 
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Figure 6.23 – The refolded scFv H8 showed activity by ELISA. Using the same method tried for scFv 
G3, other antibody fragments were expressed in bacteria as insoluble aggregates and were refolded by 
stepwise removal of urea. These scFv were tested by ELISA against the extracellular region of CSF-
1R or against soybean trypsin inhibitor (STI), as a control. Bound scFv were detected with anti-myc 
tag, 1:10000 (Bethyl Laboratories). Reaction was developed with TMB substrate. 
 
 
Storage stability of the refolded scFv was tested next. scFv activity was reduced but 
still detectable after storage at 4
o
C for 1 week. The refolded scFv G3 was maintained in the 
elution solution from Ni-NTA purification (in imidazole, pH 7.75). The stored scFv was then 
compared in ELISA with a recently-purified counterpart. The binding signal was reduced 




























































































Figure 6.24 – The refolded scFv G3 could be stored at 4
o
C for 1 week. scFv G3 was extracted under 
denaturing conditions, refolded by dialysis, affinity purified and was stored at 4
o
C for 1 week. After 
the storage period, the scFv was compared to a recently-purified counterpart. Specific binding could 
still be seen after one week. “EL1-5” refers to different elution fractions from the affinity column. 
Binding to the extracellular portion of CSF-1R or to soybean trypsin inhibitor (STI, Sigma), as a 
control, was tested by ELISA. CSF-1R and STI were used at 400 ng/well in 50 µl of PBS to coat the 
plate. scFv G3 was detected with an anti-c-Myc tag, HRP-conjugated (1:10000, Bethyl Laboratories). 
Negative controls received only the secondary antibody. 
 
 
The biological activity of scFv G3 and H8 against BMDM was tested in a 
proliferation assay. BMDMs were treated with either scFv G3/H8, the parental mAb 3.1 (at 
the same concentration) or PBS, as the vehicle control for the scFv. The murine fibroblast 
NIH/3T3 cell line was used as a control to assess if the effect of scFv was not indiscriminate 
or dependent on any bacterial contaminant remaining from the purification process. Whereas 
mAb 3.1 marginally reduced BMDM proliferation at the concentration used, the scFv G3 
and scFv H8 reduced BMDM survival even when compared to mAb 3.1 (Figure 6.25 A). 
Also, scFv did not reduce NIH/3T3 survival, actually apparently increasing cellular 
proliferation (Figure 6.25 B). This indicates that the effect on BMDM was dependent on the 
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Figure 6.25 – The scFv G3 and H8 significantly reduced BMDM proliferation. (A) Canine BMDM 
were grown with rhCSF-1 (20 ng/ml, Invitrogen) and treated with 10 – 20 µl of scFv G3/H8 or of the 
parental mAb 3.1 (at 0.3 mg/ml). PBS was used as a vehicle control for the scFv. Notice the effect of 
scFv G3 compared to mAb 3.1. (B) The murine fibroblast NIH/3T3 cell line was used as a control to 
assess if bacterial products remaining from the purification had toxic effects. These cells received the 
same treatments as the BMDM (but no CSF-1). Cells were incubated with the treatments for 60 h. The 
treatment had no effect on these cells. Proliferation results as measured by luciferase activity 
(CellTiter-Glo, Promega). Results are the means of at least 8 wells. Data representative of three 
independent experiments. Data analysed by ANOVA. Statistically significant differences are indicated 
by differing letters above each group. 
 
 
 To further assess the specificity of the scFv G3, it was used to stain canine duodenal 
sections. The slides were probed with either the neat scFv solution (0.3 mg/ml) or with 1:2, 
1:5 or 1:10 dilutions of the scFv in blocking buffer. Staining could only be detected up to the 
1:5 dilution. The stained cells were isolated and were rare (1 cell/ 20 × field) (Figure 6.26).  
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Figure 6.26 – The scFv G3 stained isolated cells in the canine duodenum. Tissue was fixed in 
paraformaldehyde and frozen in OCT (Fisher). Cryosections were permeabilized with PBS + Triton 
X-100 (0.2 %), blocked with PBS + goat serum (10 %) and probed with scFv G3 (pictures show 1:2 
dilution of 0.3 mg/ml in blocking buffer). The secondary antibody was mouse anti-c-Myc tag (1:3000, 
Cell Signalling). The tertiary antibody was goat anti-mouse Ig, Alexa 488-conjugated (1:300, 
Invitrogen). The negative control was received the secondary and tertiary antibodies. “40 ×” refers to 
the magnification used to acquire the images. 
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 The scFv H8 was tested by flow cytometry for binding to canine peripheral blood 
mononuclear cells (PBMC). This scFv bound exclusively to live canine monocytes. Staining 




Figure 6.27 – Refolded scFv H8 bound to canine monocytes. Live or fixed (1 % PFA) canine 
peripheral blood mononuclear cells were stained with 50 µl of urea-refolded scFv H8 for 40 min on 
ice. After washing cells, bound scFv was detected using mouse anti-His tag (1:700, Invitrogen) and 
goat anti-mouse, Alexa 488-conjugated (1:800, Invitrogen). scFv bound selectively to live monocytes, 
but not to fixed monocytes. 
 
 
 It was tested whether combining the mutated Vh and VL chains improved antibody 
binding. The Vh-mutated scFv D8, G3 and H8 received the VL chain from scFv 24. These 
antibodies were then expressed as insoluble proteins, and were refolded in urea. These 
antibody fragments were tested by ELISA. Adding a mutated VL chain to the Vh chain from 
scFv G3 or H8 did not seem to improve the binding characteristics of these clones (see 
Figures 6.22 and 6.23, above). scFv D8, which did not show binding in Figure 6.23, above, 
displayed affinity for CSF-1R after being expressed with the VL from scFv 24 (Figure 6.28). 
 
 




Figure 6.28 – Shuffling of mutated VL chains only affected binding of scFv D8. The mutated VL 
from scFv 24 was coupled to the mutated Vh from scFv D8, H8 and G3. The proteins were expressed 
and refolded as previously described, and were tested by ELISA (two separate experiments were made 
for scFv D8/H8 and scFv G3). scFv D8, which did not bind to CSF-1R in its original form, became 
active after receiving the VL chain from scFv 24. Bound scFv were detected with anti-myc tag, 





In Chapter 4, it was shown that mAb 3.1 failed to bind to the recombinant 
extracellular CSF-1R. The reduced capacity to bind to the CSF-1R may be due to differences 
in conformation between the antigen used to create mAb 3.1 and the native CSF-1R protein. 
mAb 3.1 was produced using a small recombinant protein produced in bacteria, whereas the 
full extracellular CSF-1R possesses the correct folding and conformation, since it was 
generated by mammalian cells in culture. Immunization with a non-conformational peptide 
is known to reduce the formation of antibodies that recognize the conformational epitopes 
(Beil et al., 1973). 
Analysing the number of mutations/CDR in mAb 3.1 compared to the germline 
genes, it could be verified that few residues were altered by hypermutation, especially in the 
VL chain. The number of mutations is linked at least partially to the maturity of an antibody 
(Willis et al., 2013). VL had a reduced number of mutations when compared to the Vh chain 
of mAb 3.1. It is known that there is a disparity in the onset of hypermutation between the 
chains, with the Vh being prioritized (Van Der Keyl et al., 2000). In an average naïve (non-
immunized) antibody library, about 55 % of antibody sequences display more mutations in 
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VL than 3.1. Regarding the VH, around 35 % of naïve antibodies have more mutations than 
3.1 (Tomlinson et al., 1996).  
Therefore, two semi-synthetic libraries were produced by mutating the variable 
region of mAb 3.1. The CDR2 of the Vh chain was mutated, while the CDR3 of the VL 
chain was altered. Even small alterations of the CDRs are sufficient to alter the binding 
specificity and affinity of an antibody (Gilliland et al., 1999; Mahon et al., 2013). It was 
therefore expected that some of the mutants should present improved binding characteristics 
when compared to the parental antibody. 
The mutated antibody libraries were created with small numbers of possible clones 
in order to verify the capacity of such reduced libraries in generating improving mutations. 
Also, it was intended that the mutations would be selected in parallel and then coupled in a 
single new scFv. This new scFv would contain mutated VL and Vh chains which had been 
selected for improved binding separately. Another group has successfully explored this 
possibility with an anti-GM-CSF library, altering the same CDRs changed in the present 
chapter (Steidl et al., 2008). Smaller, separate libraries also have technical advantages, such 
as not requiring extreme bacterial transformation efficiencies (Martineau, 2010).  
These scFv libraries with reduced numbers of clones can be screened in few 
biopanning rounds. Enrichment by biopanning favours the growth of clones that bind to the 
antigen. Once full enrichment is reached, further rounds of selection allow the selection of 
phage that have a growth advantage over the binding phages. Phage clones that do not 
express the scFv coupled to the pIII protein have growth advantages, for instance, since this 
protein is necessary for infecting the E. coli. Given that the VL library is very small (8000 
clones), two rounds of biopanning were sufficient to enrich the desired clones, and further 
rounds probably selected for non-specific phage which possessed growth advantage. 
Therefore, in the third selection round of the VL library, the majority of the bacteriophages 
present were likely to not express scFv, reducing the binding in the polyclonal ELISA assay.  
The mutated variable heavy chain library was considerably larger than the VL 
counterpart (the Vh contained 3.2 × 10
6
 clones). After four rounds of biopanning, there was 
significant enrichment in the ELISA binding of the polyclonal output phage, and several 
monoclonal scFv were identified with strong results by ELISA. Of the 14 clones sequenced 
from the VH mutated library, 5 contained an unexpected VL chain. This VL chain was 
already present in the plasmid before the library was constructed, and was not fully removed 
from all the phagemids by restriction digest. 
It has been found that frequently antibodies of different specificities possess similar 
or equal VL chains, with variations between them being present only in the VH chains. The 
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contrary is not true, and rarely is antibody variability only confined to the VL domain (Kabat 
and Wu, 1991). This may justify why scFv which contained the “wrong” VL chain were so 
numerous after phage panning. The fact that 5 clones presented the same sequence indicates 
that there was selective enrichment of these scFv through strong binding to CSF-1R.  
 The remaining 9 monoclonal scFv sequenced from the Vh mutated library contained 
TAG stop codons within the mutation sites. However, XL-1blue is an amber suppressor 
strain and reads through the TAG codon as a glycine in around half of the translations 
(O’Brien and Aitken, 2004). Whether the reduced expression of scFv due to the stop codon 
conferred a growth advantage to these clones is not known, but irrespective of that these 
scFv bound to the CSF-1R specifically in ELISA. It could be speculated that a truncated 
version of the scFv was expressed, starting after the TAG codon, and this truncated protein 
could have affinity for the CSF-1R. However, the antibody fragment must have been 
expressed in its entirety, since the leader sequence coded by the plasmid at the N-terminus of 
the scFv is essential for the production of the phage particle, which is needed for the 
biopanning of the library. 
 Hyperphage is an altered helper phage which does not contain gIII, which translates 
the viral coat protein pIII. This protein is required for phage infectivity. The role of the 
helper phage is to package a phagemid library containing gIII coupled to a scFv. Therefore, 
when Hyperphage packages the phagemid library, all infective viruses will contain the scFv, 
frequently with more than one copy per virus. The more common M13KO7 helper phage 
contains wild viral gIII, and therefore the resultant bacteriophages do not need to express the 
scFv-coupled pIII in order to become infective. Also, the M13 phages that do express the 
scFv tend to only express a single copy per virus (Rondot et al., 2001).  Therefore, the 
Hyperphage packaged Vh mutated library was expected to produce better results when 
compared to the M13KO7 library. Although the number of output colonies after biopanning 
was increased using the Hyperphage, this result did not translate into active scFv in the 
ELISA assay. 
 Because of the difficulties in testing scFv coupled to the bacteriophage, the scFv 
were expressed independently as soluble proteins. The presence of the phage introduces a 
confounding factor when interpreting the BMDM inhibition assay, since some of the effect 
over the BMDM could have originated by the presence of the phage particle, as could be 
seen with the use of the helper phage as a control. Also, phage scFv expression is low and 
production is time-consuming. Therefore, the scFv were transferred to a new vector, 
pOPE101, to allow the independent expression of the antibody fragments.  
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 However, the soluble scFv, expressed and folded in the bacterial periplasm, showed 
strong cross-reactivity with a control protein in ELISA. Protein folding within the bacterial 
periplasm is dependent on a number of factors, such as the intensity of protein expression 
and the very identity of the protein (Baneyx and Mujacic, 2004). As an example, scFv 24 and 
G3, originated respectively from the VL and Vh mutant libraries, showed significant 
differences in solubility and activity after periplasm production, although these antibody 
fragments were only different by a few amino acids. To avoid issues with periplasm protein 
folding and to increase protein production, the scFv G3 was produced as an insoluble 
aggregate by increasing expression intensity (altering IPTG concentration, growth 
temperature, the starting point for induction and induction time). Refolding was then carried 
out in a controlled manner, by removing the denaturing reagent by dialysis.  
 This insoluble and “refolded” mAb G3 showed significant improvements in binding 
to the CSF-1R compared to the periplasm-produced soluble counterpart. The refolded scFv 
preferentially bound to CSF-1R and had reduced cross-reaction with a control protein also 
when compared to the parental mAb 3.1, whose sequence was the framework for the 
construction of the scFv libraries. This indicates that mutation of the CDR 2 of the Vh chain 
of mAb 3.1 was a step towards perfecting the binding properties of the parental mAb. The 
refolding was tested with other scFvs (D8, H8 and 24). Of these, scFv H8 also showed 
specific binding after refolding. 
 Phage display offers a significant advantage over hybridoma screening of antibody 
clones in the ease with which non-specific clones can be eliminated from the process. Before 
the phage library is incubated with the immobilized target antigen, it can be “blocked” to 
remove any undesired cross-binders (O’Brien and Aitken, 2004). In the present study, the 
libraries were blocked using bovine milk, which de-selected clones that bound to BSA and 
other proteins. The parental mAb 3.1 showed significant cross-reactivity with BSA, and 
mutant clones displaying this characteristic were easily removed from the screened pool by 
the blocking step. Further improvements of the mutant scFv could be accompanied by 
blocking the library with proteins of similar structure to CSF-1R, such as c-Kit and the 
platelet-derived growth factor receptor (PDGFR) (Qiu et al., 1988). In this manner, 
antibodies that undesirably recognized these related proteins would be removed. 
 The scFv D8 was one of the selected clones that expressed the VL chain that was 
present in the plasmid before library construction. After expression and refolding of this 
scFv, it did not bind to CSF-1R by ELISA. However, this was the only scFv that benefited 
from receiving the mutated VL chain from scFv 24. The intent of shuffling the VL chain was 
to improve the binding of the Vh-mutated clones. However, scFv G3 and H8 showed no 
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improvement by ELISA after receiving a mutated VL. Therefore, it is possible that scFv D8 
would have equally benefited from receiving the scFv from mAb 3.1, non-mutated, that is. 
 The “refolded” scFv G3 still presented some aggregation after purification. 
Aggregation is a common occurrence in the production and purification of scFv (Borras et 
al., 2010). However, only a minor amount of scFv aggregated, and this seemed not to 
interfere with the binding properties of scFv G3. The refolded G3 could be stored for at least 
1 week at 4
o
C, albeit with some loss of activity. This is in accordance with the literature 
(Shepherd and Dean, 2000). These proteins are expected to be stable at up to 50
o
C (Borras et 
al., 2010). 
 Addition of refolded scFv G3 or H8 affected BMDM proliferation to a greater extent 
than the parental mAb 3.1. Confounding factors include contaminant E. coli bacterial 
proteins after scFv purification, since affinity chromatography did not completely remove 
non-specific proteins, as shown by Coomassie staining. The scFv (or the impurities) had no 
effect over the proliferation of a murine fibroblast cell line (NIH/3T3) that was used as a 
control. Both macrophages and NIH/3T3 cells express at least some pathogen-associated 
molecular pattern receptors, such as Toll-like receptors, that could recognize residues of E. 
coli and negatively affect cellular proliferation. Since NIH/3T3 proliferation was unaffected 
by the scFv solution there is an indication that bacterial contaminants were not an issue. 
Nevertheless, macrophages are more sensitive to some bacterial products than the fibroblast 
cell line, and could have been more negatively affected by the presence of residues (Jung et 
al., 2005; Lin et al., 2000). Since the scFv antibody fragment does not possess an Fc fraction, 
Fc receptor binding can be excluded as a confounding factor in affecting cellular 
proliferation. 
 Staining of canine duodenum was not conclusive in establishing if scFv G3 could 
bind to canine tissue macrophages. Only few and isolated cells were stained using this scFv, 
which is significantly different from the staining patterns of the parental antibody 3.1 
(Chapter 4). This could indicate a significant change in the binding properties between the 
original and the mutant antibody versions. However, protein stability of the scFv in the assay 
conditions needs to be considered when interpreting the results. scFv can have varying 
stability and have been subject to several engineering studies to improve constancy 
(Brockmann et al., 2005).  
 Confirming that the binding properties were greatly changed by mutation of CDR2, 
scFv H8 was shown to specifically bind to unfixed monocytes from canine peripheral blood. 
This is in contrast with the parental mAb 3.1, which could not stain cells from blood 
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(Chapter 4). This confirms the specificity of scFv H8 to CSF-1R, since other peripheral 
blood cells do not express this receptor (Moffat et al., 2014). 
 Future steps in this work would be to add further mutations to the already improved 
scFv. These should be screened for blocking ability against a cell line dependent on 
recombinant CSF-1R for survival. Mutation could also be inserted into mAb 12.2, which was 
later found to bind to a wider range of CSF-1R glycoforms than mAb 3.1, which was used to 




 In this chapter, two semi-synthetic antibody fraction libraries were successfully 
constructed by mutating the CDRs of a murine anti-canine CSF-1R antibody, mAb 3.1. By 
panning these libraries using the phage display method, it was possible to identify scFv 
clones that bound to the extracellular region of the canine CSF-1R with improved 
characteristics when compared to the parent mAb 3.1. Production of functional scFv 
benefited from a process of insoluble expression followed by refolding of the protein by 
dialysis, as tested with the scFv G3 and H8. The refolded scFv bound to the CSF-1R by 
ELISA and seemed to specifically inhibit BMDM proliferation. 
 Overall, these results show that it is possible to change and improve antibody 
specificity and binding through the construction and selection of small libraries of mutant 
antibodies created with only selected CDR alterations. These findings enable further 













 With the purpose of producing anti-canine CSF-1R antibodies, two antigens were 
produced: the complete extracellular (EC) portion of the receptor, expressed in 
mammalian cells, and a smaller fraction of the EC, comprising only the region 
responsible for receptor dimerization, expressed in bacteria. 
 The EC portion was structurally accurate, since it was capable of binding to CSF-1. The 
dimerization domain was expressed either with a His tag or with a GST tag. The former 
formed multimers, the latter was of difficult purification. 
 Mice were immunized with both the extracellular and the dimerization domains and 
mAbs were generated. The extracellular region produced mainly IgM clones. The 




Monoclonal antibodies are most commonly generated through the hybridoma technique. 
Hybridomas are created by the fusion of splenocytes from immunized mice with a myeloma 
cell line. This fusion immortalizes the antibody-producing cells of the spleen and allows 
continuous antibody production. In order to generate blocking antibodies against the canine 
CSF-1R, mice were immunized with two recombinant fractions of this protein. The complete 
extracellular portion of the CSF-1R was cloned and expressed in mammalian cells. The 
dimerization domain, which is a component of the extracellular portion of the receptor, was 
expressed in bacteria. The extracellular region of CSF-1R was a glycosylated protein and 
was probably folded similarly to the wild-type receptor, since it was capable of binding to 
one of its ligands, CSF-1. The dimerization domain formed aggregates, although at low 
concentrations. After immunization with these proteins, mouse sera were shown to be 
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strongly reactive against the antigens by dot blots or ELISA. In an initial test to identify 
blocking activity, the immunized sera could not affect the proliferation of bone marrow 
macrophages, cancer cells or of cells stably expressing recombinant CSF-1R. The 
subsequent procedures for hybridoma production from these mice are described. The 
extracellular region hybridomas generated a disproportional amount of IgM clones which 
could not be avoided with magnetic cell sorting depletion of IgM
+
 lymphocytes before 





The CSF-1 receptor (CSF-1R) is composed of five extracellular immunoglobulin-
like domains, with high glycosylation content (Yeung and Stanley, 2003). Domains 2 and 3 
are responsible for ligand binding.  Following contact with CSF-1/IL-34, the ligands of CSF-
1R, the fourth domain responds for receptor dimerization (Chen et al., 2008), which leads to 
the formation of intracellular receptor complexes and protein phosphorylation. This process 
of receptor activation drives increased protein expression, cytoskeletal remodelling, cellular 
motility and chemotaxis (Stanley and Chitu, 2014). This signalling process through the CSF-
1R is crucial for the survival and activation of many macrophage subsets and their 
development from the progenitor cells (Sasmono et al., 2003).  
CSF-1R expression within tumours, both by the cancer cells themselves and by 
infiltrating macrophages, is associated with poor clinical prognosis (Król et al., 2013; 
Patsialou et al., 2009). Therefore, this receptor is believed to be a potential target for cancer 
therapies (Hume and MacDonald, 2012). Several studies have verified that blocking the 
CSF-1R reduces cancer cell growth and invasion, diminishes neovascularization and cancer 
intravasation, among other benefits (Haegel et al., 2013; MacDonald et al., 2010; Pyonteck 
et al., 2013). 
 
7.1.1 Constructing antibodies against the CSF-1R 
 
With the goal of producing blocking antibodies against the canine CSF-1R, two 
proteins were produced for immunization of mice. The entire extracellular (EC) region of the 
receptor was expressed in HEK293T cells, and the dimerization domain – which is a fraction 
of the extracellular region – was expressed in BL21 (DE3) bacteria. 
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Other groups have produced blocking antibodies against the CSF-1R. The antigen 
production strategies for immunizing mice varied between each of the publications, but 
while the expression format varied, animals were generally immunized with the extracellular 
region of CSF-1R or the full receptor. Sherr and colleagues raised mAb 2-4A5, which targets 
the human CSF-1R. For this, rats were immunized with normal rat kidney cells expressing 
the human CSF-1R (Sherr et al., 1989). M279, an antibody that targets the murine receptor, 
was obtained by immunizing rats with the mouse CSF-1R coupled to the human Fc region. 
The strategy for antibody production of mAb H27K15 was not stated, but this mAb binds to 
the first two (N-terminal) extracellular domains of CSF-1R (Grellier et al., 2014). 
 
7.1.2 The hybridoma technology 
 
The generation of monoclonal antibodies is commonly accomplished using the 
hybridoma technique. It consists of immortalizing the antibody-producing cells to allow the 
continuous generation of antibodies in culture. To achieve immortalization, the mortal 
splenocytes are “fused” with an immortal myeloma cell line, generating a hybrid organism, 
called a hybridoma (Köhler and Milstein, 1975). Each myeloma cell fuses with a different B-
lymphocyte, and therefore after the fusion process the culture contains a mixture of 
hybridoma clones. Each hybridoma clone secretes a different antibody, as also would the B-
lymphocytes from which they originated. These clones can be separated and grown 
individually, producing antibodies derived from a single B-lymphocyte. These are thus 
termed monoclonal antibodies (Figure 7.1).  
Figure 7.1 – Overview of the process of hybridoma production of antibodies. Mice were immunized 
until antibody responses could be detected in the murine serum. Spleens were collected and 
splenocytes were harvested. These cells were fused with a murine myeloma cell line, generating a 
hybridoma. Stable hybridomas were selected using a specific medium. Monoclonal antibodies were 
derived by growing hybridoma cells individually (subcloning). The mAbs were then characterized by 
ELISA. 
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Stable hybridomas are selected using medium containing aminopterin. Aminopterin 
blocks the de novo DNA synthesis pathway. An alternative salvage pathway of DNA 
synthesis exists, but the myeloma cells are mutated so as not to produce hypoxanthine-
guanine phosphoribosyltransferase (HGPRT), which is necessary for the salvage route. 
Therefore, myeloma cells cannot survive in medium containing aminopterin. The B-
lymphocytes have a functional salvage pathway. In the presence of aminopterin, the de novo 
DNA synthesis is also blocked for the B-lymphocytes, as for the myelomas. However, these 
cells can activate the salvage pathway because they express HGPRT. The selection medium, 
beyond providing negative selection through aminopterin, also provides two necessary 
intermediates for the salvage pathway, hypoxanthine and thymidine. Nevertheless, B-
lymphocytes are mortal cells and cannot survive beyond a few days in culture (Figure 7.2).  
The process of cell fusion generates a hybrid with the cell culture immortality of the 
myelomas and with the DNA salvage pathway from the B-lymphocytes, ensuring that cells 
















Figure 7.2 – Selection of stable hybridomas is made based on the ability to survive in an aminopterin-
containing medium, called HAT. Splenic B-lymphocytes are mortal and do not survive for prolonged 
periods in culture. The myeloma cells are mutated and do not possess the salvage pathway for DNA 
synthesis (shown as the cross-ended arrow). Aminopterin in the selection medium blocks the de novo 
pathway. Therefore, the HAT medium, containing aminopterin, only allows the survival of hybrid 
fused cells. 
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7.1.3 Protein production 
 
Proteins used for immunization are commonly produced as recombinant products, 
which can be derived from different expression systems. Each system offers benefits and 
disadvantages, which are relevant to the work presented in this chapter. 
Bacteria are commonly used as hosts for protein expression because these organisms 
can be grown in large culture volumes and can stably produce substantial quantities of 
recombinant protein. However, it is common for proteins to be incorrectly folded by the 
bacteria and to become aggregated as inclusion bodies. Also, the most commonly used 
bacterial expression systems do not glycosylate proteins (Chen, 2012). Therefore, protein 
purification can be challenging and may require the use of strong denaturing conditions. In 
most cases, recombinant protein purification and refolding after bacterial expression is a 
complicated multi-step process (Sørensen and Mortensen, 2005; Terpe, 2006). Immunization 
with incorrectly folded antigens can generate responses against the primary protein structure 
that do not recognize conformational epitopes (Beil et al., 1973). Because of these 
characteristics, bacteria are usually chosen as expression hosts when the protein to be 
produced is relatively small and does not require post-translational modifications. 
The most common bacterial host for protein expression is the E. coli BL21. It is non-
pathogenic and is deficient in proteases, maintaining the integrity of the recombinant 
products (Sørensen and Mortensen, 2005). 
The advantage of mammalian cells as expression hosts is the ability to carry out any 
necessary post-translational modifications. However, compared to bacteria, these cells have 
very slow growth rates and expansion of the culture volume is expensive. Also, mammalian 
cells do not maintain episomal plasmid DNA and stable transfection requires a long selection 
process. Therefore, the total yields of protein production are several folds lower than the 
bacterial system (Dietmair et al., 2012).  
Human embryonic kidney 293T (HEK293T) and Chinese hamster ovary (CHO) cells 
are commonly used for protein production. These cells are easily transfectable and express 
relatively high amounts of protein even after transient transfection. The glycosylation 
patterns are similar between cells originated from different species, although there are some 
differences in the post-translational modifications when comparing human and hamster cells, 
for example, which can alter protein immunogenicity (Butler and Spearman, 2014). 
 
This chapter describes the production of the antigens used for mouse immunization 
and the antibody production process that followed. 
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The extracellular region of CSF-1R, synthesized in mammalian cells, was correctly 
folded and was glycosylated. The dimerization domain, produced in bacteria, was highly 
expressed, but formed aggregates. Both were administered into mice, and the antibody 
response was monitored in the serum. In total, 4 hybridoma fusions were made for 
production of anti-CSF-1R monoclonals. Three of these were made having the full 
extracellular region of the receptor as the immunogen and one fusion was made after 
immunization with the dimerization domain. In the initial screens several clones were found 
with binding activity against the CSF-1R. The screening process is presented here. 
Immunization with the extracellular region led to the production of mostly IgM clones. 
Depleting IgM
+
 B-cells through magnetic cell sorting could not prevent this. Among the few 
IgG generated by immunizations with the extracellular region are mAbs 1C6 and 2H1, 
described in Chapter 4. The dimerization domain hybridoma produced several IgG clones, 
among which are mAbs 3.1 and 12.2, described in Chapters 4 and 5.  
 
7.2 Materials and methods 
 
Basic methodological descriptions and brands not stated here are presented in 
Chapter 2. HotStarTaq polymerase kit and Omniscript RT kit are supplied by Qiagen. 
Phusion polymerase kits are supplied by Thermo Scientific. Pfu polymerase kit, dNTPs, 
RNAsin and GoTaq PCR Core System I Taq Polymerase are supplied by Promega.  
 
7.2.1 Bioinformatics analyses 
 
Sequence accession numbers were: canine CSF-1R, XM_546306; murine, 
AAH36343.1; human, AAH47521, NCBI; feline, ENSFCAG00000003633, Ensembl. 
Comparisons between the sequences were performed using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Evaluation of the mRNA structure of the canine CSF-1R and HPRT (accession 
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7.2.2 Amplification of the canine CSF-1R 
 
Primers for the canine CSF-1R were constructed based on the published canine 
genome (accession XM_546306, NCBI). The extracellular region and the dimerization 
domain of the CSF-1R were amplified and cloned for the purpose of expressing the proteins 
and performing mouse immunizations. The positioning of the primers is displayed in Figure 
7.3 and in Table 7.1.  
The entire CSF-1R receptor was used for expression on the cell surface and testing 
of antibodies by flow cytometry. Three nucleotides were added before the “ATG” in the 
forward primer to create a Kozak sequence (CSF1R full sequence forward, Table 7.1). The 
stop codon was not in the reverse primer (CSF1R full sequence reverse, Table 7.1) to allow 
the translation of the tags encoded by the pEF6-V5-His plasmid (Invitrogen), into which the 
sequence was cloned. 
Canine samples were collected from animals from the Edinburgh Dog and Cat home 
euthanized for humane reasons. CSF-1R mRNA was obtained from canine liver. RNA 
extraction was conducted using RNeasy Mini Kit (Qiagen). Quality was assessed by the 
presence and integrity of ribosomal 28S/18S bands after electrophoresis of the sample in a 1 
% agarose gel. 
The initial attempt at reverse transcription of CSF-1R mRNA using oligodT priming 
used the Omniscript enzyme. The optimized protocol for the PCR amplification of the CSF-




Figure 7.3 – Position of primers for the reverse transcription and amplification of the canine CSF-1R. 
Primers are indicated by the arrows (drawing is not to scale). The black horizontal line indicates the 
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Table 7.1 – Primers used in this chapter. Primers shown as 5` to 3`.  
Primer Sequence 
Position on the canine 
CSF-1R nucleotide 
sequence starting 











































HPRT forward AGCTTGCTGGTGAAAAGGAC / 
HPRT reverse TTATAGTCAAGGGCATATCC / 
T3 GCAATTAACCCTCACTAAAGG / 
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Table 7.2 – Protocol for amplification and cloning of the CSF-1R fractions. Primers shown in Table 
7.1. Wizard SV Gel and PCR Clean-Up System, pFN2a, JM109, Flexi and restriction digestion 
reagents (Promega). QIAquick Gel Extraction Kit, QIAprep Spin Miniprep Kit (Qiagen). pTriex 1.1 
(Millipore). pEF6-V5-His TOPO plasmid and Top 10 bacteria (Invitrogen). Random nonamers 
(Sigma). 
 
After overnight growth in LB plates with ampicillin at 37
o
C, colony-PCR of pEF6 + 
extracellular region was conducted using GoTaq DNA polymerase. Reaction protocol: 
MgCl2 (to 1.5 mM), 5 × GoTaq buffer (to 1 ×), dNTP (to 0.2 µM), primers (same as for 
product amplification) (to 0.25 mM), GoTaq polymerase (0.625 U), template (colony 
Full CSF-1R 







As shown to the right, 
exchanging the specific 
primer for random 
nonamers (10 µM). 
Step 1: Mixed the RT reaction primer (20 pmol), RNA (500 ng), DMSO (to 10 %), 
nuclease-free water (to 5 µl). Incubated for 95
o
C for 5 min, then 42
o
C. The reaction was 
put on hold. Added to the same tube: 10 × RT buffer (to 1 ×), dNTPs (to 0.625 mM), 
RNAsin enzyme (4 U), reverse transcription Omniscript RT enzyme (4 U), DMSO (to 10 
%), nuclease-free water (to 15 µl). Kept at 42
o
C for 1 h, then 72
o
C for 15 min.  
PCR 
Reaction: 5 × HF buffer 
(to 1 ×), dNTP (to 0.2 
mM), primers “CSF1R 
full seq FWD/RVS” (to 
0.5 µM), cDNA (1µl), 
Phusion polymerase (0.4 
U), nuclease-free water 





C for 2 min, 
35 × [98
o
C for 10 sec, 
72
o
C for 2 min 35 sec], 
72
o
C for 10 min. 
Reaction: 10 × Pfu buffer 
(to 1 ×), dNTP (to 0.5 
mM), primers 
“Extracellular region 
FWD/RVS” (to 0.25 µM), 
MgCl2 solution (to 2 mM), 
cDNA (1 µl), Pfu 
polymerase (3 U), 
nuclease-free water (to 
50 µl).  
 
Thermal cycling protocol: 
95
o
C for 1.5 min, 35 × 
[95
o
C for 30 sec, 59.5
o
C 
for 30 sec, 72
o
C for 3.5 
min], 72
o
C for 5 min. 
Reaction: 10 × Pfu buffer (to 
1 ×), dNTP (to 0.3 mM), 
primers “Dimerization domain 
forward/reverse for pFN2a 
ligation” (to 0.25 µM), cDNA 
(1µl), Pfu polymerase (3 U), 
nuclease-free water (to 50 
µl).  
 
Thermal cycling protocol: 
95
o
C for 1.5 min, 35 × [95
o
C 
for 30 sec, 65
o
C for 30 sec, 
72
o
C for 45 sec], 72
o
C for 5 
min. 
 















Specific bands were 
extracted from gel. 
Specific bands were 
extracted from gel. 
The PCR product was purified using a PCR clean-up kit. 
Addition of adenosine overhangs Restriction digest Restriction digest 
After gel purification, dNTP (to 0.25 µM) and 1.25 U 
of GoTaq polymerase were added to the PCR 
product. Incubated at 72
o
C for 15 min. 
PCR digest: 5 × Flexi Digest 
Buffer (to 1 ×), purified PCR 
product (500ng), Flexi 
Enzyme Blend (SgfI & PmeI) 
(4 µl) 
Plasmid digest: Nuclease-
free Water 12 µl, 5 × Flexi 
Digest Buffer 4 µl, pFN2a 
(200ng) 2 µl, Flexi Enzyme 
Blend (SgfI & PmeI) 2 µl  
PCR digest: PCR product 
(1 µg), Buffer H (to 1 ×), 
acetylated BSA (0.2 µl), 
EcoRI (6 U), Xho I (6 U), 
nuclease-free water to 20 
µl  
Plasmid digest: pTriex1.1 
(500 ng), other reagents 
as above 
PCR product was subjected to PCR clean-up, and plasmid was gel purified (except for pEF6 TOPO). 
Ligation: PCR product (4 µl), salt solution (1 µl), pEF6 
TOPO vector (1 µl). Incubated at room temperature 
for 30 min. 
 
Transformation: Top10 chemocompetent cells. 
Ligation: 2 × Flexi Ligase 
Buffer (to 1 ×), pFN2a, 
digested (50ng), PCR product 
(100ng), T4 Flexi DNA Ligase 
(HC) (20 U). Incubated at 
room temperature for 1 h. 
Transformation: JM109 
chemocompetent cells. 
Ligation: T4 ligase buffer 
(to 1 ×), pTriex1.1 (100 
ng), insert (17 ng), T4 
DNA ligase (0.6 U), 




The plasmids were extracted from transformed bacteria by miniprep. 
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dilution in LB (1 µl)), nuclease-free water (to 25 µl). Thermal cycling conditions were: 95
o
C 
for 2 min, 35 × [95
o
C for 30 sec, 59.5
o
C for 30 sec, 72
o
C for 2 min], 72
o
C for 10 min.  
Three positive colonies were sent for sequencing at the Sequencing Services at the 
University of Dundee. Primers used for sequencing the His-tagged dimerization domain 
were “pTriex sequencing primer UP/DOWN”. The extracellular region was sequenced with 
primers T3 and T7 (Table 7.1, above). The GST-tagged dimerization domain was sequenced 
with primer T7.  
 
7.2.3 Expression and initial purification of rCSF-1R peptides 
 
The pEF6 vector containing the extracellular region of canine CSF-1R (EC region) 
was transfected into HEK293T cells using Lipofectamine 2000 (Invitrogen). Lipofectamine 
was titrated down from the volume indicated by the manufacturer by transfecting cells with 
different concentrations of the reagent (from 100 % to 25 % of the volumes indicated by the 
manufacturer). After standardization, 75 % of the recommended volumes of Lipofectamine 
were used. Cells were allowed to express the protein for 48 h before the medium was 
harvested and cells were lysed using RIPA buffer (NaCl (150 mM), NP-40 (1 %), DOC (0.5 
%), SDS (0.1 %), Tris (50 mM), pH 8.0).  
The full CSF-1R was transfected into CHO-K1-S cells using the protocol in Chapter 
5. 
The pFN2A and pTriex 1.1 vectors containing the dimerization domain were 
transformed into chemocompetent BL21 (DE3) E. coli. Bacteria were grown in LB medium 
at 37
o
C shaking (200 rpm) until OD600nm = 0.6 and expression was induced by addition of 
IPTG (to 1 mM, Sigma). The bacteria were allowed to express the protein for 3 h at 37
o
C, 
and were then centrifuged (3200 × g for 20 min at 4
o
C).  
For clearing the GST-tagged dimerization domain (in pFN2a), bacteria were lysed 
by addition of lysis buffer (Tris (20 mM), NaCl (150 mM), EDTA (1 mM), NP-40 (0.5 %), 
PMSF (2 mM), lysozyme (1 mg/ml, Thermo Scientific), pH 8.0) at 1:50 of the bacterial 
culture volume, left on ice for 30 min. This was followed by four cycles of sonication of 30 
sec each with 10 sec breaks on ice and centrifugation at 9000 × g. The supernatant contained 
the desired protein. 
For clearing of the His-tagged dimerization domain (in pTriex1.1), denaturing 
conditions were used. Buffer B (NaH2PO4 (100 mM), Tris-Cl (10 mM), urea (8 M), pH 8.0) 
was added at 1:50 of the bacterial culture volume. The bacteria were subjected to 8 
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sonication steps of 30 sec, done on ice, with 10 sec breaks between sonications. This was 
followed by centrifugation at 10000 × g for 30 min. The supernatant was collected. 
For the test bleeds with the extracellular region, which was produced in pEF6, the 
tags contained in this vector were expressed alone, that is, with no insert attached. To 
produce the pEF6 vector tags alone, the vector was “closed” with a start codon (TOPO 
vectors are linearized). Two oligos were synthesized to create an insert. These were perfectly 
reverse and complementary with the exception of two adenosine overhangs on both ends. In 
conjunction, the two oligos formed a double-strand with a start codon (5` - GCTATGGTAA 
and 5` - ACGATACCAT). These oligos were ligated with pEF6. It was then transformed 
into bacteria as for the extracellular region. This plasmid was transfected into HEK293T 
cells by lipofection and the tags were expressed. The tags were then affinity purified from 
the culture supernatant as for the extracellular region. 
 
7.2.4 Western blotting and gel stains 
 
The expression of both protein fragments (extracellular region and dimerization 
domain) was verified by western blotting against the respective tags. Samples were loaded at 
the concentrations indicated in each figure. The pEF6 vector (containing the extracellular 
fraction) and pTriex 1.1 (containing the dimerization domain) expressed a His tag, and 
western blot probing was done under denaturing conditions using a primary mouse anti-His 
(1:500, Invitrogen) for 2 h at room temperature. Secondary antibody was rabbit anti-mouse, 
HRP-conjugated (1:1000, Dako), left for 1 h at room temperature. The pFN2A plasmid (also 
containing the dimerization domain) expressed the GST tag, and western blot was done 
using a mouse anti-GST (1:3000, Sigma) and rabbit anti-mouse, HRP-conjugated (1:3000). 
For determination of protein aggregation of the His-tagged dimerization domain, the proteins 
were mixed with non-reducing sample buffer and were not heated before loading the gel.  
The extracellular region and the GST-tagged dimerization domain were resolved 
with 10 % acrylamide gels. The His-tagged dimerization domain was resolved with 4 – 12 % 
gradient NuPAGE Bis-Tris gels (Invitrogen). Where stated, gels were silver or Coomassie 
stained. 
 
7.2.5 Purification of recombinant CSF-1R peptides 
 
Transfected HEK293T cells were allowed to express the extracellular region of CSF-
1R protein for 48 h before the medium was harvested and protein was purified using a native 
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protocol with a Ni-NTA resin (Qiagen). The purified fractions were buffer-exchanged into 
PBS by centrifuging and concentrating the samples in a concentrator tube containing a semi-
permeable membrane (10000 MWCO, Vivascience). After adding the samples to the 
Centricon tube, it was centrifuged for 30 min at 3000 × g. The concentrated protein fraction 
was diluted to the original volume using PBS. The procedure was repeated 3 times to 
completely exchange the buffer. 
The GST-tagged dimerization domain was purified using a glutathione column. The 
glutathione beads (1 ml, Amersham) were placed on 12 ml Poly-Prep columns (Bio-Rad). 
The beads were washed with GST purification buffer (Tris (20 mM), NaCl (250 mM), 
EDTA (1 mM), NP-40 (0.5 %), pH 8.0) to remove the storage solution and prepare for 
protein binding. The bacterial cell lysate was added to the column beads and incubated in a 
tube at 4
o
C with agitation for 2 h. The contents were allowed to flow through the column 
(the “unbound” fraction). The resin was washed by the addition of 20 column volumes of 
GST purification buffer. The bound protein was eluted from the resin by the addition of one 
column volume of elution buffer thrice (Tris (100 mM), reduced glutathione (20 mM), NaCl 
(120 mM), pH 8.0).  
The pTriex1.1 vector containing the dimerization domain was affinity purified after 
bacterial lysis. The supernatant was incubated with Ni-NTA resin pre-washed with Buffer B 
(see section 7.2.3). The resin was then washed with 20 column volumes of Buffer B at pH 
6.3 to remove non-specific binders. Elution was performed with Buffer B at pH 5.9 (four 
elution fractions of 1 column volume) and then pH 4.5 (another four elution fractions of 1 
column volume). The eluates were dialyzed against PBS four times after purification to 
remove the urea in 1 litre of PBS. Urea was reduced to 4 M, 2 M, 1 M and no urea. Dialysis 
was performed using a 3000 MWCO cellulose ester membrane (Spectrum Labs). 
Protein concentration of the purified fractions was performed using the Bradford 
method and by spectrophotometry using a Nanodrop (Thermo Scientific) with reading at 280 
nm. For spectrophotometry, the extinction coefficient of the proteins was calculated using 
ExPASy (web.expasy.org/protparam/). The purified proteins were aliquoted and stored at – 
20
o
C until used.  
 
7.2.6 De-glycosylation of the extracellular region 
 
N-linked oligosaccharides were removed from the extracellular region of CSF-1R 
using PNGase F (Promega). The purified EC region (50 µg in 12 µl of 0.5 M sodium 
phosphate buffer, pH 7.5) was mixed with 1 µl SDS (5 %) and 1 µl DTT (1 M). The sample 
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was denatured at 95
o
C for 5 min and was cooled at room temperature for 5 min. Sodium 
phosphate buffer, NP-40 (10 %) and PNGase F (2 µl each) were added to the mixture. This 
was incubated at 37
o
C for 2 h. Samples were resolved in a 10 % SDS-PAGE gel and were 
analysed by Ponceau S staining of the proteins transferred to a nitrocellulose membrane. 
 
7.2.7 CSF-1 binding activity 
 
To test the capacity of the recombinant extracellular region of CSF-1R of binding to 
one of its ligands, CSF-1, a transparent ELISA plate (Thermo Scientific) was coated with the 
recombinant receptor (300 ng/well in 50 µl of PBS) overnight at 4
o
C. The plate was also 
coated with BSA at the same concentration, as a control. The following day, the plate was 
blocked with PBS + BSA (2 %) for 1 h at 37
o
C. rhCSF-1 (Biolegend) was added to the wells 
at the stated concentrations in blocking buffer and was incubated for 2 h at 37
o
C. The plate 
was washed 6 × 2 min with PBST. Bound CSF-1 was detected with a biotinylated rabbit 
anti-human CSF-1 (1:1000, Peprotech) incubated for 2 h at 37
o
C. After washing the plate, 
Streptavidin-HRP (1:10000, Thermo Scientific) was added for 30 min at room temperature. 
The plate was washed and the reaction was developed with 50 µl of TMB Ultra (Pierce) and 
was stopped with the same volume of H2SO4 (2 M). The developed colour was read at 450 
nm using the Victor3 plate reader (Perkin Elmer). 
 
7.2.8 Mass spectrometry 
 
The purified His-tagged dimerization domain of CSF-1R was evaluated by mass 
spectrometry to assess purity and conformation status. This was performed by the 
Proteomics service at the Roslin Institute using amaZon ETD (Brucker). The sample was run 
in 8 M urea. 
 
7.2.9 Immunization of mice and test bleeds 
 
Mice were immunized every 21 days (extracellular fragment of CSF-1R at 15 
µg/dose) or every 28 days (dimerization domain, His-tagged, at 50 µg/dose) using Freund’s 
adjuvant (50 µl). The dimerization domain was conjugated to BSA to increase 
immunogenicity (performed by the Regional Centre for Applied Molecular Oncology, 
Masaryk Memorial Cancer Institute, Brno). Four doses were used for both antigens. Initial 
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doses were administered via intraperitoneal route, with adjuvant, and the last dose for each 
immunization was administered intravenously, without adjuvant. 
 The immunization using the dimerization domain was performed at the Regional 
Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech 
Republic and the immunizations using the extracellular region were performed at the 
Scottish National Blood Transfusion Service, Pentlands Science Park, Penicuik, UK. The 
immunizations and sera collection were performed under the license of the Scottish National 
Blood Transfusion Service. 
 Serum was collected from the animals before and after the third dose of 
immunization. The mice sera were tested by dot blots and ELISA to assess antibody 
production. For testing the immune response against the extracellular region, dot blots were 
carried out by dotting 1 µl of the target protein on a nitrocellulose membrane (GE Healthcare 
Life Sciences) (protein concentration of at least 0.2 mg/ml). The membrane was then 
blocked in PBST + milk (5 %). The membrane was cut to separate the dots. Each of these 
was then incubated with a dilution of the mouse serum, from 1:400 to 1:204800 in a 1:2 
progression. Secondary rabbit anti-mouse, HRP-conjugated (1:1000, Dako) was incubated 
for 1 h at room temperature in blocking buffer. The membranes were washed thrice with 
PBST after the primary and secondary antibody incubations. The substrate used for dot blot 
was ECL reagent (GE Healthcare), added to the membrane for 1 min.  
ELISA was performed by coating the 96-well plate with 200 ng/well of the 
extracellular fraction of CSF-1R in 50 µl of PBS overnight at 4
o
C. The plate was blocked 
with PBS + BSA (1 %) for 1 h at 37
o
C. Serum was diluted from 1:50 to 1:800 in in PBS + 
BSA (0.1 %). Wells were washed 5 times with PBST (2 min each). Secondary rabbit anti-
mouse, HRP-conjugated (1:1000, Dako) was used and incubated for 1 h at 37
o
C (for the 
ELISA). The substrate used for ELISA was TMB Ultra (Pierce).  
The dot blot for the dimerization domain was performed by the laboratory 
responsible for the immunizations in the Czech Republic. The technique used, therefore, 
differed from the one used for the immunization using the extracellular region. Dot blot was 
performed as follows. The membrane was wetted in PBS and afterwards covered with the 
protein in solution in PBS (20 μg/ml) for 1 h at 37
o
C. The protein solution was removed and 
the membrane was blocked for 1 h at room temperature in DMEM complete medium 
(Gibco). Blocking medium was removed, the membrane was dried with blotting paper and 
the mouse serum was added to the membrane in 2 µl dots per sample. The membrane was 
incubated at room temperature in a humid environment for 1 h. Membrane was washed 3 
times in PBS (5 min washes). Secondary antibody (HRP conjugated) was added and also 
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incubated for 1 h, at room temperature. Membrane was washed again 3 times in PBS to 
remove unbound secondary. Chloronaphtol (Sigma) was used as substrate, which 
precipitates on the membrane generating a visible blue dot on the positive samples. 
 
7.2.10 Effect of immune serum on cellular proliferation 
 
Either BMDM (7 × 10
3
 cells/well), REM134 cells (5 × 10
3
 cells/well) or Ba/F3 cells 
(2 × 10
4
 cells/well) were plated in 100 µl of media in black opaque 96-well plates. Ba/F3 
cells expressed either the ovine or the swine CSF-1R and were dependent on signalling 
through this receptor for survival. Produced by Lindsey Waddell and Anna Raper (The 
Roslin Institute) (L. Moffat et al., 2014). Cells were treated with pre-immune/immune serum 
from mice immunized against the extracellular regions of CSF-1R. BMDM and Ba/F3 cells 
were treated with serum at 1:2000 in DMEM medium. REM134 cells were treated with 
serum at different concentrations. BMDM received rhCSF-1 (Invitrogen) at 20 ng/ml. Where 
indicated, CSF-1 was added to the other cells at 100 ng/ml. All Ba/F3 cells also received IL-
3 (5 % of conditioned medium from X63 cells expressing IL-3, provided by Lindsey 
Waddell). All cells were grown for 48 h in the presence of the serum and cell viability was 
assessed using CellTiter-Glo (Promega). 
 
7.2.11 Hybridoma fusions 
 
Sp2/0 mouse myeloma cells were selected in 8-azaguanine (Sigma) for one week 
before fusions to ensure that the HGPRT pathway was defective. Sensitivity to HAT 
supplement (Invitrogen) was tested after selection by adding HAT containing medium and 
evaluating cellular survival over two days. Absence of mycoplasma in the Sp2/0 was tested 
using MycoAlert (Lonza).  
 The fusion using the animals immunized with the dimerization domain of CSF-1R 
was performed by the Regional Centre for Applied Molecular Oncology, Brno. The fusions 
using the animals immunized with the EC region of CSF-1R were made using a protocol 
adapted from several sources (Clonacell; Harlow and Lane, 1988), and is shown in Annex 1. 
Three fusions were performed from mice immunized with the extracellular region of CSF-
1R. The hybridoma fusions 1 and 2 used semi-solid medium (medium D) containing HAT 
selection supplement for colony growth after fusion. All cells were diluted in 10 × 96-well 
plates after fusion number 3, containing 200 µl of DMEM with HAT. Magnetic cell 
exclusion of IgM cells was used for the second fusion with the extracellular region of CSF-
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1R, as published elsewhere (Apiratmateekul et al., 2009) and as detailed in the Annex. 
Fusions were performed two days after the last dose of antigen.  
 
7.2.12 Screening the hybridoma fusions 
 
Screening of the resulting clones from fusion number 1 for the EC region and for the 
dimerization domain was done by dot blot following the protocol described above for 
screening the immune serum for the dimerization domain (section 7.2.9), with the difference 
that the colour substrate used was DAB-HCl (Sigma) (DAB (0.05 %), H2O2 (0.015 %) in 
PBS). Isotyping was performed by dotting the hybridoma supernatant on a membrane coated 
with an anti-mouse immunoglobulin [no HRP] (1:1000, Dako) and detecting the bound 
hybridoma antibody with anti-mouse IgG or IgM, HRP-conjugated (1:1500, Southern 
Biotech). The mouse immune serum (1:4000) was used as a positive control. 
Screening of hybridomas 2 and 3 for the EC region was done by ELISA. Plates were 
coated with the EC CSF-1R and tested similarly to the mouse serum, above (section 7.2.9). 
The mouse immune serum (1:4000) was used as a positive control. The secondary antibody 
was used as the negative control. 
For the hybridoma 3 for the EC region, positive clones in the initial ELISA were 
tested for cross-reactivity to BSA by coating wells with the same concentration of BSA and 
testing the same hybridoma antibody in both CSF-1R/BSA coated wells. IgG or IgM 
production was tested by coating the plate with an anti-mouse immunoglobulin [no HRP] 
(1:1000, Dako). The hybridoma supernatants were incubated in the wells and the bound 
isotype was detected by adding anti-mouse IgG or IgM, HRP-conjugated (1:1500, Southern 
Biotech). The IgG positive control (and also IgM negative control) was a murine IgG1 
isotype control (1:1000, Abcam). The IgM positive control (and also IgG negative control) 
was a murine IgM isotype control (1:1000, eBioscience). 
 For flow cytometry, CHO-K1-S cells were transfected with the full canine CSF-1R 
receptor using Lipofectamine, as described in Chapter 5. Transfected and non-transfected 
cells (10
6
/test) were incubated with the hybridoma supernatants on ice for 30 min. Cells were 
washed 3 × on ice cold PBS and incubated for 30 min on ice with an anti-mouse, Alexa 488-
conjugated secondary antibody (1:800, Invitrogen). The positive control was the serum of 
mice immunized with the extracellular CSF-1R, diluted 1:4000 in PBS. The cells were 
analysed on a FACScalibur flow cytometer (Becton Dickinson). The results were analysed 
using Summit 4.1 software (Dako). 
 




Subcloning was carried out by laying 200 cells of each desired clone into a well of a 
96-well plate. The cells were sequentially diluted 1:2 in medium for 12 wells. Individual 
clones after 10 days were and re-screened by dot blot, as above, and by functional assays 
(Chapter 4). 
Isotyping of the subclones was carried out by resolving the hybridoma supernatants 
by SDS-PAGE and detecting the isotype using rabbit anti-mouse IgG or IgM, HRP-
conjugated (1:1500, SouthernBiotech). Isotyping of the most relevant clones was confirmed 
using IsoQuick IgG strips (Sigma). 
 
7.2.14 Antibody purification by protein G chromatography 
 
The antibodies from the hybridomas were purified using Protein G Sepharose 4 Fast 
Flow (GE Healthcare). The resin (500 µl) was placed in a 12 ml Poly-Prep Chromatography 
Column (BioRad). Twenty volumes of sodium phosphate equilibration buffer (Na3PO4 (20 
mM), pH 7.0) were run through the column to remove the storage buffer. The hybridoma 
was grown in low-IgG FBS (Gibco) for 3 days and the culture supernatant was collected, 
centrifuged at 400 × g and was incubated with the resin for 30 min. The supernatant was 
allowed to flow through the column with the unbound fraction. Non-specific binders were 
removed by washing the resin with 40 column volumes of the sodium phosphate buffer. One 
column volume of glycine elution buffer (0.1 M, pH 2.7) was added in each of four steps to 
remove the IgG from the resin. Tris-HCl (1 M, pH 9.0), was added to the eluates at 130 
µl/ml to neutralize the acidity. 
After purification, protein concentration was assessed using Nanodrop 2000 
(Thermo Scientific) at 280 nm using the extinction coefficient for IgG set in the software of 
the equipment. The blank point for measurement was set using the neutralized elution buffer.  
 
7.2.15 Statistical analyses 
 
 The effect of immunized murine serum on REM134 proliferation was analysed by 
two-way ANOVA with a Bonferroni post-test. Its effect on BMDM was analysed by Mann-
Whitney. Its effect on Ba/F3 proliferation was analysed by Student’s t-test. For all tests, P < 
0.05. The assumption tests were performed on Minitab 16 (Minitab Inc.). The statistical tests 
and graphs were made on GraphPad Prism 5 (GraphPad Inc.).  




7.3.1 The extracellular region of the canine CSF-1R differs from that of 
mice and humans 
 
This project intended to identify an antibody against the extracellular region of 
canine CSF-1R. Therefore it was relevant to identify if existing antibodies generated for 
other species were likely to already target the canine receptor. Dog (Canis familiaris), mouse 
(Mus musculus), human (Homo sapiens) and cat (Felis catus) possess similar CSF-1R, 
comprised of 967 – 982 amino acids, with the biggest differences between the primary 
structures occurring up to the 540
th
 amino acid of the mouse sequence. These amino acids 
correspond mainly to the five immunoglobulin domains which constitute the extracellular 
portion of the protein (NCBI/Dog Genome Project) (Table 7.3). As expected, the feline and 
canine sequences are the most similar among these species, while the mouse is the most 
diverse from the dog (Figure 7.4). 
 
Table 7.3 – CSF-1R inter-species variation is derived from differences in the extracellular region. 
Identity matrix between the CSF-1R sequences of different species (NCBI and Ensembl), comparing 
either the entire receptor or the intra/extracellular regions. Values indicate the percentage identity 




 Mouse Human Dog Cat 
Mouse 100.00 75.03 76.40 75.82 
Human 75.03 100.00 84.47 84.31 
Dog 76.40 84.47 100.00 89.04 
Cat 75.82 84.31 89.04 100.00 
Intracellular region of the CSF-1R 
 Mouse Human Dog Cat 
Mouse 100.00 91.70 91.45 89.91 
Human 91.70 100.00 94.96 94.12 
Dog 91.45 94.96 100.00 96.72 
Cat 89.91 94.12 96.72 100.00 
Extracellular region of the CSF-1R 
 Mouse Human Dog Cat 
Mouse 100.00 60.39 62.94 62.94 
Human 60.39 100.00 75.44 75.83 
Dog 62.94 75.44 100.00 82.16 















Figure 7.4 – Neighbour joining tree of CSF-1R. Branches are calculated based on the percent distance 
between two species in relation to the amino acid sequence of CSF-1R. Constructed using Clustal 
Omega. Sequences from NCBI and Ensembl. 
 
 
7.3.2 Cloning and expression of the canine CSF-1R extracellular region 
 
Messenger RNA (mRNA) was obtained from canine liver. As seen in Figure 7.5 A, 
the canine CSF-1R RNA has several folds and sub-folds of high affinity binding. This can 
cause early termination or “slippage” of the reverse transcription, where large folds of RNA 
are skipped by the cDNA synthesis machinery (Zhang et al., 2001). When comparing to 
HPRT, as a control, it can be seen that the entropy in the CSF-1R mRNA is considerably 
higher (Figure 7.5 B). While amplification of HPRT was possible using oligodT priming, the 
same approach yielded no results for amplification of CSF-1R by PCR (Figure 7.6). Thus, a 
primer was used to perform specific cDNA synthesis with a starting point close to the 
extracellular region. The RNA strand was denatured at a higher temperature to break the 
folds. 
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Figure 7.5 – The canine CSF-1R mRNA showed high folding and entropy. (A) Canine CSF-1R 
mRNA structure (above) and the mountain plot of the entropy (below) (NCBI accession number 
XM_546306). (B) Canine HPRT mRNA (accession AY283372.1), showed for comparison. CSF-1R 
showed greater number of folds, with higher entropy. The colours on the linear sequence of mRNA 
indicate higher (red dots) or lower (purple dots) affinity clamps. On the mountain plot, the y-axis 
indicates entropy. The x-axis shows the nucleotide numbering of the respective sequences. The three 
colours on the mountain plots indicate three possible models for entropy calculation (Gruber et al., 
2008). Constructed with http://rna.tbi.univie.ac.at. 
 
Figure 7.6 – The extracellular region of CSF-1R could not be amplified using oligo-dT priming. Total 
mRNA was extracted from canine spleen and cDNA was created using OligodT (Promega) and 
Omniscript RT Kit (Qiagen). (A) Amplification of HPRT from three spleen samples (primers “HPRT 
forward/reverse”. (B) CSF-1R amplification (primers “Extracellular region forward/reverse”) using 
cDNA template from spleen sample 1. Rows in (B) show different magnesium concentration in the 
PCR reaction. “Neg ctrl” is the no-template control. The expected size of each PCR product is 
indicated. 
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When cDNA was synthesized using a specific primer for the canine CSF-1R, the 
fraction of cDNA correspondent to the extracellular region of this receptor could be 
amplified by PCR. In an attempt to facilitate the PCR, various concentrations of dimethyl 
sulfoxide (DMSO) were tested. However, it was found that the reaction was better developed 
in the absence of this substance (Figure 7.7). 
 
 
Figure 7.7 – The extracellular portion of CSF-1R was amplified after the primer-specific RT reaction. 
Total mRNA was extracted from canine spleen and cDNA was created using “RT reaction primer” 
and Omniscript RT Kit (Qiagen). PCR reaction for CSF-1R (primers “EC region FWD” and “EC 
region RVS”) was tested using different concentrations of DMSO (0-10%). The arrow indicates the 
product that corresponded to the CSF-1R. 
 
 
The extracellular region of CSF-1R was ligated into the pEF6-V5-His TOPO vector, 
creating a construct of the CSF-1R extracellular region attached to a V5-His tag. The correct 
placement of the insert in the vector was confirmed by sequencing the samples. The results 
showed that between the obtained CSF-1R sequence and the expected sequence (NCBI) 
there were only a few changes in isolated bases, which lead to a change in a single amino 
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Predicted        MGLGAPLVLLVATAWHVRGVPVIEPRGPELVVEPGTAVTLRCVGNGSVEWEGPISPHWNL 60 
Sequenced      MGLGAPLVLLVATAWHVRGVPVIEPRGPELVVEPGTAVTLRCVGNGSVEWEGPISPHWNL 60 
                         
 
Predicted        DPDSPSSILSTNNATFLNTGTYRCTEPGSPLGGSATIHIYVKDPVRPWKVLTQEVTVLEG 120 
Sequenced      DPDSPSSILSTNNATFLNTGTYRCTEPGSPLGGSATIHIYVKDPVRPWKVLTQEVTVLEG 120 
       
 
Predicted        QDALLPCLLTDPALEAGVSLMRVRGRPVLRQTNYSFSPWYGFTIHKAQFTETQGYQCSAR 180 
Sequenced      QDALLPCLLTDPALEAGVSLMRVRGRPVLRQTNYSFSPWYGFTIHKAQFTETQGYQCSAR 180 
                   
 
Predicted        VGGRTVTSMGIWLKVQKVIPGPPTLTLKPAELVRIQGEAANIECSASNVDVNFDVFLQHE 240 
Sequenced      VGGRTVTSMGIWLKVQKVIPGPPTLTLKPAELVRIQGEAANIECSASNVDVNFDVFLQHE 240 
                   
 
Predicted        DTKLTIPQQSDFQGNQYQKVLTLELDHVGFQDAGNYTCVATNVRGISSTSMIFRVVESAY 300 
Sequenced      DTKLTIPQQSDFQGNQYQKVLTLELDHVGFQDAGNYTCVATNVRGISSTSMIFRVVESAY 300 
                   
 
Predicted        LNLTSEQSLLQEVTVGEKVDLQVKVEAYPSLEGYNWTYLGPFSDQQAKLKFVITKDTYRY 360 
Sequenced      LNLTSEQSLLQEVTVGEKVDLQVKVEAYPSLEGYNWTYLGPFSDQQAKLKFVITKDTYRY 360 
                   
 
Predicted        TSTLSLPRLKPSEAGRYSFLARNTRGGDSLTFELTLLYPPEVRITWTTVNGSDALLCEAS 420 
Sequenced      TSTLSLPRLKPSEAGRYSFLARNTRGGDSLTFELTLLYPPEVRITWTTVNGSDALLCEAS 420 
                   
 
Predicted        GYPQPNVTWLQCRGHTDRCDEAQALVLEDSYSEVLSQEPFHKVIVHSLLAMGTMEHNMTY 480 
Sequenced      GYPQPNVTWLQCRGHTDRCDEAQALVLEDSYSEVLSQEPFHKVIVHSLLAMGTMEHNMTY 480 
                   
 
Predicted        ECRALNSVGNSSQAFRPIPIGAHI 504 
Sequenced      ECRALNSVGNSSQAFRPISIGAHI 504 
 
                   
Figure 7.8 – The canine extracellular CSF-1R differed by one amino acid from the predicted sequence 
(NCBI, accession number XM_546306). The figure shows the amino acid sequence of the 
extracellular region of CSF-1R after cloning with the pEF6 vector (shown as “Sequenced” in the 
figure). The highlight indicates where the obtained sequence varied from the predicted sequence. 
Alignment made with Clustal Omega. 
 
 
Expression of the extracellular fraction of CSF-1R was conducted in HEK293T 
cells. A titration of Lipofectamine 2000 was made to assess the amount of the reagent 
required to successfully transfect the cells. The volume of Lipofectamine used for transient 
protein expression could be reduced to 75 % of the recommended amount. The extracellular 
region of CSF-1R was successfully expressed; a large proportion of the protein was secreted 
by the cells into the culture medium, since the recombinant extracellular fraction did not 
include a transmembrane region (Figure 7.9). 
The predicted size of the extracellular region of CSF-1R, based on its amino acid 
composition, was of 61 kD. However, the bands observed on western blot were between 76 
kD and 102 kD. The difference in size and the diffuse form of the bands indicate that the 
recombinant protein was glycosylated (Figure 7.9).  
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Figure 7.9 – Expression of CSF-1R extracellular region by transient transfection of HEK293T cells. 
The amount of Lipofectamine 2000 (Invitrogen) for transfecting HEK293T cells was reduced from the 
recommendation of the manufacturer (from 100 % to 25 % of the recommended volume). Cells were 
lysed with RIPA buffer. Cell protein (20 µg) and culture supernatant (30 µl) were loaded under 
denaturing conditions in a 10 % SDS gel. (A) Western blot detection of the His tag on the culture 
supernatant (B) Detection of the His tag in the transfected cells. Western blot was performed with 
mouse anti-His tag (1:500, Invitrogen) and a secondary rabbit anti-mouse Ig, HRP-conjugated 
(1:1000, Dako). (C) Ponceau red staining of the nitrocellulose membrane loaded with the culture 
supernatant, shown as a loading control for the supernatant. The expected size of BSA and the size of 
extracellular region of CSF-1R (as seen on western blot) are indicated by the arrows.  
 
 
The extracellular region of CSF-1R was purified by affinity chromatography using a 
resin containing nickel-agarose, which binds to the His tag present in the vector pEF6. A 
single affinity chromatography step was sufficient to extract the CSF-1R extracellular region 
from the culture supernatant with the purity required for immunization (Figure 7.10). 
Purification of the recombinant protein from the transfected cells yielded reduced amounts 
when compared to the culture supernatant, and affinity chromatography was insufficient to 
remove contaminants. Therefore, CSF-1R extracellular region was routinely purified from 
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Figure 7.10 – Purification of recombinant CSF-1R extracellular region. (A) Silver stain of SDS-PAGE 
resolved fractions from the purification of the extracellular region of CSF-1R from the tissue culture 
supernatant of transfected HEK293T. Proteins were resolved under denaturing conditions with 10 % 
gel. Notice purified bands in the elution fractions. (B) Purification steps from the transfected cells. 
The lanes show proteins still bound to the resin after elution (labelled as “Resin”), the flow-through 
contents from the resin with unbound proteins (“Unbound”), the fraction of proteins removed by 
washing (“Wash”) and the purified CSF-1R in the elution fractions (“Elution fractions”). Lanes were 
loaded with 30 µl/well of each sample. The arrow indicates the size of the CSF-1R protein, as 
determined by western blot.   
 
 
 The glycosylation status of the purified extracellular region of CSF-1R was 
confirmed by removing N-linked oligosaccharides from purified CSF-1R extracellular region 
with the enzyme N-Glycosidase F. The difference in size between glycosylated and 
deglycosylated CSF-1R was evaluated by resolving the digested and the control undigested 
CSF-1R by SDS-PAGE, transferring to a nitrocellulose membrane and staining the proteins 
using Ponceau red. After deglycosylation, the size of CSF-1R extracellular region 
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Figure 7.11 – The recombinant extracellular region of CSF-1R was glycosylated. The recombinant 
protein was digested with PNGase F and the resulting difference in molecular size was evaluated by 
SDS-PAGE separation of the deglycosylated and control CSF-1R. The band around 30 kD is expected 
to be the PNGase F enzyme. 
 
 
 The correct folding of the recombinant extracellular region of CSF-1R was tested by 
assessing its capacity to bind to CSF-1. The receptor bound sensitively to increasing 














Figure 7.12 – The recombinant extracellular region of CSF-1R was folded to a functional state. Either 
the recombinant CSF-1R extracellular region or BSA (control) (300 ng/well in 50 µl PBS) was used to 
coat an ELISA plate. rhCSF-1 (Biolegend) was added at three concentrations and unbound ligand was 
washed away. Bound ligand was detected using a rabbit anti-CSF-1, biotinylated (1:1000, Peprotech). 
CSF-1R bound to CSF-1 in a dose-dependent manner. Streptavidin-HRP (1:10000, Thermo Scientific) 
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7.3.3 Cloning and expression of the canine CSF-1R dimerization 
domain 
 
The dimerization domain of CSF-1R was amplified using cDNA produced as 
described for the extracellular region. The dimerization domain was PCR-amplified using 
two pairs of primers, either for insertion into pFN2a, a vector containing a GST tag, or into 
pTriex1.1, which contains a His tag (Figure 7.13). The insertion into the vectors was 




Figure 7.13 – Amplification of the dimerization domain of CSF-1R. The dimerization domain was 
amplified with primers for insertion into pFN2a, which couples the peptide to a GST tag (primers 
“Dimerization domain forward/reverse for pFN2a ligation”) or pTriex1.1, which couples the peptide 
to a His tag (primers “Dimerization domain forward/reverse for pFN2a ligation”). 
 
 
The His-tagged dimerization domain protein was expressed in BL21 (DE3) E. coli 
and was affinity purified by nickel chromatography. After solubilisation of the protein from 
the bacteria under denaturing conditions (8 M urea), purification was carried out also in the 
presence of urea. Protein elution from the nickel resin was done by acidifying the resin. 
Affinity purification was able to enrich for the desired protein, although some contaminants 
were still present after a single round of chromatography (Figure 7.14).  
 




Figure 7.14 - Purification of the His-tagged dimerization domain of CSF-1R. Protein was purified 
from BL21 (DE3) bacteria under denaturing conditions. The protein was affinity-purified in urea (8 
M) and eluted by acidifying the resin. pH 5.9 and 4.5 were tested for protein elution, as shown in the 
figure. Proteins (30 µl/sample) were resolved in denaturing conditions in a 4 – 12 % Bis-tris-PAGE 
gel and were detected by silver staining. The expected size for the His-tagged dimerization domain is 
indicated by the arrow. Non-specific proteins which did not adhere to the resin are shown as 
“Unbound”. Proteins washed away from the resin are shown in “Wash”.  
 
 
However, the recombinant His-tagged dimerization domain formed aggregates even 
in the presence of 8 M urea. Resolving the protein with or without reducing conditions 
demonstrated the presence of several bands higher than the original 15 kD dimer domain in 
non-reducing conditions (Figure 7.15 A). In order to allow the purified protein to be used for 
immunization, urea was removed by sequential dialysis in solutions with lower 
concentrations of urea. The level of protein aggregation was maintained also after urea 
removal, although at low levels, since these multimers could not be detected by silver stain 
(Figure 7.15 B). 
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Figure 7.15 - The His-tagged dimerization domain formed multimers. (A) Samples in the presence of 
8 M urea, after affinity purification. Samples in reducing and non-reducing conditions (20 µl of each 
sample) were resolved with 4 – 12 % Bis-Tris PAGE and were detected using silver stain and western 
blot. The His tag was detected in western blot using mouse anti-His (1:500, Invitrogen). Secondary 
antibody was rabbit anti-mouse, HRP-conjugated (1:1000, Dako). (B) Purified fractions of dimer-His 
were dialyzed to remove the urea from the buffer. The resulting protein band is shown in silver 
staining and western blot detecting the His tag. Notice that the 15 kD band had depleted the 
luminescent signal in the western blot (“ghost band”) and there are multimers at 27 kD and ~ 35 kD 
that cannot be seen on the silver stain. The expected size for the His-tagged dimerization domain is 
shown by the arrows.  
 
 
The protein aggregation was confirmed by mass spectrometry of the samples in 8 M 
urea (samples shown in Figure 7.15 A, above). However, no discrete peak could be 
identified. A large plateau was distinguishable, with a left shift that indicated the presence of 
a His tag in all the peptides present (Figure 7.16). Therefore, mice that were immunized with 
the dimerization domain received not only the pure monomer form of the peptide, but also 
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Figure 7.16 – The His-tagged dimerization domain showed multiple aggregates by mass spectrometry. 
The sample from Figure 7.15 A was analysed by mass spectrometry under denaturing conditions. The 
peak indicated by the arrow has the molecular weight of 13.8 kD, similar to the expected size of the 
His-tagged dimerization domain. Notice the contaminant proteins surrounding that peak, probably of 
aggregates of the dimerization region. 
 
 
For the screening of the hybridoma from mice immunized with the His-tagged 
dimerization domain, this fraction of the CSF-1R was also expressed with the vector pFN2a 
(Promega), containing the GST tag. The vector was transformed into BL21 (DE3) bacteria. 
The protein was expressed and purified by affinity chromatography in a column containing 
glutathione resin, which binds to the GST tag present in the pFN2A vector (Figure 7.17). 
The complete solubilisation of the protein after bacterial production required sonication steps 
that denatured the GST tag, reducing binding of the protein to the resin. Significant amounts 
of the recombinant protein were lost during the binding and washing steps. Complete 
removal of contaminant proteins could not be accomplished after a single affinity 
purification round. 
 




Figure 7.17 - Purification of the GST-tagged dimerization domain of CSF-1R. BL21 (DE3) bacteria 
expressed the GST-tagged dimerization domain. The protein was extracted from bacteria by 
sonication and was affinity purified. The purification steps (30 µl of each sample) were resolved by 
SDS-PAGE (10 % gel) and proteins were detected by Coomassie stain. Non-specific proteins that did 
not adhere to the resin are shown as “Unbound” in the figure. Proteins washed away from the resin are 
shown in the rows marked “Washes”. Elution was carried out in several steps by the addition of free 
reduced glutathione, shown in the rows marked “Elutions”. The expected size of GST-tagged 
dimerization domain is indicated by the arrow. The contaminants of lower molecular weight could not 
be removed by washing or repeated GST purification. 
 
 
7.3.4 Test bleed 
 
Sera from the four mice immunized with the recombinant extracellular portion of the 
CSF-1R protein were tested for the production of antibodies by dot blots (Figure 7.18) and 
ELISA (Figure 7.19). Post-immunization sera were compared to the pre-immunization sera. 
There was a strong immune response following immunization, and reactive titres against the 
CSF-1R recombinant protein could be detected until the last serum dilution tested, at 
1:204800. 




Figure 7.18 – Immunization against the extracellular region of CSF-1R induced antibody production 
as assessed by dot blot. Serological response was tested against the target protein (extracellular region 
of CSF-1R) [long arrow at each dilution] or against the V5-histidine tag only [short arrow at each 
dilution] before and after the immunizations. The target protein and tag were dotted on the membrane 
(1 µl) and probed using the immunized/pre-immune mouse sera in the dilutions shown. Notice the 
strong reaction of immunized sera against the CSF-1R. Secondary antibody was rabbit anti-mouse, 
HRP-conjugated (1:1000, Dako). This is a representative result of one of the four mice tested. 
 
 
Figure 7.19 – Immunization against the extracellular region of CSF-1R induced antibody production 
as assessed by ELISA. CSF-1R extracellular region was coated onto ELISA plates (200 ng/well in 
PBS). Sera from mice were serially diluted and were tested against CSF-1R, with positive results from 
all animals. The bound complex was detected using rabbit anti-mouse Ig, HRP-conjugated (1:2000, 
Dako). 
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The sera of mice immunized against the extracellular region (EC) of CSF-1R were 
also tested for the capacity to inhibit the proliferation of CSF-1R
+
 cells. When added to 
REM134 cells, the immune sera induced reduction in the cell viability at some 
concentrations. The difference was statistically significant in an overall analysis of the 
dilutions for the sera of two mice (2 and 3). In the individual analysis of each dilution, the 
difference was significant in two points (mice 1 and 3). However, the results were not 
consistent with serum concentration, as some effects were only seen at low serum doses. The 
immune serum of mouse 4 (at 1:2000) had no effect on BMDM cellular viability and 





















































Figure 7.20 – Effect of sera of mice immunized against the extracellular CSF-1R on cells expressing 
the receptor. (A) REM134 cells were treated with different concentrations of the (pre-)immune sera of 
4 mice, diluted from 1:100 to 1:12800. Control wells received rhCSF-1 (100 ng/ml, Invitrogen). 
Statistical differences in an individual dilution are shown by an asterisk. The overall effect of the 
treatment is shown next to the figure legends, when present, as analysed by two-way ANOVA with a 
Bonferroni post-test. The effects of the immune sera were inconsistent. (B) BMDM cells were grown 
with rhCSF-1 (20 ng/ml) and were treated with the immune serum of mouse 4 at 1:2000. Analysed by 
Mann-Whitney. (C) Ba/F3 cells expressing the swine, ovine or no (naïve) CSF-1R were treated with 
the (pre-)immune serum of mouse 4 at 1:2000. Where indicated, cells received CSF-1 (100 ng/ml). 
All Ba/F3 cells received IL-3. Immune sera induced Ba/F3 proliferation. Statistical difference between 
treatments by two-way ANOVA with a Bonferroni post-test is indicated by an asterisk. The statistic 
relevance of the overall effect of the treatment is indicated next to the figure legend. All cells were 
incubated for 48 h with the treatments. Proliferation results as measured by luciferase activity 
(CellTiter-Glo, Promega). 
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The sera of the two mice immunized with the His-tagged dimerization domain of the 
canine CSF-1R were tested by dot blot and the reaction was developed with a colorimetric 
method (Figure 7.21). Serological responses were apparent after immunizations, although the 











Figure 7.21 – Dot blot test of the immune mouse sera against the dimerization domain. The His-
tagged dimerization region was used to coat a nitrocellulose membrane (20 µg/ml). The murine sera 
were serially diluted and dotted onto the membrane. Bound antibody was detected using an anti-
mouse Ig, HRP-conjugated secondary. The dot blot reaction was developed with chloronaphtol [blue 
colour] (Sigma).  
 
 
7.3.5 Hybridoma screening 
 
As presented above, mice were immunized with one of two antigens from the canine 
CSF-1R: either the full extracellular region or the dimerization domain of CSF-1R. After the 
fusion of the spleen of the mice with the myeloma cell line (fusions were performed at 
different time points for each mouse and antigen), the hybridoma culture supernatants were 
screened for the presence of antibodies that reacted against the target protein (either the 
dimerization domain or the extracellular region of CSF-1R).   
The first hybridoma fusion for the extracellular region of CSF-1R and the only 
fusion for the dimerization domain were screened by dot blot; for this, membranes were 
coated with the recombinant GST-tagged dimerization domain or extracellular region, 
respectively. 
The overall antibody production (regardless of specificity) was also tested to assist in 
the choice of the clones to be selected. The antibodies that bound to the antigens were then 
analysed to detect the isotype (IgM or IgG) (Figure 7.22). 

















Figure 7.22 – Representative dot blots of the first hybridoma screening procedures. (A) The 
supernatant of each isolated hybridoma colony was dotted on a nitrocellulose membrane coated with 
rabbit anti-mouse immunoglobulin (no HRP, 1:1000, Dako) for detection of antibody production. 
Each dot represents a single colony. The dark spots represent positive colonies. (B) Supernatants were 
also tested for reactivity against CSF-1R (20 µg/ml, dimerization or extracellular region, depending on 
which hybridoma was being tested). “+” indicates the mouse immune serum, used as a positive 
control (1:4000). The bound antibodies were detected with rabbit anti-mouse Ig, HRP-conjugated 
(1:1000, Dako). (C) The best results from (A) and (B) were then tested for antibody isotype. The 
supernatants were again dotted on membranes coated with anti-mouse Ig. The bound antibodies were 
detected with anti-mouse IgG or anti-mouse IgM (1:1500, Southern Biotech). In the example, all 
colonies tested were IgM
+
. The reactions were developed using DAB HCl (Sigma). 
 
 
 The second and third hybridoma fusions for the extracellular region of CSF-1R were 
screened by ELISA. The plates were coated with the antigen and colonies were evaluated for 
binding (Figure 7.23 A). In the third fusion, positive colonies were further screened on a 
plate comparing CSF-1R to BSA binding, as well as IgM to IgG production (7.23 B). The 
final selection step for the third fusion was by flow cytometry. CHO-K1-S cells were 
transfected to express the canine CSF-1R on the cell surface, and the positive clones from 
ELISA were screened to identify antibodies that bound specifically to transfected cells 
(Figure 7.23 C).  
In all three hybridoma fusions from mice immunized with the EC region, more IgM 
than IgG -producing clones were generated. To avoid this, in the second fusion IgM
+
 cells 
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were excluded using magnetic-activated cell sorting (MACS). However, this did not affect 
the proportion of IgM/IgG clones. Only one CSF-1R-binding IgG clone was identified for 
each of the first and second hybridoma fusions using the extracellular region, respectively 
mAbs 1C6 and 2H1. Only two mAbs from the third hybridoma bound to the CSF-1R on 
CHO cells as assessed by flow cytometry, clones 6D9 and 6F4 (Figure 7.23 C). 6D9 and 6F4 
did not affect BMDM proliferation (not shown), and were therefore not investigated further. 
 
Figure 7.23 – Screening procedures for the third extracellular region hybridoma. (A) Clones were 
initially assessed by ELISA for binding to CSF-1R-coated plates (200 ng/ml). Each bar shows the 
result of a clone. Well A12 is the mouse immune serum positive control (1:4000). The bound complex 
was detected using rabbit anti-mouse Ig, HRP-conjugated (1:2000, Dako). Well B12 shows the 
secondary antibody negative control. (B) mAbs were then tested for cross-reactivity with BSA and for 
IgG/IgM production by ELISA. Plates were coated with either CSF-1R or BSA (as above); for 
detection of antibody production, plates were coated with anti-mouse Ig (no HRP, Dako). For 
instance, wells A1 and B1 in both plates contain one mAb clone. Red highlights indicate positive 
results. Grey highlights show poor results. A12 and B12 show the positive controls: mouse immune 
serum (1:4000) (CSF-1R/BSA plate) or isotype antibodies (IgG1 or IgM, 1:1000, Abcam) (IgG/IgM 
plate). Binding to the CSF-1R/BSA plate was detected using anti-mouse Ig, HRP-conjugated (1:1000, 
Dako). Binding to the isotype plate was detected with anti-mouse IgM or anti-mouse IgG (1:1500, 
Southern Biotech). G12 and H12 show the negative controls. (C) As a last selection round, hybridoma 
supernatants containing mAbs were tested for binding to CSF-1R-transfected CHO-K1-S cells versus 
binding to non-transfected cells. The murine immune serum was used as the positive control (1:4000). 
Secondary antibody was goat anti-mouse, Alexa 488-conjugated (1:800, Invitrogen). 
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The best antibody clones identified in the screening assays were then subcloned by 
limiting dilution to guarantee antibody monoclonality. The screening assays shown in 
Figures 7.22 and 7.23 above were then repeated for the subcloned monoclonal antibodies. 
Antibodies that were subcloned based on the above assays include: all the antibodies 
shown in other chapters against the dimerization domain (including mAbs 3.1 and 12.2); the 
anti-CSF-1R extracellular region mAbs 1C6, 2H1, 7G3 (IgM) and 6C2, the only IgM clone 
to be chimerized. These antibodies were characterized by immunostaining assays and the 
capacity to inhibit cellular proliferation. This is detailed in Chapter 4. 
 
7.3.6 IgG purification from mouse hybridomas 
 
The IgG hybridoma colonies that were selected based on dot blots/ELISA as well as 
on immunostaining and cellular inhibition properties (Chapter 4) were cultured in 175 cm
2
 
flasks with low IgG-FBS and supernatant was collected to purify the immunoglobulins. 
Protein G chromatography was successful in removing most tissue culture contaminant 













Figure 7.24 – Purification of IgG from hybridoma supernatants. Antibodies were grown in low IgG- 
medium and were affinity purified with protein G. (A) Ponceau red staining of the membrane 
containing the purification steps. (B) Western blot using the membrane in (A) probed using rabbit 
anti-mouse Ig, HRP-conjugated (1:1000, Dako). Non-specific proteins which did not adhere to the 
resin are shown as “Unbound” in the figure. Proteins washed away from the resin are shown in 
“Wash”. The purified IgG collected from the resin is shown in the “Elution” fractions. Notice the 
purified Ig heavy (50 kD) and light (25 kD) chains in the elution fractions. Mouse serum IgG (Sigma) 
is the positive control. 
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 7.4 Discussion 
 
 With the purpose of blocking CSF-1R in canine cancer patients, antibodies were 
generated against this receptor by immunization of mice. Two different antigens were used 
for mouse immunization and the generation of hybridomas in this study: the extracellular 
portion of the canine CSF-1R and the dimerization domain of the receptor (Figure 7.25). 
Given that the antibodies should be able to inhibit signal transduction through the receptor in 
vivo, it was necessary that the antigen was positioned in the extracellular compartment, 
allowing targeting by the antibody. The extracellular portion of the receptor is responsible 
for binding the CSF-1R ligands, CSF-1 and IL-34, as well as for the dimerization of two 













Figure 7.25 – Immunization strategy for the production of antibodies against the canine CSF-1R. (A) 
Representation of the full CSF-1R molecule. The rectangles marked “Ig” depict the five extracellular 
regions of the receptor. “TM” depicts the transmembrane region. (B) The antigens used for mouse 
immunization. Animals were administered either the complete extracellular portion of the canine 
CSF-1R or the dimerization domain, coupled to protein tags. 
 
 
When injected into mice, the recombinant extracellular portion of CSF-1R should 
elicit the formation of antibodies against several epitopes in that region. Antibodies that 
targeted the ligand binding site or the dimerization domain would potentially block receptor 
function (Bradbury et al., 2011). 
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However, the CSF-1R has two ligands which bind to different positions on the CSF-
1R (Ma et al., 2012). Because of this characteristic, it is possible for an antibody to block the 
binding of one ligand but not the other (Chihara et al., 2010). Also, immunizing mice with 
the whole extracellular portion of CSF-1R also leads to the production of antibodies against 
regions of the receptor which do not directly affect receptor function. Consequently, the 
dimerization domain was also used as an antigen, to increase the probability that the mice 
would produce blocking antibodies against the CSF-1R. 
The two immunization strategies used in this chapter were devised to take advantage 
of different protein expression systems. The extracellular portion of the canine CSF-1R was 
produced in mammalian cells in culture and the dimerization domain was produced in E. 
coli.  
The mammalian cell culture system was chosen to express the extracellular region 
recombinant protein because the extracellular portion of the receptor is highly glycosylated 
(Sherr, 1990), and this post-translational modification cannot usually be performed in a 
bacterial system in the same proportion or containing the same carbohydrates as those seen 
in mammalian cells (Abu-Qarn et al., 2008). As was expected, the recombinant extracellular 
CSF-1R protein was glycosylated after production in HEK cells. The glycosylation patterns 
can change when using cells derived from different species (Butler and Spearman, 2014). 
This is relevant because it raises the possibility that antibodies produced against a protein 
derived from HEK cells, a human cell line, could not recognize the canine version of the 
same protein. However, the immune mouse serum, produced with the peptide from HEK, 
was also able to recognize the recombinant protein when expressed by CHO cells, a hamster 
cell line.  
The recombinant extracellular region was also able to bind to CSF-1, indicating that 
folding of the protein was correct. The transfected HEK cells secreted the largest part of the 
expressed extracellular region to the cell culture medium, facilitating purification of the 
protein. This protein was highly purified after a single round of affinity chromatography 
using a nickel resin, and this antigen was used for mouse immunization.  
As a drawback of the use of mammalian cells for expression, mice immunized with 
this antigen received reduced quantities of the protein (15 µg) when compared to the 
indicated protocols in the literature, which recommend from 50 to 100 µg (Harlow and Lane, 
1988), since the production yield of the system is low. The small antigen dose of the 
extracellular region may have contributed for the large number of IgM clones identified after 
all three hybridoma fusions from this antigen. Immune activation following immunization is 
necessary for the affinity maturation and isotype switch of the antibodies (Teng and 
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Papavasiliou, 2007), and this is affected by antigenic load (Harlow and Lane, 1988). For the 
second fusion from the extracellular region immunizations, IgM
+
 cells were depleted using 
magnetic cell sorting, as it had been published that this would greatly increase the proportion 
of IgG mAbs generated (Apiratmateekul et al., 2009). This had no effect on the proportion of 
IgM/IgG colonies produced, and IgM still largely surpassed the number of IgG monoclonals 
created. Despite the apparent lack of immune activation driving IgG formation after 
immunizations with the extracellular region, the primed sera were able to avidly bind to the 
antigen in dot blots and ELISA even to very low dilutions. Another possibility for the low 
production of IgG could be that the Sp2/0 myeloma fusion partner expresses CSF-1R. If this 
is the case, productive fusions with inhibitory IgG would have killed the myeloma cells, 
reducing the yield of IgG-producing clones.  
The sera from mice immunized with the extracellular CSF-1R were also able to 
reduce viability of the canine mammary cancer cell line, REM134. This cell line expresses 
the CSF-1R and is capable of replicating in response to receptor activation (Chapter 3). 
However, the effect was not correlated to the concentration of the serum, indicating that it 
was not a result of antibody function. This is corroborated by the lack of effect of the 
immune serum against canine BMDM, which require CSF-1R signalling for maturation and 
survival (Garcia-Morales et al., 2014; Temeles et al., 1993). Another possibility is that the 
immune serum also provided agonist antibodies, which would have counteracted the effect 
of antagonistic clones (Bradbury et al., 2011). 
Ba/F3 cells can be induced to replicate in the presence of foreign kinase receptors. 
This cell line usually depends on IL-3 for survival, but this signal can be substituted for CSF-
1 after transfection with CSF-1R (Gow et al., 2012; Liu et al., 1999). Ba/F3 cells were 
present in greater number after incubation with immune serum when compared to pre-
immune serum. The immune serum had an overall effect of increasing Ba/F3 cell 
proliferation, independently of the expression of CSF-1R by these cells, as assessed by two-
way ANOVA. After immunization of mice, IL-3 levels are increased in the serum (Valensi 
et al., 1994), and this may be justify the general induction of proliferation of Ba/F3 cells in 
the presence of immune serum. 
The His-tagged dimerization domain, used for immunization, avidly formed 
multimers of several different sizes. Since the aggregates of dimerization-His tagged protein 
could not be seen in silver staining, it was evaluated that their presence would not impede the 
use of the recombinant protein for immunization. Also, the presence of contaminant proteins 
after purification of the GST-tagged dimerization domain precluded its use for inoculations.  
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However, as later identified when studying mAb 3.1, originated from this 
immunization strategy, the presence of aggregates may have affected the quality of the 
derived antibodies. mAb 3.1 showed cross-reactivity with at least two control proteins in 
ELISA, and its variable regions seem not to have undergone extensive hypermutation 
(Chapters 4 and 5). These results indicate that immunization was not successful in maturing 
the antibodies. Lymphocyte activation following immunization with the dimerization domain 
may not have been directed towards a single immunogen, and could have been dispersed 
between the several aggregation formats. Consequently, although immunization with the 
dimerization domain led to the production of several IgG clones, antibody maturation may 
have been dispersed between several different antigens, instead of being directed against a 
single protein format. Also, the multimer format does not occur with the soluble receptor 
expressed by cells. If the mAbs were generated against the multimer, it is likely that they 
would not recognize the native antigen.  
The sera of the animals immunized with the dimerization domain were not made 
available by the institute that performed the injections in the Czech Republic. It would be 




 The CSF-1R extracellular region was successfully expressed as a recombinant 
protein. Mouse inoculations using this protein led to the production of highly reactive sera, 
which could identify the recombinant receptor in dot blots, ELISA and flow cytometry. 
Three hybridoma fusions were performed from this immunization strategy. However, several 
IgM antibodies resulted from these fusions. The His-tagged dimerization domain of CSF-1R 
generated several IgG clones, among which mAb 3.1, which is extensively described in 
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7.6 Annex  
 
7.6.1 Hybridoma Fusion 
 
Materials: 
□ 3 ml syringe 
□ 50 ml falcon tubes and cell strainer (100 μm) 
□ H2O deionized, sterile 
□ Erythrocyte lysis buffer (150 mM NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA, pH 7.2) 
□ PEG 1500 at 50 % (Roche) 
□ 100 mm tissue culture-treated plates 
□ Ice 
□ 250 ml of Cell Mab Medium, Quantum Yield (BD) with pen/strep/fungizone + Glutamax + 
10 % FBS + 10 % BM Condimed H1 Hybridoma Cloning Supplement (Roche). This 
medium can be substituted for RPMI (add IL-6 (Sigma)). 
□ 200 ml of  Advanced RPMI with pen/strep/fungizone + 20 % FBS + glutamax 
□ 300 ml of Advanced RPMI with pen/strep/fungizone + glutamax NO SERUM 
□ Clonal cell medium D with HAT, if using this for growth of clones after fusion (Stemcell). 
This can be substituted for RPMI + 10 % FBS + 10 % BM Condimed H1 Hybridoma 
Cloning Supplement (Roche) + pen/strep/fungizone + glutamax + IL-6 supplement (36 µl, 
Sigma) + HAT supplement 
□ Sp2/0 myeloma cells, previously selected with 8-azaguanine; 107 to 108 cells are 
needed. 
□ If carrying out magnetic sorting: LD column, MidiMACS separator, anti-mouse IgM 
microbeads (all from Miltenyi Biotech) and PBS + 2 mM EDTA + 0.5 % BSA.  
□ If desired, feeder cells can be used: 10 ml of RPMI is injected into the peritoneum of a 
recently euthanized mouse. The abdominal contents are shaken for 2 min and the 
volume is then withdrawn. This is diluted to 100 ml and plated on 10 × 96-well plates. 
This is done 2 days before the fusion.  
 
The recommendations in italics were obtained from the manual of Medium D 
(Stemcell). 
A total of 1 × 10
7
 Sp2/0 cells (i.e., 1:10 ratio to immune spleen cells) are used for 
fusion. Cell viability at the time of collection should be greater than 95 %. To ensure 
that cells are collected in log phase of growth, adjust the cell density to 2 × 10
5
 cells/ml 
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1. Warm up the media and the PEG at 37oC (except medium D)  
2. Remove all possible fat from the murine spleen 
3. Transfer the spleen to a cell strainer placed on top of a 50 ml conical centrifuge tube, 
perforate the spleen several times with a needle and perfuse it with RPMI NO SERUM. 
After this is done several times, use the plunger of a 3 ml syringe to grind the remaining 
cells out of the spleen. Rinse the screen with RPMI (5 to 10 ml) to assist the cells through 
the screen. Only the spleen capsule should remain on the screen. Gently pipette the cells up 
and down to disrupt clumps, but try not to cause the solution to foam 
4. Centrifuge the tube at 400 × g for 10 min. 
5. Resuspend the pellet in the residual medium (drops of medium left after inverting the tube 
to discard SN) – important step, as the cells must be very loose for the next step 
6. Lyse erythrocytes using 5 ml of lysis buffer for 5 min on ICE, without agitating 
7. Add 25 ml of RPMI NO SERUM 
8. Centrifuge at 400 × g for 10 min and discard supernatant 
9. If the pellet is clear, carry on to step 10. If it is still red, repeat the steps 5, 6, 7 and 8. 
10. If carrying out magnetic sorting of cells, go to step 11. If not, go to step 12. 
11. Resuspend pellet in 80 μl of PBS + BSA + EDTA per 107 cells. Incubate 1 × 107 spleen 
cells with 20 μl of anti-mouse IgM microbeads for 30 min on ice (scale up as necessary, 
never down). Cells are then washed twice with PBS containing 2 mM EDTA and 0.5 % 
BSA and centrifuged. Prepare LD Column by rinsing with buffer: apply 2 ml of degassed 
buffer on top of the column and let the buffer run through. LD Columns are "flow stop" and 
do not run dry. Discard effluent and change collection tube. The LD Column is now ready 
for magnetic separation. 
The cell pellet is resuspended in 500 μl of PBS + EDTA + BSA and is then applied onto 
the pre-prepared LD column and separated by MidiMACS separator. For cell numbers 
above 1.25 × 10
8
, scale up the volume. Collect unlabelled cells which pass through. Wash 
LD Column with 2 × 1 ml degassed buffer, adding buffer each time once the column 
reservoir is empty. Collect total effluent. This is the unlabelled (depleted) cell fraction. ** 
The negative fraction (the flow through) is collected and used for fusion. 
12. Centrifuge the negative fraction at 400 × g for 12 min and discard supernatant.  
13. Wash the pellet with 25 mL of RPMI NO SERUM 
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14. Centrifuge at 400 × g for 12 min and discard supernatant.  
15. During the centrifugation, take myeloma cells from bottles. Spin down myelomas and wash 
with 30 ml RPMI NO SERUM. Centrifuge at 400 × g for 12 min. Perform viable cell count 
with trypan blue exclusion, and wash cells with 30 ml of RPMI NO SERUM. Spin down as 
above, resuspend in 20 ml RPMI NO SERUM and disperse. Leave at 37°C until spleens 
are retrieved. 
16. Resuspend splenocytes in 20 ml of RPMI NO SERUM and count cells 
17. Mix myeloma and splenocytes in the ratio of 1:5 (myeloma:splenocyte) [if fusing IgM 
depleted cells, fuse at 1:3].  
18. Complete the volume to 50 ml with RPMI NO SERUM. 
19. Centrifuge at 400 × g for 12 min and discard supernatant with vacuum line or with pipette 
(all media must be removed not to dilute the PEG) 
20. Break up pellet by gently tapping on the flow hood surface. Add 1 ml PEG1500 
(prewarmed to 37°C) dropwise with a 1 ml needle over 1 minute. Swirl and tap the conical 
gently while adding the PEG to resuspend the cells. 
21. Continue to mix for 1 min 30 seconds (IMPORTANT STEP) 
22. Add 1 ml of RPMI NO SERUM to the PEG cells gently over 1 min while swirling (to 
dilute the PEG). 
23. Add 8 ml RPMI NO SERUM over 2 min to slowly dilute out the PEG. 
24. Incubate the cells in the 37°C water bath for 10 min (do not disturb the cells!!).   
25. If using ClonaCell-HY Hybridoma Selection Medium (Medium D), go to step 26. If not, 
Centrifuge the tube at 400 × g for 5 min. Resuspend the cells in 100 ml of RPMI containing 
cloning supplement, IL-6 and HAT. Plate the hybridomas on the plates containing the 
feeder cells. Culture for 7 days. Change medium to HT supplementation. Screen colonies 
within 3 – 4 days. 
26. Slowly add 30 ml of RPMI WITH SERUM and centrifuge the cells at 250 × g for 15 min. 
Discard the supernatant and wash cells with 40 ml of RPMI WITH SERUM without 
resuspending the cells to ensure that all PEG is removed. 
27. Slowly resuspend the cell pellet in 10 ml of CellMab Medium with BM condimed 
supplement. 
 Transfer the cell suspension to a T-75 cm
2
 tissue culture flask containing 20 ml of the same 
medium (total culture volume = 30 ml). Incubate for 16 – 24 hours at 37°C in 5 % CO2 
atmosphere.  
28. On the day of the fusion, place ClonaCell-HY Hybridoma Selection Medium (Medium D) 
at 2 – 8°C and thaw overnight. On the day after the fusion, shake vigorously to mix 
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contents well and let warm to room temperature (do NOT use a water bath).  
29. Transfer fused cell suspension into a 50 ml conical tube and centrifuge for 10 min at 400 x 
g at RT or 37°C. Remove the supernatant. Resuspend the cells in CellMab Medium with 
BM condimed supplement to a total of 10 ml (that is: 1 ml of CellMab Medium + 9 ml of 
Condimed). 
 
It is critical not to exceed the 10 ml final volume. If you wish to add any additional cytokines 
or growth factors to Medium D, include this volume in the total 10 ml volume that the cells 
are being resuspended in.  
To achieve optimal colony density for colony picking, plating at several cell densities is 
recommended as fusion efficiency may vary.  
 
30. Transfer the 10 ml cell suspension into the 90 ml of Medium D. Mix thoroughly by gently 
inverting the bottle several times. Let sit for 15 min at RT or 37°C to allow the bubbles to 
rise to the top.  
31. Using a 12 ml syringe and 16 gauge blunt-end needle, aseptically plate out 9.5 ml of cell 
suspension medium into each of ten 100 mm petri plates. Tilt each plate to evenly 
distribute the medium to cover the bottom of the plate. Avoid the introduction of bubbles 
during plating. Incubate plates at 37°C in 5 % CO2 atmosphere. Do not disturb plates for 
10 – 14 days.  
 
It is advisable to put the plates in a separate plastic container together with a 100 mm petri 
dish containing 10 mL sterile distilled water (no lid!) to maintain moisture content 
methylcellulose cultures. It is important not to disturb the plates for the first 10 days; doing 
so will result in runny or hazy colonies. 
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7.6.2 Hybridoma Maintenance when using Medium D 
 
1. 10 – 14 days after cells are plated in Medium D, examine the plates for the presence of 
colonies visible to the naked eye. A typical fusion will produce 1000 or more colonies over 
the ten plates. Remove isolated colonies (usually 500 – 1000 colonies are harvested) from 
the plates using a pipette set to 10 µl and sterile pipette tips. Pipette each clone into an 
individual well of a 96-well tissue culture plate containing 200 µl of BD Clonacell WITH 
SERUM and HT. With the pipette set at 150 µl, pipette the entire contents of the well up and 
down several times to resuspend the colony. The colony does not need to be resuspended 
into a perfect single-cell suspension but should be dispersed sufficiently to get good growth. 
 The resuspension of the colonies may be performed using a multi-channel pipette after 
all selected colonies have been transferred to 96-wells. Ensure a new sterile tip is used for 
each clone to maintain monoclonality of the colony. Incubate the plates at 37°C in 5 % CO2 
for 1 - 4 days without feeding. 
  
 By the fourth day, each well should have a high cell density and medium that is 
turning yellow. As the colonies have different growth rates, some wells may have media that 
turns yellow sooner than 4 days. It is a good idea to pick clones of different sizes as slower 
growing clones (i.e. smaller colonies) are often very good antibody producers.  
 
2. Transfer 150 µl of supernatant from each hybridoma to a separate well on a new 96-well 
plate and analyse by using an assay system appropriate for the antigen involved (e.g. ELISA, 
flow cytometry, western Blotting, etc.).  
3. Add 150 µl of fresh BD Clonacell WITH SERUM and HT to every well of the original 
hybridoma containing plates.  
4. Gently resuspend the hybridomas that showed a positive response in Step 2. Transfer 100 µl 
of cells to each of 2 wells of a 24-well plate, containing 1 ml of BD Clonacell WITH 
SERUM and HT.  
5. When cells have grown to a suitable density (approximately 4 × 105 cells/ml), freeze the 
cells from one well and expand the remaining positive clones in a T-25 cm
2
 tissue culture 
flask containing 5 ml of BD Clonacell WITH SERUM and 5 mL of BD Clonacell WITH 
SERUM and HT. This step adapts the cells to growth in BD Clonacell WITH SERUM. In 
addition, keep a sample of cells in BD Clonacell WITH SERUM and HT, in case the cells 
don’t adapt well to the 1:1 mixture.  
6. When cells have grown to a suitable density (approximately 4 × 105 cells/ml), transfer 5 - 10 
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ml of cell culture by pipette into 20 ml of BD Clonacell WITH SERUM in a T-75. Adjust the 
volume of cells to ensure the final cell concentration is between 1 × 10
4
 – 5 × 10
4
 cells/ml. 
Maintain expanded hybridomas in 100 % BD Clonacell WITH SERUM at a concentration of 
5 × 10
4
 – 5 × 10
5
 cells/ml. More aliquots of cells can be frozen at this point in order to secure 
the supply of the hybridoma. This is also the time to gradually wean cells off the BM 
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Conclusions and future perspectives 
 
The negative role of tumour-associated macrophages (TAMs) in cancer is currently 
receiving great attention. In a variety of studies, TAMs correlate to malignant progression of 
cancer by contributing towards several mechanisms of aggressiveness, such as invasiveness 
and immunosuppression (Noy and Pollard, 2015). CSF-1R is an important receptor for 
mononuclear phagocytes, including TAMs. CSF-1R mediates cell survival, recruitment and 
regulates the activation phenotype. Overexpression of CSF-1R and its ligands by cancer cells 
has also been shown to provide a transforming signal that sustains tumour growth (Hume 
and MacDonald, 2012). Therefore, in many cancers, CSF-1 or CSF-1R expression levels 
have been associated with poor prognosis (Chambers et al., 1997; Lin et al., 2001). 
In this thesis, the interaction between macrophages and canine mammary cancer 
cells was confirmed. Mammary carcinoma cells reduced macrophage inflammatory 
activation, while macrophages stimulated mammary cancer cell proliferation and metabolic 
activity. In the cross-talk between these two cells, CSF-1R signalling was likely to have a 
pivotal role. Both canine mammary carcinoma cells and macrophages proliferated in 
response to exogenous CSF-1. Two canine cancer cell lines were repressed by a CSF-1R-
selective small molecule kinase inhibitor. Cancer cells also proliferated and expressed more 
CSF-1R in response to macrophage-conditioned medium. When CSF-1 was competitively 
inhibited, the effects of cancer cells over macrophages were annulled. Finally, while CSF-1 
alone could lead to expression of macrophage inflammatory markers, it reduced Toll-like 
receptor-induced activation of macrophages. 
Further study is needed to fully clarify the role of CSF-1R in macrophage 
inflammatory activation. The response of CSF-1-conditioned macrophages to LPS 
stimulation is varied in different studies. CSF-1 has been shown to induce and suppress the 
production of inflammatory factors in response to LPS (Saccani et al., 2006; Sierra-Filardi et 
al., 2011; Sweet and Hume, 2003). Also, some of the inflammatory cytokines CSF-1-
conditioned macrophages are reported to express following LPS stimulation (e.g. IL-6) have 
been shown to promote anti-inflammatory characteristics under conditions found in tumours 
(Lewis and Pollard, 2006; Yasukawa et al., 2003). Therefore, it is necessary to fully dissect 
the biological relevance of CSF-1R activation in monocytes and macrophages from different 
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origins (blood, tissue, different tumours and various tumour sites) and the consequences of 
an inflammatory stimulus such as LPS. Isolated cultures of macrophages extracted from 
these various origins could be stimulated with CSF-1/IL-34 or their “opposite” factor, GM-
CSF. The effect of LPS stimulation of these cells then needs to be analysed holistically, with 
special relevance to functional assays, since it is hard to predict the biological effects of 
cytokine production based on their label of “pro-inflammatory” or “anti-inflammatory”, as 
was shown in the case of IL-6. Furthermore, although LPS is used as a model of 
inflammation, it is unlikely to be relevant in the context of cancer. Other inflammatory 
agonists, such as bacterial DNA, have very different effects from LPS on macrophage 
activation, showing that LPS is not an universal inflammatory model (Sweet et al., 2002). It 
can also be argued that the complexities of the tumour microenvironment are unlikely to be 
reproduced by addition of one or two factors in 2-dimensional cultures. Analysis of the 
cancer cell/macrophage secretome in more complex 3-dimensional cultures and the 
transcriptome from cancer samples will assist in piecing together the many factors involved 
in TAM/cancer interactions (Makridakis and Vlahou, 2010; Tang et al., 2011; Thoma et al., 
2014). 
While CSF-1R is not expressed by most epithelial cells during maturity, it would be 
important to understand how and when its expression is upregulated in carcinomas (Ide et 
al., 2002). Although this study was originally aimed at reducing the effects of TAMs in 
cancer, it is likely that blocking CSF-1R expressed by epithelial cancer cells will also be of 
benefit. The isolated effect of blocking CSF-1R in the carcinoma cells (isolated from the 
effect of blocking CSF-1R in TAMs) has received little attention, but will be important for 
understanding how anti-CSF-1R therapies will work. 
 
In order to block the cancer-promoting effects of tumour-associated macrophages 
and of CSF-1R signalling, monoclonal antibodies were raised against this receptor. Mice 
were immunized using either the extracellular region or the dimerization domain of canine 
CSF-1R as antigens.  
Immunization with the extracellular region of CSF-1R induced strong antibody 
responses, as measured by the serum reactivity. Nevertheless, this approach consistently 
produced more IgM than IgG clones after three hybridoma fusions, perhaps as a result of the 
low doses of antigen used. It is also possible that the myeloma fusion partner expresses CSF-
1R and production of IgG inhibited the survival of the hybridomas. Serum reactivity after 
immunization with the dimerization domain seemed weaker, but many IgG clones were 
isolated from this approach. 
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Hybridoma fusions were screened by dot blots or ELISA, followed by 
immunostaining and inhibition of carcinoma cell/bone marrow macrophage proliferation. 
The best antibodies from these assays were carried on to replicate assays and further studies, 
such as chimerization. The canine mammary carcinoma cell line used for the first 
proliferation assays was shown to express the CSF-1R and to proliferate in response to CSF-
1. However, responsiveness to CSF-1 and CSF-1R expression proved to be very sensitive to 
culture cell contact inhibition, and this may have affected the initial proliferation screenings. 
All clones that did not affect proliferation were no longer studied. Carcinoma cells were used 
due to the limited availability of canine primary macrophages at the time.  
Although the macrophages responded sensitively to antibody inhibition, these cells 
introduced confounding factors: the expression of Fc receptors (Luo et al., 2010) and 
pathogen-associated molecular pattern (PAMP) receptors (Jung et al., 2005). Fc receptors 
may have affected the results seen with some of the antibody clones studied here, such as 
mAb 12.2 after chimerization. Fc receptors can alter the binding affinity of some antibodies 
(Haegel et al., 2013). PAMP receptors may have interfered in the analysis of the proliferation 
effects of bacterially produced scFv. Residual bacterial contamination from the expression 
host could have affected the proliferation of canine macrophages when studying the effect of 
scFv. Future attempts in finding blocking antibodies against the CSF-1R should concentrate 
in using cell lines stably transfected with the CSF-1R and that rely on it for survival (Gow et 
al., 2012; Roussel and Sherr, 1989). This has the advantage of removing the confounding 
factors cited above and of permitting direct comparison against a non-transfected 
counterpart, against which the antibodies should have no effect. Also, intermediary assays 
such as ELISAs and immunostaining could be avoided. The first screening of the hybridoma 
clones should be a proliferation assay using the cell line expressing CSF-1R compared to 
non-transfected cells. Antibodies with specific proliferation inhibition could then be further 
analysed in other assays such as flow cytometry or western blots to confirm their identity.  
Using immunostaining and inhibition of cell proliferation as the selection criteria, 
mAb 3.1 was selected as a promising antibody. This clone could stain cells in known 
macrophage tissue niches and could inhibit macrophage and REM134 cell proliferation. 
Although other antibodies such as mAb 12.2 showed better cell inhibition properties, these 
clones could not stain cells, making their characterization difficult. The immunoprecipitation 
assay shown in Chapter 4, which confirms the specificity of mAb 12.2, was performed after 
the first submission of this work. Chimerization did not affect the binding properties of mAb 
3.1, and the chimerized mAb inhibited CSF-1-induced macrophage proliferation, but did not 
affect IL-4-conditioned macrophages. IL-4 induces macrophage survival independently of 
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CSF-1R, and it was expected that IL-4-macrophages were not affected by the anti-CSF-1R 
mAbs (Arpa et al., 2009; Jenkins et al., 2013).  
However, this antibody did not bind to circulating monocytes and showed cross-
reactivity against other proteins in ELISA. This is likely to be a result from the conformation 
of the antigen used for mouse immunization, which was produced in bacteria and formed 
stable aggregates. Immunoprecipitation confirmed that mAb 3.1 bound to few CSF-1R 
glycoforms. In this way, mAb 3.1 may bind to fixed antigens in tissue sections but not to the 
native CSF-1R expressed by monocytes. Another CSF-1R blocking antibody has been 
shown not to bind to the surface antigen by flow cytometry possibly due to epitope 
accessibility (Haegel et al., 2013). The bacterial peptides produced for immunization in this 
study proved complex to express and purify in the correct conformation, and future efforts to 
generate antibodies active against native canine molecules should concentrate on the 
mammalian expression system.  
Another explanation for the results with mAb 3.1 is the possible low antibody 
affinity. The cells stained by mAb 3.1 in the lymph node and spleen have been reported to 
express high levels of CSF-1R (MacDonald et al., 2010; Sasmono et al., 2003). Since ELISA 
showed that affinity of this antibody is likely to be low, mAb 3.1 may only recognize cells 
expressing high levels of CSF-1R, and blood monocytes have lower levels than tissue 
macrophages (Byrne et al., 1981). 
Therefore, to find antibodies with higher affinity and specificity towards the soluble 
conformation of CSF-1R, antibody libraries were constructed and screened by phage display. 
One complementarity-determining region of each of the variable chains (heavy and light) of 
mAb 3.1 was mutated by PCR. These were inserted into phagemids to construct two phage 
display libraries. Although library sizes were small, both libraries produced clones with 
lower cross-reactivity against control proteins than mAb 3.1, as assessed by ELISA. Some of 
the clones found by phage display, scFv G3, D8 and H8, were also successfully produced in 
bacteria isolated from the bacteriophage. scFv H8 was shown to bind to the native CSF-1R 
by flow cytometry of peripheral blood mononuclear cells. Expression of the scFv had to be 
performed by purifying in the presence of urea and refolding the protein by stepwise dialysis. 
This was an initial attempt at modifying mAb 3.1. The literature also often describes the use 
of sequential steps of mutation of the variable regions to accumulate positive alterations. 
Therefore, after the identification of these positive clones by phage display, further 
mutations can be added to them, generating new libraries that will possibly contain clones 
with even superior characteristics (Martineau, 2010). Mutation of mAb 12.2 could also yield 
better results than for mAb 3.1. This antibody inhibited macrophage proliferation more 
Chapter 8 - Conclusion    283 
 
intensely than mAb 3.1. Immunoprecipitation proved the specificity of mAb 12.2, and it 
seemed to bind to a wider range of CSF-1R glycoforms than mAb 3.1. However, 
immunoprecipitation was only performed after the production of phage display libraries with 
mAb 3.1. 
These mutated versions of mAb 3.1 can also be tested in the chimerization vectors 
pVH and pVL, tested here using several antibodies. These vectors allow the expression of 
the antibodies containing all post-translational modifications and in their full conformation. 
For future pre-clinical trials using chimeric antibodies, an improved expression system will 
need to be used, since expression levels using pVH/pVL is low. This may be due to the need 
of using two plasmids and the fact that only transient transfections were tested in the present 
work. However, even in fully optimized culture conditions antibody production costs are 
high. The monoclonal antibodies that are reaching the veterinary market at the time of 
writing are unlikely to be used by a wide audience due to the price of the products (Pollack, 
2014). Future advancements in antibody expression will be necessary for increasing 
production efficiency and reducing costs. The creation of transgenic animals and plants 
expressing recombinant antibodies has a high implantation cost but low maintenance. These 
may represent viable alternatives for the cost-efficient production of biologicals in the future 
(Frenzel et al., 2013; Schillberg et al., 2005).  
In future experiments, some of the techniques tested in the present work can be 
further explored. The CAM assay can be used with co-cultures of canine macrophages and 
cancer cells while testing the efficacy of therapeutic antibodies. The CAM assay shown here 
only tested the direct effect of mAb 3.1 over mammary carcinoma cells. However, there is 
great importance in repeating this assay including macrophages.  
The full antibody caninisation procedure (altering the variable regions) should be 
compared to chimerization with regards to binding properties and generation of anti-antibody 
responses. Although this could not be tested in the present work due to time constraints, if 
caninisation is successful it can increase the value of the resulting therapeutic mAb by 




CSF-1R signalling can have tumour-promoting abilities by stimulating direct cancer 
cell growth and by influencing the phenotype of tumour-associated macrophages. In order to 
block this receptor in canine cancer patients, antibodies were raised in this study by mouse 
immunizations. mAb 3.1, one of such antibodies, was able to inhibit the proliferation of bone 
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marrow-derived macrophages and of canine mammary carcinoma cells bearing CSF-1R. 
This antibody also stained putative macrophages in tissues, but showed specificity and 
affinity deficiencies. Some of the binding characteristics of mAb 3.1 were then improved by 
mutations to its complementarity-determining regions. Additional work is required to 
confirm the initial findings with these mutated clones and to further improve their properties. 
When satisfactory antibodies are identified, these can be altered by chimerization or 
caninisation and be used for clinical tests. However, these results indicate that interesting 
antibodies for blocking canine CSF-1R have been identified. 
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